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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition associated with increased risk 
of liver failure, diabetes and numerous further conditions. In NAFLD, lipid build-up and the resulting 
damage occurs most severely in hepatocytes at the pericentral end of the capillaries (sinusoids) which 
supply the cells with blood [1-3]. Due to the complexity of studying individual regions of the sinusoids, 
the causes of this zone specificity and its implications on treatment have largely been ignored in 
previous research. In this study, a computational model of liver glucose and lipid metabolism was 
developed which includes zone-dependent enzyme expression. This model was then used to study the 
development of NAFLD across the sinusoid. By simulating insulin resistance and high intake diets 
leading to the development of steatosis in the model, we propose a novel mechanism leading to 
pericentral steatosis in NAFLD patients. Sensitivity analysis on the rate parameters in the model was 
then used to highlight key inter-individual variations in hepatic metabolism with the largest effect on 
steatosis development. 
Secondly, the model, in combination with cell culture experiments, was used to assess potential drug 
targets for clearing steatosis across the sinusoid without disrupting other aspects of metabolism. 
Adverse effects were highlighted when targeting (stimulating or inhibiting through altering the rate 
constants) for most processes in the model, and these were largely validated in the hepatocyte-like 
cell culture line through the addition of small molecule inhibitors. However, inhibition of lipogenesis 
combined with stimulation of β-oxidation was predicted to clear steatosis, reduce hepatic FFA levels, 
reduce excess ETC flux and increase hepatic ATP concentrations across the sinusoid without causing 
adverse effects elsewhere in metabolism. Furthermore, in the cell culture model, inhibition of 
lipogenesis combined with stimulation of β-oxidation using acetyl-CoA carboxylase inhibitor TOFA, 
resulted in clearance of steatosis, improved cell viability, reduced oxidative stress and increased 
mitochondrial function.  
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Aims of the Project 
Non-alcoholic fatty liver disease (NAFLD), the build-up of fats in the liver in the absence of alcohol 
abuse, drug abuse and viral infection, is present in around one third of US and UK adults [1-5]. High 
liver fat increases the probability of developing liver failure, type 2 diabetes, kidney failure, liver cancer 
and cardiovascular problems [6-14]. Due to the high prevalence of the disease, it is expected to 
become the largest cause of liver transplant in the coming decades [8]. No approved drug for reducing 
steatosis in NAFLD is currently available and lifestyle change, which is known to be associated with 
low compliance rates, remains the only effective treatment. Therefore, study of both the development 
and treatment of NAFLD is urgently required, particularly in the early, reversible stages. 
Hepatocytes in vivo are known to show vast heterogeneity in enzyme expression depending upon their 
position along the liver sinusoid. This heterogeneity in enzyme expression causes groups of 
hepatocytes to specialise in different functions. In adult NAFLD, patients tend to show higher lipid 
content in cells near the central vein (pericentral) [15-17]. Additionally, the resulting damage tends to 
occur more rapidly in these cells. However, due to the experimental difficulty in studying a large 
number of variables (such as concentrations, enzyme activities or conversion rates) in specific regions 
of the sinusoid, researchers instead tend to study homogenised tissue and only measure averaged 
changes in the liver as a whole. Therefore, the causes of this increased pericentral susceptibility to 
steatosis remain unclear. Additionally, the implications of hepatic heterogeneity are rarely considered 
when assessing potential drug targets. It is possible that a drug may have beneficial effects on one 
region of the sinusoid whilst causing damage in another. 
The aim of this project was to study the implications of zonation in NAFLD development and treatment 
through a combination of computational modelling and cell culture experimentation. These 
simulations and experimental data will provide a basis for targeted and minimised future in vivo 
experimentation.  
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The first objective was to build a model capable of representing hepatic glucose and lipid metabolisms 
across the sinusoid (chapter 2). This model should include blood flow and variation in enzyme activity 
across the sinusoid based on experimental data in the literature. It should additionally provide realistic 
output data when simulating both metabolically normal and insulin resistant individuals, when 
compared with a range of experimental data. 
The second objective was to simulate conditions leading to the development of NAFLD (chapter 3). 
This included simulating the effects of high fat intake, IR and other metabolic dysregulation in the 
model and comparing with the metabolic changes known to occur in NAFLD. After establishing a 
representation of NAFLD, the next goal was to assess the major differences between periportal and 
pericentral cells that cause higher susceptibility to steatosis in pericentral cells. In a computational 
model, the concentrations of a large number of molecules and the rates of processes can be studied 
in individual regions of the sinusoid under a range of conditions, which would not be feasible 
experimentally. The model predictions can then be used to motivate targeted experimental validation. 
The third objective was to assess the effects of inter-individual heterogeneity in hepatic metabolism 
on susceptibility to steatosis and on the pattern of steatosis development (chapter 3). Around 25% of 
obese individuals fail to develop steatosis whilst 16% of lean individuals show excess liver fat [18]. 
Furthermore, whilst pericentral cells tend to show the highest lipid content, variation is seen in the 
predominant location of steatosis from pericentral to azonal or pan-sinusoidal [15-17]. Computational 
modelling allows each parameter to be modified individually, or several parameters to be modified as 
required, where experimentally, large scale studies would be required to correlate liver fat percentage 
or liver fat distribution with enzyme activities and confounding factors would have to be accounted 
for. Furthermore, use of a computational model allows detailed study of the mechanisms leading to 
change in liver fat percentage or distribution. 
The fourth objective was to assess the impact of pharmacologically targeting various processes in the 
model to clear steatosis in NAFLD without further disrupting energy metabolism (chapter 4). Through 
12 
 
changes to the rate constants of particular processes, pharmacological inhibition or stimulation of key 
enzymes can be simulated. By performing this analysis in a computational model, the effects on a wide 
range of variables can be studied under a range of conditions. Additionally, the effects of targeting 
each process can be studied in each individual region of the sinusoid.   
The final objective was to provide validation of key model predictions using an in vitro HepG2 cell 
culture model (chapter 5). Firstly, the impact of FFA treatment on the cells was studied to ensure they 
replicate the major metabolic changes occurring in hepatocytes in NAFLD in vivo and seen in model 
simulations. Once a cell culture model of the metabolic changes had been established, the next goal 
was to treat the cells with a range of small molecule inhibitors to mirror the pharmacological targeting 
simulated in the model and assess the effects on metabolism, comparing with the simulated data. 
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1 Chapter 1: Introduction 
In this chapter, a review of the relevant literature is provided. Firstly, in section 1.1, the structure 
and physiology of the liver are reviewed. In section 1.2 the causes and consequences of zonation in 
liver function across the sinusoid are discussed with a focus on zonation in metabolism. In section 
1.3 a review of liver disease and failure is presented focussing on NAFLD, NASH and related 
conditions. Finally, in section 1.4 a brief review of previously published computational models 
relevant to hepatic metabolism or zonation across the sinusoid is presented. 
1.1 The Liver 
1.1.1 Structure of the Liver 
The liver is the largest internal organ in the body (1.44-1.66kg) [19] and is involved in a vast range of 
essential processes including glucose and lipid metabolism, drug and xenobiotic detoxification, plasma 
protein synthesis and bile production. Despite its regenerative capacity, disease of the liver is the fifth 
largest cause of death in the UK and the only major cause of death to be rising year on year [1]. The 
following sections will review the structure and function of the liver. 
1.1.1.1 Blood Supply and Microstructure 
On the micro scale, the liver is built from ~1-2mm long structural units called lobules. In cross-section, 
these consist of rows of liver cells extending outwards from a central vein to form a hexagonal shaped 
unit which tessellates with adjacent lobules (see figure 1.1) [20]. Blood is supplied to the liver through 
two vessels, the hepatic artery and the portal vein. The hepatic artery supplies oxygenated blood from 
the heart. The portal vein provides blood which has passed through the gastrointestinal tract, spleen 
and pancreas containing the nutrients and toxins absorbed from food. Upon entering the liver, the 
hepatic artery and portal vein divide into branches which pass between the corners of neighbouring 
lobules. These branches subdivide into capillaries known as sinusoids which extend into the lobule 
between each row of cells, supplying them with oxygenated blood from the hepatic artery and 
nutrient filled blood from the digestive system [21] (figure 1.2). After passing through the sinusoid, 
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blood exits the lobule through the central vein. The central veins from each of the lobules join to form 
the hepatic vein, through which blood leaves the liver. As well as the blood vessels, intrahepatic bile 
ducts pass between each lobule which join and provide bile to the digestive system. 
 
Figure 1.1: A cross sectional view of a hepatic lobule and its neighbouring lobules showing the portal 
triads, central veins and the sinusoids and a 3D projection of the lobule. 
1.1.1.2 The Sinusoid – Cell types and zonation 
Hepatocytes are the major cell types in the liver making up roughly 80% of its volume [20]. They are 
the worker cells of the liver, involved in the vast range of functions described in section 1.1.2. The 
other cells, referred to as non-parenchymal cells, make up roughly 40% of the total number of cells in 
the liver but only 6.5% of its volume [22]. These include sinusoidal endothelial cells, Kupffer cells 
(macrophages), hepatic stellate cells and liver associated natural killer cells. A fenestrated single cell 
wall composed largely of endothelial cells along with some Kupffer cells lines the sinusoid vessel [20]. 
The fenestrae are small enough to block platelets or cells from passing through, but allow plasma to 
enter the space between the wall and the hepatocytes known as the space of Disse [20]. The rare Pit 
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cells (the natural killer cells of the liver) also inhabit the sinusoid space, attached to the luminal surface 
[20]. Ito cells inhabit the space of Disse and are strongly bound to the endothelial cells. The liver also 
contains a residual stem cell population known as Oval cells that are thought to be involved in 
regeneration. Under normal conditions the liver contains relatively little connective tissue [23]. 
 
Figure 1.2: The liver sinusoid showing the portal triad (hepatic artery, portal vein, bile duct) and the 
central vein. 
The focus of this study is on hepatocytes, the cells responsible for performing the major functions of 
the organ. Hepatocytes are large polarised cells, having distinct membranes on their basolateral and 
canalicular sides. The basolateral side faces the sinusoid and so is covered in microvilli to maximize 
the surface area presented to the blood. The canalicular surfaces of neighbouring groups of 
hepatocytes form bile canaliculi, the thin ducts which join to form the bile duct [20].  
The relative contributions of each hepatocyte to different functions performed by the liver vary as a 
function of their position along the sinusoid. For example, in glucose metabolism, the cells in the 
region closest to the hepatic artery and portal vein, the periportal zone, tend to be more active in 
glucose production whilst cells in the region closest to the hepatic vein play a more prominent role in 
glucose uptake [24]. This heterogeneity, known as zonation, is seen in almost all functions of the liver 
[24]. The primary cause of zonation is the change in abundance of substances in the blood as it passes 
through the sinusoid. For example, the average blood oxygen concentration falls from 60-65mmHg in 
the periportal zone to 30-35 mmHg in the pericentral zone [24]. As well as changes in the enzymatic 
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content of hepatocytes across the sinusoid, there are also changes in the numbers and types of non-
parenchymal cells. Zonation is reviewed in detail in section 1.2. 
1.1.2 Liver Physiology  
The liver performs a vast number of processes in the body such that, at rest, it produces 20% of the 
body’s heat. These include roles in detoxification, synthesis and storage section.  
Ammonia is the main toxic waste resulting from protein catabolism and its detoxification occurs 
mostly in hepatocytes [20]. It is generally converted to urea which is removed by the kidney, although 
specific subgroups of hepatocytes (pericentral) are able to convert ammonia to glutamine [25]. 
Bilirubin, a degradation product of haemoproteins, is conjugated with glucuronic acid to make it 
soluble. It is then removed in the bile. Bile acids are also produced in the liver using cholesterol as a 
substrate.  
The liver is responsible for the breakdown of several hormones such as insulin and glucagon along 
with certain proteins [20]. It also removes most xenobiotics from the blood. Hydrophobic xenobiotics 
are solubilised so that they can be removed [20]. This is a two-stage process with different enzymes 
responsible for each process. The first step involves oxidation of the xenobiotic by attaching a polar 
group. In the second step, a second group of enzymes conjugate small hydrosoluble molecules (amino 
acids, glutathione, glucuronic acids etc.) to the protein [20]. It also has immunological roles containing 
many active cells which destroy pathogens in the portal vein [20]. 
The liver plays important roles in the synthesis of proteins, hormones (such as insulin-like growth 
factor-1) and amino acids [20]. The liver produces albumin, which makes up 50% of the protein content 
of blood, along with various coagulation factors and antithrombin [20]. 
The liver plays a vital role in carbohydrate metabolism, storing glucose and other sugars as glycogen 
(section 1.1.2.1). It also plays several roles in fatty acid (FA) metabolism (section 1.1.2.2). It is these 
roles in the metabolism of carbohydrate and fat which are studied in the subsequent chapters. As well 
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as glycogen, the liver stores a vast range of other substances including vitamins A, D, B and K, iron and 
copper [20]. 
1.1.2.1 Glucose and Carbohydrate Metabolism 
Most carbohydrates and sugars are broken down to glucose in the digestive system before entering 
the blood stream in the intestine. Glucose is a simple monosaccharide that acts as the major source 
of energy for most cell types. After meals, glucose is absorbed into the blood stream whilst between 
meals, especially during exercise, sugars are utilised in organs and muscle for energy. Since these rates 
of input and consumption are not constant, excess glucose must be stored to stop the blood 
concentration rising above or falling below safe bounds. This storage occurs in liver and muscle cells 
where glucose molecules are attached to polysaccharide (glycogen) chains. 
When blood glucose levels are high, the hormone insulin is released by the pancreas prompting the 
liver to remove glucose from the blood stream. Glucose molecules are converted to glucose-6-
phosphate (G6P) by the enzyme glucokinase (GK) before the G6P is polymerised to glycogen by 
glycogen synthase (GS). Alternatively, G6P can also be converted to pyruvate through a process known 
as glycolysis (predominantly rate-limited by enzymes phosphofructokinase (PFK) and pyruvate kinase 
(PK)). Excess pyruvate is then converted to acetyl-CoA for use in oxidative ATP synthesis or lipid 
metabolism or released into the blood as lactate. 
When blood glucose levels are low, the hormone glucagon is released triggering the breakdown of 
glycogen to glucose. Similarly, during exercise catecholamines such as epinephrine promote glucose 
release. This breakdown of glycogen to G6P is mediated by glycogen phosphorylase (GP). This G6P is 
converted to glucose by glucose-6-phosphatase (G6Pase) before being released into the blood. 
Additionally, under the influence of glucagon, the liver converts lactate, pyruvate and certain amino 
acids to G6P in a process known as gluconeogenesis (predominantly rate-limited by enzymes 
phosphoenolpyruvate kinase (PEPCK) and fructose-bisphosphatase (FBPase)). 
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GS and GP, along with the key enzymes in both glycolysis and gluconeogenesis, can exist in active and 
inactive states depending on their phosphorylation. When insulin, glucagon and other hormones bind 
to surface receptors on a cell, it triggers a series of downstream effects which alter the 
phosphorylation state of these enzymes. Through this feedback loop between the liver and pancreas, 
blood glucose levels are maintained in a safe range. Furthermore, transcription of glucose metabolism 
enzymes is increased or suppressed when exposed to long term increased insulin or glucagon 
concentrations [20]. Zonation in glucose metabolism is discussed in detail in section 1.2, whilst each 
of the individual processes and their representations in the model are discussed in chapter 2. 
1.1.2.2 Fatty Acid Metabolism  
Although adipose tissue is the major tissue responsible for mediating blood free fatty acid (FFA) and 
triglyceride concentrations, liver plays important role in synthesizing triglyceride (combining three 
FFAs with a glycerol molecule) and releasing them into the plasma, predominantly as very low density 
lipoproteins (VLDL). Although the majority of fats in liver arise from uptake of circulating FAs, some de 
novo lipogenesis also occurs in hepatocytes [26]. When studied in the livers of patients with NAFLD, 
around 26% of the FAs contained in hepatic triglycerides and VLDL were produced in liver [26].  
FAs are taken up from the plasma by fatty acid transport proteins, FATP2 and FATP5 along with 
scavenger receptor CD36 and caveolins [27-33]. For de novo FA synthesis to occur, acetyl-CoA (and 
related malonyl-CoA) molecules, derived predominantly from sugars, proteins or previous FA 
oxidation, are combined into FA chains (under the influence of enzymes acetyl-CoA carboxylase (ACC) 
and fatty acid synthase (FAS)). This process is stimulated by insulin and inhibited by glucagon [34, 35]. 
However, de novo lipogenesis is counter-intuitively upregulated in insulin resistant livers [36-39]. 
Numerous FAs can be produced or absorbed from food with different chain lengths and with saturated 
and unsaturated tails. The most common of FA is palmitate in humans, plants animals and micro-
organisms comprised of the equivalent of 8 acetyl-CoA molecules [40], whilst the most common FA in 
adipose tissue is oleic acid [41, 42]. 
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Triglyceride synthesis (also promoted by insulin and glucagon) involves combining three FAs with a 
glycerol backbone for storage (rate-limited by enzyme glycerophosphate acyltransferase [43]). Post-
prandially, when FFA and glucose concentrations are high, triglyceride synthesis removes the FFAs 
from the blood stream preventing damage. The liver also utilises FFAs as its primary source of energy 
through β-oxidation [44]. Here the FA chains are broken down to acetyl-CoA, which can in turn enter 
the citric acid cycle to produce cellular ATP [20]. The liver also plays a major role in the production of 
ketone bodies and in cholesterol synthesis. Zonation in lipid metabolism is reviewed in section 1.2, 
whilst each of the individual processes their representation in the model are discussed in chapter 2. 
1.2 Zonation 
Zonation is the variation of enzyme expression and liver function between hepatocytes across the 
sinusoid. Almost all functions performed by the liver show zonation. In some cases a very specific 
group of hepatocytes in a particular location perform a function, whilst in other cases a more gradient-
like and variable distribution exists [45]. In section 1.2.1, the zonation of enzymes and functions 
involved in energy, glucose and lipid metabolism are reviewed. These follow the latter class of 
gradient-like changes in function across the sinusoid [45]. In section 1.2.2, possible mechanisms 
involved in the promotion of a zonated phenotype are discussed. Zone specific damage in liver disease 
is discussed in section 1.3.6. 
1.2.1 Zonation of hepatic enzymes and function 
1.2.1.1 ATP production through oxidative phosphorylation 
Adenosine tri-phosphate (ATP) is produced from adenosine diphosphate (ADP) and inorganic 
phosphate (Pi) through the electron transport chain (ETC) in the mitochondrial membrane of cells. The 
ETC relies on nicotinamide adenine dinucleotide (NADH) or flavin adenine dinucleotide (FADH) as well 
as oxygen to occur. Since transporting cytoplasmic NADH into the mitochondria consumes energy, the 
majority of the NADH and FADH required are generated through the degradation of acetyl-CoA in the 
citric acid cycle inside the mitochondria. Periportal hepatocytes contain a greater volume of 
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mitochondria [46], a larger mitochondrial membrane area [46] and increased concentrations of key 
enzymes involved in both the citric acid cycle [47] and the ETC [48], demonstrating that they have a 
higher capacity for generating energy through this mechanism. This is consistent with the observation 
that pericentral cells inhabit a low oxygen environment. If the ETC is active in the absence of oxygen, 
it can lead to the production of toxic metabolites such as the superoxide anion radical, hydrogen 
peroxide or the hydroxyl radical [45, 49]. Therefore, these cells contain less of the machinery for 
oxidative energy production to avoid producing reactive intermediates in the absence of oxygen as an 
acceptor [45, 50]. 
Due to the reduced oxidative phosphorylation in pericentral hepatocytes, they tend to produce acetyl-
CoA from glucose through glycolysis whilst periportal cells consume FAs through β-oxidation [45]. The 
breakdown of glucose to pyruvate through glycolysis produces a small amount of ATP without the 
requirement for oxygen. This pyruvate can then by converted to acetyl-CoA or released into the blood 
as lactate. Pericentral hepatocytes specialise in this process as an additional mechanism to produce 
ATP [45]. Generating acetyl-CoA from FAs meanwhile consumes a small amount of ATP. Periportal 
hepatocytes inhabit a higher oxygen environment and are able to generate sufficient acetyl-CoA from 
FA oxidation [45]. This is discussed in more detail in the following sections. 
1.2.1.2 Carbohydrate metabolism 
There is a bias for the glycogen stores in periportal hepatocytes to fill more quickly after feeding. 
However, glycogen is seen across the sinusoid, and the dominant section has been shown to vary from 
periportal to intermediate with feeding state [51].  
The mechanism by which glycogen stores are filled varies across the sinusoid [45]. These differences 
are related to the heterogeneity in oxidative energy metabolism described in the previous section. 
Pericentral cells cannot produce sufficient ATP through the citric acid cycle alone and instead 
specialise in processes that produce additional ATP. Periportal cells meanwhile inhabit the high oxygen 
environment near the periportal artery and can specialise in the more ATP intensive processes.  
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In the context of glycogen storage, pericentral cells tend to fill their glycogen stores from glucose and 
release them as pyruvate and lactate. This is because the conversion of glucose or glycogen to 
pyruvate and lactate through glycolysis results in the production of ATP without the requirement of 
oxygen. Periportal cells show higher rates of gluconeogenesis and glycogen synthesis from lactate, 
which requires ATP to occur. Periportal glycogen stores are then released as glucose. The high oxygen 
environment allows periportal cells to produce sufficient ATP through oxidative phosphorylation to 
fuel gluconeogenesis. Evidence for this glucose-lactate cycling across the sinusoid (figure 1.3) firstly 
comes from studies looking at the relative concentrations and activities of enzymes involved in 
glycolysis and gluconeogenesis across the sinusoid ([52-73] see chapter 2: table 2.2). A number of 
studies have also shown higher gluconeogenesis in periportal cells than in pericentral cells [73-78] and 
higher glycolysis in pericentral cells [77, 79] either using metabolic flux analysis in perfused whole 
livers or using cultured primary periportal and pericentral hepatocytes.  
 
Figure 1.3: Glucose/lactate cycling in the liver. 
Amino acids can also enter carbohydrate metabolism through conversion to intermediates in the citric 
acid cycle or to pyruvate or related molecules. Since periportal hepatocytes contain higher 
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concentrations of the components of both the citric acid cycle and gluconeogenesis, it is likely that 
these cells will specialise in both the catabolism of amino acids and the production of glucose from 
them (e.g. reviewed in [80])._+ 
1.2.1.3 Lipid metabolism 
The liver plays several roles the metabolism of lipids. FAs are broken down to form acetyl-CoA through 
β-oxidation. The majority of FFAs in the blood stream originate from dietary triglycerides or from 
adipose tissue [26]. However, the liver also synthesizes FAs from substrates such as glucose, lactate, 
amino acids and ethanol. Hepatocytes, along with adipose tissue, combine FAs and glycerol to form 
triglycerides and phospholipids. Hepatocytes also package triglycerides into VLDL and release them 
into the blood stream. The liver is the only organ responsible for the production of ketone bodies and 
the major organ responsible for cholesterol production [45].  
Zonation in lipid metabolism is less clearly defined than in oxidative energy and glucose metabolisms 
and tends to vary with feeding state. However, as a general trend periportal cells are more involved 
in uptake and β-oxidation of FAs [81-87], whilst pericentral cells are more involved in de novo synthesis 
of FAs from acetyl-CoA [45, 81, 83, 86-89] (in turn produced from glucose through glycolysis) and the 
production and release of triglycerides [83, 86]. There is some evidence that ketogenesis is specialised 
to pericentral cells (e.g. increased β-hydroxybutyrate dehydrogenase expression in pericentral region 
[81, 90]), whilst cholesterol synthesis is restricted to a small number of cells surrounding the periportal 
artery [45, 91]. 
Guzman et al, used isotope labelling to show that that that β-oxidation of palmitate (the most common 
FA) occurred 1.2 and 1.5 times as quickly in isolated periportal hepatocytes from fed and starved 
animals respectively compared to the isolated pericentral hepatocytes [87]. However, when refeeding 
after starvation and in cold-exposed animals the pericentral section became more prominent in β-
oxidation highlighting the flexibility in the zonation of lipid metabolism. Consistent with this, the rate 
of FA synthesis was higher in pericentral than periportal hepatocytes from fed and starved rats, whilst 
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the rate was higher in periportal hepatocytes in refed and cold-exposed animals [87]. Additionally 
Guzman and Castro showed that the rate of FA synthesis was 1.59 times higher in pericentral 
hepatocytes in the absence of hormones [83]. The rates of cellular and VLDL triglyceride, phospholipid 
and cholesterol production from FAs were all increased by 1.3-1.6 times in pericentral hepatocytes 
[83, 86]. Meanwhile, after liver perfusion with blood containing fluorescently labelled FAs, a higher 
signal was seen in periportal cells than in pericentral cells demonstrated increased uptake [92]. The 
triglyceride, phospholipid and cholesterol content of pericentral cells were slightly, but not statistically 
significantly, higher in this study. Zonation of key enzymes in lipid metabolism is discussed in chapter 
2 and table 2.2.  
1.2.1.4 Zonation in other liver functions 
Zonation is seen in almost all liver functions including ammonia detoxification, protective metabolism, 
xenobiotic removal and bile formation. For a detailed review of zonation in liver function see [45].  
1.2.2 Signals Promoting Zonation 
The following section reviews the possible signals responsible for promoting a zonated phenotype in 
vivo. These include blood based metabolites along with nervous input. 
1.2.2.1 Oxygen 
The most important of signal promoting zonated enzyme expression is oxygen [50]. The average 
concentration of oxygen falls from 65mmHg to around 35mmHg between periportal and pericentral 
ends of the sinusoid [69]. Oxygen is required for ATP production via oxidative phosphorylation [50]. 
Studies have shown that the blood oxygen concentration at which cells begin to lose some of their 
ability to produce ATP is around 20-30mmHg [69]. One study calculates the half maximum oxygen 
uptake to be 14mmHg [93]. Although the average oxygen concentration remains above this across the 
sinusoid, there is a radial gradient in concentration from the centre of the sinusoid to the plasma 
membrane of cells. The actual oxygen concentration reaching the cells was on average was measured 
to be 25mmHg [94]. Therefore, as an approximation, we might expect the average concentration at 
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the cell surface to fall from 32.5mmHg at the periportal end to 17.5mmHg at the pericentral end across 
the sinusoid. It is, therefore, beneficial for hepatocytes near the hepatic artery to specialise in more 
ATP intensive processes, whilst pericentral cells should specialise in those the produce ATP without 
the requirement of oxygen. 
In vitro experiments have demonstrated the importance of oxygen as a determinant of zonated 
enzyme expression. When cells are stored at higher oxygen concentration for 1-2 days in culture, it 
has been demonstrated that concentrations of PEPCK, an enzyme involved in gluconeogenesis, rise 
whilst concentrations of GK and PK, enzymes involved in glycolysis, fall [77]. It was also demonstrated 
that the rate of gluconeogenesis increases and the rate of glycolysis falls after pre-treatment 
increasing oxygen concentration (4->13% 02 in atmospheric gas) with the measurements being 
performed at equal oxygen concentrations. Furthermore, on a shorter time scale Nauck et al. showed 
that cells incubated in arterial oxygen concentrations show higher induction of PEPCK expression by 
glucagon than those incubated in venous oxygen concentrations [69]. It was also demonstrated that 
these increases results from increased synthesis rather than a change in the rate of degradation [45]. 
There is evidence to suggest that oxygen acts via reactive oxygen species (ROS), in particular hydrogen 
peroxide to provide a zonated phenotype [95]. Hydrogen peroxide is toxic substances created as a 
result of electron transfer in the oxidative phosphorylation chain. A smaller increase in expression of 
periportal enzyme PEPCK occurred as a result of increased oxygen concentrations when accompanied 
by an increase in catalase, the enzyme responsible for the conversion of the ROS hydrogen peroxide 
to water and oxygen [95]. Furthermore, it has been demonstrated that knocking out manganese 
superoxide dismutase, which catalyses the dismutation of superoxide to oxygen and hydrogen 
peroxide, leads to a loss of zonation [96].  
1.2.2.2 Substrates and Products 
There is evidence to suggest that zonated enzyme expression is linked with feeding state, most 
strongly in the enzymes mediating lipid metabolism (e.g. in lipogenesis [81, 88, 89] and β-oxidation 
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[81, 82]). Furthermore, it has been shown that in starvation, the prominent function of pericentral 
hepatocytes switches from glycolysis to gluconeogenesis [45, 97]. However, a full study of the effect 
of carbohydrates, lactate or fatty acids on enzyme expression has yet to be performed. Since oxygen 
and hormones are removed from the blood by hepatocytes across the sinusoid independent of feeding 
conditions, they are likely to provide stronger signal molecules for sustained zonation than metabolic 
substrates such as glucose which may be removed from or released into the blood by hepatocytes 
depending upon feeding conditions. 
1.2.2.3 Hormones 
The concentrations of insulin and glucagon are also thought to contribute to the development of 
zonation [45]. The rate at which insulin is removed across the sinusoid depends upon feeding state. 
Between meals the concentration falls by around 50% whilst postprandially only 15% of insulin is 
removed between periportal and pericentral sections [45]. The glucagon concentration meanwhile 
falls by around 50% independent of food intake [45]. As a result, a higher insulin to glucagon ratio is 
seen postprandially in pericentral than periportal cells consistent with their role in glucose uptake. 
As discussed by Jungermann et al. [45], if enzyme synthesis was induced by absolute hormone 
concentration alone we would expect all enzymes to be upregulated in the periportal section due to 
the fall in concentration of both insulin and glucagon across the sinusoid. The induction of enzyme 
synthesis must instead either be dependent on the relative concentrations of hormones or dependent 
on a modulator formed as the blood passes through the sinusoid.  
Some in vitro experiments suggest the former of these mechanisms. When hepatocytes are incubated 
with insulin alone, expression of GK increases [98]. However, when the cells are also incubated with 
glucagon, this induction is inhibited [98]. When hepatocytes are incubated with glucagon alone, 
expression of PEPCK is increased. In this case insulin and adenosine act as inhibitors [99-101]. It is 
therefore likely that the increasing insulin to glucagon ratio across the sinusoid is at least partially 
responsible for inducing the zonation enzyme expression. Furthermore, additional experiments have 
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looked at the overall gluconeogenic and glycolytic activity of cells incubated for 48 hours in varying 
quantities of either insulin or glucagon. In these experiments, incubation with insulin led to increased 
glycolysis whilst incubation with glucagon led to increased gluconeogenesis [77]. 
1.3 Liver Disease and Failure 
In 2014, 11,597 people in the UK died of liver disease making it the fifth biggest cause of death and it 
is the only major cause of death to rise year by year [102]. Liver conditions can broadly be split into 
two categories, those which gradually increase in severity over time, known as chronic, and those in 
which severe symptoms suddenly arise, known as acute. A third category, where a sudden insult 
occurs in an individual with chronic liver disease is known as acute on chronic. This report focusses on 
NAFLD, a slowly developing chronic form of liver disease, and its interaction with IR. 
1.3.1 Chronic Liver Disease 
Chronic liver conditions occur when the liver experiences repeated damage over a long period of time. 
This repeated process of injury followed by regeneration leads to fibrosis, cirrhosis and problems 
stemming from the inflammatory response. There can be numerous causes of this such as alcohol and 
substance abuse, hepatitis B and C or NAFLD. If the condition persists until liver failure occurs, the only 
current proven treatment is transplant. Due to the limited availability of organ donors, the waiting list 
can be up to a year for low risk chronic patients (average 140-150 days [103, 104]). Between 1st April 
2012 and 31st March 2013, only 52.7% of patients on the transplant list received transplants whilst 
5.4% of patients the waiting list died [105]. The development of treatments to provide an alternative 
to transplant, and to prevent the progression from early to late stage liver disease is therefore crucial. 
Numerous stages mark the progression of chronic liver disease. Steatosis, the build-up of excess fats 
occurs in the majority of liver diseases, including most notably NAFLD and excess alcohol consumption 
[106, 107]. Simple fatty liver alone is asymptomatic in the vast majority of patients but increases the 
probability of development of liver disease and cardiovascular disease [8, 106, 108].  
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Fibrosis is the development of excessive fibrous tissue (extracellular matrix proteins such as collagen), 
generally as a result of repeated damage and repair [109]. It is associated with a stiffening of the liver 
and can prevent blood flow to regions of the liver. Fibrosis is often accompanied by inflammation and 
liver cell ballooning, particularly in NAFLD and non-alcoholic steatohepatitis (NASH) [110]. 
Once sufficient fibrosis and cell death occurs such that the liver no longer functions properly, the 
condition is referred to as cirrhosis. The precise definition for the transition from fibrosis and cirrhosis 
is ill-defined. Liver failure causes fatigue, weakness, swelling in the lower legs, ascites (fluid build-up 
in the abdomen that often becomes infected), spider angiomas (spider-like blood vessels in the skin) 
and yellow skin due to defective bilirubin clearance [20]. Additionally, increased plasma 
concentrations of nitrogen and other molecules due to defective liver function cause damage and 
reduced function in the brain, known as hepatic encephalopathy [109]. This can results in confusion, 
coma and death [109]. 
1.3.2 Acute Liver Failure (ALF) 
Acute liver failure (ALF) results from the rapid loss of a large number of liver cells (80-90% of total cell 
mass) and leads to the sudden onset of severe symptoms. The most common cause of ALF in 
developed countries is paracetamol poisoning whilst in the developing world it is hepatitis [111]. Other 
causes include a wide range of viral infections, extreme alcohol abuse, idiosyncratic reaction to 
medication and causes linked to pregnancy. If ALF occurs in a patient with a chronic liver condition 
that was previously stable, it is known as acute-on-chronic liver failure (ACLF) [112]. While a small 
number of patients (~20%) will recover from ALF spontaneously, this is not true of the majority, and 
the only effective existing treatment is transplant [113]. 
1.3.3 Diabetes, IR and the Metabolic Syndrome 
1.3.3.1 Diabetes Mellitus 
Diabetes mellitus is the name given to a group of conditions in which either disrupted insulin release 
or reduced insulin reception lead to hyperglycaemia. Since insulin promotes glucose uptake, problems 
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in its release or detection result in dangerously high blood glucose levels post-prandially. Additionally, 
the lack of glycogen storage can then result in hypoglycaemia and diabetic coma between meals. 
Standard tests for diagnosis of diabetes include a fasting blood glucose concentration of greater than 
7mM or a concentration of greater than 11mM two hours after a 75g oral glucose tolerance test [114]. 
Diabetes mellitus can be split in to two categories; type 1 diabetes mellitus (or insulin-dependent 
diabetes mellitus) resulting from deficient insulin production by the pancreas and type 2 diabetes 
mellitus (T2DM or non-insulin-dependent diabetes mellitus) resulting from problems with insulin 
reception. Type 1 diabetes results from loss of pancreatic β-cells, often caused by infection in 
genetically susceptible individuals [115]. 
T2DM is largely associated with lifestyle factors such as obesity and lack of exercise as well as genetic 
susceptibility[116]. Sustained increased FFA, glucose and insulin concentrations cause damage to 
hepatic insulin reception leading to decreased glucose uptake. This triggers a feedback cycle in which 
increased plasma FFA and glucose concentrations cause to worsening insulin release causing further 
hyperglycaemia, hyperlipidaemia and hyperinsulinaemia. 
As of 2014, 3.2 million people in the UK, 32 million people in Europe and 29.1 million people in the 
USA were estimated to suffer from T2DM. Additionally, the number of people showing signs of 
‘prediabetes’ increased from 10% to 33% in the UK between 1996 and 2011, and from 79 million to 
86 million in the USA between 2010 and 2012 [1-5]. 
1.3.3.2 Metabolic Syndrome 
Metabolic syndrome is the name given to a broader range of conditions associated with dysfunction 
of energy, lipid and carbohydrate metabolism. It is associated with lifestyle as well as genetic factors 
and is strongly linked with the development of heart disease and T2DM. Criteria for diagnosing 
metabolic syndrome vary but generally patients are required to show three of the following 5 
conditions with varying definitions of the severity required: obesity, diabetes or hyperglycaemia, 
hypertriglyceridaemia, reduced HDL-cholesterol and raised blood pressure [114, 117-120]. 
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Prevalence of the metabolic syndrome is the U.S has been estimated to be as high as 34% [121]. If the 
disease is still in its early form, the major treatment is lifestyle change. Later interventions tend to 
focus on treatment of the individual conditions and some publications have questioned the usefulness 
of grouping the disorders under one name [122, 123]. 
1.3.4 NAFLD and NASH 
NAFLD is the abnormal retention of lipids in liver in the absence of alcohol abuse, drug abuse or viral 
infection [8]. As of 2004, prevalence of NAFLD in the United States was around 34% [124-126]. 
Similarly as of 2014, 25-30% of the UK adult population were thought to suffer from the condition [6] 
(30-40% in men and 15-20% in women [8, 124]). These numbers continue to rise year on year, and 
there is considerable overlap with patients showing ‘prediabetes’, which increased from 10% to 33% 
between 1996 and 2011 in the UK [1-3]. It is also becoming the most common cause of liver disease 
amongst children [127]. 
As discussed below, NAFLD can progress to NASH which can result in fibrosis, cirrhosis and liver failure. 
It is estimated that 30-40% of NAFLD progresses to NASH [108], which is associated with development 
of fibrosis in 40-50% of patients [108], cirrhosis in 20% of patients and liver-related death in 12% [6, 
7]. Even in the absence of cirrhosis, NASH is associated with hepatocellular carcinoma [8-11], cardiac 
diseases [12], chronic kidney disease [13] and a range of further conditions [8, 14]. A meta-analysis 
study has suggested that, depending on the severity of fibrosis, NASH increases the probability of liver 
related death 5-10 fold [12]. It has additionally been suggested that NASH may also be responsible for 
many cases in which cirrhosis occurs with unknown causes [128, 129]. In terms of population, it is 
thought that 2-5% of adults in the UK suffer from NASH [1, 12].  
The risk of mortality to each individual suffering from NAFLD is comparatively low (one study 
suggested a 57% increase in mortality in NAFLD individuals relative to individuals without hepatic 
steatosis largely due to liver failure or cardiovascular disease [12]), and the majority of patients are 
asymptomatic. However, due the vast prevalence of the disease, it has been predicted that NAFLD will 
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become the major cause of liver transplant by 2030 [8]. Even as of 2009, NASH was the third biggest 
cause of liver transplant in the United States, accounting for 10% of total transplants [130]. 
1.3.4.1 Risk Factors 
1.3.4.1.1 Insulin Resistance and T2DM 
NAFLD is strongly linked with IR, the metabolic syndrome and T2DM [18, 131-134]. The presence of 
IR, the metabolic syndrome and T2DM all increase the risk of NAFLD [135-137], and the presence of 
NAFLD increases the risk of T2DM (section 1.3.4.2.2). Around 70% of T2DM sufferers show excess liver 
fat [8, 138].  
IR leads to increased plasma FFA and triglyceride concentrations resulting in increased lipid uptake 
into hepatocytes [139, 140]. IR in liver and muscle cells causes deficient glycogen synthesis, increasing 
the glucose concentration as a substrate for lipogenesis [139, 141]. Even in insulin resistant patients, 
insulin stimulation of lipogenesis appears to remain intact, further increasing the production of fats 
from sugars (see chapter 3) [36-39]. Additionally, IR in adipose tissue prevents insulin stimulation of 
triglyceride synthesis and inhibition of lipolysis in these tissues. This results in fats stored in adipose 
tissue being broken down and released into the plasma FFAs, which can then enter liver cells [142, 
143]. It has been shown that diabetic individuals are 3 times more likely to die of liver failure than 
non-diabetics [144], and it has been suggested this is predominantly due to the increase NAFLD 
prevalence [8]. It should be noted, however, that many individuals with NAFLD are neither diabetic 
nor obese, and understanding the condition across the range of patients is vital to developing effective 
therapies [145, 146]. 
1.3.4.1.2 Obesity and Exercise 
Obesity is strongly linked with the development of NAFLD. Firstly, the amount of fat in the liver 
correlates with percentage fat mass and BMI [147-154]. In obese individuals, higher plasma FFA 
concentrations result in increased uptake of FFAs in liver and muscle [146, 155]. NAFLD is also linked 
with high calorie intake, particularly with a high fat content [6, 18, 133]. In addition to overall adipose 
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tissue mass, the type of adipose tissue in an individual affects their probability of developing NAFLD. 
Liver fat shows an even stronger correlation with visceral fat mass than overall adiposity [147-152]. 
Visceral adipose tissue is both more active and less insulin sensitive than subcutaneous adipose tissues 
and performs lipolysis and lipogenesis at faster rates [156-160]. This contributes to an increased 
plasma FFA concentration, redirecting fats to liver and muscle. Numerous studies have demonstrated 
that increased hepatic lipid supply arising from either dietary intake or adipose tissue contribute 
significantly to hepatic steatosis [155, 158, 161, 162].  
Adipocytes in obese individuals additionally release inflammatory cytokines such as tumour necrosis 
factor alpha (TNFα) and interleukin-6 (IL-6) and show reduced adiponectin release [163-167]. Although 
the role of cytokines and hormones in NAFLD and NASH development is not yet fully understood, the 
suppression of adiponectin release in particular is thought to have an effect on liver and muscle fat, 
where TNFα and IL-6 have a largely paracrine effect (within the adipose tissue) [155, 161, 165].  
Regular physical exercise shows a negative correlation with liver fat mass, although it is not known 
whether this results from reduced visceral adipose mass rather than a direct effect [153, 154, 168, 
169].  However, it has been suggested that exercise may metabolise lipids in muscle cells and promote 
non-insulin dependent glucose uptake, reducing IR both in muscle and around the body independent 
of weight loss [155, 168-172]. Aerobic fitness and mitochondrial function have been shown to 
inversely correlate with liver fat percentage and prevalence of NAFLD [172-176]. 
1.3.4.1.3 Lipoatrophy: 
Despite the strong link between visceral fat mass and hepatic steatosis, NAFLD has been shown to 
develop in a notable percentage of lean individuals [145]. In a study by Wong et al, fatty liver was 
shown to develop in 8% of the individuals whose BMI was below the overweight threshold (23kg/m) 
at both baseline and follow up [153]. Similarly, Xu et al. studied the incidence of NAFLD in non-obese 
Chinese individuals. At baseline, NAFLD was measured in 7.27% of 6905 individuals [177]. Of 5562 lean 
individuals who did not show signs of NAFLD at baseline, 8.8% had developed the condition after 5 
32 
 
years [177]. In the US, 11613 individuals who did not frequently consume alcohol were assessed for 
NAFLD and NASH. 431 of 4457 normal weight individuals were observed to suffer from NAFLD 
compared with 2061 of 7156 overweight or obese individuals [178].  
NAFLD does show a strong correlation with obesity, but given that a sizeable number of lean 
individuals develop NAFLD whilst many obese individuals show healthy liver fat content, additional 
factors must be considered. It has been hypothesized that the underlying factor causing the 
development of NAFLD is the inability to store excess plasma lipids correctly within adipose tissue, 
rather than the presence of excess adiposity itself [146]. As discussed above, it is particularly increased 
mass of the less insulin sensitive visceral adipose tissue which correlates with NAFLD. Therefore, it 
may be an excess of this less insulin responsive adipose tissue that causes improper storage of plasma 
FFAs and a build-up of fats in other organs around the body such as liver and muscle. Consistent with 
this, lipoatrophic mice lacking adipose tissue develop hepatic steatosis and IR [179, 180]. 
Transplantation of white adipose tissue protects against these factors [180]. It has been shown that 
FATPs and CD36 (proteins involved in FA uptake) both show increased hepatic expression but reduced 
adipose expression in individuals with NAFLD, compared with individuals of the same weight group 
without fatty liver [146, 181, 182].  
Reduced overall activity of proliferator-activated receptor gamma (PPARγ), a protein which promotes 
adipose FA uptake, leads to increased susceptibility to NAFLD [183] whilst liver specific knockout of 
the protein protects against excess liver fat [184, 185]. This is consistent with the idea that it is not 
just excess fat, but the incorrect storage of excess fat which cases NAFLD. It should be noted that lean 
NAFLD patients show higher mortality than obese NAFLD, and treatment options for resolving NAFLD 
across the range of patient weights must be developed [186]. 
1.3.4.1.4 Genetics 
Genetic variability is involved in the progression of NAFLD in the susceptibility to the build-up of fats 
in liver, the development of fibrosis and the rate of progression to cirrhosis. A brief review of the role 
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of genetics in NAFLD susceptibility is provided here. For more information see recent reviews by 
Anstee et al. [187, 188] and Marzuillo et al. [189]. No single gene has been identified as mediating 
NAFLD risk alone, and instead inter-individual variability results from the combined effect of common 
polymorphisms identified by both genome-wide association studies (GWAS) and candidate gene 
studies [187, 188]. However, across a range of studies two genes have been repeatedly highlighted as 
strongly associated with NAFLD; patatin-like phospholipase domain-containing protein 3 (PNPLA3) 
and transmembrane 6 superfamily member 2 (TM6SF2) [187, 188]. 
The Met148Ile allele of (PNPLA3), which is prevalent in Hispanic populations [190], has been linked 
with the development of NAFLD and IR [187, 188, 191-193]. A second SNP in the same gene has also 
been implicated. The mechanism by which this polymorphism of PNPLA3 alters hepatic liver 
triglyceride levels is unknown and the gene is likely to have wide ranging functions [146, 155, 187, 
188]. However, it is thought to play a role in fatty-acid selective hepatic triglyceride remodelling [194]. 
PNPLA3 SNPs are not only associated with altered liver triglyceride content but also severity of 
steatohepatitis and fibrosis. 
A number of studies have shown an association between a TM6SF2 SNP and both hepatic triglyceride 
content and the development of fibrosis [187, 188]. As with PNPLA3, the role of TM6SF2 has yet to be 
fully elucidated. However, the current hypothesized role of TM6SF2 is in hepatic VLDL assembly, 
suggesting reduced removal of triglycerides from liver [189, 195].  
In addition to these two genes, NAFLD is associated with a wide range of common polymorphisms 
with roles in insulin sensitivity, carbohydrate metabolism, lipid metabolism, alcohol metabolism, 
oxidative stress, inflammation and fibrosis amongst others [187, 188].  
1.3.4.1.5 Hormones: 
It has been suggested that imbalance of several hormones may play a role in the development of 
hepatic steatosis. Hyperinsulinaemia and IR are both involved in the development of fatty liver [196, 
197]. Insulin largely stimulates lipogenesis in hepatocytes through the action of sterol-regulatory 
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element binding protein 1c (SREBP-1c), which mediates expression of numerous FA and triglyceride 
synthesis enzymes [155, 158, 198]. However, as discussed in chapter 3, a counterintuitive increase in 
SREBP-1c expression is seen in insulin resistant and steatotic livers suggesting that this pathway 
continues to contribute to de novo lipogenesis [36-39]. However, it has been shown that sustained 
supplementary provision of insulin in hyperinsulinaemic T2DM individuals lowers rather than raises 
liver fat content [199]. An additional protein to SREBP-1c in stimulating this lipogenesis is the 
carbohydrate response element-binding protein (ChREBP), which is activated by hyperglycaemia and 
has similar stimulatory effects to SREBP-1c. In mouse models of NAFLD, both SREBP-1c and ChREBP 
show increased activity [36-39, 200]. 
Plasma adiponectin concentration negatively correlates with liver fat and hepatic IR [152, 201-203] 
while polymorphisms in the adiponectin receptor gene have been linked to variation in both hepatic 
fat content and IR [30]. Despite being released by adipocytes, plasma adiponectin concentration 
negatively correlates with adipose tissue mass. Adiponectin promotes lipid oxidation in liver and 
skeletal muscle via AMP-activated protein kinase (AMPK), whilst decreasing the activity of ACC and 
FAS [167, 204-206]. This provides an additional link between hepatic fat content and obesity via 
plasma FFA concentrations [207]. The drug pioglitazone (a thiazolidinedione) has been shown to both 
increase circulating adiponectin and reduce hepatic fat content in NAFLD individuals, although this 
may have additional mechanisms of action beyond stimulating adiponectin release [208]. 
Leptin, also produced in fat tissue, may also play a role in reducing hepatic steatosis. Beyond its role 
in reducing appetite and food intake, the hormone is also thought to have direct effects on lipogenesis 
and lipid oxidation [155, 209]. However, the magnitude of these effects relative to those of other 
hormones such as insulin and adiponectin are currently not known. 
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1.3.4.2 Consequences of NAFLD 
1.3.4.2.1 Progression to NASH, Fibrosis and Cirrhosis 
Early stage NAFLD is generally diagnosed when the liver fat concentration is greater than 5% after 
alcohol abuse, drug abuse and viral infection have been rules out as causes, although a higher 
threshold of 5.6% has been suggested based on the 95th percentile [15, 210, 211]. Once steatohepatitis 
develops, the condition is referred to as NASH. NASH is diagnosed when the presence of inflammation 
and hepatocellular ballooning is detected in addition to steatosis [212]. Around 30-40% of NAFLD 
patients progress to NASH [108]. 40-50% of NASH patients develop fibrosis [108], 20% develop 
cirrhosis and liver-related death occurs in 12% [6, 7].  
Since NAFLD and NASH are generally asymptomatic in their early stages, diagnosis of both conditions 
tends to be notably delayed relative to onset. In general, measurements of individual biochemical 
markers do not allow for an effective judgement of the severity of lipid build-up in an individual [213]. 
The most accurate method of assessing NAFLD/NASH severity is biopsy [213]. However, this is 
inherently invasive and is not recommended for asymptomatic, incidentally discovered NAFLD [213]. 
Instead liver fat content is often measured using non-invasive imaging techniques (e.g. [214-224]).  
Hepatic steatosis may progress to inflammation and steatohepatitis through a number of mechanisms 
[155]. Increased oxidative stress is seen in humans with NASH [225], which has been suggested to 
stimulate an inflammatory responses and mitochondrial dysfunction [155, 165, 226]. It has been 
shown that increased lipid availability is associated with a reduction in insulin stimulated ATP synthesis 
in muscle in obese and non-obese individuals [227]. Similarly it has been shown that hepatic ATP 
synthesis is lower in T2DM individuals, who were also demonstrated to have high hepatic fat content, 
than controls [228]. It is therefore possible that the progression from NAFLD to NASH results from a 
combination of inflammatory responses, reduced mitochondrial function, mitochondrial stress and 
the build-up of ROS [229, 230]. 
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Changes in the microflora of the gut may promote inflammation through an effect on liver 
macrophages, the Kupffer cells [155]. NAFLD patients are more likely than controls to show intestinal 
bacterial overgrowth [231, 232]. Gut bacterial overgrowth results in both ethanol and bacterial 
lipopolysaccharide production [233]. Both of these molecules stimulate the production of pro-
inflammatory cytokine TNF-α in Kupffer cells [155, 234]. Furthermore, alterations to the microbiome 
of the gut have been shown to reduce liver inflammation [235-238].  
1.3.4.2.2 IR and T2DM 
As discussed, diabetic individuals are far more likely to suffer from NAFLD than metabolically normal 
individuals. Furthermore, it has been shown in a large number of studies that individuals with excess 
liver fat are more likely to develop hepatic IR, peripheral IR and T2DM [150, 214-224, 239-243]. A 
number of these studies have shown that increasing severity of pre-existing NAFLD increases this risk 
of T2DM development [8, 218, 221, 223, 224]. It has also been shown that risk of incident T2DM 
returns to baseline in individuals who had pre-existing fatty liver, but whose liver fat percentage 
returned to a healthy level over a 5 year trial [224]. Similarly, individuals whose liver fat percentage 
increased over the period showed an increased risk of incident T2DM development [224]. This 
demonstrates a clear benefit to NAFLD patients of reducing steatosis level. NASH patients are more 
likely to develop T2DM than NAFLD patients. In a study by Ekstedt et al., over a 13.7-year period 71% 
of individuals who suffered from NASH at the start of the study went on to develop T2DM period 
compared with 46% of individuals who suffered from NAFLD (p=0.01) [108]. In this study, NAFLD and 
NASH score were assessed by biopsy rather than non-invasive imaging, allowing greater confidence in 
the measurements [108]. As well as hepatic IR, hepatic steatosis is also associated with whole-body IR 
independent of visceral fat mass [240, 244-246].  
Although hepatic fat build-up, predominantly in the form of triglycerides, is associated with increased 
risk of T2DM and other conditions, triglycerides are generally considered to be a less potent form of 
fat in promoting progression to NASH and IR. Instead, the adverse effects are thought to arise due to 
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the FAs themselves (in particular palmitic acid) [247], ceramides [248] and diacylglycerides (DAGs) [8, 
146]. It is thought that the protein kinase C (PKC) family of kinases enzymes play a key role in the 
development of IR as reviewed in Birkenfeld et al [146]. In particular, PKCε is highly expressed in liver. 
PKCε knockout mice are protected against IR when fed a high fat diet leading to steatosis [249]. There 
is some evidence to suggest that this may involve DAGs [8, 146]. In particular, DAGs in contact with 
the plasma membrane of hepatocytes, rather than in lipid droplets or endoplasmic reticulum [250]. 
DAGs are an intermediate in the sequential addition of three FAs to a glycerol backbone in triglyceride 
synthesis. In a liposyn (intravenous fat emulsion) plus heparin infusion rodent model, muscle IR 
developed and protein kinase C-θ (PKC θ) became active before any changes in triglyceride or 
ceramide concentration, but at roughly the same time as the DAG concentration increased [251]. 
Similar results are seen in liver, where hepatic IR develops after DAG concentrations begin to rise and 
is accompanied by activation of PKCε [252]. This was accompanied by reduced glycogen synthesis as 
a result of reduced activity of insulin receptor kinase. This hepatic IR was noted before the onset of IR 
elsewhere in peripheral tissues [252]. However, DAGs are not thought to be the solely responsible for 
the development of inflammation and IR, and a number of molecules both derived from FAs and the 
FAs themselves are likely to contribute [247, 248, 253-259].  
The link between the development of hepatic IR in NAFLD and the subsequent development of 
peripheral IR has yet to be fully understood. However, numerous hepatokines may be involved 
including retinol binding factor protein 4, fetuin A, fibroblast growth factor 21 or markers of 
inflammation such as IL-6,  TNFα or C-reactive protein [260]. 
1.3.4.2.3 NAFLD and Hepatocellular Carcinoma 
Obesity and T2DM are strongly linked with the development of hepatocellular carcinoma [261]. 
Similarly, NASH, and possibly NAFLD, are linked to increased susceptibility to hepatocellular carcinoma 
[9-11, 262]. This may occur as a result of the inflammation and metabolic stress common to both NASH 
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and T2DM patients. Furthermore, changes in the microbiota have been suggested as playing a 
potential role (discussed in [8]). 
1.3.4.2.4 NAFLD and Cardiovascular Disease 
It have been demonstrated that individuals with excess liver fat, with or without diabetes, are at 
greater risk of cardiovascular disease after other CVD factors have been accounted for [263-274]. 
Consistent with this, a meta-analysis of several cross-sectional studies showed an increase in several 
markers of atherosclerosis in individuals of NAFLD independent of other CVD risk factors [275]. As 
reviewed in Byrne et al. ([8]-table 2) around 20 retrospective and prospective studies show an overall 
trend of increased CVD risk in individuals suffering from NAFLD and NASH. In particular, the studies in 
which NAFLD presence and severity were assessed by biopsy rather than non-invasive imaging 
demonstrate an increase in risk of mortality resulting from both CVD and liver failure (along with 
overall mortality) in individuals with NAFLD [108, 276-281]. The presence of fibrosis has been 
highlighted as a particular determinant of risk of mortality [8]. 
Non-obese non-diabetic and diabetic adults with NAFLD have been shown to suffer from a higher risk 
of disturbed myocardial energy metabolism, cardiac steatosis, myocardial IR and (in most but not all 
studies) left ventricular diastolic dysfunction [282-290] than adults without excess liver fat. 
Additionally recent studies have suggested an association exists between NAFLD and both cardiac 
arrhythmias [291-296] and aortic valve sclerosis [289, 297-299] independent of other known risk 
factors (reviewed in [8]). 
The mechanism linking NAFLD and CVD has yet to be fully established. Although it has yet to be 
conclusively shown that NAFLD is causative in the development of CVD rather than simply a marker, 
based on the strength and consistency of the data it is generally considered that this is the case [8]. It 
has also yet to be demonstrated that reducing hepatic liver fat content results in a reduced risk of CVD 
in individuals with pre-existing NAFLD.  
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1.3.4.2.5 NAFLD and Chronic Kidney Disease 
Excess liver fat is additionally associated with increased prevalence of chronic kidney disease (CKD) in 
both diabetic and non-diabetic individuals [13, 300-313]. Furthermore, increased severity of NAFLD is 
associated with increased severity of CKD [306-309]. As with CVD, a causative link between NAFLD and 
CKD has yet to be demonstrated, and it has not yet been investigated whether improvement in hepatic 
lipid levels results in an improvement in either incident CKD risk or severity of pre-existing CKD. As a 
result, further large-scale studies with long follow-up periods are required to investigate these links. 
1.3.5 Current Treatment of NAFLD 
Despite the vast prevalence of NAFLD and the large number of deaths and liver transplants associated 
with it, as of 2016, there is no approved drug for the treatment of NAFLD or NASH [314]. Historically, 
liver fat was considered to be benign and large scale population studies (reviewed above) were 
required to demonstrate that excess liver fat (both in diabetic and non-diabetic individuals) is 
associated with an increase in risk of both liver failure-related and overall mortality. As discussed by 
Ratziu et al. [314], NAFLD has also often been considered a complication of diabetes and therefore 
would be treated by anti-diabetic drugs. However, metformin, sulfamides and insulin are ineffective 
in treating NASH [314] and, although diabetes greatly increases the risk of NAFLD, many individuals 
with excess liver fat are not diabetic. At present the only effective methods of treating NAFLD are 
improvement in diet and increased exercise. However, obese patients requiring treatment for NAFLD 
and NASH often have a long history of failed attempts at changes in diet and exercise such that the 
resources and expertise required to ensure successful sustained weight loss and increased exercise 
are often not feasible [314-316]. Additionally, as discussed in section 1.3.4.1.3, a significant proportion 
of NAFLD sufferers are neither obese nor diabetic. As reviewed  below (and in detail by Ratziu et al. 
[314]), some potential drug target pathways have shown the potential to reduce hepatic damage in 
mouse models of insulin resistant NAFLD. However, when tested in humans these have been 
ineffective. These include anti-TNFα, PDE4 inhibitors, selective caspase inhibitors, resveratrol and 
omega 3 FA preparations [304, 317-320]. 
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1.3.5.1 Dietary and Lifestyle Change 
1.3.5.1.1 Physical exercise 
Exercise has been shown to reduce hepatic fat content even in the absence of overall weight loss 
[321], although the effects on fibrosis and cirrhosis in later stage NASH have yet to be fully explored. 
Exercise also has known effects on IR, T2DM and hypertension [322, 323]. People who regularly 
exercise are less likely to develop NASH and NASH-derived fibrosis [322, 324].  
Type and duration of exercise are also important, with cardiovascular exercise more effective than 
walking [322, 324]. Particular benefits have also been noted for resistance training [325, 326] despite 
no overall change in weight and adipose distribution [326]. It is thought this may result from the 
removal of fats from muscle and liver, where they are known to promote IR. Finally, minimising 
sedentary time has been shown to improve insulin sensitivity [327, 328]. 
However, NAFLD is associated with fatigue such that compliance with increased exercise plans can be 
low [314]. Furthermore, many individuals are unable to put additional stress on their cardiorespiratory 
system [148, 314, 325]. 
1.3.5.1.2 Dietary changes and weight loss 
Given that NAFLD is strongly linked with obesity, excess calorie intake and over/under consumption 
of specific foods, it is unsurprising that dietary change has been demonstrated to provide an 
improvement in severity of NASH. In a randomised control trial (RCT), intensive lifestyle intervention 
was shown to be a significantly more effective treatment for NASH patients than standard education 
on how to lead a healthy lifestyle (67% resolution vs 20%; p=0.02) [329]. Additionally, it was 
demonstrated that, in either group, a 7% loss of weight correlates with an improvement in 
physiological score. A second RCT, conducted in diabetic individuals, also showed improvements in 
hepatic fat content as measured by non-invasive imaging after dietary intervention and exercise [330]. 
Peterson et al. demonstrated that small amounts of weight loss are associated with an improvement 
in insulin sensitivity and reduction in liver fat [239]. Another study by Suzuki et al. showed that weight 
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loss is associated with a reduced plasma alanine aminotransferase (ALT) concentration, a marker of 
liver injury [154]. 
Substantial weight loss following bariatric surgery is associated with improvements in liver steatosis, 
fibrosis and even cirrhosis in morbidly obese individuals [165, 331-333]. Reductions in pro-
inflammatory molecules released from adipose tissue have also been demonstrated on weight loss 
[165, 334]. 
Some data exists to suggest that the dietary composition, rather than solely caloric intake, is important 
in the development of NAFLD. Firstly, it is thought that a diet containing higher amounts of 
polyunsaturated and monounsaturated FAs can improve hepatic steatosis in the absence of weight 
loss [335]. A number of studies have suggested that increased fructose intake is linked with increased 
liver fat and hepatic de novo lipogenesis [336-339]. However, other studies have suggested that 
fructose is no more damaging than alternative sugars [340-343]. High intake of saturated fats, 
cholesterol and meat are common amongst NAFLD patients along with low intake of vitamins and 
omega-3 FAs [314, 344-347]. Some trials have investigated the impact of omega-3 FA supplements 
and of L-carnitine supplements on NAFLD with variable results in both cases (reviewed in Ratziu et al. 
[348]).  
1.3.5.1.3 Problems with lifestyle change as a therapy 
It is clear that both weight lost and increased exercise (even in the absence of weight loss) are 
beneficial both in preventing the development of NAFLD. However, the major problem with lifestyle 
change as a treatment is the known low-compliance of individuals, even when incentivised in clinical 
trials [314-316, 349]. Increasing this compliance rate would require considerable resources unfeasible 
for most hepatology centres [314, 316]. As a result, given the increasing prevalence of NAFLD and its 
cost to health services, alternative therapies must be considered. 
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1.3.5.2 Pharmacological Intervention 
As discussed, no approved drug exists for NAFLD or NASH. When considering NAFLD, any 
pharmacological treatment should focus on removing the lipids from the liver. When considering 
NASH, it may also be desirable for a pharmacological intervention to have anti-fibrotic effects. 
However, sustained removal of excess fats from liver cells alone is likely to lead to an improvement of 
fibrosis. A drug focussed purely on reducing fibrosis without removing steatosis may lead to some 
short-term improvements in liver histology, but would not remove the fundamental cause of 
fibrogenesis. 
The largest scale trial to be performed for a NAFLD/NASH drug so far tested the effects of pioglitazone 
and vitamin E over 96 weeks in 247 individuals without diabetes [350]. Pioglitazone (a 
thiazolidinedione) is an insulin sensitizers which act primarily on adipose tissue [351]. 
Thiazolidinediones promote expansion of insulin sensitive adipose mass which, despite causing weight 
gain, also directs fats away from tissues such as liver muscle and heart where they are known to cause 
most damage [351-354]. Thiazolidinediones also promote adiponectin release which stimulates β-
oxidation in liver and muscle [206, 355]. Vitamin E, meanwhile, is an antioxidant, reducing the 
production of ROS during β-oxidation and preventing the resulting mitochondrial toxicity as well as 
blocking apoptotic pathways [356-358]. 
Pioglitazone treatment caused a higher rate of improvement of NASH (34% vs 19% resolution; p=0.04), 
reduced ALT and (aspartate aminotransferase) AST, improved lobular inflammation and steatosis, 
partially improved IR but failed to cause an improvement in fibrosis score compared to placebo [350]. 
As would be expected from the drug’s action on adipocytes, weight gain was also seen with 
pioglitazone compared with placebo [350]. Similar results have been reported in two smaller trials 
[359-361]. 
Unfortunately however, side effects have been noted with pioglitazone use. Firstly, the increased 
adipose proliferation and weight gain is undesirable, particularly since this often remains after an 
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individual ceases to take the drug [314, 362]. Pioglitazone is not available in parts of Europe due to 
concerns that it may raise the risk of bladder cancer, although this was not seen in large scale studies 
[361, 363, 364]. An increase in the rate of bone fractures in the hands, feet and upper arms of women 
has been noted for the drug. An additional major concern of pioglitazone as a treatment is that the 
benefits of Pioglitazone use on steatohepatitis, insulin sensitivity (HOMA) and liver damage (ALT) do 
not remain after termination of the treatment [365]. 
Vitamin E also cause an increase in the rate of resolution of NASH (46% vs 19%), improvements in ALT 
and AST, improvements in lobular inflammation and hepatic steatosis relative to placebo but no 
significant improvement in fibrosis score. No significant difference in weight gain was seen between 
the placebo and vitamin E groups. Additionally, in a paediatric trial vitamin E caused an improvement 
in resolution of NASH compared with placebo (58% vs 28%) but did not improve steatosis, fibrosis, 
inflammation of ALT [362]. In this case vitamin E, therefore, reduced the hepatic damage caused by 
NAFLD but did not remove the underlying cause itself [362].  
It should be noted that the positive findings in these two studies are countered by alternative studies 
demonstrating no benefit from vitamin E consumption [366]. It has therefore yet to be fully proven 
that vitamin E has a positive effect on NAFLD [348]. Furthermore, fairly severe negative side effects of 
vitamin E consumption have been suggested in the literature including increased overall risk of 
mortality [367], increased risk of stroke [368] and increased risk of prostate cancer in over 50 year 
olds [369]. There are also concerns that at high doses vitamin E may act as a pro-oxidant [370]. 
An additional insulin sensitizer tested for use in NAFLD/NASH treatment is metformin. Metformin is a 
biguanide used in the treatment of T2DM due to its action in suppressing hepatic gluconeogenesis 
[371]. However, it has been demonstrated to have little effect on hepatic steatosis and NASH [213] 
(for review see Ratziu et al. [348]). Similarly there is no data to suggest that statins, commonly 
prescribed to reduce low density lipoprotein (LDL)-cholesterol levels, are beneficial to NAFLD/NASH 
other than a possible slight reduction in steatosis [213, 348, 372]. 
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Some data exists to suggest that bile acids, and particularly Ursodeoxycholic acid (UDCA) may be 
effective in treating NAFLD. However, in relatively small scale trials, treatment with UDCA has shown 
variable results [348]. UDCA, therefore, requires a large-scale, well designed RCT to assess its impact 
in NAFLD and NASH.   
Obeticholic acid, a farnesoid X receptor agonists, has recently been tested in a clinical trial involving 
283 NASH patients [373]. It was associated with improvement in histological features of NASH, but its 
long-term efficacy and safety as a treatment require further study [373]. Additionally, synthetic 
farnesoid X receptor agonists aiming to mimic the effects of bile acids are in development [213]. 
Pentoxifylline, a phosphodiesterase inhibitor, has been shown to have a beneficial effect on NASH in 
animal models [374]. Additionally, in a small RCT, pentoxifylline was demonstrated to improve 
histological features of NASH, steatosis and NAS score. [375].  However, a large-scale human trial is 
still lacking [348]. 
Recent review papers have addressed treatment currently in development for NAFLD [314, 376]. 
1.3.6 Zonated Damage in NAFLD 
Numerous studies have reported that pericentral cells tend to be most susceptible to triglyceride 
build-up in both NAFLD and alcoholic fatty liver disease (AFLD) [15-17]. Additionally, the inflammation 
and fibrosis tend to be more severe towards the pericentral end of the sinusoid [15-17, 377-379].  
Although pericentral centred steatosis is widely reported in NAFLD, the causes of the zonation in fat 
build-up are not fully understood, and this forms the focus of the simulations run in chapter 3. Since 
pericentral cells show higher rates of in insulin stimulated lipogenesis whilst periportal cells show 
higher rates of FFA uptake, periportal-centred steatosis might be expected in NAFLD given the context 
of insulin resistance and increased plasma FFA levels. However, it is thought that insulin may continue 
to stimulate lipogenesis through transcription factor SREBP-1c  despite insulin resistance in the rest of 
metabolism (discussed in more detail in chapter 3) [36-39, 380, 381]. Alternatively, it has been 
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suggested pericentral cells may retain insulin sensitivity after periportal cells become IR [380]. 
However, a complete explanation of the heterogeneous development of steatosis across the sinusoid 
has yet to be presented in the literature. 
After development of steatosis, numerous factors are thought to contribute to the pericentral-centred 
hepatic damage. Firstly, enhanced lipid peroxidation, a marker of oxidative stress, is seen in the 
pericentral compartment [225, 382]. Secondly disruptions to energy metabolism are more severe in 
pericentral cells [229, 230]. Finally, direct lipotoxicity resulting from the increased concentration of 
FFAs may contribute to the higher cellular damage in pericentral cells [8, 146, 247, 248].  
1.4 Existing Mathematical Models of Liver Processes Including Zonation 
Previous computational models of glucose homeostasis and liver energy metabolism have varied from 
those studying liver metabolism within the body as a whole to those focussed in detail on the 
regulation of specific enzymes depending upon the particular purpose of the study. For example, Kim 
et al. [383] and Xu et al. [384] developed whole body models to study the hormonal regulation of 
glucose homeostasis during exercise (Kim et al. [383]) and under varying feeding conditions (Xu et al. 
[384]), whilst Liu et al. [385] developed a model focussed in detail on the GLUT proteins responsible 
for glucose uptake and output. Additionally, representations of glucose regulation vary from black box 
models, for example with the purpose of calculating optimal insulin input for insulin responsive 
diabetic patients [386], to mechanistic models aiming to understand the metabolic changes occurring 
in disease in detail [387-392]. Of these mechanistic models, the vast majority of existing models of the 
liver are single hepatic compartment models, and zonation in the context of hepatic energy 
metabolism has yet to be addressed.  
Numerous models of glucose regulation and other processes in liver have been presented since as 
early as 1965 [386]. As a result, the following review will focus on key recent mechanistic models. For 
a more detailed discussion of liver metabolism and diabetes modelling, see the reviews of Bogle et al. 
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and Balakrishnan et al. [386, 393] and for a detailed discussion of the application of systems biology 
techniques to NAFLD see the review of Fisher et al. [394].  
Most recently, Somvanshi et al. published a detailed single compartment model of glucose, lipid and 
amino acid metabolism, including regulation at both a signalling and transcription level [387]. This 
model, which incorporated a number of previously published sub-models, was used to understand the 
effects of varying dietary compositions on metabolism. König et al. developed a detailed model of 
enzymatic conversions in glucose homeostasis including much of the allosteric regulation known to 
occur in glucose regulation [388]. This model (a set of ordinary differential equations with 49 localised 
metabolites and 36 reactions) included all of the enzymatic conversions involved in gluconeogenesis 
and glycolysis, with separate cytoplasmic and mitochondrial compartments within hepatocytes. 
Hetherington et al. developed a composite model of hormone signalling in glycogen storage, 
comprising of established and ab initio developed sub-models [389]. This was used to understand key 
features of insulin signalling including ultradian oscillations [389, 390]. Chalhoub et al. developed a 
single hepatic compartment model focussing on gluconeogenesis and lipid metabolism in the 
hepatocyte [391]. The model was adapted to give results corresponding to the liver in either in vivo or 
in an ex vivo perfusion system to allow comparison with different experimental data. It was then used 
to simulate concentrations of various molecules and fluxes of different reactions in response to 
changes in the composition of the perfusion medium. Calvetti et al. developed a sophisticated spatially 
distributed model of glucose regulation in liver [392]. This used a set of grid points to measure fluxes 
of various molecules. However, despite the inclusion of spatial distribution, this model did not include 
zonation in enzyme expression. 
Whilst single compartment, homogenous hepatocyte models are useful for studying the function of 
liver as a whole, they do not allow simulation of changes within specific regions of the sinusoid, and 
exclude the implications of zonation in disease progression. Only a few models have included a 
representation of hepatic zonation in enzyme expression, and none of these have focused on liver 
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energy metabolism. Ohno et al. investigated heterogeneity in ammonia detoxification [395]. They set 
up a model in which substances enter the sinusoids from the periportal tract, pass through 8 
compartments (hepatocytes) in series, before exiting the sinusoid in the central vein. The model was 
tested with homogenous enzyme expression in all compartments and with zonated expression of 
carbonyl phosphate synthase, glutamine synthase and ornithine aminotransferase to understand the 
roles of zonated enzyme expression. Anissimov et al. created a similar model with 8 compartments to 
study hepatic availability and clearance [396]. A model by Sheikh-Bahaei et al. also studied hepatic 
zonation xenobiotic toxicity focussing on the development of zonation in key enzymes, rather than 
the effects of this zonation on metabolite concentrations [397]. Pang et al. looked at the various 
different ways of modelling heterogeneity for studying pharmacokinetics, starting with a simple 
compartmental PBPK model, followed by a zonal model and moving on to more complex circulatory 
and fractal models [398]. The compartmental and zonal models were compared with clinical data for 
digoxin and estradiol 17β D-glucuronide (E217G). For digoxin, the zonal model provided little 
improvement over the compartmental model. However, for E217G results improved significantly if 
Sult1e1 was expressed heterogeneously, suggesting that zonation is a more important for some drugs 
than others. 
Other than this, models have been developed including zonation of closely related non-liver 
metabolism. König et al. published a model of glucose metabolism in cancer cells including localized 
gradients in metabolites and oxygen and regional hypoxia across a tumour [399]. Although this is for 
metabolism in cancer cells rather than liver, many similarities are seen including increased glycolysis 
and reduced oxidative phosphorylation in the most hypoxic cells. Davidson et al. studied the 
development of zonation within a bioartificial device [400]. This study did not model the metabolism 
in cells but instead focused on optimisation of oxygen input, blood flow and the dimensions of the 
device to try set-up a liver-like gradient in oxygen expression across the cells to promote a zonated 
phenotype. 
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1.5 Conclusions of Chapter 
From the review presented in this chapter, it is clear that an understanding of the role of zonation 
within NAFLD is both important and currently missing. A description of the metabolic changes across 
the sinusoid leading to steatosis and damage centred focussed on pericentral cells has yet to be 
presented in the literature. This is vital for understanding the progression of the disease. Furthermore, 
as discussed above, no pharmacological treatment for NAFLD has yet to be approved. One 
confounding factor is that studies investigating the effects of pharmacological treatments tend to 
study the changes in the liver as a whole by investigating changes within homogenised tissue, rather 
than within individual hepatocyte groups. If a treatment disrupts energy production in a subset of 
hepatocytes, this may not be seen in preliminary studies but could adversely affect patients over time. 
The role of zonation in NAFLD has largely been neglected because studying the effects of disease in 
individual regions of the sinusoid experimentally is time consuming and costly, especially given the 
vast number of variables when considering metabolism. However, integrating existing knowledge 
about hepatocyte heterogeneity into a computational model of metabolism across the sinusoid and 
using this to simulate NAFLD development and treatment would allow rapid analysis of changes in 
metabolic fluxes and metabolite concentrations under these conditions. These model simulations 
would then allow for more targeted experimentation, focusing on key predictions. Despite modelling 
of glucose metabolism having been performed for 50 years, a suitable model representing zonation in 
glucose, lipid and ATP metabolisms across the sinusoid is not available in the literature.  
It is these gaps in our understanding of NAFLD and in the tools required for studying zonation in NAFLD 
that this study aimed to address according to the aims listed at the start of the chapter. 
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2 Model Development  
2.1 Introduction to Chapter 
In this chapter, the development of a computational model of hepatic glucose and lipid metabolisms 
capable of representing zonation is discussed in detail. The equations representing each conversion 
are presented along with the experimental data used to determine the forms of the equations and to 
set parameter values. In supplementary material S1, comparison of model simulations with 
experimental data are provided under a range of conditions including simulations for metabolically 
normal and insulin resistant individuals. In chapter 3 additional validation of the model simulations 
focussed specifically on representing NAFLD is provided. Several sections of this chapter were 
published in the supplementary material of Ashworth et al. [401]. 
2.2 Model Building 
2.2.1 Model Structure, Blood Flow 
The first aim of this study was to build a computational model of glucose and lipid metabolisms 
capable of representing the zone-specific changes occurring under conditions of IR and NAFLD. In 
order to include zonation, a computational model of liver function must firstly be able to represent 
the changes in concentrations of metabolites and hormones occurring as blood passes through the 
sinusoid. Secondly, it must include the variation in enzyme expression between hepatocytes 
dependent upon their position along the sinusoid. Conventional two compartment 
(blood/hepatocyte) models, which treat the hepatocyte as the repeating unit of the liver, are unable 
to include these features. Instead, following the structure suggested by Ohno et al. in a model of 
hepatic xenobiotic metabolism, we treat the porto-central axis of the sinusoid as the repeating unit 
[395]. The blood and surrounding hepatocytes in the sinusoid are split into compartments according 
to their position along this axis (proximal periportal -> distal pericentral) (figure 2.1). 
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Figure 2.1 – The structure of the model. The porto-central axis of the sinusoid is treated as the repeating unit of the liver. Cells and blood are compartmentalized 
into groups according to their position along the liver sinusoid. This allows the model to include changes in blood oxygenation, hormone concentrations and substrate 
and product concentrations across the sinusoid as well as differences in hepatic enzyme expression between compartments. Blood exits the sinusoid into a larger 
compartment representing the rest of the body. Blood in this compartment interacts with the pancreas, lungs and adipose tissue. Glucose and FFA inputs and 
consumption also occur in this compartment. Modified from diagrams in Ashworth et al. [402] and Ashworth et al. [401]. 
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Since blood is compartmentalized with average concentrations of variables in each compartment, 
rather than represented as a continuous change in plasma concentrations, a simplified representation 
of blood flow was used. In each time step, a proportion of the blood in each compartment moves to 
the subsequent compartment and is replaced by blood from the previous compartment. The plasma 
concentration of each metabolite or hormone (M) in each compartment changes according to the 
following equations. 
𝑑𝑀𝑖=1:𝑛
𝑑𝑡
= 𝑏𝑓 ∗ 𝑀𝑖−1 − 𝑏𝑓 ∗ 𝑀𝑖 = 𝑏𝑓 ∗ (𝑀𝑖−1 − 𝑀𝑖) 
𝑑𝑀0
𝑑𝑡
=
𝑏𝑓 ∗ (𝑀4−𝑀0)
𝑠
 
Rate of blood flow: 𝑏𝑓 = 0.15 ∗ 𝑛 s-1 -> (𝑏𝑓 = 1.2s-1 for the 8 compartments used in this report.) 
Rest of body to hepatic compartment ratio: 𝑠 = 5 ∗ 𝑛 -> (𝑠 = 40 for the 8 compartments used in this report.) 
Compartments 𝑖 = 1 → 𝑛  correspond to the proximal periportal to distal pericentral sinusoidal 
compartments while compartment 𝑖 = 0  is the body compartment. 𝑛  is the number of hepatic 
compartments set to 8 for the simulations throughout this report (motivated below). The constant 𝑠 
is included since the body compartment is much larger than each liver compartment. The blood flow 
and relative size of the hepatic and body compartments were set such that blood takes around a 
minute to make a circuit of the body and so that the liver blood volume is equal to roughly 0.8L with 
a total blood volume of 5L [20, 403-405]. 
When building the model, simulations were run for both metabolically normal and insulin resistant 
individuals with varying compartment numbers to assess for an appropriate number to use. The 
number of compartments was increased from 3 (the minimum allowing separation of periportal, 
intermediate and pericentral zones) to well beyond the number after which no further qualitative 
changes in simulated data across the sinusoid (such as the appearance of missing maxima or minima) 
were seen when adding further compartments. Up to 48 were simulated, which is additionally several 
times larger than the actual number of hepatocytes per sinusoid (~10-13).  
52 
 
On the basis this preliminary data, 8 compartments were chosen for the simulations in this report 
since no under-sampling effects were noted when comparing with higher compartment numbers and 
because 8 compartments allows simple comparison with experimental studies which tend to split the 
sinusoid into 2-4 zones, up to a maximum of 8 (e.g. [406]). This is also consistent with previous 
computational models of zonation in liver [395, 396]. 
Blood flows from the periportal to the pericentral end of the sinusoid. After leaving the distal 
pericentral compartment, it enters a larger body compartment where it interacts with simple 
representations of the pancreas (hormone input), adipose tissue (FFA and triglyceride regulation) and 
with glucose and FFA inputs/outputs in the rest of the body (figure 2.1). The model simulates an 
individual at rest and does not include the blood flow, blood oxygenation and hormonal changes 
occurring during exercise. 
Although this representation of the sinusoid allows inclusion of zonated enzyme expression, it remains 
a simplification. Several sinusoids extend between each portal triad and central vein following indirect 
paths through the cells, and the number of cells fed by each sinusoid will vary. Due to the hexagonal 
shape of the lobule, each sinusoid is likely to be supplying a larger number of cells nearer the portal 
triad than the central vein. Additionally, given that the oxygen concentration is the primary signal 
molecule promoting zonated expression [50], cells further from the capillary (but in the outer 
periportal region of the lobule) are likely to show more pericentral expression than those neighbouring 
the capillary. Therefore, there is scope for development of models to refine predictions in the future 
by representing distributed effects across 2D and 3D representations of the lobule. 
2.2.2 Modelling and Parameterisation Strategy 
2.2.2.1 Representation of Processes in the Model 
Conversions are represented by Hill function dependences on the substrates and allosteric activators 
and inhibitors with a hormone dependent rate constant.  
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𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝑛𝐻𝑖𝑙𝑙
𝐾𝑀
𝑛𝐻𝑖𝑙𝑙 + [𝑆]𝑛𝐻𝑖𝑙𝑙
 
Where 𝐾𝑀(mM) determines the substrate concentration at which enzymes are saturated, 𝑉𝑚𝑎𝑥(s
-1) is 
the maximum rate and 𝑛𝐻𝑖𝑙𝑙  quantifies deviation from Michaelis-Menten behaviour. This form is 
based on Michaelis-Menten kinetics, a common method of representing enzymatic conversions. 
Michaelis-Menten kinetics are applicable to a reaction in which a substrate, S, reversibly binds to an 
enzyme, E, to form a complex, SE, before this complex then undergoes an irreversible reaction to form 
the product, P, as long as certain assumptions are met. 
𝑆 + 𝐸  
→𝑘
+
←𝑘
−
  𝑆𝐸 →𝑘
𝑐𝑎𝑡
𝑃 + 𝐸 
Defining [𝑥] as the concentration of 𝑥. 
𝑑[𝑆]
𝑑𝑡
= 𝑘+[𝑆][𝐸] − 𝑘−[𝑆𝐸] 
𝑑[𝑆𝐸]
𝑑𝑡
= 𝑘−[𝑆𝐸]−𝑘+[𝑆][𝐸]−𝑘𝑐𝑎𝑡[𝑆𝐸] 
𝑑[𝑃]
𝑑𝑡
= 𝑘𝑐𝑎𝑡[𝑆𝐸] 
One of the assumptions required for the derivation is that the substrate is in instantaneous chemical 
equilibrium with the substrate such that: 
𝑘+[𝑆][𝐸] = 𝑘−[𝑆𝐸] 
The free enzyme concentration relative to the total enzyme concentration, [𝐸]0, can be calculated as: 
[𝐸] = [𝐸]0 − [𝑆𝐸] 
Putting the previous three equations and rearranging gives: 
𝑣 =
𝑑[𝑃]
𝑑𝑡
= 𝑘𝑐𝑎𝑡[𝑆𝐸] =
𝑘𝑐𝑎𝑡[𝐸]0[𝑆]
𝑘−
𝑘+
+ 𝑆
 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑀 + [𝑆]
 
Where 𝑉𝑚𝑎𝑥 = 𝑘
𝑐𝑎𝑡[𝐸]0  is the maximum rate of the process and 𝐾𝑀  is the Michaelis-Menten 
constant which determines the saturation of the reaction with increasing substrate concentration. The 
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dependence of the reaction rate of the substrate concentration for an example reaction in which 
𝑉𝑚𝑎𝑥=2s
-1 and KM=0.5mM is shown below. 
 
Hill coefficients, nHill, are used to represent conversions which deviate from the Michaelis-Menten 
assumptions. Higher Hill coefficients cause a more rapid increase towards the maximum reaction rate 
with increasing substrate concentration, but do not alter the maximum rate or the substrate 
concentration at which half maximum rate is reached. The change in the reaction rate vs substrate 
curve when nHill=2 compared with nHill=1 is shown. 
 
As substrate concentrations increase, 
the reaction rate tends to Vmax 
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Many of the equations correspond to processes with a number of intermediate enzymes rather than 
a single enzyme. In these cases, Hill functions are still used to represent the substrate dependence of 
these processes, with KM, and where applicable nHill, values based on the literature for the rate limiting 
enzyme in the process or estimated through fitting to experimental data. 
Multiple substrates are represented in the model by multiplying the Hill function substrate 
dependences. E.g. for three substrate S1, S2 and S3. 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆2]
𝑛𝑆1
𝐾𝑀
𝑆1𝑛𝑆1 + [𝑆1]𝑛𝑆1
∗
[𝑆2]𝑛𝑆2
𝐾𝑀
𝑆2𝑛𝑆2 + [𝑆2]𝑛𝑆2
∗
[𝑆3]𝑛𝑆3
𝐾𝑀
𝑆3𝑛𝑆3 + [𝑆2]𝑛𝑆3
 
Allosteric inhibition and activation are represented using a similar dependence on the inhibiting or 
activating molecule with inhibition or activation constants taken from the literature. E.g. for an 
inhibitory molecule, 𝑖, with concentration [𝑖]: 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝑛𝐻𝑖𝑙𝑙
𝐾𝑀
𝑛𝐻𝑖𝑙𝑙 + [𝑆]𝑛𝐻𝑖𝑙𝑙
(1 −∝𝑖𝑛ℎ
[𝑖]𝑛𝑖𝑛ℎ
𝐾𝑖
𝑛𝑖𝑛ℎ + [𝑖]𝑛𝑖𝑛ℎ
) 
Where ∝𝑖𝑛ℎ≤ 1 determines the maximum inhibition by 𝑖, 𝐾𝑖
𝑛𝑖𝑛ℎ  determines the concentration of 𝑖 at 
which inhibition is at half maximum, and 𝑛𝑖𝑛ℎ acts as the equivalent of the Hill coefficient.  
In addition to the enzymatic conversions, the transport of molecules across the cell is represented in 
the model. A conversion factor 𝑐𝑡𝑜𝑏 = 4 is used to account for the difference in sinusoidal plasma 
and sinusoid volume. For uni-directional active uptake, Hill functions are used, treating the plasma 
molecule as the substrate and the cytoplasmic molecule as the product. For bidirectional facilitated 
diffusion, a Hill-type equation dependent on the difference in concentration between the cytoplasm 
and plasma is used. It is assumed that molecules from both inside and outside the cell contribute to 
the saturation of the reaction (cross membrane transport protein is blocked by molecules moving both 
into and out of the cell) such that the reaction is represented by an equation of the form: 
𝑣𝑝𝑙𝑎𝑠𝑚𝑎→𝑐𝑦𝑡𝑜 =
𝑉𝑚𝑎𝑥([𝑆𝑝𝑙𝑎𝑠𝑚𝑎] − [𝑆𝑐𝑦𝑡𝑜])
𝐾𝑀 + [𝑆𝑝𝑙𝑎𝑠𝑚𝑎] + [𝑆𝑐𝑦𝑡𝑜]
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Although these are heuristic representations of cross-membrane transport based on the stated 
assumptions, previous experimental studies have used Hill-function equations with effective 
Michaelis-Menten constants to represent uptake [407-409], and these forms have been used in 
previous models of liver metabolism [388]. 
Hormonal regulation is represented in slightly different ways depending on how strongly and rapidly 
hormones are known to act on the process. In each case, hormonal regulation is based on the plasma 
concentration rather than modelling the receptors and downstream signalling in detail, as has been 
performed in previous models (e.g. [389]).  The hormonal regulation of each process is discussed in 
the following sections. 
2.2.2.2 Level of Detail 
The model is limited to the major processes determining triglyceride levels, ATP concentrations and 
FA oxidation rates in liver, calculating the overall rates of these processes rather than for each 
intermediate enzyme. Furthermore, as discussed in section 2.2.4, only simple representations of 
essential processes occurring outside of liver are included, rather than including separate detailed 
adipose tissue and muscle compartments. A larger model may, for example, include cholesterol 
synthesis, include detailed adipose metabolism or individually simulate every enzyme mediating each 
process. Whilst these extra components would allow the model to simulate additional features of 
metabolism, for example regarding hepatic intermediate concentrations, it is not expected that they 
would alter the data presented in this report which were focussed towards a specific aim of 
understanding lipid build-up across the sinusoid. Conversely, given that each of the processes included 
in the model are fundamental to energy metabolism and regulation across the sinusoid, exclusion of 
any of the processes in the model would be expected to significantly alter the observations presented 
in this report. A major aspect of lipid metabolism which is relevant to current study of NAFLD but could 
not be studied within the model is the effect of changes in fatty acid compositions (chain 
length/saturation). In particular, the PNPLA3 gene, which is believed to play a role in determining the 
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fatty acid composition of triglycerides, is associated with changes in NAFLD and NASH susceptibility 
(see section 1.3.4.1.4). This is therefore a limitation of the model when considering interindividual 
variability. However insufficient data was available for the biochemical parameters of the enzymes 
interconverting between the different fatty acids and mediating oxidation and triglyceride synthesis 
from each individual fatty acid to include these in the model separately. Therefore, only overall 
changes in fatty acid concentration and triglyceride concentration can be studied using the model, 
and the heterogeneous effects of different fatty acid compositions are left to future work. 
2.2.2.3 Parameterization 
For each conversion, a search of the literature, along with online databases such as BRENDA [410], 
was first performed to establish allosteric and hormone dependences of the key enzymes mediating 
the process. The allosteric dependences of each process on other molecules in the model were 
included in the form of Hill functions with constants taken directly from the literature. The 
dependences on the various energy molecules in the model (ATP, GTP, UTP etc.) were also included 
as Hill functions with constants taken from the literature for each process. Where possible, the Hill 
function dependences on the various metabolic intermediates acting as substrates for each process 
were also taken directly from published experimental data. However, for some processes, e.g. 
glycolysis and gluconeogenesis, the rate limiting enzyme is not the first in the chain. As a result, in 
these cases, the substrate dependences were based on experimental data for metabolite 
concentrations and metabolic flux rates under varying conditions from a number of sources as 
described below and in supplementary material S1. For each process, the rate constant and constants 
mediating the insulin and glucagon dependences were also fitted to experimental data.  
Since the exact rates at which glucose and lipids enter the bloodstream after feeding in experimental 
studies are unknown and would vary depending upon the size of the meal, the content of the meal 
and individual digestion rates, automated least-squares fitting parameters to any specific data set was 
not considered appropriate. Instead, the focus was placed on ensuring the simulated plasma and 
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hepatic concentrations both quantitatively remained within the experimentally measured ranges and 
matched qualitative features in the data such as periods of increase or decrease, and appropriately 
timed peaks and troughs when simulating a wide range of different feeding conditions and insulin 
sensitivities using a number of data sets. The fitting was performed by hand, first ensuring the model 
produced realistic hepatic and plasma concentrations and rates of oxidation when provided with 
constant inputs (comparing with concentration and rate ranges measured in the literature and with 
the simulations from an existing model of glycogen storage [389]), before extensively refining the 
parameter values by comparison with more complex data sets. Where possible, time-series 
measurements for variation in the concentrations of several molecules or rates of several processes 
before, during and after feeding were used, including data for both metabolically normal and insulin 
resistant patients. These comparisons of the model predictions with experimental data are provided 
in supplementary material S1. Due to inter-individual variability in metabolism, there is inevitably non-
uniqueness in parameter values and the model can be considered to represent a single near-average 
individual. The sensitivity analysis performed in chapter 3 aims to understand the consequences of 
variability in these parameters.  
To allow for the inclusion of zonated enzyme expression, the base values of the rate constant (which 
are zone-independent) were altered in each compartment according to whether the enzymes in each 
process are known to be upregulated or downregulated in that region of the sinusoid (figure 2.2). 
Since continuous changes in enzyme expression are seen for all of the processes included in the model, 
rather than the step-wise changes in, for example, cholesterol synthesis, the zonation of each process 
could be set based on the experimentally measured periportal to pericentral ratio of the rate limiting 
enzymes with a continuous change between compartments. The periportal to pericentral ratio used 
is stated for each process in table 2.2. The representation of zonation in the model along with the 
experimental data used to set the zonation in rate constants across the sinusoid is discussed in detail 
in section 2.2.6.  
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2.2.2.4 Simulations and Testing 
Simulations were run using the XPPAUT ODE solver using a 4th order Runge-Kutta method. The model 
file was published in Ashworth et al. [401]. The concentrations of the various plasma and cytoplasmic 
molecules are calculated in µM (µmoles/L) except for the concentrations of hormones which are 
calculated in pM (pMoles/L). To allow easier comparison with experimental data, the hepatic 
concentration of triglycerides, roughly equal to the total lipid concentration, was converted to a 
percentage of total cell mass before being presented. Two assumptions were made for this calculation. 
Firstly, that in a cell containing no fat, the combined protein and cytoplasm concentration is 1000g/L. 
Secondly, that the protein and cytoplasm content of each cell remain constant independent of the 
lipid content, such that the cell volume (and total liver volume) expands as the lipid content increases, 
rather than the protein or cytoplasm content falling. In this case, the combined cytoplasm and 
triglyceride concentration becomes 1000g/v where v is the increased volume after including the lipid 
and the percentage lipid content is calculated as: 
𝑇𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒 𝑚𝑎𝑠𝑠/𝑣𝑜𝑙𝑢𝑚𝑒
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠/𝑣𝑜𝑙𝑢𝑚𝑒
=
𝑇𝐺(𝑔/𝑣)
𝑇𝐺(𝑔/𝑣) + 𝐶𝑦𝑡𝑜(𝑔/𝑣) + 𝑃𝑟𝑜𝑡𝑒𝑖𝑛(𝑔/𝑣)
=
𝑇𝐺(𝑔/𝑣)
𝑇𝐺(𝑔/𝑣) + 1000(𝑔/𝑣)
 
An average molecular mass of 0.807 was used for triglyceride (equal to that of tripalmitin): 
𝑇𝐺(𝑔/𝑣)
𝑇𝐺(𝑔/𝑣) + 𝐶𝑦𝑡𝑜(𝑔/𝑣) + 𝑃𝑟𝑜𝑡𝑒𝑖𝑛(𝑔/𝑣)
=
(100%) ∗ 0.81 ∗ 𝑇𝐺(𝑀𝑜𝑙/𝑣)
0.81 ∗ 𝑇𝐺(𝑀𝑜𝑙/𝑣) + 1000
 
Due to the spatially discretised representation of blood flow and the discrete time steps used in 
simulations, several tests were performed to ensure the simulated data are stable and do not show 
numerical diffusion. Firstly, simulations were run with varying time steps and compartment numbers 
to assess stability in the model outputs. The time step was increased from 0.01 seconds to 1 second, 
and the simulated data were stable and consistent for time steps below 0.4 seconds. When running 
simulations for the data in the report, a time step of 0.05 seconds was used. Similarly, when the 
number of compartments was varied from 3 to 48, no numerical diffusion effects were seen for low 
60 
 
compartment numbers. For greater than 6 compartments, no qualitative changes in the simulated 
data for concentrations and rates across the sinusoid occurred due to under-sampling (such as the 
appearance of missing maxima or minima) for either metabolically normal or insulin resistant 
individuals. Finally, oxygen, insulin and glucagon are degraded at constant rates across the sinusoid in 
the model such that a theoretical concentration curve can be calculated and compared with the values 
produced by the model. In each case, when using 8 compartments and a time step of 0.05 seconds, 
the average difference between simulated and theoretical value was less than 0.1% of the average 
value.  
2.2.3 Hepatic Metabolism 
2.2.3.1 Summary 
Figure 2.2 shows the variables and processes included in each hepatic compartment of the model. 
Each hepatic compartment interacts with a corresponding blood compartment as shown in figure 2.1. 
The model focusses on the storage of glucose as glycogen, the cycling between glucose and lactate, 
adenosine triphosphate (ATP) production, FFA synthesis and the storage of FFAs as triglycerides.  
 
Figure 2.2 – Hepatic metabolism in the model. The variables and conversions included in each hepatic 
compartment across the sinusoid (see figure 2.1). In addition to the hormonal regulation, almost all of 
the glucose and lipid metabolism conversions show some form of allosteric regulation. Lipolysis is also 
included but it occurs at very slow rate in hepatocytes. Diagram previously published in Ashworth et al. 
[401]. 
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2.2.3.1.1 Glucose Metabolism 
The liver is the major organ responsible for the control of blood glucose concentrations. When blood 
glucose levels are high, glucose enters hepatocytes through the transmembrane carrier protein 
glucose transporter 2 (GLUT2) before being converted to glycogen via glucose-6-phosphate (G6P) 
under the influence of insulin (glycogenesis). When blood glucose levels are low, glucagon stimulates 
the release of glucose from glycogen stores (glycogenolysis). Insulin also stimulates the breakdown of 
glucose to two pyruvate molecules through glycolysis. This pyruvate can either be released into the 
blood as lactate or converted to acetyl-CoA for use in oxidative phosphorylation or in lipid metabolism. 
Glucagon, meanwhile, stimulates the reverse reaction converting pyruvate and lactate to glucose 
through gluconeogenesis. Glyceraldehyde-3-phosphate (GADP), an intermediate of glycolysis and 
gluconeogenesis, can be rapidly converted to glycerol-3-phosphate (G3P) which forms the glycerol 
backbone in triglyceride synthesis. Additionally, glycerol released in lipolysis is converted to G3P and 
GADP via the enzyme glycerol kinase. Most lipolysis occurs outside of the liver in adipose tissue. 
However, very little glycerol kinase activity is seen in adipose tissue and instead glycerol released in 
adipose tissue is recycled in the liver [411]. 
2.2.3.1.2 Lipid and Energy Metabolism 
The liver plays an important role in lipid metabolism and there exists a strong link between lipid 
metabolism and liver disease. Hepatic steatosis is seen in a range of liver conditions most commonly 
linked with alcohol, viruses such as hepatitis c or metabolic dysregulation and is known to play a role 
in the development of IR.  
Pyruvate is converted to acetyl-CoA by a complex of three enzymes known as the pyruvate 
dehydrogenase complex (PDC). These acetyl-CoA molecules can either enter the citrate cycle to 
provide fuel for oxidative phosphorylation of ADP to ATP or can be joined to form FA chains through 
de novo lipogenesis. Numerous FAs are produced in vivo with varying chain lengths. However, to 
reduce the computation required, the model assumes all FAs to be palmitate. Palmitate is the most 
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common FA in animals, plants and microorganisms and corresponds to a chain of 8 acetyl-CoA 
molecules (16 carbons). Both the production of acetyl-CoA and lipogenesis are stimulated by insulin 
whilst the breakdown of palmitate back to 8 acetyl-CoA molecules (β-oxidation) is stimulated by 
glucagon.  
When blood glucose levels peak, it is beneficial to remove alternative cellular energy sources from the 
blood including FAs. Insulin stimulates the synthesis of triglycerides, in which three FAs are attached 
to a glycerol backbone for storage. While FFAs can be used as an energy source by the majority cells 
in the body, most cell types are unable to break down triglycerides. The liver has only a very small 
capacity to breakdown triglycerides through lipolysis [412]. Although the liver plays a role in lipid 
metabolism, adipose tissue is the primary regulator of blood lipid levels. As a result, it was also 
necessary to include a simple representation of adipose tissue in the model for it to produce valid 
blood FFA and triglyceride concentrations. 
FFA uptake through the FATP proteins is included through two terms corresponding to passive 
concentration dependent uptake and the insulin dependent pumping of FFAs into the cytoplasm. 
Triglyceride release as VLDL is included along with a term representing triglyceride uptake from the 
blood. 
2.2.3.1.3 Hepatic Rate Equations 
A reduced description of the representation of metabolism in each hepatic compartment in the model 
is provided in tables 2.1 and 2.2 before a full description of each equation is provided in the following 
sections. Table 2.1 contains the differential equations for each hepatic variable in terms of the 
metabolic processes occurring. Table 2.2 defines the processes included in each hepatic compartment 
in the model and references the sections in which the full equations can be found.  
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Table 2.1 – The rate equations for the variables included in the hepatic compartments of the model. 
Hepatic Variable Rate Equations 
Glucose 𝑑𝐺𝑐
𝑑𝑡
= −ℝ𝐺𝐾 + ℝ𝐺6𝑃𝑎𝑠𝑒  + ℝ𝐺𝑙𝑢𝑡  
G6P 𝑑𝐺6𝑃
𝑑𝑡
= ℝ𝐺𝐾 − ℝ𝐺6𝑃𝑎𝑠𝑒  + ℝ𝐺𝑃−ℝ𝐺𝑆 + ℝ𝐹𝐵𝑃 − ℝ𝑃𝐹𝐾 
Glycogen 𝑑𝐺𝑙𝑦
𝑑𝑡
= ℝ𝐺𝑆 − ℝ𝐺𝑃 
G3P/GADP 𝑑𝐺3𝑃
𝑑𝑡
= ℝ𝑃𝐸𝑃𝐶𝐾 − 2 ℝ𝐹𝐵𝑃 + 2 ℝ𝑃𝐹𝐾 − ℝ𝑃𝐾 + ℝ𝐺𝐶𝑜𝑛𝑣  −  ℝ𝑇𝑆𝑦𝑛 
Pyruvate/Lactate 𝑑𝐿𝑎𝑐𝑐
𝑑𝑡
= ℝ𝐿𝑎𝑐𝑡− ℝ𝑃𝐸𝑃𝐶𝐾 + ℝ𝑃𝐾 − ℝ𝑃𝐷𝐻 
Acetyl-CoA 𝑑𝐴𝐶𝑜𝐴
𝑑𝑡
= ℝ𝑃𝐷𝐻 − 8 ℝ𝐿𝑔𝑒𝑛 +  8 ℝ𝛽𝑜𝑥𝑖 −  ℝ𝐴𝑇𝑃𝑆 
FFA (Palmitate) 𝑑𝐹𝐹𝐴𝑐
𝑑𝑡
=  ℝ𝐹𝐹𝐴𝑡 +  3 ℝ𝐿𝑝𝑙𝑦 −  3 ℝ𝑇𝑆𝑦𝑛 + ℝ𝐿𝑔𝑒𝑛 −  ℝ𝛽𝑜𝑥𝑖 
Triglycerides 𝑑𝑇𝐺𝑐
𝑑𝑡
= ℝ𝑇𝐺𝑡 + ℝ𝑇𝑆𝑦𝑛 − ℝ𝐿𝑝𝑙𝑦 
Glycerol 𝑑𝐺𝑙𝑦𝑐
𝑑𝑡
= ℝ𝐺𝑙𝑦𝑡 − ℝ𝐺𝐶𝑜𝑛𝑣 + ℝ𝐿𝑝𝑙𝑦 
ATP - Adenosine 
Triphosphate 
𝑑𝐴𝑇𝑃
𝑑𝑡
= 12 ℝ𝐴𝑇𝑃𝑆 − ℝ𝐴𝐾 −  2 ℝ𝑃𝐸𝑃𝐶𝐾 − ℝ𝑃𝐹𝐾 +  3.25 ℝ𝑃𝐾 − ℝ𝐺𝐾  
− ℝ𝑁𝐷𝐾𝐺− ℝ𝑁𝐷𝐾𝑈 − ℝ𝐴𝑇𝑃𝑢 − 2 ℝ𝛽𝑜𝑥𝑖 − 7 ℝ𝐿𝑔𝑒𝑛 − ℝ𝐺𝐶𝑜𝑛𝑣
+ 2.5 ℝ𝑃𝐷𝐻 − 3 ℝ𝑇𝑆𝑦𝑛 
ADP - Adenosine 
Diphosphate 
𝑑𝐴𝐷𝑃
𝑑𝑡
= −12  ℝ𝐴𝑇𝑃𝑆 + 2 ℝ𝐴𝐾 +  2 ℝ𝑃𝐸𝑃𝐶𝐾 + ℝ𝑃𝐹𝐾 −  3.25 ℝ𝑃𝐾 + ℝ𝐺𝐾
+ ℝ𝑁𝐷𝐾𝐺+ℝ𝑁𝐷𝐾𝑈 + ℝ𝐴𝑇𝑃𝑢 + 7 ℝ𝐿𝑔𝑒𝑛 + ℝ𝐺𝐶𝑜𝑛𝑣 +  ℝ𝛽𝑜𝑥𝑖
−  2.5 ℝ𝑃𝐷𝐻 
AMP - 
Adenosine 
Monophosphate 
𝑑𝐴𝑀𝑃
𝑑𝑡
= − ℝ𝐴𝐾 + ℝ𝛽𝑜𝑥𝑖 + 3 ℝ𝑇𝑆𝑦𝑛 
Pi - Inorganic 
Phosphate 
𝑑𝑃𝑖
𝑑𝑡
= −12 ℝ𝐴𝑇𝑃𝑆− ℝ𝐺𝑃 + ℝ𝐺6𝑃𝑎𝑠𝑒  + 2 ℝ𝐺𝑆 − 2.25 ℝ𝑃𝐾 + 2 ℝ𝑃𝐸𝑃𝐶𝐾 + ℝ𝐹𝐵𝑃
− ℝ𝑃𝑅𝑒𝑔 + ℝ𝐴𝑇𝑃𝑢 + 7 ℝ𝐿𝑔𝑒𝑛 + ℝ𝛽𝑜𝑥𝑖− 2.5 ℝ𝑃𝐷𝐻 + 7 ℝ𝑇𝑆𝑦𝑛 
UTP  - Uridine 
Triphosphate  
𝑑𝑈𝑇𝑃
𝑑𝑡
= ℝ𝑁𝐷𝐾𝑈 − ℝ𝐺𝑆 
UDP - Uridine 
Diphosphate  
𝑑𝑈𝐷𝑃
𝑑𝑡
= − ℝ𝑁𝐷𝐾𝑈+ ℝ𝐺𝑆 
GTP - Guanosine 
Triphosphate 
𝑑𝐺𝑇𝑃
𝑑𝑡
= ℝ𝑁𝐷𝐾𝐺 −  ℝ𝑃𝐸𝑃𝐶𝐾 
GDP - Guanosine 
Diphosphate 
𝑑𝐺𝐷𝑃
𝑑𝑡
= − ℝ𝑁𝐷𝐾𝐺 + ℝ𝑃𝐸𝑃𝐶𝐾 
The rates/processes (ℝ) are defined in table 2.2 and discussed in detail (along with the non-hepatic 
processes) in the following sections. References to the specific sections in which the full equation for 
each process can be found are also provided in table 2.2. 
64 
 
Table 2.2 – The processes included in each hepatic compartment in the model. 
Process Conversion  
ℝ𝐺𝑙𝑢𝑡 – Glucose Uptake. 
Section 2.2.3.2.1 
𝐺𝐵  
⟶
⟷
 𝐺𝐶   (Blood Glucose 
⟶
⟷
 Cellular Glucose) 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐺𝐾 – GK. 
Section 2.2.3.2.2 
𝐺𝐶 + 𝐴𝑇𝑃 → 𝐺6𝑃 + 𝐴𝐷𝑃 
Periportal to pericentral ratio in rate constant - 1:2.5  
ℝ𝐺6𝑃𝑎𝑠𝑒  – G6Pase. 
Section 2.2.3.2.3 
𝐺6𝑃 → 𝐺𝐶 + 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 1.9:1 
ℝ𝐺𝑆 – Glycogen Synthesis. 
Section 2.2.3.3.1 
𝐺6𝑃 + 𝑈𝑇𝑃 → 𝐺𝑙𝑦𝑐𝑜𝑔𝑒𝑛 + 𝑈𝐷𝑃 + 2 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 3:1 
ℝ𝐺𝑃 – Glycogen Phosphorylation. 
Section 2.2.3.3.2 
𝐺𝑙𝑦𝑐𝑜𝑔𝑒𝑛 + 𝑃𝑖 → 𝐺6𝑃 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝑃𝐹𝐾 – Glycolysis stage 1, primarily rate-
limited by PDK. 
Section 2.2.3.4.1 
𝐺6𝑃 + 𝐴𝑇𝑃 → 2 𝐺𝐴𝐷𝑃/𝐺3𝑃 + 𝐴𝐷𝑃 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝑃𝐾  – Glycolysis stage 2, primarily rate-
limited by PK. 
Section 2.2.3.4.2 
𝐺𝐴𝐷𝑃
𝐺3𝑃
+ 2𝐴𝑇𝑃 + 𝑃𝑖 → 𝑃𝑦𝑟/𝐿𝑎𝑐 + 2𝐴𝑇𝑃  + additional 
indirect 1.25 ATP from NADH. 
Periportal to pericentral ratio in rate constant – 1:2.1 
ℝ𝑃𝐸𝑃𝐶𝐾  – Gluconeogenesis stage 1, 
primarily rate-limited by PEPCK. 
Section 2.2.3.4.3 
𝑃𝑦𝑟/𝐿𝑎𝑐 + 2𝐴𝑇𝑃 + 𝐺𝑇𝑃
→ 𝐺𝐴𝐷𝑃/𝐺3𝑃 + 2𝐴𝐷𝑃 + 𝐺𝐷𝑃 + 2 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 2.4:1 
ℝ𝐹𝐵𝑃 – Gluconeogenesis 2, primarily rate-
limited by FBPase. 
Section 2.2.3.4.4 
2 𝐺𝐴𝐷𝑃/𝐺3𝑃 → 𝐺6𝑃 + 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 1.75:1 
ℝ𝑃𝐷𝐻  – Pyruvate oxidation mediated by 
PDH. 
Section 2.2.3.5.1 
𝑃𝑦𝑟/𝐿𝑎𝑐 → 𝐴𝐶𝑜𝐴 + indirect 2.5 ATP from NADH 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝛽𝑜𝑥𝑖  – β-Oxidation. 
Section 2.2.3.5.2 
𝐹𝐹𝐴 + 2 𝐴𝑇𝑃 → 8 𝐴𝐶𝑜𝐴 + 𝐴𝐷𝑃 + 𝐴𝑀𝑃 + 3 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 1.6:1 
ℝ𝐴𝑇𝑃𝑆 - ATP Synthesis via the citrate cycle 
and electron transport chain. 
Section 2.2.3.6.1 
𝐴𝐶𝑜𝐴 + 12𝐴𝐷𝑃 + 12  𝑃𝑖 → 12 𝐴𝑇𝑃 
Periportal to pericentral ratio in rate constant – 1.5:1 
ℝ𝑁𝐷𝐾𝐺/ℝ𝑁𝐷𝐾𝑈 – NDKs. 
Section 2.2.3.6.2 
(NDKG): 𝐺𝐷𝑃 + 𝐴𝑇𝑃 → 𝐺𝑇𝑃 + 𝐴𝐷𝑃 
(NDKU): 𝑈𝐷𝑃 + 𝐴𝑇𝑃 → 𝑈𝑇𝑃 + 𝐴𝐷𝑃 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐴𝐾  – AK. 
Section 2.2.3.6.3 
𝐴𝑇𝑃 + 𝐴𝑀𝑃 ⟷ 2 𝐴𝐷𝑃 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐴𝑇𝑃𝑢 – Cellular ATP consumption. 
ℝ𝑃𝑅𝑒𝑔 – Pi Regulation. 
𝐴𝑇𝑃 → 𝐴𝐷𝑃 + 𝑃𝑖 
𝑃𝑖  ⟷  − 
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Full equations along with the values of constants, the experimental data used as references and a 
detailed discussion are provided in the following sections, including the equations used to calculate the 
rates of processes occurring in the blood/body compartments in addition to the hepatic processes listed 
in the table. 
2.2.3.2 Glucose Uptake and Output 
2.2.3.2.1 Glucose uptake by GLUT2 – terms to represent pumping and passive diffusion 
 
The major glucose transporter in the liver is GLUT2 [413]. Two terms represent pumping and diffusion 
of glucose into the cytoplasm. Uni- and bi- direction Michaelis-Menten equations are used to 
represent these terms respectively. GLUT2 has a higher KM value than other common glucose 
transporters (GLUT1,3,4) allowing rapid uptake by hepatocytes when blood glucose levels rise for 
storage, where glucose uptake in other cells types would be determined by the energetic 
requirements of the cell. 
Section 2.2.3.6.4 Periportal to pericentral ratio in both rate constant – 1:1 
ℝ𝐿𝑔𝑒𝑛 – Lipogenesis. 
Section 2.2.3.7 
𝐴𝐶𝑜𝐴 + 7 𝐴𝑇𝑃 → 𝐹𝐹𝐴 + 7 𝐴𝐷𝑃 + 7 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 1:1.6 
ℝ𝑇𝑆𝑦𝑛 – Triglyceride Synthesis. 
Section 2.2.3.8.1 
3 𝐹𝐹𝐴 + 𝐺3𝑃/𝐺𝐴𝐷𝑃 + 3 𝐴𝑇𝑃 →  𝑇𝐺 + 3 𝐴𝑀𝑃 + 7 𝑃𝑖  
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐿𝑝𝑙𝑦 – Lipolysis. 
Section 2.2.3.8.2 
𝑇𝐺 → 𝐺𝑙𝑦𝑐 + 3 𝐹𝐹𝐴 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐺𝐶𝑜𝑛𝑣 - Glycerol Kinase. 
Section 2.2.3.8.3 
𝐺𝑙𝑦𝑐 + 𝐴𝑇𝑃 → 𝐺3𝑃/𝐺𝐴𝐷𝑃 + 𝐴𝐷𝑃 
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐿𝑎𝑐𝑡 – Lactate Output/Uptake. 
Section 2.2.3.9.1 
𝐿𝑎𝑐𝐵 ⟷ 𝐿𝑎𝑐𝐶  
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐹𝐹𝐴𝑡 – FFA Output/Uptake. 
Section 2.2.3.9.2 
𝐹𝐹𝐴𝐵 
⟷
⟶
 𝐹𝐹𝐴𝐶 
Periportal to pericentral ratio in rate constant – 1.5:1 
ℝ𝑇𝐺𝑡 – Triglyceride Output/Uptake. 
Section 2.2.3.9.3 
𝑇𝐺𝐵 
⟷
⟵
 𝑇𝐺𝐶  
Periportal to pericentral ratio in rate constant – 1:1 
ℝ𝐺𝑙𝑦𝑡  – Glycerol Output/Uptake. 
Section 2.2.3.9.4 
𝐺𝑙𝑦𝑐𝐵 ⟷ 𝐺𝑙𝑦𝑐𝐶  
Periportal to pericentral ratio in rate constant – 1:1  
Hormone Reception Periportal to pericentral ratio in insulin reception – 1:1.35 
Periportal to pericentral ratio in glucagon reception – 1.35:1 
66 
 
𝑣𝑝𝑢𝑚𝑝 ∗ 𝐺𝐵
(𝐾𝑀
𝑝𝑢𝑚𝑝
+ 𝐺𝐵)
+
𝑣𝑑𝑖𝑓𝑓 ∗ (𝐺𝐵 − 𝐺𝐶)
(𝐾𝑀
𝑑𝑖𝑓𝑓
+ 𝐺𝐵 + 𝐺𝐶)
 
  𝐾𝑀
𝑝𝑢𝑚𝑝
= 17𝑚𝑀 [407], 𝐾𝑀
𝑑𝑖𝑓𝑓
= 17𝑚𝑀 [407]. 
2.2.3.2.2 Glucokinase  
 
GK mediates the conversion of glucose to G6P taking a phosphate from ATP in the process. GK is 
allosterically dependent on the concentration of various molecules, either directly or indirectly via GK 
regulatory protein (GKRP). GKRP competitively binds to GK and moves the enzyme into the nucleus 
when glucose concentrations are low or when the concentrations of glycolysis intermediates such as 
F-6-P and F-1,6-P are high. G6P has a direct inhibitory effect. These dependences ensure increased 
uptake when glucose concentrations are high or when increased glycolysis is required to meet cellular 
energetic requirements. In the model, the effects glucose on GKRP (causing the release of GK) are 
included with constants taken from experimental data. Furthermore, the allosteric inhibition by G6P 
is included. F-6-P and F-1,6-P are not represented as independent variables in the model and their 
inhibitory effects (through GKRP) could not be included directly. However, conversion between G6P 
and F-6-P is rapid relative to the processes occurring in the model and so the two can be considered 
to be in constant equilibrium. In the model, a single G6P dependent inhibition term represents the 
allosteric inhibition of both G6P and F-6-P. The allosteric inhibition of F-1,6-P could not be included. 
𝑣𝑔𝑘 ∗ 𝐺𝑐
𝑛𝑓𝑟𝑒𝑒
(𝐾𝑀
𝑔𝑘𝑟𝑝𝑛𝑓𝑟𝑒𝑒
+ 𝐺𝑐
𝑛𝑓𝑟𝑒𝑒)
∗
𝐺𝑐
𝑛𝑔
(𝐾𝑀
𝐺 𝑛𝑔 + 𝐺𝑐
𝑛𝑔)
∗
𝐴𝑇𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)
∗ (1 −
𝐺6𝑃𝑛𝑖𝑛ℎ
(𝐾𝑖
𝐺6𝑃𝑛𝑖𝑛ℎ + 𝐺6𝑃𝑛𝑖𝑛ℎ)
) 
𝐾𝑀
𝐺  = 7.5mM [414, 415], 𝐾𝑀
𝑔𝑘𝑟𝑝
 = 15mM [414, 416]. 
𝑛𝑓𝑟𝑒𝑒 = 2 [414, 416], 𝑛𝑔 = 1.4 [414, 416]. 
 𝐾𝑖
𝐺6𝑃  = 240µM - [417, 418]. 
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𝐾𝑀
𝐴𝑇𝑃  = 240µM – a fairly wide range of values measured in the literature (e.g. 140µM [419], 
410µM [415]). The value chosen for model is roughly in the middle of these. However, since the 
values are much lower than the average ATP concentration under all but severe pathological 
conditions, small changes in the KM value do not notably affect results. 
𝑛𝑖𝑛ℎ = 4 – As discussed, the activity of GK is strongly inhibited both directly by G6P and indirectly 
by intermediates of glycolysis such as F6P [420]. F6P is not included in the model as an 
independent variable. However, conversion between F6P and G6P occurs rapidly relative to 
other processes included in the model. Therefore, the two can be expected to remain in 
constant equilibrium and a single allosteric dependence is included to represent both. A high 
ninh of 4 is used to provide strong allosteric inhibition when G6P (/F6P) concentrations rise and 
a rapid reduction in inhibition when the concentration falls [389]. 
2.2.3.2.3 G6Pase 
 
G6P is converted to glucose by the enzyme G6Pase releasing the phosphate. No strong allosteric or 
hormonal regulation has been demonstrated for this enzyme. 
𝑣𝐺6𝑃𝑎𝑠𝑒 ∗ 𝐺6𝑃
𝐾𝑀
𝐺6𝑃 + 𝐺6𝑃
 
𝐾𝑚
𝐺6𝑃 = 2.41mM [421, 422] 
2.2.3.3 Glycogen Synthesis and Breakdown 
In order to control the rates of glycogenesis and glycogenolysis, insulin and glucagon bind to surface 
receptors causing a downstream cascade which determines the phosphorylation state, and hence 
activity, of glycogen synthase (GS) and glycogen phosphorylase (GP). In the model, a hormone 
dependent maximum activity is calculated for each enzyme before multiplying by Michaelis-Menten-
type substrate dependences. The hormone signalling pathways have been modelled in detail in 
68 
 
previous two compartment models (for example Hetherington et al. [389]). However, in this study, 
since the focus is placed on understanding the effects of zonation rather than hormone signalling, 
hormone dependences of processes are calculated directly based on the blood hormone 
concentration in the region of the cells, rather than including a detailed representation of the 
downstream signalling. 
2.2.3.3.1 Glycogen Synthase 
 
G6P is converted to glucose-1-phosphate (G1P) before binding with a uridine triphosphate (UTP) 
molecule to give UDP-glucose (and pyrophosphate (PP) which is rapidly broken down to give two 
phosphates (Pi)). GS, the rate limiting enzyme in glycogen synthesis, uses this UDP-glucose to extend 
a glycogen chain. As well as the hormonal regulation, GS is allosterically activated by an increased G6P 
concentration. 
𝐾𝑠𝑦𝑛
𝑚𝑎𝑥 =
(𝐼𝑛𝑠 + 𝐾𝐼𝑆)
(𝐺𝑙𝑔𝑛 + 𝐾𝐿𝑆)
 
𝑣𝑠𝑦𝑛 ∗ 𝐾𝑠𝑦𝑛
𝑚𝑎𝑥 ∗ 𝐺6𝑃𝑛𝑠𝑦𝑛
(𝐺6𝑃𝑛𝑠𝑦𝑛 + 𝐾𝑚
𝐺6𝑃𝑛𝑠𝑦𝑛)
∗
𝑈𝑇𝑃
𝐾𝑀
𝑈𝑇𝑃 + 𝑈𝑇𝑃
 
𝐾𝑚
𝑈𝑇𝑃 = 48µM [423, 424] 
𝐾𝐼𝑆 = 13.33pM, 𝐾𝐿𝑆 = 62.5pM, 𝐾𝑀
𝐺6𝑃  = 50µM, 𝑛𝑠𝑦𝑛 = 4 set such that the simulated data match 
experimental data from [425-431] for plasma concentrations of key glucose metabolism 
molecules throughout a daily feeding cycle [425] (section S1.1.4), for hepatic glycogen and 
plasma concentrations after a mixed meal [428] (section S1.1.2), and for average glycogen and 
hepatic glucose metabolism intermediate concentrations [426, 427, 429, 430] (section S1.1.1) 
along with simulations from the model presented by Hetherington et al. [389, 390], which 
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contained a detailed representation of the pathways involved hormone reception and 
downstream regulation of GS and GP (see supplementary material S1 for comparison with 
experimental data). A low KM value but high Hill coefficient (𝑛𝑠𝑦𝑛 ) was used for the G6P 
dependence. This rapidly reduces glycogen synthesis when G6P concentrations fall below their 
metabolically normal range due to the dependence on G6P both as a substrate (via G1P and 
UDP glucose) and as an allosteric activator (GS activity nearly doubles in the presence of high 
concentrations of G6P compared with no G6P [432]), whilst ensuring that the rate of synthesis 
is primarily determined by the effects of hormones under metabolically normal conditions. 
When G6P dependences that were less steep (lower 𝑛𝑠𝑦𝑛) but reached saturation at higher G6P 
concentrations (higher KM) were tested, glycogen stores failed to empty when simulating IR. 
2.2.3.3.2 Glycogen Phosphorylase 
 
GP depolymerises glycogen adding a phosphate to give G1P. This G1P is then rapidly converted to G6P 
by phosphoglucomutase. 
𝐾𝑝ℎ𝑜𝑠
𝑚𝑎𝑥 =
(𝐺𝑙𝑔𝑛 + 𝑘𝐿𝑃)
(𝐼𝑛𝑠 + 𝑘𝐼𝑃)
 
𝑣𝑏𝑟𝑘 ∗ 𝐾𝑃ℎ𝑜𝑠
𝑚𝑎𝑥 ∗ 𝐺𝑙𝑦𝑛𝑏𝑟𝑘
(𝐺𝑙𝑦𝑛𝑏𝑟𝑘 + 𝐾𝑚
𝐺𝑙𝑦𝑛𝑏𝑟𝑘
)
∗
𝑃ℎ𝑜𝑠
𝐾𝑀
𝑝ℎ𝑜𝑠
+ 𝑃ℎ𝑜𝑠
 
𝐾𝑀
𝐺𝑙𝑦
− 100mM (units of glucose), 𝐾𝑀
𝑝ℎ𝑜𝑠
 = 4000µM [433] – for the active form of GP 
𝐾𝐼𝑃  = 26.66pM, 𝐾𝐿𝑃  = 45pM, 𝑛𝑏𝑟𝑘 = 4 – set such that the model simulations match 
experimental data from [425-431] for plasma concentrations of key glucose metabolism 
molecules throughout a daily feeding cycle [425] (section S1.1.4), for hepatic glycogen and 
plasma concentrations after a mixed meal [428] (section S1.1.2), and for average glycogen and 
hepatic glucose metabolism intermediate concentrations [426, 427, 429, 430] (section S1.1.1) 
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along with the simulations of the model of hormone signalling and its effects on GS and GP 
presented by Hetherington et al. [389, 390]. 
2.2.3.4 Gluconeogenesis and Glycolysis 
The rates of gluconeogenesis and glycolysis are strongly affected by the concentrations of insulin and 
glucagon (e.g. [431]). As with glycogenesis and glycogenolysis, when calculating the rates of the 
glycolytic and gluconeogenic processes a maximum enzyme activity is first calculated based on the 
blood hormone concentrations. This is then multiplied by Michaelis-Menten type substrate 
dependences. 
2.2.3.4.1 Glycolysis 1: G6P to GADP 
 
G6P is broken down to two GADP molecules via a sequence of enzymes. The rate limiting enzyme in 
this conversion is PFK (producing fructose-1,6-bisphosphate (F-1,6-BP)) which is highly allosterically 
regulated. It is also the only unidirectional enzyme in the chain, with the reverse conversion mediated 
by FBPase. PFK requires the removal of a phosphate molecule from ATP, releasing ADP. The enzyme 
is allosterically activated by ADP and inhibited by ATP such that the rate of glycolysis is increased or 
slowed depending on the energy (ATP) requirements of the cell. The effects of ATP and ADP are 
included with KM, activation and inhibition constants taken from the literature. After the production 
of F-1,6-BP, the subsequent enzyme in the chain, fructose-bisphosphate aldolase, splits the F-1,6-BP 
into one GADP molecule and one dihydroxyacetone phosphate molecule, which is converted into a 
second GADP resulting in the production of two molecules from glycolysis for each glucose/G6P. 
In addition, PFK is allosterically inhibited by GADP and phosphoenolpyruvate, products further down 
the glycolysis chain, as well as by intermediates of the citrate cycle, citrate and malate. As a result, 
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glycolysis is not only slowed when ATP levels are high but also when there is a surplus of substrate for 
the citrate cycle. Of these effectors, only GADP is included as an independent variable in the model 
and, therefore, the inhibition of the molecules further down cannot be directly included. Instead, the 
inhibition of GADP included in the model is assumed to represent the inhibition of all glycolytic 
intermediates. Finally, PFK is also allosterically activated by fructose-2,6-bisphosphate (F-2,6-BP). The 
concentration of F-2,6-BP is predominantly determined by the action of insulin and glucagon, such 
that the PFK activity increases when plasma glucose, and hence insulin, concentrations are raised. As 
a result, although F-2,6-BP is also not included in the model as an independent variable, this allosteric 
dependence is included in the fitted hormone dependences. 
𝐾𝑃𝐹𝐾
𝑚𝑎𝑥 =
(𝐼𝑛𝑠 + 𝐾𝐼𝑃𝐹𝐾)
(𝐺𝑙𝑔𝑛 + 𝐾𝐿𝑃𝐹𝐾)
 
𝑣𝑃𝐹𝐾 ∗ 𝐾𝑃𝐹𝐾
𝑚𝑎𝑥 ∗ 𝐺6𝑃
𝐾𝑀
𝐺6𝑃 + 𝐺6𝑃
∗
𝐴𝑇𝑃
𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃
∗
𝐴𝐷𝑃
𝐾𝑎
𝐴𝐷𝑃 + 𝐴𝐷𝑃
(1 − 𝛽𝐴𝑇𝑃
𝐴𝑇𝑃
𝐾𝑖
𝐴𝑇𝑃 + 𝐴𝑇𝑃
) (1 − 𝛽𝐺𝐴𝑑𝑃
𝐺𝐴𝐷𝑃
𝐾𝑖
𝐺𝐴𝐷𝑃 + 𝐺𝐴𝐷𝑃
) 
𝐾𝐼𝑃𝐹𝐾 = 2666.7𝑝𝑀, 𝐾𝐿𝑃𝐹𝐾 = 1250𝑝𝑀 – set so that the model simulations match the data in 
references [425-431, 434] for plasma concentrations of glucose and lactate throughout a daily 
feeding cycle [425] (section S1.1.4), after a glucose load [434] (section S1.2.2) and after a mixed 
meal [428] (section S1.1.2), for average hepatic glucose metabolism intermediate 
concentrations including glucose, G6P, pyruvate, lactate, G3P and GADP [426, 427, 429, 430] 
(section S1.1.1), and for the rates of glucose use in the various pathways after intake in the 
presence or absence of hormones [431] (section S1.1.3).  Additionally set so that the model 
simulations match the data in references [141, 425, 435] for the FFA and triglyceride 
concentrations throughout a mixed meal [425] (section S1.1.4) and for average concentrations 
of FFAs and triglycerides in individuals of varying weight and with varying insulin sensitivities 
[141, 435] (section S1.2.1) due to the role of GADP/G3P in triglyceride synthesis. 
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𝐾𝑀
𝐺6𝑃  = 5 µM – Since PFK doesn’t act directly from G6P, a KM value couldn’t be taken from the 
literature. A very low value was used based on the observation that the rate of glycolysis does 
not increase when the glucose concentration is increased in insulin resistant patients [434]. 
This suggests that in metabolically normal individual’s glycolysis increases due to the effects of 
insulin rather than increased substrate when plasma glucose concentrations are raised.  
𝐾𝑀
𝐴𝑇𝑃  = 42.5µM [436], 𝛽𝐴𝑇𝑃  = 1, 𝐾𝑎
𝐴𝐷𝑃  = 83.6μM [436, 437], 𝐾𝑖
𝐴𝑇𝑃  = 2.1mM [436, 437], 
𝛽𝐺𝐴𝐷𝑃 = 0.75, 𝐾𝑖
𝐺𝐴𝐷𝑃  = 20.7 µM [438] 
2.2.3.4.2 Glycolysis 2: GADP to Lactate/Pyruvate 
 
In the second half of glycolysis, each GADP molecule is converted to pyruvate (and lactate). Since 
conversion between pyruvate and lactate is reversible and relatively rapid, they are represented by a 
single variable in the model. Here we assume a constant pyruvate to lactate ratio. In vivo, the ratio is 
altered under conditions which effect the NAD:NADH ratio such as after heavy ethanol intake. 
Therefore, if in future work the model is used to study the metabolism of ethanol (or other drugs) 
across the sinusoid, modifications would be required to represent pyruvate and lactate as separate 
variables and to include NAD/NADH as separate variables rather than just through their effects on ATP 
concentrations.  
The rate limiting enzyme in the conversion of GADP to pyruvate is PK. Both the phosphate contained 
in the GADP and an additional free inorganic phosphate are combined with ADP molecules to produce 
two ATP molecules in this part of glycolysis. One ATP molecule is released by phosphoglycerate kinase 
and the second by PK. Additionally an NAD+ molecules is converted to NADH. Note that because 2 
GADP molecules are produced per glucose in the previous stage of glycolysis, when considering the 
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glycolysis of each glucose molecule, 4 ATP, 2 NADH and 2 pyruvate/lactate molecules are produced in 
this stage. 
NADH can produce a theoretical maximum of 3 ATP when entering the ETC. However, a ratio of closer 
to 2.5 ATP per NADH is achieved for mitochondrial NADH. In the case of PK, the NADH is cytosolic and 
cannot cross the mitochondrial membrane. Instead a shuttle reactor of NADHcyto + NAD+mito-> NADHmito 
+ NAD+cyto occurs to transport NADH into the mitochondria which requires the consumption of 1 ATP 
molecule. Here a relatively low rate of 1.25 ATP per cytosolic NADH is assumed to account for these 
difficulties in transport and further inefficiency in the use of NADH. PK is allosterically inhibited by 
acetyl-CoA. 
𝐾𝑃𝐾
𝑚𝑎𝑥 =
(𝐼𝑛𝑠 + 𝐾𝐼𝑃𝐾)
(𝐺𝑙𝑔𝑛 + 𝐾𝐿𝑃𝐾)
 
𝑣𝑃𝐾 ∗ 𝐾𝑃𝐾
𝑚𝑎𝑥 ∗ 𝐺𝐴𝐷𝑃
𝐾𝑚
𝐺𝐴𝐷𝑃 + 𝐺𝐴𝐷𝑃
∗
𝐴𝐷𝑃
𝐾𝑀
𝐴𝐷𝑃 + 𝐴𝐷𝑃
(1 − 𝛽𝑎𝑙𝑙𝑜𝑠
𝑎𝐶𝑜𝐴
𝐾𝑖
𝑎𝐶𝑜𝐴 + 𝑎𝐶𝑜𝐴
) 
𝐾𝐼𝑃𝐾 = 1066.6𝑝𝑀 , 𝐾𝐿𝑃𝐾 = 500𝑝𝑀, 𝐾𝑚
𝐺𝐴𝐷𝑃  = 250µM – set so that the model simulations 
match the data in references [425-431, 434] for plasma concentrations of glucose and lactate 
throughout a daily feeding cycle [425] (section S1.1.4), after a glucose load [434] (section 
S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic glucose metabolism 
intermediate concentrations including glucose, G6P, pyruvate, lactate, G3P and GADP [426, 
427, 429, 430] (section S1.1.1), and for the rates of glucose use in the various pathways after 
intake in the presence or absence of hormones [431] (section S1.1.3).  Additionally set so that 
the model simulations match the data in references [141, 425, 435] for the FFA and triglyceride 
concentrations throughout a mixed meal [425] (section S1.1.4) and for average concentrations 
of FFAs and triglycerides in individuals of varying weight and with varying insulin sensitivities 
[141, 435] (section S1.2.1) due to the role of GADP/G3P in triglyceride synthesis. 
𝐾𝑀
𝐴𝐷𝑃  = 240µM [439], 𝐾𝑖
𝑎𝐶𝑜𝐴 = 30µM [440], 𝛽𝑎𝑙𝑙𝑜𝑠 = 0.8 [440] 
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2.2.3.4.3 Gluconeogenesis 1: Lactate/Pyruvate to GADP (Glyceroneogenesis) 
 
The conversion of pyruvate to GADP is highly energy intensive, requiring the removal of phosphates 
from 2 ATPs and a GTP. The rate limiting enzyme in this conversion is PEPCK which hydrolyses GTP to 
provide a phosphate, allowing the production of phosphoenolpyruvate. PEPCK is not known to be 
strongly allosterically regulated. 
𝐾𝑃𝐸𝑃𝐶𝐾
𝑚𝑎𝑥 =
(𝐺𝑙𝑔𝑛 + 𝑘𝐿𝑃𝐸𝑃𝐶𝐾)
(𝐼𝑛𝑠 + 𝑘𝐼𝑃𝐸𝑃𝐶𝐾)
 
𝑣𝑃𝐸𝑃𝐶𝐾 ∗ 𝐾𝑃𝐸𝑃𝐶𝐾
𝑚𝑎𝑥 ∗ 𝐿𝑎𝑐
𝐾𝑀
𝐿𝑎𝑐 + 𝐿𝑎𝑐
∗
𝐴𝑇𝑃
𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃
∗
𝐺𝑇𝑃
𝐾𝑀
𝐺𝑇𝑃 + 𝐺𝑇𝑃
 
𝐾𝐼𝐹𝐵𝑃 = 2266.6, 𝐾𝐿𝐹𝐵𝑃 = 1062.5, 𝐾𝑀
𝐿𝑎𝑐  = 500mM – set so that the model simulations match 
the data in references [425-431, 434] for plasma concentrations of glucose and lactate 
throughout a daily feeding cycle [425] (section S1.1.4), after a glucose load [434] (section 
S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic glucose metabolism 
intermediate concentrations including glucose, G6P, pyruvate, lactate, G3P and GADP [426, 
427, 429, 430] (section S1.1.1), and for the rates of glucose use in the various pathways after 
intake in the presence or absence of hormones [431] (section S1.1.3).  Additionally set so that 
the model simulations match the data in references [141, 425, 435] for the FFA and triglyceride 
concentrations throughout a mixed meal [425] (section S1.1.4) and for average concentrations 
of FFAs and triglycerides in individuals of varying weight and with varying insulin sensitivities 
[141, 435] (section S1.2.1) due to the roles of GADP/G3P in triglyceride synthesis and pyruvate 
in lipogenesis. 
𝐾𝑀
𝐴𝑇𝑃  = 10 µM – set very low since, although ATP is required for the conversion of lactate to 
GADP, the ATP is required by enzymes which, under normal conditions, are not rate-limiting. 
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Using a low KM value means that large drops in ATP concentration will inhibit the process but 
variation in the physiological range will not affect the rate. 
𝐾𝑀
𝐺𝑇𝑃 = 64µM - [441] 
2.2.3.4.4 Gluconeogenesis 2: GADP to G6P 
 
The rate limiting enzyme in the conversion of two GADP molecules to G6P is FBPase. FBPase is 
allosterically inhibited by F-2,6-BP. The F-2,6-BP concentration is primarily determined by the action 
of insulin and glucagon, such that hepatic glucose production is reduced when plasma glucose (and 
hence insulin) concentrations are high. Therefore, although F-2,6-BP is not included as an independent 
variable, its allosteric effects are included in the fitted hormone dependences. 
𝐾𝐹𝐵𝑃
𝑚𝑎𝑥 =
(𝐺𝑙𝑔𝑛 + 𝑘𝐿𝐹𝐵𝑃)
(𝐼𝑛𝑠 + 𝑘𝐼𝐹𝐵𝑃)
 
𝑣𝐹𝐵𝑃 ∗ 𝐾𝐹𝐵𝑃
𝑚𝑎𝑥 ∗ 𝐺𝐴𝐷𝑃
𝐾𝑚
𝐺𝐴𝐷𝑃 + 𝐺𝐴𝐷𝑃
 
𝐾𝐼𝐹𝐵𝑃 = 2666.6, 𝐾𝐿𝐹𝐵𝑃 = 1250, 𝐾𝑚
𝐺𝐴𝐷𝑃  = 250µM – set so that the model simulations match 
the data in references [425-431, 434] for plasma concentrations of glucose and lactate 
throughout a daily feeding cycle [425] (section S1.1.4), after a glucose load [434] (section 
S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic glucose metabolism 
intermediate concentrations including glucose, G6P, pyruvate, lactate, G3P and GADP [426, 
427, 429, 430] (section S1.1.1), and for the rates of glucose use in the various pathways after 
intake in the presence or absence of hormones [431] (section S1.1.3).  Additionally set so that 
the model simulations match the data in references [141, 425, 435] for the FFA and triglyceride 
concentrations throughout a mixed meal [425] (section S1.1.4) and for average concentrations 
of FFAs and triglycerides in individuals of varying weight and with varying insulin sensitivities 
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[141, 435] (section S1.2.1) due to the roles of GADP/G3P in triglyceride synthesis and pyruvate 
in lipogenesis. 
2.2.3.5 Acetyl-CoA Production 
2.2.3.5.1 Pyruvate Oxidation. 
 
The conversion of pyruvate to acetyl-CoA is mediated by PDC. PDC is allosterically inhibited by acetyl-
CoA to ensure that excessive acetyl-CoA does not enter the citrate cycle causing mitochondrial stress. 
PDC also converts a mitochondrial NAD+ to NADH allowing for the production of 2.5 ATP molecules 
through the ETC. 
𝐾𝑃𝐷𝐻
𝑚𝑎𝑥 = (1 +
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑎𝑠𝑦𝑛 −
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑎𝑠𝑦𝑛) 
𝑣𝑎𝑠𝑦𝑛 ∗ 𝐾𝑃𝐷𝐻
𝑚𝑎𝑥 ∗ 𝐿𝑎𝑐
𝐾𝑀
𝐿𝑎𝑐 + 𝐿𝑎𝑐
(1 −
𝐴𝐶𝑜𝐴
𝐴𝐶𝑜𝐴 + 𝑘𝑖
𝐶𝑜𝐴−𝑖𝑛ℎ𝑖𝑏
) 
𝑘𝑖
𝐶𝑜𝐴−𝑖𝑛ℎ𝑖𝑏 = 35 µM [442] 
𝐾𝑀
𝐿𝑎𝑐  = 540, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑎𝑠𝑦𝑛
 = 1.33nM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑎𝑠𝑦𝑛
 = 375pM – set so that the model simulations match 
the data in references [141, 425-431, 434, 435, 443, 444] for plasma concentrations of key 
glucose and lipid metabolism molecules throughout a daily feeding cycle [425] (section S1.1.4), 
after a glucose load [434] (section S1.2.2) and after a mixed meal [428] (section S1.1.2), for 
average hepatic glucose metabolism intermediate concentrations including acetyl-CoA, 
pyruvate, glucose, G6P, lactate, G3P and GADP [426, 427, 429, 430] (section S1.1.1), for 
average concentrations of FFAs and triglycerides in individuals of varying weight and with 
varying insulin sensitivities [141, 435] (section S1.2.1), and for the rates of glucose use in the 
various pathways after intake in the presence or absence of hormones [431, 443, 444] (section 
S1.1.3).   
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2.2.3.5.2 Acetyl-CoA production from FAs (β-oxidation) 
 
In β-oxidation, acetyl-CoA molecules are produced from the breakdown of FAs. In vivo, numerous FAs 
are found with varying chain lengths and with varying properties. As discussed, in the model all FAs 
are synthesized from 8 acetyl-CoA molecules corresponding to palmitate, the most common FA in 
animals. Initially the FA is combined with a CoA molecule requiring the conversion of an ATP to AMP. 
An additional ATP molecule is required to transport the resulting acyl-CoA into the mitochondria, 
where it is sequentially broken down. The transfer across the mitochondrial membrane, mediated by 
carnitine palmitoyltransferase 1 (CPT1), is considered to be rate-limiting in this process. β-oxidation is 
allosterically inhibited by its product acetyl-CoA to ensure a steady acetyl-CoA supply for the citrate 
cycle [445, 446].  
𝐾𝛽𝑜𝑥𝑖
𝑚𝑎𝑥 = (1 −
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝛽𝑜𝑥𝑖
+
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛
𝑟𝑒𝑓
𝛽𝑜𝑥𝑖
) 
𝑣𝛽𝑜𝑥𝑖 ∗ 𝐾𝛽𝑜𝑥𝑖
𝑚𝑎𝑥 ∗ 𝐹𝐴
𝐾𝑀
𝐹𝐴 + 𝐹𝐴
(
𝐴𝑇𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)
) (1 − 𝛽𝑖𝑛ℎ
𝐴𝐶𝑜𝐴
𝐴𝐶𝑜𝐴 + 𝑘𝑖
𝐶𝑜𝐴−𝑖𝑛ℎ𝑖𝑏
) 
𝐾𝑀
𝐹𝐴=5 µM – it is difficult to define a single KM value for all FAs. KM values for palmitate and a 
few additional FAs are provided below for fatty acid synthetase, the enzyme responsible for the 
initial activation of the FFA with CoA, when measured in rats. All KM values are in the range 1-
10µM. 5-8.6µM Palmitate (16:0) [447]; 3.6-8.6µM Palmitate (16:0), 3-8.6µM Oleate (18:1), 6.5-
10µM Arachidonate (20:4) [448]; 2.78µM Palmitate (16:0), 2.04µM Palmitoleate (16:1), 1.39 
µM Oleate (18:1), 2.22µM Linoleate  (18:2), 1.64µM Linolenate (18:3) [449]. 
𝐾𝑀
𝐴𝑇𝑃  = 87µM [450]  
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𝑘𝑖
𝐶𝑜𝐴−𝑖𝑛ℎ𝑖𝑏 = 47.8µM, [451] 𝛽𝑖𝑛ℎ = 0.4 [451] 
𝐼𝑛𝑠𝑟𝑒𝑓
𝛽𝑜𝑥𝑖
 = 666.7pM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝛽𝑜𝑥𝑖
 = 875pM - set so that the model simulations match the data in 
references [141, 425-431, 434, 435, 443, 444, 452, 453] for plasma concentrations of key 
glucose and lipid metabolism molecules throughout a daily feeding cycle [425] (section S1.1.4), 
after a glucose load [434] (section S1.2.2) and after a mixed meal [428] (section S1.1.2), for 
average hepatic glucose metabolism intermediate concentrations including acetyl-CoA, 
pyruvate, glucose, G6P, lactate, G3P and GADP [426, 427, 429, 430] (section S1.1.1), for 
average concentrations of FFAs and triglycerides in individuals varying weight and with varying 
insulin sensitivities [141, 435] (section S1.2.1), and for the rates of lipid and glucose use in the 
various pathways after intake in the presence or absence of hormones [431, 443, 444, 452, 
453] (sections S1.1.3, S1.3).  
2.2.3.6 Oxidative phosphorylation and the energy molecules 
2.2.3.6.1 Oxidative phosphorylation/the citrate cycle 
 
Rather than modelling the citrate cycle and ETC in detail, they are represented by a single equation. 
For each acetyl-CoA molecule that enters the citrate cycle, 12 ATP molecules are produced from ADP 
and Pi (based on the system working slightly below its maximum efficiency yield of 14 ATP per acetyl-
CoA). An oxygen dependence is included based on the plasma oxygen concentration reaching the cells. 
𝑣𝐴𝑇𝑃𝑆 ∗ 𝐴𝐶𝑜𝐴
𝐾𝑀
𝐴𝐶𝑜𝐴 + 𝐴𝐶𝑜𝐴
∗
𝑂𝑥𝑦𝐵
𝐾𝑀
𝑂𝑥𝑦𝐵 + 𝑂𝑥𝑦𝐵
∗
𝑃ℎ𝑜𝑠
𝐾𝑀
𝑃ℎ𝑜𝑠 + 𝑃ℎ𝑜𝑠
∗
𝐴𝐷𝑃
𝐾𝑀
𝐴𝐷𝑃 + 𝐴𝐷𝑃
 
𝐾𝑀
𝐴𝐶𝑜𝐴 = 0.4 µM – [454]  (measured in heart) 
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𝐾𝑀
𝑂𝑥𝑦𝐵  = 28mmHg for the oxygen concentration in the blood near the cell, based on the value 
of 14mmHg from Matsumura et al. [93] which was doubled since it is estimated the the blood 
concentration of oxygen reaching cells is half of the average concentration in the sinusoid [94]. 
𝐾𝑀
𝑃ℎ𝑜𝑠 = 3830mM based on the average phosphate concentration in the model – The constant 
hasn’t been measured for humans in the literature and widely ranging values have been 
measured for other organisms (8.9mM [455], 0.55mM [456], ~10mM [457]). However, when 
simulating normal conditions, less than a 5% change in phosphate concentration is seen 
throughout the day, so ATP production is not strongly affected by phosphate concentration in 
the model. 
𝐾𝑀
𝐴𝐷𝑃  = 410 µM – not measured in human or other mammals, based on data for thermophilic 
Bacillus PS3 [455]. 
2.2.3.6.2 Nucleoside Diphosphate Kinases 
Nucleoside diphosphate kinases (NDKs) mediate the exchange of phosphate groups between various 
nucleoside di- (and tri-) phosphates. KM values were taken from the literature whilst the rate constants 
were fitted to average values for the 3 sets of di- and tri- phosphates included in the model. 
 
𝑣𝑁𝐷𝐾𝐺 (
𝐴𝑇𝑃 ∗ 𝐺𝐷𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)(𝐾𝑀
𝐺𝐷𝑃 + 𝐺𝐷𝑃)
−
𝐴𝐷𝑃 ∗ 𝐺𝑇𝑃
(𝐾𝑀
𝐴𝐷𝑃 + 𝐴𝐷𝑃)(𝐾𝑀
𝐺𝑇𝑃 + 𝐺𝑇𝑃)
) 
 
𝑣𝑁𝐷𝐾𝑈 (
𝐴𝑇𝑃 ∗ 𝑈𝐷𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)(𝐾𝑀
𝑈𝐷𝑃 + 𝑈𝐷𝑃)
−
𝐴𝐷𝑃 ∗ 𝑈𝑇𝑃
(𝐾𝑀
𝐴𝐷𝑃 + 𝐴𝐷𝑃)(𝐾𝑀
𝑈𝑇𝑃 + 𝑈𝑇𝑃)
) 
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𝐾𝑀
𝐴𝑇𝑃  = 290µM (200-380µM [458]), 𝐾𝑀
𝐺𝐷𝑃  = 33.5µM (31-36 [459]), 𝐾𝑀
𝐴𝐷𝑃  = 24µM [458], 𝐾𝑀
𝐺𝑇𝑃 = 
120µM [458], 𝐾𝑀
𝑈𝐷𝑃  = 175µM (160-190 [459]), 𝐾𝑀
𝑈𝑇𝑃 = 21.5mM (16-27mM [460]). 
2.2.3.6.3 Adenosine Kinase 
Adenosine kinase (AK) mediates the bi-directional transfer of a phosphate from ATP to AMP, providing 
two ADP. KM values were taken from the literature whilst the rate constant was fitted to experimental 
data for average hepatic ATP, AMP and ADP concentrations 
 
𝑣𝐴𝐾 (
𝐴𝑇𝑃 ∗ 𝐴𝑀𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)(𝐾𝑀
𝐴𝑀𝑃 + 𝐴𝑀𝑃)
−
𝐴𝐷𝑃2
(𝐾𝑀
𝐴𝐷𝑃2 + 𝐴𝐷𝑃2)
) 
𝐾𝑀
𝐴𝑇𝑃  = 90µM [461], 𝐾𝑀
𝐴𝑀𝑃  = 80µM [461], 𝐾𝑀
𝐴𝐷𝑃  = 110µM [461]. 
2.2.3.6.4 Additional ATP Consumption 
2.2.3.6.4.1 Cellular ATP usage term 
ATP is consumed by hepatic processes other than the glucose and lipid metabolism represented in the 
model. A single Michaelis-Menten type equation was introduced to represent this consumption of 
ATP. The rates of ATP production and use were fitted so that the average ATP, ADP and Pi 
concentrations matched that measured in [429] (section S1.1.1). Additionally, Ainscow and Brand 
performed a study in which they determined the relative rates of various processes under conditions 
of rapid glycogen breakdown in cultured hepatocytes [444] (section S1.1.3). Under these conditions, 
10% of G6P derived from glycogen breakdown entered glycolysis but was not released as lactate (46% 
overall entered glycolysis). Of this 10%, the vast majority would be expected to have entered the 
citrate cycle given that a very low rate of lipogenesis was measured. This allows an estimation of the 
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rate of use of glucose for ATP production. Finally, the simulated data were compared with 
experimental data published by Edgerton et al. for the rates of various metabolic processes in canine 
livers under varying insulin concentrations [443], and by Mandarino et al. for the rates of glucose 
disposal and glucose oxidation and β-oxidation in muscle cells experiencing different insulin 
concentrations [431] (section S1.1.3). While the liver derives a higher percentage of its energy from 
plasma FFAs than muscle, this gives an idea of the effects of hormonal stimulation. 
𝑣𝑎𝑡𝑝𝑢𝑠𝑒 ∗ 𝐴𝑇𝑃
(𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃)
 
𝐾𝑀
𝐴𝑇𝑃 = 2500 – roughly equal to the average ATP concentration in pericentral compartment. 
2.2.3.6.4.2 Control of cellular phosphate levels 
The rate of cytosolic phosphate production or usage in glucose metabolism is strongly dependent on 
the feeding state and, in initial simulations, the concentration varied massively over time. As a result, 
an additional heuristic term was added representing the control of the cytosolic phosphate 
concentration. 
𝑣𝑐𝑜𝑛(𝑃𝑖 − 𝑟𝑒𝑓𝑃𝑖) 
𝑣𝑐𝑜𝑛  = 0.1, 𝑟𝑒𝑓𝑃𝑖 = 4.15mM fitted so that the average phosphate concentration matched that 
presented in Veech et al. [429] and didn’t fluctuate significantly from this value under different 
feeding conditions (section S1.1.1). 
2.2.3.7 Lipogenesis 
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An acetyl-CoA molecule is converted to malonyl-CoA by ACC before combining with a second acetyl-
CoA molecule under the influence of FAS. FAS then mediates the addition of subsequent malonyl-CoA 
molecules forming the FA chain. Of the two ACC isoforms, only ACC1 contributes to lipogenesis. The 
malonyl-CoA produced by mitochondrial ACC2 is physically separated from FAS under normal 
physiological conditions and, instead, is involved in the allosteric inhibition of β-oxidation [462]. In the 
model, all FAs are produced from 8 acetyl-CoA molecules corresponding to palmitate (16:0). 
Lipogenesis is allosterically inhibited by various FAs. 
𝐾𝑙𝑔𝑒𝑛
𝑚𝑎𝑥 = (1 +
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑔𝑒𝑛 −
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑔𝑒𝑛) 
𝑣𝑙𝑔𝑒𝑛 ∗ 𝐾𝑙𝑔𝑒𝑛
𝑚𝑎𝑥 ∗ 𝐴𝐶𝑜𝐴
𝐾𝑀
𝐴𝐶𝑜𝐴 + 𝐴𝐶𝑜𝐴
∗
𝐴𝑇𝑃
𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃
(1 −
𝐹𝐴
𝐹𝐴 + 𝑘𝑖
𝐹𝐴−𝑖𝑛ℎ𝑖𝑏
) 
𝐾𝑀
𝐴𝐶𝑜𝐴  = 58µM [463] for ACC. FAS also directly requires acetyl-CoA in the initial step of 
lipogenesis where an acetyl-CoA molecules is joined with a malonyl-CoA molecule before 
additional malonyl-CoA molecules are added to the FA chain. However, the KM value for FAS is 
very low such that under normal physiological conditions further increase in acetyl-CoA will not 
increase the rate. Instead, FAS is rate limited by the malonyl-CoA produced by ACC [464, 465]. 
𝐾𝑚
𝐹𝐴−𝑖𝑛ℎ𝑖𝑏  = 300µM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑔𝑒𝑛
 = 8000pM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑔𝑒𝑛
 = 875pM – set so that the model 
simulations match experiment data for plasma concentrations of key glucose and lipid 
metabolism molecules throughout a daily feeding cycle [139, 425] (sections S1.1.4, S1.2.1), 
after a glucose load [434] (section S1.2.2) and after a mixed meal [428] (section S1.1.2), for 
average hepatic glucose metabolism intermediate concentrations including acetyl-CoA, 
pyruvate, glucose, G6P, lactate, G3P and GADP [426, 427, 429, 430] (section S1.1.1), for 
average plasma concentrations of FFAs and triglycerides in individuals varying weight and with 
varying insulin sensitivities [141, 435, 466] (section S1.2.1), for the hepatic triglyceride 
concentration [211] (section S1.1.1), and for the effects of insulin and glucagon on the rate of 
lipogenesis and activity of ACC (in adipose tissue rather than liver) [467-469].  
𝐾𝑀
𝐴𝑇𝑃  = 120µM [463]. 
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2.2.3.8 Triglyceride Synthesis and Breakdown 
2.2.3.8.1 Triglyceride Synthesis 
 
Each FFA must be joined with a coenzyme A (CoA) to form acyl-CoA before being used for triglyceride 
synthesis, requiring the conversion of 3 ATP molecules to AMP. An acyl-CoA is attached to a glycerol 
backbone derived from glycerol-3-phosphate (G3P) by G3P-acyltransferase forming a 
monoacylglycerol. Since conversion between G3P and GADP is rapid and reversible they are 
represented by a single combined variable in the model. Another two acyl-CoA molecules are 
sequentially added by acyltransferases forming DAGs followed by triglycerides. In the model these 
conversions are currently represented by one equation rather than as individual reactions. Triglyceride 
synthesis is promoted by insulin and inhibited by glucagon. Note that DAGs are also used to produce 
various phospholipids not currently included in the model.  
𝐾𝑡𝑠𝑦𝑛
𝑚𝑎𝑥 = (1 +
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑡𝑠𝑦𝑛 −
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑡𝑠𝑦𝑛) 
𝑣𝑇𝐺𝑠𝑦𝑛 ∗ 𝐾𝑡𝑠𝑦𝑛
𝑚𝑎𝑥 ∗ 𝐹𝐴
𝐾𝑀
𝐹𝐴 + 𝐹𝐴
∗
𝐺𝐴𝐷𝑃
𝐾𝑀
𝐺𝐴𝐷𝑃 + 𝐺𝐴𝐷𝑃
 
𝐾𝑀
𝐺𝐴𝐷𝑃 = 460µM [470]. 
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑇𝐺𝑠𝑦𝑛
 = 500pM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑇𝐺𝑠𝑦𝑛
 = 1.066nM – set so that the model simulations match 
experiment data for plasma concentrations of key glucose and lipid metabolism molecules 
throughout a daily feeding cycle [139, 425] (sections S1.1.4, S1.3.1), after a glucose load [434] 
(section S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic glucose 
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metabolism intermediate concentrations including acetyl-CoA, pyruvate, glucose, G6P, lactate, 
G3P and GADP [426, 427, 429, 430] (section S1.1.1), for average plasma concentrations of FFAs 
and triglycerides in individuals varying weight and with varying insulin sensitivities [141, 435, 
466] (section S1.2.1), for the hepatic triglyceride concentration [211] (section S1.1.1), and for 
the effects of hormones on the rate of triglyceride synthesis and the activities of various 
triglyceride synthesis enzymes (in adipose tissue rather than liver) [467, 471]. 
𝐾𝑀
𝐹𝐴 = 645µM – as discussed for β-oxidation, it is not possible to measure a single KM value for 
all FFAs in general. The value used is high relative to the low cellular FFA concentration such 
that the dependence of the rate on the concentration is almost linear. This ensures that 
triglyceride synthesis increases and falls when hepatic FFA concentrations fluctuate throughout 
the day. 
2.2.3.8.2 Lipolysis 
 
Each triglyceride is broken down to three FFAs and a glycerol molecule by a sequence of lipases 
(predominantly rate limited by the first enzyme in the chain, triacylglycerol lipase [472]. Hepatic 
lipolysis is stimulated by glucagon and suppressed by insulin. 
𝐾𝑙𝑝𝑙𝑦
𝑚𝑎𝑥 = (1 −
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑝𝑙𝑦 +
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑝𝑙𝑦) 
𝑣𝑙𝑝𝑙𝑦 ∗ 𝐾𝑙𝑝𝑙𝑦
𝑚𝑎𝑥 ∗ 𝑇𝐺
𝐾𝑀
𝑇𝐺 + 𝑇𝐺
 
𝐾𝑀
𝑇𝐺 = 50.715mM – It is difficult to base a KM value on experimentally measured values since 
numerous triglycerides exist and widely ranging KM values are measured for both different 
triglycerides and in different studies of the same triglyceride (e.g. tripalmitin (three palmitic 
acids attached to a glycerol backbone) [473, 474]). A relatively high value was chosen relative 
to the average hepatic concentrations such that increases in hepatic triglyceride levels cause 
85 
 
increased lipolysis. However, since the rate of lipolysis is very slow in hepatocytes, hepatic 
lipolysis is not a major determinant of the hepatic or plasma triglyceride concentrations and 
has very little effect on the rest of hepatic metabolism. When triglyceride breakdown is 
required this predominantly occurs in adipose tissue. 
𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑝𝑙𝑦
 = 1.067nM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑝𝑙𝑦
 = 625pM – set so that the model simulations match experiment 
data for plasma concentrations of key glucose and lipid metabolism molecules throughout a 
daily feeding cycle [139, 425] (sections S1.1.4, S1.2.1), after a glucose load [434] (section 
S1.2.2) and after a mixed meal [428] (section S1.1.2), for average plasma concentrations of 
FFAs and triglycerides in individuals varying weight and with varying insulin sensitivities [141, 
435, 466] (section S1.2.1), for the hepatic triglyceride concentration [211] (section S1.1.1), and 
for the effects of hormonal regulation on triglyceride synthesis [467] (section S1.1.1 – discussed 
but not presented). 
2.2.3.8.3 Conversion of glycerol of G3P/GADP 
 
Glycerol is converted G3P by glycerol kinase requiring the conversion of ATP to ADP. G3P is then 
rapidly and reversible converted to GADP. 
𝑣𝑔𝑐𝑜𝑛𝑣 ∗ 𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙
𝐾𝑀
𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙
+ 𝐺𝑙𝑦𝑐𝑒𝑟𝑜𝑙
∗
𝐴𝑇𝑃
𝐾𝑀
𝐴𝑇𝑃 + 𝐴𝑇𝑃
 
𝐾𝑀
𝐺𝑙𝑦
 = 41µM – 36-46µM measured in rat [475] 
𝐾𝑀
𝐴𝑇𝑃  = 15µM – no data for human, ranging from 6µM to 3mM for different bacteria (BRENDA 
enzyme database). Changes in the glycerol concentration are very small compared to the 
glucose, lactate and lipid concentrations so changes in the parameters defining this term do 
not have a large effect on the system as a whole. 
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2.2.3.9 Membrane Transport 
2.2.3.9.1 Lactate 
 
Lactate uptake/output is represented through a diffusion term dependent on the relative blood and 
cytoplasmic lactate concentrations. 
𝑣𝑙𝑎𝑐𝑡 ∗ (𝐿𝑎𝑐𝐵 − 𝐿𝑎𝑐𝐶)
(𝐾𝑀
𝐿𝑎𝑐 + 𝐿𝑎𝑐𝐵 + 𝐿𝑎𝑐𝐶)
 
𝐾𝑀
𝐿𝑎𝑐 = 1.2mM – Roughly equal to the average lactate concentration. 𝐾𝑀
𝐿𝑎𝑐 and 𝑣𝑙𝑎𝑐𝑡 were set 
so that the model simulations match the experimental data for plasma concentrations of 
glucose and lactate throughout a daily feeding cycle [425] (section S1.1.4), after a glucose load 
[434] (section S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic glucose 
metabolism intermediate concentrations including glucose, G6P, pyruvate, lactate, G3P and 
GADP [426, 427, 429, 430] (section S1.1.1), and for the rates of glucose use in the various 
pathways after intake in the presence or absence of hormones [431] (section S1.1.3). 
2.2.3.9.2 Free Fatty Acids 
 
FFA uptake is complex and not fully understood [29]. It is known FA transport proteins FATP2 and 
FATP5 play an important role since uptake is reduced in mice lacking either protein [27-29]. 
Additionally, overexpression of scavenger receptor CD36 (known to occur in NAFLD) promotes 
increased uptake [30-32]. Knockout of liver-type FA binding protein also reduces FFA uptake [33]. 
Passive, unfacilitated diffusion also contributes to hepatic uptake although this process is relatively 
slow [476, 477]. Once FFAs enter the liver they are rapidly bound to a CoA molecule to form acyl-CoA 
preventing efflux. Cellular FFAs are rapidly utilized in β-oxidation or attached to a glycerol backbone 
to form di- and triglycerides. As a result, the hepatic concentration is low (<50µM). 
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Insulin causes increased FFA uptake by stimulating FATPs [478-480]. In the model, FFA uptake is 
represented by two terms. Firstly, an insulin-dependent, unidirectional uptake term corresponding to 
the active scavenging by transport proteins. Secondly a non-hormone dependent, bidirectional term 
accounting for both unfacilitated diffusion and bidirectional facilitated diffusion. Given that the 
cellular concentration is very small compared to the plasma concentration, these both act strongly as 
uptake terms, even when simulating IR. 
𝑣𝑎𝑐𝑡𝑖𝑣𝑒 ∗ 𝐹𝐹𝐴𝐵
(𝐾𝑀
𝑎𝑐𝑡𝑖𝑣𝑒 + 𝐹𝐹𝐴𝐵)
(1 +
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑎𝑐𝑡𝑖𝑣𝑒
) +
𝑣𝑑𝑖𝑓𝑓 ∗ (𝐹𝐹𝐴𝐵 − 𝐹𝐹𝐴𝐶)
(𝐾𝑀
𝑑𝑖𝑓𝑓
+ 𝐹𝐹𝐴𝐵 + 𝐹𝐹𝐴𝐶)
 
𝐾𝑀
𝑎𝑐𝑡𝑖𝑣𝑒  = 2µM, 𝐾𝑀
𝑑𝑖𝑓𝑓
 = 200µM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑎𝑐𝑡𝑖𝑣𝑒  = 21.333pM – set so that the model simulations 
match experiment data for plasma concentrations of key glucose and lipid metabolism 
molecules throughout a daily feeding cycle [139, 425] (sections S1.1.4, S1.2.1), after a glucose 
load [434] (section S1.2.2) and after a mixed meal [428] (section S1.1.2), for average hepatic 
glucose metabolism intermediate concentrations including acetyl-CoA, pyruvate, glucose, G6P, 
lactate, G3P and GADP [426, 427, 429, 430] (section S1.1.1), for average plasma concentrations 
of FFAs and triglycerides in individuals varying weight and with varying insulin sensitivities 
[141, 435, 466] (section S1.2.1), for the rates of lipid and glucose use in the various pathways 
after intake in the presence or absence of hormones [443] [431, 444, 452, 453] (sections S1.1.3, 
S1.3), for the hepatic triglyceride concentration [211] (section S1.1.1), and for the effects of 
hormones on the rate of lipogenesis and release, and the activities of various lipogenic enzymes 
(in adipose tissue rather than liver) [467, 471]. 
2.2.3.9.3 Triglycerides 
 
Two terms represent movement of triglycerides between the cytoplasm and the blood stream. The 
first term represents the production and release of VLDL. Liver is the major organ responsible for 
packaging triglycerides into VLDL such that this is the major cause of triglyceride output from the cell 
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[481]. It should be noted that, in the model, once triglycerides are in the blood, free triglycerides along 
with triglycerides contained in lipoproteins are represented by a single variable. The second term 
represents very slow uptake of triglycerides from transporter molecules in the plasma and the slow 
output in forms other than VLDL. It has been shown in numerous species that hepatocytes are able to 
uptake triglycerides from plasma lipoproteins, although the proteins involved in the transport have 
yet to be fully characterised [482-484]. Therefore, a simple bidirectional Hill function with KM value 
based on the average plasma and hepatic triglyceride concentration was used. Since the hepatic 
triglyceride concentration is much higher than the plasma concentration (healthy livers store up to 5% 
fat), a conversion constant 𝑇𝐺𝑟𝑒𝑓 was included to ensure this bi-directions transfer term did not result 
in constant output. 
−
𝑣𝑉𝐿𝐷𝐿 ∗ 𝑇𝐺𝐶
(𝐾𝑀
𝑉𝐿𝐷𝐿 + 𝑇𝐺𝐶)
+
𝑣𝑑𝑖𝑓𝑓 ∗ (𝑇𝐺𝐵 −
𝑇𝐺𝐶
𝑇𝐺𝑟𝑒𝑓
)
(𝐾𝑀
𝑑𝑖𝑓𝑓𝑖
+ 𝑇𝐺𝐵 +
𝑇𝐺𝐶
𝑇𝐺𝑟𝑒𝑓
)
 
 𝐾𝑀
𝑉𝐿𝐷𝐿  = 33.81mM, 𝐾𝑀
𝑑𝑖𝑓𝑓𝑖
= 1mM, 𝑇𝐺𝑟𝑒𝑓 =33.81 – Roughly equal to experimental data for 
average plasma [141, 435, 466] (section S1.2.1), and hepatic TG concentrations [211] (section 
S1.1.1). Due to the slow rate of lipogenesis, short-term variations in the hepatic concentration 
have little effect on the rest of metabolism. 
2.2.3.9.4 Glycerol 
 
Glycerol released primarily by WAT during lipolysis is cleared from the blood by hepatocytes. Uptake 
is represented by a simple diffusion term. 
𝑣𝐺𝑙𝑦𝑐𝑡 ∗ (𝐺𝑙𝑦𝑐𝐵 − 𝐺𝑙𝑦𝑐𝐶)
(𝐾𝑀
𝐺𝑙𝑦𝑐
+ 𝐺𝑙𝑦𝑐𝐵 + 𝐺𝑙𝑦𝑐𝐶)
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𝐾𝑀
𝐺𝑙𝑦𝑐
 = 270µM (250-402µM measured in rat [475]) – In simulations, glycerol kinase is rate-
limiting in glycerol clearance rather than uptake such that moderate changes in 𝐾𝑀
𝐺𝑙𝑦𝑐
 do not 
have a large effect on the overall rate of uptake. 
2.2.4 Adipose Tissue, Muscle and Dietary Inputs and Outputs 
In addition to the liver, organs including the intestine, adipose tissue and muscle play important roles 
in FFA and glucose metabolism and consumption required for the model to produce realistic data. 
Given that the focus of this report is on hepatic metabolism rather than the gut or adipose tissue, 
rather than treating these organs as separate compartments containing complex sets of pathways, a 
minimal representation of these lipid metabolism processes was included which produces plasma lipid 
levels consistent with those measured experimentally in metabolically normal and insulin resistant 
individuals, but does not include the changes occurring in the concentrations of metabolites within 
the adipose tissue.  
Lipids enter the body compartment of the model as FFAs. A single equation then calculates the 
synthesis of triglycerides in the gut (and other organs in the body excluding liver). Two equations 
represent adipose lipogenesis and adipose lipolysis. A final equation represents insulin dependent FFA 
uptake by muscle and other body cells.  Since a separate adipose tissue compartment was not included 
in the model, adipose lipid storage could not be included. Instead, the adipose and muscle equations 
act directly on the blood concentrations of glucose, FFAs and triglycerides. The constants in these 
equations were fitted by eye so that the FFA and triglyceride concentrations matched those measured 
throughout the day for healthy patients by Daly et al. [425] (section S1.1.4), so that the average FFA 
and triglyceride concentrations matched those measured for diabetic and non-diabetic patients by 
Sindelka et al. [141] and Berndt et al. [435] (section S1.2.1) and so that the contribution of de novo 
lipogenesis to hepatic and plasma triglyceride content matched that presented by Donnelly et al. [26]. 
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2.2.4.1 Adipose and Gut Equations 
2.2.4.1.1 De novo synthesis 
De novo FA synthesis is represented by a single equation in which 4 glucose molecules, and hence 8 
acetyl-CoA molecules, are converted to a FFA. 
𝑣𝑑𝑛𝑊𝐴𝑇 ∗ 𝐺𝐵
𝐾𝑀
𝐺𝐵 + 𝐺𝐵
(1 +
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑑𝑛𝑊𝐴𝑇 −
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑑𝑛𝑊𝐴𝑇) 
𝐾𝑀
𝐺𝐵= 4.5mM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑑𝑛𝑊𝐴𝑇=1.87nM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑑𝑛𝑊𝐴𝑇=250pM 
2.2.4.1.2 Triglyceride Synthesis and Lipolysis 
When representing gut triglyceride synthesis and adipose lipolysis, time constants needed to be added 
to slow the effect of hormones. This is to compensate for the fact that adipose triglyceride storage 
was not included in the model. In initial model building, the rates of triglyceride synthesis and lipolysis 
were set to depend only on the current plasma insulin and glucagon concentrations (as with the rest 
of the equations in the model). However, this led to the rapid breakdown of triglycerides and a large 
spike in FFA concentration as soon as glucose concentrations dropped between meals. Instead, in vivo, 
the FFA concentration increases more steadily over time between meals, and FFAs continue to be 
released until the next meal (or lipid stores begin to empty). The difference between the simulated 
and experimental data is likely to be accounted for by the release of stored adipose triglycerides, not 
accounted for in the model. After the addition of time constants to account for this, the simulated FFA 
concentration was consistent with the values measured by Daly et al. [425], Sindelka et al. [141] and 
Berndt et al. [435] without the need to include adipose lipid storage.  
2.2.4.1.2.1 Triglyceride Synthesis 
Three FFAs attached to a G3P backbone corresponding to half of a blood glucose molecule to form a 
triglyceride.  
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𝐼𝑓 (
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛 − 𝑣𝐺) > 0; then: 
𝑑𝑣𝐺
𝑑𝑡
=
(
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛
𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛−𝑣𝐺)
𝜏𝐺𝑢𝑝
; else: 
𝑑𝑣𝐺
𝑑𝑡
=
(
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛
𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛−𝑣𝐺)
𝜏𝐺𝑑𝑜𝑤𝑛
 
𝐼𝑓 (
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛 − 𝑣𝐼) > 0; then: 
𝑑𝑣𝐼
𝑑𝑡
=
(
𝐼𝑛𝑠
𝐼𝑛𝑠
𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛−𝑣𝐼)
𝜏𝐼𝑢𝑝
; else: 
𝑑𝑣𝐼
𝑑𝑡
=
(
𝐼𝑛𝑠
𝐼𝑛𝑠
𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛−𝑣𝐼)
𝜏𝐼𝑑𝑜𝑤𝑛
 
𝑣𝑡𝑟𝑖𝑠𝑦𝑛𝐻 = 𝑣𝑡𝑟𝑖𝑠𝑦𝑛 ∗ (1 + 𝑣𝐼 − 𝑣𝐺) 
𝑣𝑡𝑟𝑖𝑠𝑦𝑛𝐻 ∗ 𝐺𝐵
𝐾𝑀
𝐺𝐵 + 𝐺𝐵
𝐹𝐹𝐴
𝐾𝑀
𝐹𝐹𝐴 + 𝐹𝐹𝐴
 
𝐾𝑀
𝐺𝐵=10mM, 𝐾𝑀
𝐹𝐹𝐴=645mM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛
=800pM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑡𝑟𝑖𝑠𝑦𝑛
=37.5pM 
 𝜏𝐼
𝑢𝑝 =1000s-1,  𝜏𝐼
𝑑𝑜𝑤𝑛 =15000s-1, 𝜏𝐺
𝑢𝑝=10000s-1, 𝜏𝐺
𝑑𝑜𝑤𝑛=700s-1 
2.2.4.1.2.2 Lipolysis 
A triglyceride is removed from the blood and broken down into three FFAs and a glycerol. 
𝐼𝑓 (
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦 − 𝑣𝐺) > 0; then: 
𝑑𝑣𝐺
𝑑𝑡
=
(
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛
𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦−𝑣𝐺)
𝜏𝐺𝑢𝑝
; else: 
𝑑𝑣𝐺
𝑑𝑡
=
(
𝐺𝑙𝑐𝑔𝑛
𝐺𝑙𝑐𝑔𝑛
𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦−𝑣𝐺)
𝜏𝐺𝑑𝑜𝑤𝑛
 
𝐼𝑓 (
𝐼𝑛𝑠
𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦 − 𝑣𝐼) > 0; then: 
𝑑𝑣𝐼
𝑑𝑡
=
(
𝐼𝑛𝑠
𝐼𝑛𝑠
𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦−𝑣𝐼)
𝜏𝐼𝑢𝑝
; else: 
𝑑𝑣𝐼
𝑑𝑡
=
(
𝐼𝑛𝑠
𝐼𝑛𝑠
𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦−𝑣𝐼)
𝜏𝐼𝑑𝑜𝑤𝑛
 
𝑣𝑙𝑖𝑝𝑜𝑙𝑦𝐻 = 𝑣𝑙𝑖𝑝𝑜𝑙𝑦𝑠𝑖𝑠 ∗ (1 − 𝑣𝐼 + 𝑣𝐺) 
𝑣𝑙𝑖𝑝𝑜𝑙𝑦𝐻 ∗ 𝑇𝐺𝐵
𝐾𝑀
𝑇𝐺𝐵 + 𝑇𝐺𝐵
 
𝐾𝑀
𝑇𝐺𝐵= 2mM, 𝐼𝑛𝑠𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦𝑠𝑖𝑠
= 800pM, 𝐺𝑙𝑐𝑔𝑛𝑟𝑒𝑓
𝑙𝑖𝑝𝑜𝑙𝑦𝑠𝑖𝑠
=37.5pM 
𝜏𝐼
𝑢𝑝=1000s-1, 𝜏𝐼
𝑑𝑜𝑤𝑛=15000s-1, 𝜏𝐺
𝑢𝑝=10000s-1, 𝜏𝐺
𝑑𝑜𝑤𝑛=700s-1 
2.2.4.2 Input 
Carbohydrates are broken down to sugars before entering the blood stream. Dietary lipids are broken 
down to FFAs before being absorbed by the enterocytes of the intestinal wall. Short to medium chain 
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FFAs can enter directly into the portal vein. Longer chain FFAs are converted back into triglycerides 
and released into the bloodstream as chylomicrons via the lymph system, although some long chain 
FFAs have been shown to enter directly to the portal vein [485]. In the model, all dietary carbohydrates 
enter the bloodstream as glucose, whilst lipids enter the blood as FFAs. A triglyceride synthesis term 
represents both the reforming of triglycerides in the gut, and triglyceride synthesis around the body. 
Glucose and FFA inputs of any form can be inputted to the model. Throughout this report, spiked 
glucose and FFA inputs with a period of 4 hours were used to approximate a daily feeding cycle 
excluding sleep. 
𝑣𝑖𝑛𝑝𝑢𝑡 ∗ sin
6 (
𝑝𝑖
2(ℎ𝑜𝑢𝑟𝑠)
)           -> Spiked inputs with 4-hour period 
The additional changes to hormone release and energy metabolism occurring during sleep or 
prolonged starvation in addition to exercise were considered beyond the scope of the model at 
present. When simulating a moderate diet, the inputs were based on the average meal values in Daly 
et al. [425]. In this study, the three meals provided to subjects each day (breakfast, lunch and dinner) 
contained an average of 78.1g of carbohydrate and 22.2g of fat. In terms of the energy provided from 
these two sources this was a ratio of 1.648 to 1. When running the simulations, the size of the glucose 
and FFA inputs were set to match these values. Each intake cycle was set to provide 86.74mmoles of 
glucose per litre of blood into the body compartment. Presuming a blood volume of 5L, this 
corresponds to 78.1g. Since FFAs have a range of molar masses, the FFA input to the model in moles 
could not be calculated from the grams of fat per meal. Instead the relative contribution of glucose 
and FFAs to energy were used. In the model, each glucose molecules that undergoes glycolysis 
followed by oxidation provides a net total of 34 ATP. Each palmitate molecules that is oxidised 
provides a net of 114 ATP. Therefore, to attain the ratio of 1.648:1 provided in the study, the FFA input 
was set to provide 15.75mmoles of fat per litre of blood per intake cycle to the body compartment. 
Using the molar mass of palmitate and assuming 5L of total blood this would correspond to 20.2g of 
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fat. The outputted data are compared with experimental data when simulating this diet in section 
S1.1.4.  
𝑣𝑖𝑛𝑝𝑢𝑡(𝐺𝑙𝑢𝑐𝑜𝑠𝑒)=19.275μM/s - (78.1g/cycle assuming 5L of blood in the body compartment) 
𝑣𝑖𝑛𝑝𝑢𝑡(𝐹𝐹𝐴) =3.5μM/s - (20.2g/cycle assuming 5L of blood in the body compartment and the 
molecular mass of palmitate). 
2.2.4.3 Consumption Terms (Muscle and Body cells) 
In the model glucose is consumed by cells (outside the liver) according to a simple Hill function with a 
low KM constant such that, under normal conditions, glucose is absorbed at a relatively constant rate 
by muscle and other body cells. In reality, other organs show hormone dependent uptake. However, 
the focus of this study is on liver which is the major determinant of plasma glucose concentration, 
hormone dependences of glucose uptake by other tissues around the body were not included. 
𝑣𝐺𝑏𝑢𝑠𝑒 ∗ 𝐺𝐵
𝐾𝑀
𝐺𝐵 + 𝐺𝐵
 
KM
GB=1mM, vGBuse = 4.93µM/s 
The rate of FFA consumption elsewhere in the body was represented by a similar term with the 
inclusion of an insulin dependence.  
𝑣𝐹𝐹𝐴𝑢𝑝𝑡𝑎𝑘𝑒 ∗ 𝐹𝐹𝐴
𝐾𝑀
𝐹𝐹𝐴 + 𝐹𝐹𝐴
(
(𝐼𝑛𝑠 + 𝑘𝐼𝑢𝑝)
(𝐺𝑙𝑔𝑛 + 𝑘𝐿𝑢𝑝)
) 
𝐾𝑀
𝐹𝐹𝐴 = 100 µM, 𝑘𝐼𝑢𝑝 = 250pM, 𝑘𝐿𝑢𝑝 = 125pM, 𝑣𝐹𝐹𝐴𝑢𝑝𝑡𝑎𝑘𝑒 = 0.982µM/s  
2.2.5 Oxygen and Hormone Inputs and Consumption 
2.2.5.1 Hormone release by the pancreas 
The representation of pancreatic hormone release developed by Hetherington et al. was used to 
calculate the rate of release of glucagon and insulin into the blood [389]. In this, insulin is only released 
when the blood glucose is above a threshold. Above this threshold, insulin is released according to a 
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Hill function acting on the logarithm of the glucose concentration relative to a reference 
concentration. Similarly, glucagon is only released when the blood glucose concentration is below the 
threshold. In this case, glucagon is released according to a Hill function acting on the inverse logarithm 
of the blood glucose concentration. 
𝑖𝑓 𝐺𝐵 < 𝐺𝑟𝑒𝑓,   𝐺𝑙𝑢𝑐𝑎𝑔𝑜𝑛 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =       
1
𝜏𝑔𝑙𝑔𝑛
ln
𝐺𝑟𝑒𝑓
𝐺𝐵
𝑛𝑔𝑙𝑔𝑛
(𝐾𝑚
𝑔𝑙𝑔𝑛𝑛𝑔𝑙𝑔𝑛
+ ln
𝐺𝑟𝑒𝑓
𝐺𝐵
𝑛𝑔𝑙𝑔𝑛
)
 
𝑖𝑓 𝐺𝐵 > 𝐺𝑟𝑒𝑓,   𝑖𝑛𝑠𝑢𝑙𝑖𝑛 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =    
1
𝜏𝑖𝑛𝑠
ln
𝐺𝑟𝑒𝑓
𝐺𝐵
𝑛𝑖𝑛𝑠
(𝐾𝑚
𝑖𝑛𝑠𝑛𝑖𝑛𝑠 + ln
𝐺𝑟𝑒𝑓
𝐺𝐵
𝑛𝑖𝑛𝑠
)
 
Constants as in [389]. 
2.2.5.2 Hormone degradation across the sinusoid 
In the model the hormones are degraded at a constant rate (per unit of hormone) as blood passes 
through the sinusoid. Experimentally, the concentration of glucagon has been measured to fall by 
around 50% between the blood entering the sinusoid and the blood exiting it [45]. To match this, the 
rate of degradation of glucagon was set to 0.03858 per unit of glucagon per second. In vivo, the insulin 
concentration falls by 50% across the sinusoid between meals but by only 15% post-prandially [45]. 
Since insulin is only released in the model when blood glucose levels are high, only the post-prandial 
rate of degradation was included and a rate of 0.01389 per unit of insulin per second was used. 
Therefore, an increase in the insulin to glucagon ratio is seen as blood passes through the sinusoid. 
2.2.5.3 Oxygen input and degradation 
A constant oxygen input was added to the body compartment along with a constant rate of 
consumption across the sinusoid. A constant rate of input of 1.35mmHg s-1 is provided to the body 
blood compartment and a constant output of 0.03525s-1 per unit of oxygen in each compartment of 
blood occurs across sinusoid. These were set such that the oxygen concentration falls from 65mmHg 
in the blood entering the proximal periportal compartment to 35mmHg in the blood leaving the distal 
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pericentral compartment [50]. Since no changes in oxygen input or blood flow were simulated in this 
study, the oxygen concentrations across the sinusoid remained fixed at the experimentally measured 
gradient for a healthy liver. However, the inclusion of a dynamic oxygen calculation may allow the 
model to be used to study changes in oxygen supply and blood flow in developing liver disease in the 
future. The rate of oxidative phosphorylation is oxygen dependent in the model, with a KM value based 
on the measurements by Matsumura et al. [93]. 
2.2.6 Rate Constants and Zonation 
Each equation in the model consists of a rate constant multiplied by a set of substrate, hormone and 
allosteric dependences. The rate constant for each process has a base-value (vb) which is then 
modified in each compartment according to the zonation of the process. The base-values for each 
process were set by comparing the simulated plasma and average sinusoidal concentration of the 
various molecules in the model with experimental data from several sources (table 2.3). As discussed 
in the section 2.2.2.3, the exact rates at which glucose and lipids enter the bloodstream after feeding 
in experimental studies is unknown. As a result, rather than least-squares fitting the rate constants to 
any specific data, they were set such that, for a range of data sets, the simulated plasma and hepatic 
concentrations both quantitatively remained within the experimentally measured ranges and 
matched qualitative features in the data such as periods of increase or decrease, and appropriately 
timed peaks and troughs.  
To allow for the inclusion of zonated enzyme expression, these base values of the rate constants were 
next altered in each compartment according to whether the enzymes in each process are known to 
be up-regulated or down-regulated in that region of the sinusoid.  
Zonation is known to be primarily regulated by the blood oxygen concentration [50]. As a result, in the 
model the blood oxygen concentration is used to assign each compartment a value, z, dictating how 
periportal-like or pericentral-like the enzyme expression in that compartment is. The following 
function was used to define z. 
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𝐼𝑓 𝑂𝑥𝑦 > 46.5𝑚𝑚𝐻𝑔 𝑡ℎ𝑒𝑛 (z = tanh (
(𝑂𝑥𝑦 − 46.5)
12
) 𝑒𝑙𝑠𝑒 (𝑧 = 2 ∗ tanh (
(𝑜𝑥𝑦 − 46.5)
24
) 
This function is plotted in figure 2.3 and was based on the data in Nauck et al. [69] and Wolfle and 
Jungermann [77] in which the concentrations of key periportal and pericentral enzymes were 
measured at a range of physiological oxygen concentration. A value of roughly z=1 is given at 
periportal oxygen concentrations (65-75mmHG) and a value of roughly z=-1 is given at pericentral 
oxygen concentrations (30-35mmHg). These were used as reference points for setting periportal-type 
and pericentral-type expression.  
  
Figure 2.3: The dependence of enzyme expression type (pericentral -> periportal) on oxygen 
concentration in the model. 
As shown in the experimental studies [69, 77], further induction of periportal-type enzymes does not 
occur at oxygen concentrations above that seen by periportal cells. However, in hypoxic conditions, 
additional induction of pericentral-type enzymes and suppression of periportal-type enzymes does 
occur.  
z=1 - Periportal 
Enzyme Expression 
 
z=-1 – Pericentral 
Enzyme Expression 
 
~Periportal Oxygen 
Concentration 
 
~Pericentral Oxygen 
Concentration 
 
Hypoxia 
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Since continuous changes in enzyme expression are seen for all of the processes included in the model, 
rather than the step-wise changes in, for example, cholesterol synthesis, the zonation of each process 
could be set based on the experimentally measured periportal to pericentral ratio of the rate limiting 
enzymes with a continuous change between compartments. For a process where the base-value of 
the rate constant is 𝑣𝑏  and the experimentally measured ratio of periportal expression to pericentral 
expression is kpp:1, the altered rate constant in compartment 𝑥, (𝑣𝑥) is calculated by: 
𝑣𝑥 = (1 + 𝑧𝑥 ∗ 𝑘𝑛)𝑣𝑏 
Where: 
𝑘𝑛 = 1 −
2 ∗ 𝑘𝑝𝑝
|𝑘𝑝𝑝| + 1
 
This equation gives the experimentally measured periportal: pericentral ratio between compartments 
with z=1 and z=-1 whilst leaving the average rate constant across the sinusoid unchanged at 
physiological oxygen concentrations. Table 2.4 shows the experimentally measured periportal to 
pericentral ratio in activity for the enzymes mediating each process along with the constant 𝑘𝑛 used 
in the model. 
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Table 2.3: The baseline rate constants used in the model and the experimental data used for fitting.  
Rate Constant Base Value in Model, 𝑣𝑏  Data used for rate constant fitting 
(See supplementary material S1 for comparisons with 
experimental data) 
Glucose Uptake 𝑣𝑝𝑢𝑚𝑝 = 118 µM s
-1, 
𝑣𝑑𝑖𝑓𝑓
𝑔𝑙𝑢
= 224 µM s-1, 
[425-431, 443, 444, 466] – Concentrations of various 
glucose metabolism molecules in blood and in liver 
under a range of conditions:[425] – time series data 
for plasma concentrations throughout a daily meal 
cycle (section S1.1.4). 
[428] – time series data for glucose and glycogen 
concentrations after a single meal (section S1.1.2). 
[426, 427, 429, 430] – hepatic concentrations of 
several energy metabolism intermediates (section 
S1.1.1). 
[431, 443, 444] – the relative rates at which lipids and 
glucose are oxidised and the relative rates of glucose 
release, glycolysis, lactate release and acetyl-CoA 
synthesis under conditions of glycogenolysis (section 
S1.3). Further comparison with the postprandial rates 
of glucose and FA oxidation is presented in [452, 453] 
in section S1.3. 
GK 𝑣𝑔𝑘  = 112 s
-1 
G6Pase 𝑣𝐺6𝑃𝑎𝑠𝑒  = 370 µM s
-1 
GS 𝑣𝑠𝑦𝑛 = 55 µM s
-1 
GP 𝑣𝑏𝑟𝑘=5 µM s
-1 
Glycolysis 1 (PFK) 𝑣𝑃𝐹𝐾  = 160 µM s
-1 
Glycolysis 2 (PK) 𝑣𝑃𝐾  = 87 µM s
-1 
Gluconeogenesis 
1 (PEPCK) 
𝑣𝑃𝐸𝑃𝐶𝐾= 35 µM s
-1 
 
Gluconeogenesis 
2 (FBPase) 
𝑣𝐹𝐵𝑃=68 µM s
-1 
 
Pyruvate 
Oxidation (PDC) 
𝑣𝑎𝑠𝑦𝑛= 15 µM s
-1 – set using [426, 427, 429] as a reference for the 
average cytosolic acetyl-CoA concentration, along 
with [425-431, 434, 443] for the glucose and lactate 
concentrations under different conditions, [141, 425, 
435] for the FFA and triglyceride concentrations under 
different conditions and [431, 443, 444, 452, 453] for 
the relative rates of glucose and FA oxidation 
(sections S1.1-S1.3). 
Β-oxidation 𝑣𝛽𝑜𝑥𝑖= 3.3 µM s
-1 
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ATP Production 
through the 
citrate cycle 
𝑣𝐴𝑇𝑃𝑆=520 µM s
-1 – set such that the concentrations of the mono- di- 
and tri- phosphate molecules matched the following 
average values/ranges: 
Pi – 3.81 (3.55-4.07)mM [429]; 
ATP – 2.78 (2.71-2.85)mM [429];  
ADP – .885 (.794-.976)mM [486];  
AMP – .237 (.200-.272)mM [429];  
UTP – .285 (.255-.315)mM [486];  
UDP – .108 (.096-.120)mM [486];  
GTP – .277 (.266-.288)mM [486];  
GDP – .098 (.091-.105)mM [486] 
Rates of ATP production and consumption were 
estimated based on the data in [431, 443, 444] 
(section S1.1.3).  
Nucleoside 
Diphosphate 
kinases 
𝑣𝑁𝐷𝐾𝐺=3000 µM s
-1 
𝑣𝑁𝐷𝐾𝑈=30 µM s
-1 
Adenosine Kinase 𝑣𝐴𝐾= 100 µM s
-1 
ATP consumption 𝑣𝑎𝑡𝑝𝑢𝑠𝑒  = 173 µM s
-1 
Lipogenesis 𝑣𝑙𝑔𝑒𝑛  = 5.5 µM s
-1 Overall lipogenesis (hepatic +WAT) was set such that 
the plasma concentrations and total lipogenesis rates 
matched to the data in [139, 425, 428, 466, 467] (see 
section S1). [426, 427, 429, 430] used as references 
for hepatic concentrations (section S1.1.1). [26] 
provides data for the relative contribution of liver to 
overall lipid metabolism (section 3.3.2.1). 
Triglyceride 
Synthesis 
vTGsyn= 10 µM s
-1 Set such that the plasma triglyceride and FFA 
concentrations and overall (hepatic + WAT + gut etc.) 
triglyceride production and degradation matched 
data in [141, 425, 428, 431, 435, 443, 466, 467, 471] 
as closely as possible. However, since adipose 
triglyceride storage is not included in the model, 
larger variation occurs in the simulated plasma 
triglyceride concentration throughout each 
intake/output cycle than is seen in vivo. Given that 
short term variations in plasma triglyceride 
Lipolysis 𝑣𝑙𝑝𝑙𝑦= 0.085 µM s
-1 
FFA Uptake 𝑣𝑎𝑐𝑡𝑖𝑣𝑒
𝐹𝐹𝐴 =0.08µM s-1 
 
𝑣𝑑𝑖𝑓𝑓
𝐹𝐹𝐴 = 1.2µM s-1 
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Triglyceride 
Uptake/Output 
𝑣𝑉𝐿𝐷𝐿= 0.3µM s
-1 
𝑣𝑑𝑖𝑓𝑓
𝑇𝐺 = 0.4µM s-1 
concentration have little effect on hepatic 
metabolism due to the slow rate of triglyceride uptake 
and lipolysis, emphasis was placed on ensuring the 
FFA concentration matched the experimentally 
measured at each time point, whilst only the time-
averaged plasma triglyceride value matched the 
experimental data. The contribution of liver to 
triglyceride synthesis was based on the data in [26] 
(section S1.3.3). The hepatic triglyceride 
concentration was set to match the data in reference 
[487] (section S1.1.1). 
Adipose Lipid 
Metabolism 
𝑣𝑑𝑛𝑊𝐴𝑇= .22µM s
-1 
𝑣𝑡𝑟𝑖𝑠𝑦𝑛= 8.5µM s
-1 
𝑣𝑙𝑖𝑝𝑜𝑙𝑦𝑠𝑖𝑠= 2µM s
-1 
Glycerol Kinase 𝑣𝑔𝑐𝑜𝑛𝑣= 5 µM s
-1  The average blood glycerol concentration was 
matched to the data in [425] (section S1.1.4). 
Lactate Uptake 𝑣𝑙𝑎𝑐𝑡= 200 µM s
-1 Changes in lactate concentration are largely 
determined by the effects of hormonal and allosteric 
regulation on glycolysis. [425-430, 466] were used as 
reference values blood/hepatic concentrations of 
lactate and glycolysis intermediates. 
Glycerol Uptake 𝑣𝐺𝑙𝑦𝑐𝑡= 100µM s
-1 Membrane transport is not considered rate limiting in 
the use of glycerol by hepatocytes. However, the 
plasma concentration was matched to the 
experimental data measured by Daly et al. [425] 
(section S1.1.4). 
101 
 
Table 2.4: The zonation of key enzymes in the model. 
Process PP:PC (model) Zonation of key enzymes (experimental) References Zonation Constant (𝑘𝑛) 
kn=0 – no zonation 
0<kn<1 – periportal 
-1<kn<0 – pericentral 
Glucose Uptake 
(Glucose -> G6P) 
1:2.5  Glucokinase (GK) 
1 : 1.5-3.5 
[52-61]  −0.429 
Glucose Output 
(G6P -> Glucose) 
1.9:1  Glucose-6-Phosphatase (G6Pase) 
2.3-1.5 : 1 
[54, 62-64] 0.31 
Glycogenesis 
(G6P-> Glycogen) 
3:1  Glycogen Synthase (GS) 
Periportal – no quantitative data found 
[66] 0.5 
Glycogenolysis 
(Glycogen -> G6P) 
1:1 Conflicting data in literature – perhaps 
dependent on feeding conditions. 
[65, 66] 0 (no zonation) 
Glycolysis 1 
(Glucose –> GADP) 
1:1 6-Phosphofructo-kinaseL (PFKL) 
1 : 1-1.3** 
[488]** reported as statistically 
insignificant difference between sections 
0 (no zonation) 
Glycolysis 2 
(GADP –> 
Pyruvate/Lactate) 
1:2.1  
 
Pyruvate KinaseL (PKL) 
1 : 1.66-2.5 
Cited in [45] 
[67] 
−0.355 
Gluconeogenesis 2 
(GADP -> Glucose) 
1.75:1 
 
Fructose-bisphosphatase (FBPase) 
1.5-2:1 
[52, 53, 68] 0.273 
Gluconeogenesis 1 
(Pyruvate/Lactate 
–> GADP) 
 
2.4:1 
 
Phosphoenolpyruvate carboxykinase 
(PEPCK) 
1.9-2.9 : 1 
Cited in [45] 
[61, 66, 69-72] 
0.412 
Pyruvate Carboxylase 
1.72:1 
[73] 
Pyruvate Oxidation 
 
1:1 
 
Pyruvate dehydrogenase complex (PDC) [73] 0 (no zonation) 
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1 : 1.69 (insignificant due to large 
variability, especially in the pericentral 
compartment) 
Oxidative 
phosphorylation 
and the citrate 
cycle 
1.5:1 Cristae volume:2.38:1 [46] 0.2 
Cristae Area: 2.05:1 [46] 
Succinate Dehydrogenase:1.9:1 
Malate Dehydrogenase 1.7:1 
[47] 
Cytochrome c oxidase >1:1 [48] 
Lipogenesis 
  
1:1.6 Acetyl-CoA Carboxylase 
Fed : 1 : 1.58 (f), 1 : 1.64 (m). 
Starved: 1 : 1.13 (f), 1 : 1.32 (m). 
Refed: 1 : 1.61 (f), 1 : 1.60 (m). 
[81] −0.23 
Fatty Acid Synthase 
Fed 1 : 1.91 (f), 1 : 1.04* (m).  
Starved: 1 : 1.26* (f), 1 : 1.27* (m).  
Refed: 1 : 2.39 (f)1 : 1.34 (m). 
[88] 
 
ATP-dependent dependent citrate lyase 
Fed: 1 : 2.4 (f), 1 : 1.82 (m).  
Starved: 1 : 1.47 (f), 1 : 1.64 (m).  
Refed: 1 : 2.5 (f), 1 : 2.78 (m). 
[89] 
G6P dehydrogenase, 
6-phosphogluconate dehydrogenase, 
Malic enzyme, Isocitrate dehydrogenase, 
Alcohol dehydrogenase, 
As a general trend 1 : >1  (pericentral) 
For review see [45] 
β-oxidation 
 
1.6:1 
 
β-Hydroxybutyryl-CoA hydrogenase 
Fed: 1.52 : 1 (f), 1.59 : 1 (m) 
Starved: 1.58 : 1 (f), 1.80 : 1 (m) 
[81, 82] 
 
 
0.23 
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Carnitine palmitoyltransferase-1 
1.26 : 1 (in the absence of hormones) 
[83] 
Liver fatty acid binding protein (L-FABP) 
1.6 : 1 
[84, 85, 489] 
Triglyceride 
Synthesis 
1:1 No data demonstrating zonation in 
triglyceride synthesis enzymes found  
 0 (no zonation) 
Triglyceride 
Breakdown 
1:1 No data demonstrating zonation in 
lipolysis enzymes found 
 0 (no zonation) 
Insulin Reception 1:1.35 Insulin Receptor proteins 
Roughly 1:2 estimated from in vitro for 
physiological glucose concentrations. P.C. 
distribution demonstrated in vivo. 
[490] −0.15 
Glucagon 
Reception 
1.35:1 Glucagon Receptor Proteins 
1-3.5:1 (for mRNA) 
[491] 0.15 
FFA membrane 
transport uptake 
1.5:1 L-FABP expression - ~1.5-1.6:1 [84, 85, 489] 0.2 
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3 Understanding zonated steatosis and damage in NAFLD. 
3.1 Introduction to Chapter 
In this chapter, the model is used to simulate conditions of high fat intake and IR leading to the 
development of steatosis across the sinusoid. The major objectives addressed in this chapter were, 
firstly, to assess the contributions of high intake, IR and additional metabolic dysregulation to NAFLD. 
Secondly to identify the major differences between periportal and pericentral cells accounting for 
higher susceptibility to steatosis in pericentral cells. Finally, to identify key metabolic variations 
accounting for inter-individual differences in susceptibility to steatosis and inter-individual differences 
in NAFLD development in the model. The graphs in this chapter along with several sections of text 
were published in Ashworth et al. [401]. 
In adult sufferers of NAFLD, steatosis is often most severe in pericentral cells [15-17]. When assessed 
by Chalasani et al., 38% of subjects showed steatosis predominantly in pericentral cells, 62%  showed 
azonal or pan-sinusoid steatosis and less than 1% showed steatosis restricted to periportal cells [15]. 
Additionally, inflammation and fibrosis tend to be more severe towards the pericentral end of the 
sinusoid [15-17, 377]. When considering the effects of IR, this pattern of lipid build-up could be 
considered counter intuitive. Pericentral cells specialise in lipogenesis, whilst periportal cells show 
increased expression of FA uptake proteins. Given the context of reduced insulin stimulation but 
raised plasma lipid levels and increased hepatic FFA uptake, it would be expected that periportal cells 
to show the most severe steatosis [380, 492].  
A potential solution to this apparent paradox suggested in the literature is that IR could be restricted 
to glucose metabolism, with insulin signalling remaining intact in lipid metabolism [380, 381]. 
Consistent with this, increased rates of lipogenesis and triglyceride synthesis are seen in insulin 
resistant NAFLD patients. Additionally, the expression of the lipid metabolism regulatory protein 
SREBP-1c, which is stimulated by insulin under metabolically normal conditions, is increased in insulin 
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resistant NAFLD livers [36-39]. Furthermore, increased expression of ChREBP, an additional 
transcription factor whose expression is primarily regulated by the presence of sugars, is seen in 
NAFLD as a result of hyperglycaemia [493, 494]. However, whilst hepatic lipogenesis is increased in 
NAFLD, it is known that the majority of the lipids in the livers of NAFLD patients arise from uptake, 
such that an explanation of pericentral-centred steatosis should not be based primarily on increased 
hepatic lipid production [26, 492, 495, 496]. Additionally, separate pathways for insulin reception 
required for a duel resistance/sensitivity effect have not been identified, and it is known that the two 
insulin receptors (IRS-1 and IRS-2) both act on glucose and lipid metabolisms [497-500]. The link 
between IR and the susceptibility of pericentral cells to steatosis, therefore, remains unexplained. 
Fully characterising the development and consequences of metabolic diseases such as NAFLD in cells 
across the sinusoid experimentally would be a challenging task due to the small size of the sinusoid 
and the large number of potential variables. As a result, it is pertinent to study the system using a 
computational model such as the one presented here in order to make predictions and minimise the 
future experimentation required.  
In section 3.3.1 we first assess whether the model can reproduce the changes to hepatic lipid levels, 
glucose storage and energy metabolism seen in steatotic livers in vivo when simulating IR. This 
provides validation of the model simulations when considering NAFLD, in addition to the comparison 
with experimental data presented in supplementary material S1 for metabolically normal and insulin 
resistant individuals. Additionally, the contributions of increased SREBP-1c expression and increased 
dietary intake to the changes in metabolism occurring in NAFLD were assessed. Ensuring that the 
model simulations under conditions of high caloric intake and IR are consistent with in vivo findings 
also provides the basis for the simulations run in chapter 4, in which the model is used to study the 
effects of inhibiting or stimulating various hepatic pathways as potential treatments for NAFLD. 
Having validated that the model outputs are consistent with in vivo observations for NAFLD, in section 
3.3.2 the model is used to investigate the key differences between cells at the periportal and 
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pericentral ends of the sinusoid that cause pericentral cells to be more susceptible to steatosis. Using 
the computational model, detailed predictions of the changes in the conversion rates and metabolite 
concentrations in specific regions of the sinusoid can be made under different feeding conditions for 
the healthy and disease states. 
Finally, inter-individual variation is seen both in susceptibility to steatosis and in the pattern of 
steatotic build-up. Around 25% of obese individuals fail to develop steatosis whilst 16% of lean 
individuals show excess liver fat [18], and variation is seen in the predominant location of steatosis 
from pericentral to azonal or pan-sinusoidal [15-17]. In section 3.3.3, the model is used to identify 
variations in hepatic metabolism likely to account for these differences. Focussing on hepatic 
processes, sensitivity analysis was performed on the rate and zonation constants in the model to 
identify those with the largest effects on hepatic triglyceride and FFA levels.  
3.2 Inputs and Model Set up 
3.2.1 Inputs 
Through this section, the 4-hour spiked input cycle discussed in section 2.2.4.2 was used to represent 
intake roughly equivalent to a daily feeding cycle excluding sleep. This provides both periods of post-
prandial glycogen and triglyceride synthesis and periods of their breakdown to glucose and FFAs 
between meals. When using this input cycle, simulations were run until equilibrium was reached 
between subsequent cycles. The average concentrations and rates over each 4-hour cycle are then 
presented. When simulating a moderate diet the carbohydrate and lipid inputs over each cycle were 
set to match the average input per meal in a study performed by Daly et al. as discussed in section 
2.2.4.2. [425].  
Because a separate adipose compartment was not included, adipose lipid storage and adipocyte 
proliferation could not be included in the model. As a result, the short and medium term effects of 
high fat diets on plasma FFA and triglyceride concentrations are exaggerated because the fats are not 
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removed from circulation. To compensate, inputs representing high fat and very high fat diets were 
set by matching the resulting outputted plasma FFA and triglyceride concentrations to those seen in 
overweight and obese individuals, rather than matching the increase in dietary intake. A 12.5% 
increase in FFA input, used to represent high fat intake, results in simulated plasma triglyceride and 
glucose concentrations close to the average of those measured in overweight  individuals by Sindelka 
et al. (25kg.m-2<BMI<30kg.m-2) [141]. A 25% increase was used to represent very high fat intake, which 
gives changes in triglyceride and FFA concentration towards the high end of the values measured in 
obese individuals (BMI>30kg.m-2), consistent with a severe increase in dietary fat content [141, 435]. 
High and very high carbohydrate intake diets were simulated using equivalent percentage increases 
in glucose input. 
3.2.2 Insulin Resistance and SREBP-1c 
IR was simulated by multiplying the detected insulin concentration by an IR constant with a value of 
less than one (KIR < 1) such that cells effectively experience an insulin concentration lower than the 
real concentration. Throughout this thesis, severe IR corresponds to a value of KIR = 0.015 and 
developing IR to KIR = 0.05. On a moderate diet, developing IR leads to hyperinsulinaemia but only a 
rise of 1.25mM in average glucose concentration as raised insulin levels compensate for decrease 
sensitivity. Severe IR, meanwhile, causes postprandial hyperglycaemia consistent with the 
development of T2DM. 
As discussed, the pro-lipogenic regulatory protein SREBP-1c has been highlighted as playing a potential 
role in the development of NAFLD [36-39]. In metabolically normal individuals, SREBP-1c is stimulated 
by insulin and, therefore, a fall in expression would be expected insulin resistant NAFLD patients [155, 
158, 198, 501]. However, an increase is seen in insulin resistant NAFLD patients [36-39]. To account 
for the counter-intuitive increase seen experimentally, simulations were run for an insulin resistant 
individual with continuous stimulation (corresponding to a high 1nM insulin concentration) of 
lipogenesis and triglyceride synthesis. 
108 
 
3.3 Results 
3.3.1 Representing NAFLD in the Model 
In the following section, IR with and without increased SREBP-1c expression and varying dietary intake 
are simulated to assess to what extent these account for the experimentally observed changes in lipid 
levels, glucose regulation, ATP levels and metabolic rates in NAFLD [18, 36, 37, 131-133]. 
3.3.1.1 Insulin Resistance and SREBP-1c 
Figure 3.1 summarises the simulated effects of IR with and without increased SREBP-1c expression on 
bulk hepatic metabolism (figure 3.1a), on zonation in metabolism (figure 3.1b) and on key plasma 
concentrations (figure 3.1c). Figures 3.2 and 3.3 show the simulated effects of IR with and without 
increased SREBP-1c expression on concentrations of hepatic metabolites (figure 3.2) and rates of key 
hepatic processes (figure 3.3) across the sinusoid.  
The majority of key metabolic changes known to occur in steatotic livers are seen when simulating the 
direct effects of IR alone (without increased SREBP-1c expression). Firstly, pericentral-centred 
steatosis occurs when simulating system-wide IR (figure 3.2a). For a severely insulin resistant 
individual on a moderate diet, the simulated average hepatic lipid content was more than doubled 
from 2.3% of total cell mass to 5.5%. The increase in concentration was largest in pericentral cells 
where the lipid content rose from 2.7% to 7.4%, consistent with the development of pericentral-
centred steatosis. A 5% (50mg/g wet weight) liver triglyceride concentration is generally used as the 
criterion for diagnosing early-stage NAFLD [15].   
Both experimentally and in the model simulations, insulin resistant livers are unable to store sufficient 
glycogen (figure 3.2d), leading to post-prandial hyperglycaemia (figure 3.1c). Consistent with 
experimental observations [502], pericentral cells show a more severe loss in their ability to store and 
release glucose throughout the meal cycle than periportal cells (Δ(compartment 1)=27.4mM vs 
Δ(compartment 8)=5.5mM (in units of glucose) (figure 3.2f)).  
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Figure 3.1 – The simulated effects of IR on metabolism. (a) The effects of simulating IR on total hepatic metabolism (averaged across the sinusoid). (b) The 
heterogeneity in the effects of simulating IR across the sinusoid. (c) The effects of simulating increasing severities of IR on plasma triglyceride, glucose and FFA 
concentrations compared with experimental data from Sindelka et al [141] and Burnt et al. [435]. 
a) b) 
c) 
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Figure 3.2 – Metabolite concentrations when simulating NAFLD. (a) The average triglyceride (b) FFA, (c) ATP, (d) glycerol-3-phosphate and (e) glycogen 
concentration and (f) the difference between postprandial peak and pre-prandial trough glycogen concentrations in the different regions of the sinusoid when 
simulating (purple) a metabolically normal individual, (orange) the effects of IR alone and (red) IR with increase SREBP-1c expression using a moderate intake 
diet.  
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Figure 3.3 – Metabolic rates when simulating NAFLD. The average rates of (a) triglyceride synthesis, (b) lipolysis, (c) triglyceride release as VLDL, (d) β-oxidation 
(e) FFA uptake, (f) lipogenesis and (g) ATP synthesis from acetyl-CoA in the different regions of the sinusoid when simulating (purple) a metabolically normal 
individual, (orange) the effects of IR alone and (red) IR with increase SREBP-1c expression using a moderate intake diet. 
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However, in order for the model to fully recreate the metabolic changes seen in vivo, raised SREBP-1c 
expression must additionally be simulated. In particular, when simulating the direct effects of IR alone, 
the outputted data differ from in vivo findings for NAFLD in the lipogenesis rates. In vivo, although the 
majority of hepatic lipids in NAFLD are known to originate from uptake, increases have also been 
measured in the rates of de novo lipogenesis and triglyceride synthesis [26, 37, 503, 504]. When 
simulating IR in the model, the average rates of these processes were roughly unchanged (figures 3.3a, 
5f) and hepatic steatosis arose as a result of increased lipid uptake alone (figures 3.3c, 3.3e). However, 
when additionally simulating increased SREBP-1c expression, the rates of lipogenesis and triglyceride 
synthesis increased to 2.31 and 2.05 times the metabolically normal rate respectively (figures 3.3a, 
3.3f), consistent with in vivo NAFLD [26, 37, 503, 504]. Increased SREBP-1c expression led to more 
severe pericentral-centred steatosis, with the simulated compartment 8 (most pericentral) lipid 
content higher than 10% of total cell mass even, for the moderate intake cycle used (figure 3.3a). 
When measured experimentally, hepatic glucose oxidation is markedly reduced in NAFLD, with almost 
all energy produced through β-oxidation [44, 227, 228, 505-508]. When simulating IR with increased 
SREBP-1c expression in the model, a 45% increase in β-oxidation (figure 3.3d) and a 13% reduction in 
glucose oxidation via glycolysis occurred, consistent with the experimental observations [44, 227, 228, 
505-509] (figure 3.3d). 
Despite the increase in FA oxidation, reduced ATP concentrations have been measured experimentally 
in NAFLD livers [44, 227, 228, 506, 510-513]. Also, increased mitochondrial ROS production has been 
measured, suggesting overactive but dysfunctional ATP synthesis pathways [501, 512, 514-516]. These 
findings are likely to be, at least partially, due to a reduction in activity in ETC proteins (reviewed in 
[501]). When simulating IR with increased SREBP-1c expression in the model, a 19.5% fall in ATP 
concentration (figure 3.2b) occurred despite a 9.3% increase in the rate of oxidation of acetyl-CoA in 
the citrate cycle (figure 3.3g). This occurred even though the model does not include the reduction in 
ETC protein activity, and results from increased ATP consumption in lipogenesis, triglyceride synthesis 
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and β-oxidation combined with reduced ATP production from glycolysis. As NAFLD develops in vivo, 
additional drops in ATP concentration would be seen due to reduced ETC protein activity [44, 227, 
228, 505, 506].  
Therefore, whilst pericentral-centred steatosis, reduced glycogenesis and key alterations to energy 
metabolism seen in NAFLD patients occur in the model when simulating IR alone, increased SREBP-1c 
expression is additionally required to fully replicate the metabolic changes occurring in NAFLD. In the 
following sections, both the effects of IR alone and IR combined with increased SREBP-1c expression 
are simulated. 
3.3.1.2 Dietary intake and the development of steatosis 
Figure 3.4 shows the simulated effects of high fat intake and very high fat intake diets on hepatic 
triglyceride, FFA and ATP concentrations. When simulating insulin sensitive individuals, high intake 
and very high intake of fats caused relatively moderate increases in the average hepatic triglyceride 
content from 2.3% on a moderate diet to 3.6% and 7.2% respectively (figure 3.4a). Therefore, hepatic 
lipid content is only higher than the 5% criteria at which early-stage NAFLD is diagnosed when 
simulating obese individuals with severe plasma hyperlipidaemia in the absence of IR. Hepatic FFA 
concentrations were increased from 21.5µM on a moderate diet to 28.6µM and 38.0µM when 
simulating high and very high fat diets respectively (figure 3.4e). A 5% reduction in ATP concentration 
occurred when simulating a very high fat diet due to increased allosteric inhibition of glucose oxidation 
(figure 3.4f). When high and very high carbohydrate diets were simulated, smaller increases in the 
simulated hepatic triglyceride content occurred than for increased lipid intake. Even for very high 
carbohydrate intake, the hepatic triglyceride concentration remained less than 5% (figure 3.4a). 
When combined with IR, high dietary intake caused far more severe steatosis in the model. In the case 
of severe IR (KIR=0.015) (figure 3.4b-d), the average concentration increased from 5.5% when 
simulating a moderate intake diet to 10.0% and 27.0% when simulating high carbohydrate and high 
fat intake diets respectively (figure 3.4c). Severe IR combined with increased SREBP-1c expression 
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caused even more extreme increases in hepatic triglyceride concentrations due to additional hepatic 
lipogenesis (figure 3.4d).  
 
Figure 3.4 – The simulated effects of varying dietary intake in the model. (a-d) The average hepatic 
lipid content across the sinusoid when simulating varying glucose and FFA intake diets in individuals 
with (a) metabolically normal insulin sensitivity (100%, KIR=1), (b) developing IR (5%, KIR=0.05), (c) 
severe IR (1.5%, KIR=0.015) and (d) severe IR in combination with increased SREBP-1c expression. (e-f) 
The effects of high fat and carbohydrate (glucose) intake on (e) ATP concentrations and (f) FFA 
concentrations across the sinusoid when simulating a metabolically normal, insulin sensitive individual. 
High and low intakes correspond to a sustained 12.5% difference in intake relative to the moderate 
intake det. Very high and raised intakes correspond to 25% and 5% increases respectively. The average 
concentrations over a 4 hours intake/output cycle are depicted. 
In reality, adipose uptake of plasma lipids and increased adipocyte proliferation are likely to prevent 
such rapid rises in hepatic steatosis concentrations. However, these severely raised values are 
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consistent with the dangerous effects of high fat intake on metabolism in untreated insulin resistant 
individuals. 
3.3.2 The causes of pericentral centred steatosis in insulin resistant NAFLD individuals. 
In the following sections, the metabolic changes occurring across the sinusoid when simulating NAFLD 
resulting from IR and increased SREBP-1c expression are analysed in order to identify the key 
differences between periportal and pericentral cells accounting for pericentral-centred steatosis. 
3.3.2.1 Triglyceride Synthesis, Output and Lipolysis 
The processes directly determining the triglyceride concentration are triglyceride synthesis (figure 
3.3a), lipolysis (figure 3.3b) and the net rate of triglyceride output (figure 3.3c) (release as VLDL minus 
the slow uptake from plasma). Lipolysis only occurs at a very slow rate in liver (88) and, although an 
increase in rate occurred when simulating IR, the process is not a major determinant of the hepatic 
triglyceride concentration. Triglyceride output and uptake, meanwhile, depend only on the plasma 
and hepatic triglyceride concentrations in the model, and cannot account for the variation in steatosis 
across the sinusoid. Instead, the zonal differences arise in the rate of synthesis. 
Even when simulating metabolically normal individuals, the rate of triglyceride production was higher 
in the pericentral half of the sinusoid than in periportal cells. The simulated periportal to pericentral 
triglyceride synthesis ratio (pp:pc) was 1:1.64 (figure 3.3a), consistent with the ratio of 1:1.58±0.34 
seen experimentally (89). When simulating metabolically normal individuals, this arises as a result of 
the upregulated lipogenic pathways in pericentral cells and upregulated β-oxidation in periportal cells. 
When simulating NAFLD (IR with increased SREBP-1c expression), the gradient in the rate of 
triglyceride synthesis across the sinusoid became steeper (pp:pc = 1:2.34), leading to greater steatosis 
in pericentral cells.  
The enzymes mediating triglyceride synthesis are homogenously expressed across the sinusoid in the 
model. The large heterogeneity in rate across the sinusoid when simulating NAFLD instead results 
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from differences in the concentrations of the two substrates of triglyceride synthesis: glycerol-3-
phosphate (G3P) and FFAs. 
3.3.2.2 FFA concentration: Lipogenesis, Uptake and Oxidation 
When simulating metabolically normal individuals, the FFA concentration was higher in the pericentral 
compartments (pp:pc=1:1.91) (figure 3.2c), which is intuitive given that pericentral cells specialise in 
lipogenesis whilst periportal cells predominantly utilise fats in β-oxidation (90). When simulating 
NAFLD, this gradient in FFA concentration becomes more pronounced (pp:pc=1:2.54). The processes 
directly determining the hepatic FFA concentration in the model are de novo lipogenesis (figure 3.3f), 
uptake and release (figure 3.3e), and β-oxidation (figure 3.3d) along with triglyceride synthesis (figure 
3.3a) and lipolysis (figure 3.3b).  
The majority of additional lipids in NAFLD arose from uptake in the simulations (ΔRate = 404nM FFA/s; 
figure 3.3e), although de novo lipogenesis also increased as a result of SREBP-1c expression (ΔRate 
=276nM FFA/s; figure 3.3f). The largest increase in uptake occurred in pericentral cells where it 
increased by 471nM FFA/s compared with 337nM FFA/s in periportal cells. FA uptake proteins have 
higher expression in periportal cells and even when simulating IR, the total rate of uptake was still 
larger in periportal than pericentral cells. However, under conditions of IR, where passive uptake 
dominates rather than insulin-stimulated scavenging, the simulated gradient in the rate of FFA uptake 
across the sinusoid was less steep. The increase in de novo lipogenesis was also larger in pericentral 
cells, where it increased by 311nM FFA/s compared with 242nM FFA/s in periportal (figure 3.3f). This 
is as a direct result of the pericentral zonation of lipogenesis enzymes. 
The rate of β-oxidation is increased by 411nM FFA/s when simulating NAFLD providing a 
compensatory mechanism by which some of the extra fats are removed (figure 3.3d). In the model 
this occurred due to increased substrate and reduced insulin inhibition, although in vivo it is thought 
that additional signalling pathways may further increase β-oxidation (reviewed in (13)). The increase 
was largest in oxygen rich periportal cells (ΔRate =490nM FFA/s) where greater quantities of acetyl-
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CoA are required for the citrate cycle compared with pericentral cells (ΔRate = 332nM FFA/s) (figure 
3.3g). Since the largest increase in uptake occurred in pericentral cells whilst the largest increase in 
lipid oxidation occurred in periportal cells, FFA availability for triglyceride synthesis increased in 
pericentral cells.  
3.3.2.3 G3P Concentration: Glycogen Storage and Carbohydrate Metabolic Intermediates 
G3P, which is closely related to glyceraldehyde-3-phosphate (GADP), an intermediate of glycolysis, 
forms the carbon backbone in triglyceride synthesis. The G3P concentration was raised across the 
sinusoid when simulating insulin resistant individuals, and this increase was larger in the pericentral 
half of the sinusoid (75μM) than in the proximal periportal cells (48μM) (figure 3.2e). Increased SREBP-
1c expression affects triglyceride concentrations through changes in lipogenesis and triglyceride 
synthesis, and has little effect on the G3P concentration.  
The increase in G3P concentration when simulating IR individuals occurred because hepatocytes, 
particularly towards the pericentral end of the sinusoid, are unable to properly clear glucose 
intermediates. When simulating IR, glycogen concentrations were severely reduced across the 
sinusoid (figure 3.2d). However, as discussed above, pericentral cells showed a more severe reduction 
in glucose storage than periportal cells when simulating IR (Additional glucose stored postprandially: 
Δ(compartment 1)=27.4mM, Δ(compartment 8)=5.5mM) (figure 3.2f). 
In addition, pericentral cells consume less glucose in oxidative metabolism than periportal cells due to 
their low oxygen environment (8.1μM acetyl-CoA/s vs 13.0μM/s when simulating NAFLD; figure 3.3g). 
These effects caused a build-up of carbohydrate metabolism intermediates, including G3P, particularly 
in pericentral cells.  
This increase in G3P concentration, which remains lower than the KM value for the glycerol backbone 
binding to glycerophosphate acyltransferase (460µM), means that FFAs are more rapidly converted to 
triglycerides, causing steatosis [470]. 
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3.3.3 The effects of metabolic variation between individuals on steatosis development in 
NAFLD. 
The results in the previous section investigated the development of NAFLD when running simulations 
with a single set of parameters. However, in reality, patients will show inter-individual variability in 
the activity of metabolic processes. In the following sections, the effects of this inter-individual 
variation in the activity of hepatic processes in the model on susceptibility to steatosis and on its 
pattern of development are assessed using two methods. Firstly, 15 example ‘patients’ were simulated 
with rate and zonation constants randomly generated from within a specified range of the standard 
values (section 3.3.3). These patients were simulated with both normal insulin sensitivity on a 
moderate intake diet and with developing IR on a high fat intake diet. Correlations were performed 
between each of the varied constants and the resulting triglyceride concentrations across the sinusoid. 
Secondly, sensitivity analysis was performed on both the rate and zonation constants to assess the 
impact of varying each constant in isolation on triglyceride concentrations across the sinusoid (section 
3.4.3). 
3.3.3.1 Simulating Individual Patients 
To assess the impact of inter-individual variability across a wide range of processes, 15 patients with 
rate constants and zonation constants for a number of key processes randomly generated within 
bounded ranges were simulated. Metabolic variations in numerous tissues around the body are likely 
to affect hepatic steatosis via plasma lipid concentrations. However, because the model presented 
here is primarily of liver metabolism, we focus specifically on variations in the expression and activities 
of enzymes mediating hepatic energy metabolism. The constants which were altered include those 
for glycolysis (glucose->G6P, G6P->GADP and GADP->pyruvate), gluconeogenesis, pyruvate oxidation, 
lipogenesis, β-oxidation, oxidative phosphorylation and triglyceride synthesis. 
The rate constants determine the overall maximum activity of the enzymes mediating each process. 
These were generated randomly using the Microsoft Excel RandBetween() function from within a 10% 
119 
 
range of the standard value (table 3.1). This function generates numbers within a range with equal 
weighting across the range of possible values. The zonation constants were selected using the same 
function from a range of ±0.2 of the standard value (table3.2). A zonation constant of 1 corresponds 
to completely periportal expression, a zonation constant of 0 corresponds to heterogeneous 
expression and a zonation constant of -1 corresponds to completely pericentral expression (see 
section 2.4.6). The altered parameter values for the 15 patients are shown in tables 3.1 and 3.2. For 
parameters not listed in the table, the standard values listed in chapter 2 were used. These ranges of 
parameter variability lie well within the inter-individual variability seen in the data used to set the 
parameters (tables 2.1 and 2.2). 
3.3.3.1.1 Simulating Inter-Individual Variability 
Figure 3.5 shows the hepatic lipid content, hepatic FFA concentration, hepatic ATP concentration, the 
plasma glucose concentration and the plasma lactate concentration when simulating the 15 example 
patients. The simulated data are shown for both normal insulin sensitivity with moderate lipid intake 
and developing insulin resistant with high fat intake.  
In all cases, the average simulated concentrations across the patients are well within one standard 
deviation from the simulated values when using the standard parameter values, although a higher 
average hepatic lipid content was seen for the 15 simulated patients compared with the content when 
using standard parameter values (figure 3.5 a,b). In all cases, the simulated concentrations for the 15 
example patients remain within the ranges measured experimentally.  
Very little variation is seen between the patients for simulated plasma glucose (figure 3.5e) and 
hepatic ATP (figure 3.5d) concentrations, consistent with the strong allosteric and hormonal 
regulation in both glucose storage and ATP synthesis. A wider variation in plasma glucose 
concentration would have occurred if the rate constants for glycogen synthesis and glycogen 
phosphorylation were additionally altered between the patients.  
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Figure 3.5: Plasma and hepatic concentrations when simulating randomly generated patients. The 
simulated (a,b) hepatic lipid content, (c) hepatic FFA concentration, (d) hepatic ATP concentration, (e) 
plasma glucose concentration and (f) plasma lactate concentration when simulating the 15 sample 
patients compared with standard parameter values. The error bars show the 84.1th and 15.9th 
percentiles corresponding to the standard deviation in a central distribution. 
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Table 3.1: The rate constants for the 15 simulated patients. 
Rate Constants Simulated ‘Patients’ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
GK 122.03 133.11 144.7 143.97 136.71 140.24 125.63 141.73 134.42 144.54 139.65 120.51 141.78 124.44 129.07 
G6Pase 400.87 370.26 379.47 370.43 361.99 350.18 387.13 360.86 353.5 372.49 352.46 384.54 342.74 404.15 374.47 
Glycolysis 1: 
G6P->GADP 
167.05 159.44 164.41 159.98 158.76 149.22 146.18 149.16 146.02 167.31 164.3 169.71 159.35 150.36 144.72 
Glycolysis 2: 
GADP->Pyr/Lac 
90.49 84.29 84.57 84.02 80.35 84.56 79.74 86.11 87.52 89.45 87.52 93.29 78.99 86.35 80.66 
Gluconeogenesis 1: 
Pyr/Lac->GADP 
36.46 31.56 37.26 32.38 37.53 33.04 31.67 34.71 37.61 33.45 32.34 33.32 36 34.28 35.81 
Gluconeogenesis 2: 
GADP->G6P 
74.78 74.75 69.6 61.71 61.24 70.52 73.24 71.71 72.97 67.87 68.42 66.38 72.54 65.83 68.48 
Pyruvate Oxidation 12.86 14.9 13.73 15.02 14.96 13.93 15.28 12.69 13.47 15.33 13.88 13.96 15.32 15.32 12.83 
Oxidative 
Phosphorylation 
499.74 482.91 540.51 519.06 473.52 540.98 500.08 559.93 567.6 561.47 518.4 496.69 529.61 489 472.15 
Lipogenesis 3.71 3.85 4.37 4.33 3.95 3.76 4.26 4.36 4.24 4.04 4.19 4.09 3.73 4.08 4.03 
Beta Oxidation 3.29 3.54 3.27 3.09 3.51 3.05 3.31 3.55 3.41 3.55 3.53 3.07 3.57 3.21 3.47 
Triglyceride Synthesis 8.23 8.57 9.79 9.03 8.15 8.15 9.16 8.88 9.18 9.79 9.02 8.26 9.62 8.41 8.38 
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Table 3.2: The zonation constants for the 15 simulated patients 
Zonation Constants Simulated ‘Patients’ 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
G6Pase 0.32 0.36 0.3 0.42 0.28 0.47 0.31 0.36 0.28 0.51 0.17 0.26 0.34 0.15 0.26 
GK -0.457 -0.309 -0.481 -0.502 -0.345 -0.331 -0.427 -0.401 -0.49 -0.278 -0.35 -0.44 -0.444 -0.422 -0.596 
Glycolysis: 
GADP->Pyr/Lac 
-0.473 -0.513 -0.538 -0.167 -0.381 -0.278 -0.35 -0.204 -0.552 -0.459 -0.175 -0.222 -0.214 -0.428 -0.175 
Gluconeogenesis 1: 
Pyr/Lac->GADP 
0.359 0.32 0.276 0.231 0.444 0.315 0.417 0.308 0.345 0.313 0.49 0.44 0.566 0.512 0.369 
Gluconeogenesis 2: 
GADP->G6P 
0.294 0.284 0.215 0.399 0.203 0.327 0.28 0.203 0.254 0.214 0.439 0.198 0.351 0.22 0.37 
Pyruvate Oxidation -0.14 0.07 -0.02 0.01 0 0.05 0 -0.02 0.18 0.02 -0.19 0.07 0.04 -0.01 0.15 
Oxidative 
Phosphorylation 
0.26 0.07 0.17 0.39 0.26 0.06 0.23 0.28 0.15 0.33 0.37 0.23 0.16 0.26 0.38 
Lipogenesis -0.16 -0.1 -0.41 -0.19 -0.42 -0.12 -0.13 -0.04 -0.23 -0.28 -0.09 -0.34 -0.37 -0.33 -0.36 
Beta Oxidation 0.06 0.43 0.24 0.25 0.16 0.23 0.34 0.37 0.09 0.26 0.31 0.22 0.22 0.37 0.39 
Triglyceride Synthesis 0.16 0.06 -0.11 -0.16 -0.11 -0.19 -0.14 -0.11 -0.09 -0.1 0.2 -0.13 -0.11 0.2 -0.05 
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Larger differences occurred in the simulated hepatic lipid content (figures 3.5a,b), hepatic FFA 
concentration (figure 3.5c) and plasma lactate concentration (figure 3.5f) between patients. When 
simulating metabolically normal individuals, the standard deviation in the hepatic lipid content is 
19.5% of the average value. When simulating NAFLD this increased to 47.1%. Therefore, inter-
individual variability in hepatic metabolism is predicted to have a marked effect on severity of steatosis 
once IR develops.  
Little change in the simulated lactate concentration occurred between metabolically normal and 
NAFLD patients. However, a standard deviation of 29-30% of the average values was seen when 
simulating under the two sets of conditions, suggesting inter-individual variability predominantly 
determined the concentration in the two groups. The simulated patients with high lactate 
concentrations when simulating metabolically normal patients also showed a high concentration 
when simulating NAFLD (Pearson’s coefficient=0.97). 
3.3.3.1.2 Correlations between parameter values and key hepatic and plasma concentrations 
Tables 3.3 and 3.4 show the Pearson’s product-moment correlation coefficients between each varied 
parameter with the hepatic triglyceride concentration, with the zonation in hepatic triglyceride 
content (pericentral to periportal ratio) and with key plasma concentrations when simulating the 
patients with developing IR and high fat intake in the 15 patients. This is a measure of the linear 
dependence between two variables with 0 corresponding to independence and +1 and -1 
corresponding to total positive and negative correlations respectively. Table 3.3 shows the 
correlations for the rate constants whilst table 3.4 shows the correlations for the zonation constants. 
The correlations are presented when simulating IR and high fat intake.  
Only the rate constants for oxidative phosphorylation and for the second half of glycolysis, converting 
GADP to G6P, showed statistically significant (negative) correlations with hepatic triglyceride content. 
The rate constant for oxidative phosphorylation determines the rate of production of ATP from acetyl-
CoA, and it is intuitive that a high rate constant would reduce the hepatic lipid content by promoting 
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increased FA oxidation. It also showed a statistically significant negative correlation with the plasma 
triglyceride and FFA concentrations. A relatively high, but non-significant, correlation was also seen 
between the rate constant for β-oxidation and the hepatic lipid content, consistent with the 
importance of the rate of oxidation of fats through these two pathways in determining susceptibility 
to steatosis. The zonation constants for both oxidative phosphorylation and β-oxidation also showed 
statistically significant correlations with the pericentral to periportal triglyceride ratio. Therefore, 
variability in the zonation of the enzymes mediating that oxidation of FAs via acetyl-CoA is predicted 
to at least partially account for the variability in steatosis location seen in vivo. 
The rate constant for the second part of gluconeogenesis (GADP to G6P) showed statistically 
significant negative correlations with plasma triglyceride and FFA concentrations as well as the hepatic 
lipid content. Upregulation of this process not only reduces de novo lipogenesis from glucose, but also 
reduces G3P production for use in triglyceride synthesis. Furthermore, it reduces the allosteric 
inhibition of β-oxidation as a result of reduced acetyl-CoA synthesis from glucose. Finally, increased 
gluconeogenesis increases the rate of ATP consumption in the cell, increasing the required oxidation 
of acetyl-CoA to replenish ATP.  The first three of these causes would be expected to be accompanied 
by an opposite correlation between glycolysis and triglyceride content. However, given the low 
correlation coefficients between the two glycolysis rate constants and hepatic triglyceride content, 
the increased ATP consumption in gluconeogenesis is likely to have been the major cause of the 
correlation between gluconeogenesis and hepatic lipid content. A relatively high, but non-significant, 
correlation was also seen between the hepatic lipid content and the first half of gluconeogenesis. 
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Table 3.3: The Pearson’s product-moment correlation coefficients between several rate constants and 
key hepatic and plasma variables. 
Rate Constants Hepatic 
Triglyceride 
PC:PP TG 
ratio 
Plasma 
TG 
Plasma 
FFA 
Plasma 
Glucose 
Plasma 
Lactate 
GK -0.35 0.00 -0.37 -0.32 -0.19 -0.30 
G6Pase 0.41 0.18 0.42 0.43 -0.09 0.25 
Glycolysis 1: 
G6P->GADP 
0.25 0.22 0.23 0.32 -0.59 * 0.60 * 
Glycolysis 1: 
GADP->Pyr 
0.07 -0.13 0.08 0.14 -0.47 0.56 * 
Gluconeogenesis 1: 
Pyr->GADP 
-0.49 -0.51 -0.47 -0.54 0.57 * -0.51 
Gluconeogenesis 2: 
GADP->G6P 
-0.59 * -0.25 -0.59 * -0.60 * 0.47 -0.35 
Pyruvate Oxidation 0.31 0.16 0.31 0.38 -0.42 -0.01 
Oxidative 
Phosphorylation 
-0.70 * -0.52 * -0.69 * -0.64 * -0.10 -0.36 
Lipogenesis 0.09 0.11 0.09 0.11 -0.34 0.07 
Beta Oxidation -0.35 0.30 -0.38 -0.38 0.32 -0.30 
Triglyceride 
Synthesis 
-0.40 -0.04 -0.41 -0.34 -0.19 -0.31 
The correlations when simulating high fat intake and developing IR using parameter values 
corresponding to 15 randomly generated patients shown in tables 3.1 and 3.2. * - statistical significance 
of correlation <0.05 
. 
Table 3.4: The Pearson’s product-moment correlation coefficients between several zonation constants 
and key hepatic and plasma variables. 
Zonation 
Constants 
Hepatic 
Triglyceride 
PC:PP TG 
ratio 
Plasma 
TG 
Plasma 
FFA 
Plasma 
Glucose 
Plasma 
Lactate 
GK -0.25 -0.15 -0.25 -0.22 -0.06 -0.21 
G6Pase -0.10 0.12 -0.13 -0.01 -0.34 0.10 
Glycolysis: 
GADP->Pyr 
0.32 0.32 0.32 0.28 -0.16 0.36 
Gluconeogenesis 1: 
Pyr->GADP 
0.03 0.02 0.03 0.04 0.10 0.04 
Gluconeogenesis 2: 
GADP->G6P 
0.22 0.38 0.20 0.17 -0.03 0.18 
Pyruvate Oxidation -0.08 -0.34 -0.05 -0.14 0.29 -0.31 
Oxidative 
Phosphorylation 
0.43 0.57 * 0.42 0.41 -0.24 0.36 
Lipogenesis -0.10 0.13 -0.10 -0.08 -0.08 0.13 
Beta Oxidation 0.32 0.64 * 0.31 0.31 -0.14 0.13 
Triglyceride 
Synthesis 
0.19 0.37 0.18 0.21 -0.05 0.28 
The correlations when simulating high fat intake and developing IR using parameter values 
corresponding to 15 randomly generated patients shown in tables 3.1 and 3.2. * - statistical significance 
of correlation <0.05. 
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3.3.3.2 Sensitivity Analysis on Key Variables 
As a second method of assessing key inter-individual variations in metabolism that account for 
differences in susceptibility to steatosis, sensitivity analysis was performed on the rate constants and 
zonation in the model. This involved altering each constant in turn and assessing the impact on 
metabolism. In addition to the processes varied in the previous section, the rate constants for 
glycogenesis, glycogenolysis, FA cross-membrane transport, triglyceride cross-membrane transport 
and active triglyceride release as VLDL were also included in the sensitivity analysis. 
3.3.3.2.1 Key determinants of total hepatic triglyceride level 
Each rate constant was increased or reduced by 10% when simulating an otherwise metabolically 
normal individual. Variations of this size are large enough to have a notable effect on hepatic and 
plasma concentrations and allow us to identify the relative importance of processes, but remain in a 
range which would realistically be expected between individuals under non-pathological conditions. 
The model was provided with constant glucose and FFA inputs such that, when using the unaltered 
parameter values, the plasma glucose, triglyceride and FFA concentrations remained at 5.03mM, 
1.05mM, and 432μM respectively. Simulations were run for 36 hours from these initial values after 
changing each rate constant.  
Hepatic and plasma triglyceride concentrations were most sensitive to the rate constants for β-
oxidation and for ATP synthesis through the citrate cycle (table 3.5), particularly when these processes 
were inhibited. Reducing the rate constants for β-oxidation and ATP synthesis caused increases in the 
simulated hepatic triglyceride concentration of 2.78mM and 1.82mM over the 36 hours respectively. 
Increasing the rate constants, meanwhile, caused reductions of 0.81mM and 1.27mM respectively. 
These large changes suggest that metabolic variations affecting the rate of oxidation of fats are likely 
to be a major determinant of inter-individual susceptibility to the development of steatosis. Consistent 
with this, the hepatic triglyceride concentrations were also sensitive to changes in the rate constants 
mediating glycolysis, gluconeogenesis and pyruvate oxidation. All these processes alter the production 
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Table 3.5: Sensitivity analysis for the rate constants. 
The effect of varying the baseline rate constants, 𝑣𝑏 , for the various hepatic metabolism processes included in the model on cellular and plasma FFA and triglyceride 
concentrations.
Process Change in Cellular FFA 
(μM) 
Change in Cellular 
Triglyceride (μM) 
Change in Plasma FFA (μM) Change in Plasma 
Triglyceride (μM) 
Increased 𝑣𝑏   
(+10%) 
Reduced 𝑣𝑏   
(-10%) 
Increased 𝑣𝑏   
(+10%) 
Reduced 𝑣𝑏   
(-10%) 
Increased 𝑣𝑏   
(+10%) 
Reduced 𝑣𝑏   
(+10%) 
Increased 𝑣𝑏   
(-10%) 
Reduced 𝑣𝑏   
(+10%) 
β-oxidation -2.7 5.4 -808.2 2782.5 -15.1 32.2 -36.6 125.7 
Oxidative Phosphorylation -1.9 2.1 -1271.9 1818.1 -12.2 13 -57.0 82.7 
Glycolysis 1: (G6P to G3P) mediated by PFK -0.6 0.6 562.6 -587.6 7.2 -7.7 17.9 -19.1 
Gluconeogenesis 2 (G3P to G6P) mediated 
by FBP 
0.0 -0.2 -517.1 599.3 -7.4 8.4 -18.5 21.1 
Glycolysis 2: (G3P to Pyr) mediated by PK  2.3 -2.4 572.0 -588.9 12.0 -12.2 26.5 -27.2 
Gluconeogenesis 2 (Pyr to G3P) mediated 
by PEPCK 
-1.5 1.8 -464.9 550.4 -8.7 10.4 -21.0 24.8 
Pyruvate Oxidation 1.6 -1.6 526.4 -549.9 9.4 -9.7 23.2 -24.3 
VLDL Synthesis and Release 0.3 -0.3 -362.9 373.6 7.0 -7.0 23.0 -23.4 
Triglyceride Synthesis -1.5 1.8 237.5 -255.9 1.0 -1 4.5 -4.6 
FFA Uptake 3.1 -3.0 260.7 -143.0 -28.5 36.4 -53.9 64.2 
Lipogenesis 0.5 -0.5 183.0 -183.4 3.1 -3.2 7.8 -9.0 
Glucokinase 1.6 -1.3 -90.4 262.8 79 -68.2 -56 65.9 
Triglyceride Cross-Membrane Transport -0.1 0.1 102.5 -114.8 -1.9 2.2 -6.4 7.2 
G6Pase -0.7 1.0 100.6 -45.5 -35 43.0 30 -31.2 
Lipolysis 0.3 -0.4 -69.0 70.3 -0.5 0.4 -1.7 1.7 
Glycogen Synthase 0.4 -0.4 -39.4 62.8 13 -14.0 -11 13.0 
Glucose Uptake 0.5 -0.4 -24.4 63.8 21 -22.7 -15.5 19.8 
Glycogen Phosphorylase -0.2 0.2 16.2 -10.1 -5.6 5.9 4.4 -4.4 
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Table 3.6: Sensitivity analysis for the zonation constants. 
The effect of altering the zonation constants kn of lipid metabolism processes on steatosis location 
(compartment1: compartment 8 triglyceride ratio) when simulating for IR patients on a moderate diet. 
of acetyl-CoA from glucose, and hence, the allosteric inhibition of β-oxidation. A 10% variation in the 
any of the five rate constants mediating these processes caused a 0.45-0.6mM variation in simulated 
hepatic triglyceride content after 36 hours (table 3.5). 
In addition to the oxidation of FAs, hepatic triglyceride levels also showed moderate sensitivity to the 
rate constant for triglyceride release as VLDL. A 10% variation in rate constant caused a 0.36-0.37mM 
change in simulated hepatic triglyceride levels after 36 hours (table 3.5).  
Hepatic lipid concentrations showed only a relatively weak sensitivity to changes in the rate constant 
for lipogenesis. Although de novo lipogenesis contributes less to hepatic lipid levels than FFA uptake, 
Enzyme Altered Periportal : Pericentral 
Triglyceride Ratio 
Difference in the change in 
triglyceride concentration 
between pericentral and 
periportal cells.  
Unchanged Metabolism: 1.80:1 
20% More Periportal 
(Δkn =+ 0.2) 
20% More Pericentral 
(Δkn = - 0.2) 
(∆𝑇𝐺𝑝𝑣 − ∆𝑇𝐺𝑝𝑝)
𝑇𝐺𝑎𝑣
 
 
(∆ 𝑓𝑟𝑜𝑚 ∆𝑘𝑛 = −0.2 𝑡𝑜 ∆𝑘𝑛 = +0.2) 
FA Uptake  1.27:1 2.62:1 0.91 
Triglyceride Release as 
VLDL  
2.22:1 1.47:1 -0.43 
Oxidative 
Phosphorylation 
2.09:1 1.53:1 -0.31 
Pyruvate Oxidation 1.64:1 1.98:1 0.22 
β-oxidation  2.01:1 1.64:1 `-0.22 
Glycolysis 1 (G6P-> GADP) 1.73:1 1.86:1 0.08 
Lipogenesis 1.75:1 1.85:1 0.08 
Gluconeogenesis (GADP  
-> G6P) 
1.88:1 1.74:1 -0.07 
Gluconeogenesis 1 (Pyr -> 
GADP) 
1.80:1 1.80:1 0.06 
Glycolysis 2 (GADP -> Pyr) 1.79:1 1.80:1 -0.06 
Triglyceride Synthesis 1.75:1 1.85:1 0.05 
Triglyceride Uptake 1.75:1 1.89:1 0.04 
Glucokinase 1.80:1 1.80:1 0.02 
G6Pase 1.81:1 1.80:1 -0.00 
Lipolysis 1.82:1 1.79:1 -0.00 
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its contribution is not insignificant and changes in the rate of lipogenesis would be expected to have 
a larger impact. However, lipogenesis is strongly allosterically regulated by the concentration of its 
product and alterations in maximum enzyme activity (rate constant) are partially compensated by 
changes in allosteric inhibition. Similarly, the rate constant for triglyceride synthesis only had a 
moderate effect on hepatic and plasma lipid levels. Due to the low concentration of cellular FFAs, the 
rate of triglyceride synthesis is predominantly determined by the availability of FFAs, rather than the 
enzyme activity. 
Finally, hepatic triglyceride levels also showed a comparatively weak sensitivity to variations in the 
rate constant for FFA uptake. However, changes in FFA uptake did have a larger effect on plasma lipid 
levels. 
3.3.3.2.2 Key determinants of sinusoidal steatosis location 
10% variations in the rate constants of the processes in the model had little effect on the predominant 
location of steatosis across the sinusoid. Instead, to determine the hepatic metabolic variations most 
likely to account for differences in the location of steatosis, sensitivity analysis was performed on the 
zonation constants in the model (table 3.6). These constants determine the difference between 
periportal and pericentral activity of enzymes mediating each process. Positive values correspond to 
periportal zonation whilst negative values correspond to pericentral zonation. The constants were 
increased or reduced by 0.2 corresponding to a 20% increase in periportal and 20% reduction in 
pericentral cells or vice versa, which is well within the range of variation expected non-pathologically 
(chapter 2 – table 2.2). The effects of these increases and reductions on the pericentral to periportal 
triglyceride ratio are presented when simulating a severely insulin resistant individual (KIR=0.015) with 
increased SREBP-1c expression on a moderate intake diet. 
While total hepatic triglyceride levels were most sensitive to changes in the rate of lipid oxidation, the 
location of steatosis is most strongly sensitive to changes in the zonation constants mediating FFA 
uptake and triglyceride output (table 3.6). Variations in the zonation constant of FFA uptake had the 
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largest effect, causing the periportal and pericentral triglyceride concentrations to change from 1:1.80 
to 1:1.27 when increased (20% more periportal expression) and 1:2.62 when reduced (20% more 
pericentral expression). Increasing the zonation constant for triglyceride release as VLDL caused more 
strongly pericentral steatosis with a ratio of 1:2.22, whilst reducing the constant gave a ratio of 1:1.47. 
This suggests that the inter-individual variation in the location of steatosis seen in vivo is likely to be 
at least partially accounted for by differences in the zonation of lipid uptake and output proteins. 
The zonation constants for oxidative phosphorylation of acetyl-CoA, β-oxidation and pyruvate 
oxidation also had a notable effect on the location of steatosis (table 3.6). Alterations to the zonation 
constant for oxidative phosphorylation and β-oxidation directly affect the rate at which fats are 
oxidised and removed from the cells in each region of the sinusoid. Similarly, alterations to the 
zonation constant for acetyl-CoA synthesis from pyruvate alter the relative amount of acetyl-CoA 
produced from glucose in each region and, as a result, the allosteric inhibition of β-oxidation. 
Consistent with the results when altering the rate constants, variations in the zonation constants for 
de novo lipogenesis and triglyceride synthesis have little effect on steatosis location in the model. This 
is despite the continuous stimulation of lipogenesis and triglyceride synthesis through increased 
SREBP-1c expression. Therefore, non-pathological inter-individual variations in the expression of 
lipogenesis enzymes are not predicted to account for differences in either susceptibility to steatosis 
or the distribution of fats across the sinusoid seen in vivo. 
3.4 Discussion 
3.4.1 Insulin resistance and increased SREBP-1c expression  
Firstly, additional validation of the model was provided in this chapter, focussing on its representation 
of NAFLD under conditions of IR and high fat intake. It was demonstrating that, when the known 
disruptions to metabolism are simulated (IR, increased SREBP-1c expression and high intake), 
pericentral-centred steatosis occurs and the model replicates the major changes in hepatic 
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metabolism known to occur in vivo. The model allows simulation of the changes in the rates of a wide 
range of metabolic processes and concentrations of intermediates in specific regions of the sinusoid 
under different feeding conditions and disease states, which would not be feasible experimentally. 
Furthermore, having established the ability of the model to provide realistic data for NAFLD, it can be 
used to make predictions of the effects of different treatments (see chapter 4). 
When simulating increased lipid intake in a metabolically normal, insulin sensitive individual, the 
hepatic triglyceride content was raised but this increase was fairly moderate. Unless a very high fat 
diet (resulting in plasma lipid concentrations at the high end of those seen in obese individuals) was 
simulated, the hepatic lipid concentration remained lower than the 5% cut off at which NAFLD is 
diagnosed. Similarly, high glucose intake primarily caused increased glycogenesis rather than steatosis 
in insulin sensitive individuals. For more serious steatosis to develop in the model, IR was required. 
Early stage steatosis arose even when simulating a healthy (moderate intake) diet in an insulin 
resistant individual. Severe build-up of lipids in the liver occurred when high lipid intake, or to a lesser 
extent high glucose intake, was simulated in addition to IR. Across the range of insulin sensitivities, 
low FFA or glucose intake returned simulated plasma triglyceride levels to a healthy range. 
Therefore, loss of insulin sensitivity in addition to excessive calorie intake is predicted to be required 
for more than early stage steatosis to arise. Given that fats in liver are known to cause both hepatic 
and peripheral desensitivity to insulin, sustained excessive calorie intake will strongly increase the 
chance of developing hepatic steatosis over time. However, these predictions highlight the 
effectiveness of a low-fat diet as a treatment for NAFLD, even in insulin resistant patients. 
In addition to the direct effects of IR, increased expression of SREBP-1c was required for the model to 
fully reproduce the metabolic changes seen in the early stages of NAFLD in vivo. In particular, 
increased SREBP-1c expression was required to replicate the increases in lipogenic rates seen in vivo. 
Additionally, both IR and increase SREBP-1c expression contributed to mitochondrial dysfunction, 
increased β-oxidation and reduced ATP levels in the simulations, consistent with in vivo observation. 
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SREBP-1c is a transcription factor which upregulates lipogenesis and triglyceride synthesis. Under 
normal conditions, its expression is stimulated by insulin. However, increased expression has been 
shown to occur in insulin resistant NAFLD patients. It is thought that insulin retains the ability to 
directly stimulate SREBP-1c expression despite the loss of insulin sensitivity [501, 517]. Alternatively, 
it is possible that SREBP-1c is stimulated by hyperglycaemia or by the fats themselves [501, 517], 
similar to the effects of ChREBP [493]. These results highlight the importance of the resulting increase 
in lipogenesis and triglyceride synthesis in the pathology of the disease. However, the presence of 
steatosis was seen when simulating the direct effects of IR alone. 
3.4.2 Pericentral-centred steatosis in insulin resistant livers results from increases in 
FFA and G3P concentrations in pericentral cells 
In addition to ensuring the model provided a valid representation of NAFLD, a major aim was to 
understand the metabolic changes leading to the development of steatosis in NAFLD, with a particular 
focus on understanding the increased susceptibility of pericentral cells to lipid build-up and the 
resulting damage. Changes in the rate of triglyceride synthesis, rather than output or lipolysis, 
accounted for the pericentral zonation in steatosis in simulations. A reduction in net triglyceride 
output also contributed to overall increased triglyceride levels but did not show zone specific 
differences. The enzymes involved in triglyceride synthesis are not zonated. The pericentral increase 
in triglyceride synthesis instead arose due to increases in the concentrations of G3P and FFAs. 
Defective postprandial glycogen storage occurred when simulating IR and caused a build-up of glucose 
metabolism intermediates including G3P in hepatocytes. Pericentral cells show lower glycogen 
synthase activity than periportal cells [45]. When simulating insulin sensitive individuals, this was 
compensated by increased insulin receptor [490] and reduced glucagon receptor expression [491] in 
pericentral cells. However, when simulating IR, the zonation in hormone receptors no longer affects 
glycogen synthesis, and glycogen depletion is most severe in pericentral cells. Additionally, pericentral 
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cells have fewer mitochondria and downregulated oxidative phosphorylation due to their low oxygen 
environment [45]. As a result, pericentral cells cannot rapidly metabolise glucose intermediates.  
Since glucose oxidation is suppressed in insulin resistant NAFLD patients and β-oxidation is 
upregulated, the periportal zonation of oxidative phosphorylation enzymes, along with those 
mediating β-oxidation, had an even larger effect on the simulated rate of oxidation of hepatic FFAs. 
Excess FFAs were metabolised more rapidly in periportal cells than pericentral. 
Increased availability of hepatic FFAs arose from both uptake and de novo lipogenesis. The enzymes 
involved in glycolysis and lipogenesis show pericentral zonation and the increase in de novo 
lipogenesis was largest in pericentral cells. The enzymes mediating FFA uptake, meanwhile, show 
periportal zonation. When simulating metabolically normal individuals, FFA uptake is dominated by 
insulin stimulated scavenging leading to strongly periportal uptake. However, when simulating insulin 
resistant individuals, FFA uptake occurs due to the high plasma FFA concentration rather than insulin 
stimulation, and passive uptake dominates. Under these conditions, the periportal zonation of FA 
uptake proteins had a smaller effect on the rate of uptake. Therefore, although total uptake was still 
higher in periportal cells, a larger increase in rate occurred in pericentral cells. 
Together these data suggest that the major differences between pericentral cells and periportal cells 
accounting for increased pericentral susceptibility to steatosis are lower expression of oxidative 
phosphorylation enzymes, β-oxidation enzymes and glycogen synthase along with higher expression 
of lipogenic enzymes in pericentral cells. These differences across the sinusoid account for a larger 
increase in FFA and G3P concentrations in pericentral cells in NAFLD and, therefore, result in higher 
triglyceride synthesis in these cells. Future experimental validation of these simulated data could be 
performed through the addition of radiolabelled substrates to measure the rates of conversion within 
individual regions of the sinusoid. As discussed supplementary material 1 (section S1.1.5), data of this 
form has previously been published for metabolically normal individuals, and the model outputs are 
consistent with experimental data in this case. Similar studies comparing metabolically normal and 
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NAFLD patients are required. Alternatively, experimental studies destroying specific regions of the 
sinusoids and measuring the remaining activity for various processes could also be used to provide 
additional insight [518]. 
3.4.3 Inter-individual variation in fatty acid oxidation rates most strongly affect 
susceptibility to steatosis. 
Two methods were used to determine the processes most likely to account for variation in the 
development of steatosis seen between individuals in vivo. By varying rate and zonation constants for 
key processes, a set of simulated patients were created and used to investigate the correlations 
between expression of the enzymes mediating each process and lipid content across the sinusoid. 
Sensitivity analysis on the rate and zonation constants for each process was then used to assess the 
effects of alterations in the rates of key processes individually on steatosis development across the 
sinusoid. 
Both sets of data suggest that any inter-individual variations in the rate of metabolism of hepatic fats 
will have a large effect on susceptibility to NAFLD development. In the sensitivity analysis, variations 
in the rate constants for β-oxidation and acetyl-CoA use in the citrate cycle had notably larger effects 
on hepatic lipid levels than equivalent variations in the rate constants of other processes. 
Furthermore, total hepatic lipid levels showed the next highest sensitivity to the rate constants for 
glucose uptake, glycolysis and acetyl-CoA synthesis from pyruvate, all of which play a role in the 
allosteric inhibition of β-oxidation by acetyl-CoA. When simulating the randomly generated sample 
patients, a strong negative correlation was also seen between oxidative phosphorylation and hepatic 
lipid content. Therefore, in both data sets, susceptibility to steatosis is predicted to be most strongly 
determined by the rate at which hepatocytes can metabolise fats.  
As validation of this prediction, there is considerable evidence to suggest mitochondrial function, 
aerobic capacity and capacity for β-oxidation inversely correlate with liver fat percentage and 
prevalence of NAFLD [155, 172-176, 519-522]. Furthermore, consistent with the high sensitivity of fat 
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storage to oxidation rates, global knockout of ACC2 (resulting in reduced allosteric inhibition of β-
oxidation) has been shown to reduce T2DM risk, obesity and adipose fat storage [523-525]. Liver 
specific knockout of ACC1 and ACC2 has been shown to reduce hepatic steatosis, although this 
resulted from both reduced lipogenesis and increased β-oxidation [526]. However, additional more 
directed studies are required to determine whether higher β-oxidation and oxidative phosphorylation 
capacities protect against hepatic steatosis independent of confounding factors such as exercise or 
caloric intake. 
Whilst the predominant location of steatosis showed some dependence to the zonation of enzymes 
mediating oxidative phosphorylation and β-oxidation, it was far more sensitive to changes in the 
zonation constants for FA uptake and triglyceride release as VLDL. Therefore, inter-individual variation 
in the distribution of steatosis is predicted to be accounted for by differences in the zonation of 
proteins mediating lipid uptake and triglyceride release. At present, little experimental data exists to 
validate this prediction due to the difficulty involved in measuring the distributed activities of large 
numbers of enzymes. However, the model simulations allow for targeted potential future 
experiments. The activities of the proteins mediating lipid uptake and triglyceride release could be 
measured in each region of the sinusoid, before comparing this data with distribution of steatosis 
across a range of samples. 
3.5 Conclusions of Chapter 
Due to the large heterogeneity in metabolism across the sinusoid, a clear description of the metabolic 
changes occurring in each zone is required to fully understand NAFLD development and to optimise 
potential pharmacological interventions. In this chapter, the computational model of sinusoidal 
metabolism presented in chapter 2 was used to simulate the development of NAFLD, focussing on the 
metabolic changes in individual zones. Consistent with experimental observation, both IR and 
increased SREBP-1c expression were required for the model to fully replicate the metabolic changes 
seen in NAFLD in vivo.  
136 
 
Simulations were run to identify the key differences between periportal and pericentral cells which 
account for higher pericentral susceptibility to steatosis. The majority of additional FFAs in NAFLD arise 
from FA uptake rather than de novo lipogenesis both in the simulated data and experimentally [26, 
492, 495, 496]. Although FA uptake enzymes show periportal zonation, the switch from predominantly 
insulin stimulated FA scavenging to passive diffusion reduced the effect of this heterogeneity on the 
rate of uptake across the sinusoid in the model simulations. Instead, the model simulations highlight 
the periportal zonation of oxidative phosphorylation and β-oxidation enzymes, along with the 
pericentral expression of lipogenesis enzymes as the key differences leading to a raised FFA 
concentration in pericentral cells when simulating insulin resistant NAFLD patients. Additionally, 
reduced insulin stimulation of glycogenesis caused the build-up of glucose intermediates, including 
G3P across the sinusoid. A more severe increase in pericentral and intermediate cells occurred due to 
the periportal zonation of glycogen synthase and of oxidative phosphorylation. 
Two methods of analysis were performed investigating the effects of changes in the rate and zonation 
constants to determine likely inter-individual differences in enzyme activities accounting for variation 
in susceptibility to NAFLD and steatosis distribution seen in vivo. Hepatic triglyceride levels were most 
sensitive to inter-individual variations in the rate of FFA oxidation, either through differences in the 
overall rate of oxidation of acetyl-CoA or differences in the relative contribution of FFAs and glucose 
to oxidation. The predominant location of steatosis across the sinusoid meanwhile was most sensitive 
to changes in the zonation of proteins mediating FFA uptake or VLDL synthesis and release. 
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4 Analysis of potential drug targets for reducing steatosis in NAFLD 
4.1 Introduction to Chapter 
In this chapter, inhibition or stimulation of various pathways as potential pharmacological targets for 
treating NAFLD are simulated. As of 2016, there is no approved drug for NAFLD or NASH [314], and to 
prevent the large number of deaths resulting from excess liver fat and the development of NASH, it is 
essential to identify drug targets which clear excess liver fat. However, due to the fundamental 
importance of lipid metabolism pathways in various essential cellular processes, the impact of any 
intervention on metabolism as a whole must also be assessed. Additionally, the heterogeneity in 
enzyme expression and function in hepatocytes across the sinusoid means that any medication must 
reduce steatosis without causing adverse effects in all regions [50]. As discussed in the previous 
chapters, when assessed in NAFLD patients in vivo, pericentral hepatocytes are known to show higher 
susceptibility to developing steatosis and the resulting damage than periportal cells, although pan-
sinusoidal and azonal steatosis patterns are also regularly seen [15-17, 377]. Experimentally studying 
the effects of targeting specific enzymes or hepatic processes on metabolism across the sinusoid 
would be time consuming, animal intensive and expensive due to the small size of the sinusoid and 
the large number of potential variables. 
In this chapter, by simulating inhibition and stimulation of various potential targets, we aim to find 
targets which reduce steatosis across the sinusoid without adversely affecting ATP production or 
causing changes likely to lead to oxidative stress such as excess FFA hepatic concentrations when 
simulating different stages of fatty liver arising from both excess fat intake alone and from IR and 
metabolic dysregulation in addition to raised intake. Here we focus on targets for removing the excess 
lipids from hepatocytes and thereby removing the underlying cause of IR, fibrosis and cirrhosis 
development. To treat effectively, it is likely that medication reducing existing inflammation in the 
cells would also be required [314]. In the chapter 5, key findings are tested in a hepatocyte-like cell 
culture model. 
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4.1.1 Inputs, insulin resistance and representing NAFLD development 
Throughout the simulations run in this chapter, the model was provided with spiked inputs at 4 hour 
intervals as a crude approximation to the intake of meals throughout the day (excluding sleep) as 
discussed in section 2.2.4.2. When simulating a moderate intake diet, the peak rates of glucose and 
FA intake were set so that each meal on average contained 78.1g of carbohydrate (glucose) and 22.2g 
of fat based on the meals provided to patients in a study by Daly et al. [425].  
The effects of potential treatments were simulated for three stages of NAFLD development, from an 
early stage entirely caused by increased fat intake, to a later stage predominantly caused by IR and 
metabolic dysregulation. These stages were based on the simulations in the previous chapter, where 
it was shown that very high fat intake is required for hepatic steatosis to develop in insulin sensitive 
individuals but, as IR develops, lower intake was required for excess fats to build up in the liver. Early- 
to late stage refers to the extent of metabolic dysregulation, and therefore the loss of immediate 
reversibility of the condition, rather than a progressive increase in the liver fat content between the 
stages. As discussed in the previous chapter, since the model does not contain adipocyte proliferation 
or swelling, excess dietary lipids remain in the plasma rather than being stored in adipocytes and 
changes in input have a larger effect on metabolism. As a result, smaller increases in lipid intake (based 
on matching the plasma lipid concentrations to values measured experimentally (section 4.2.1)) were 
used in simulations. The parameter changes (corresponding to fat intake, IR and SREBP-1c expression) 
used to represent these changes are presented in table 4.1 and the resulting changes to metabolism 
are discussed in section 4.2.1.  
In addition, the effects of targeting each pathway were simulated in metabolically normal individuals 
on a sustained low fat intake diet to identify possible dangers if medications are taken by those with 
reduced plasma FFA concentrations. For example, an individual may continue to take the medication 
after adopting a healthier diet and lifestyle. Finally, the effects of inter-individual variation in hepatic 
metabolism on key predictions are assessed in section 4.2.3. The effects of each intervention were 
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simulated until equilibrium was reached between successive input cycles. Once equilibrium was 
established, the average values over each 4 hour input cycle are presented. 
Table 4.1: The parameter value changes used to simulate the various NAFLD stages. 
NAFLD Stage FFA Input 
𝑣𝑖𝑛𝑝𝑢𝑡
𝐹𝐹𝐴  
Insulin 
Resistance 
𝑘𝐼𝑅 
SREBP-1c: 
Lipogenesis 
𝑣𝑙𝑖𝑝𝑜𝑔  
SREBP-1c: Triglyceride 
synthesis 
𝑘𝑇𝐺𝑠𝑦𝑛  
Moderate Intake, 
Metabolically Normal  
1 1 1 1 
Early Stage: Very High FFA 
Intake, Metabolically Normal 
1.25 1 1 1 
Mid-Stage: Developing IR, 
High FFA Intake;  
1.125 0.05 1 1 
Later Stage: Severe IR, Raised 
FFA Intake 
1.05 0.025 2.25  
(1nM Insulin) 
2 
(1nM Insulin) 
Low Fat Diet, Metabolically 
Normal 
0.875 1 1 1 
Values are presented relative to moderate intake in a metabolically normal individual. 
4.1.2 Inhibitions simulated 
Each process in the model is represented by a rate constant multiplied by a zonation constant and a 
series of substrate, hormonal and allosteric dependences (chapter 2). By simulating changes in these 
rate constants, which determine the maximum activity of the enzymes, we can assess the impact of 
stimulating or inhibiting key enzymes, not only on lipid concentrations but on metabolism as a whole 
across the sinusoid. 
Only potential drug targets which reduce the hepatic lipid content by removing lipids from the system, 
rather than redirecting them into the blood, are considered in this report. When interventions such 
as stimulation of triglyceride release as VLDL or blocking FA uptake from plasma were simulated, rapid 
increases in plasma triglyceride and FFA concentration occurred. These are likely to cause damage as 
a result of lipid build-up in other tissues. Given that fats in liver in particular are known to cause both 
organ specific and peripheral IR, this may still be beneficial to an individual. However, NAFLD patients 
are known to often have increased visceral adipose mass which is less responsive to insulin and less 
effective at clearing plasma lipids [8, 155, 527, 528]. As a result, rather than being stored in adipose 
tissue, these additional excess fats are likely to build-up in other tissues where they are known to 
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cause harm such as the heart, muscle and pancreas, as has been demonstrated when blocking FA 
uptake in vivo [529]. Therefore, the focus was instead on hepatic targets which removed fat from the 
system, rather than redirect them elsewhere. This includes the conversion of glucose to G6P, the 
conversion of G6P to GADP, the conversion of GADP to pyruvate, pyruvate oxidation, lipogenesis, β-
oxidation and triglyceride synthesis. These interventions are shown in figure 4.1. 
 
Figure 4.1: The processes investigated as potential targets for intervention in NAFLD. 
Inhibiting the production of pyruvate through glycolysis provides a potential method of reducing the 
available substrate for de novo lipogenesis and forcing the cells to oxidise FAs rather than glucose. In 
the model, glycolysis is represented by the initial conversion of glucose to G6P, followed by the 
conversion of G6P to two GADP molecules (closely related to G3P) and the conversion of GADP to 
pyruvate. In preliminary simulations, a range of reductions of the three rate constants, corresponding 
to the degree of inhibition of the process, were assessed. Since notable disturbances to ATP synthesis 
were seen for high degrees of inhibition, for the data presented in this report the rate constants were 
reduced by 1/3 to provide a balance between reducing de novo lipogenesis and promoting β-oxidation 
whilst allowing some glycolysis and glucose oxidation to occur for ATP synthesis when required.  
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Inhibition of pyruvate oxidation, mediated by the pyruvate dehydrogenase complex, allows a 
reduction in the production of acetyl-CoA from glucose without blocking glucose-lactate cycling. In 
initial simulations, a range of degrees of inhibition of the process were simulated. The data from these 
tests also showed that a balance was required between maximising the reduction in steatosis and 
minimising the disruption to energy metabolism. For the data in this report, the rate constant was 
halved to allow continued production of acetyl-CoA from glucose for use in oxidative phosphorylation 
when required. 
Another potential method to reduce hepatic lipid concentration is to directly target the synthesis and 
elongation of FAs from acetyl-CoA, primarily mediated by ACC and FAS. Total inhibition of lipogenesis 
was simulated (reducing the rate constant to zero), since no notable adverse effects in energy 
metabolism were noted when the process was inhibited in preliminary simulations.  
An alternative approach to clearing steatosis is to stimulate the oxidation of FAs. In initial simulations, 
various degrees of stimulation of β-oxidation were simulated. When simulating the data in this report, 
the rate was doubled to balance the reduction in lipid content resulting from high stimulation with 
potential disruptions to energy metabolism based on the preliminary simulations.  
Finally, rather than attempting to reduce the hepatic FFA concentration, steatosis may be reduced by 
directly inhibiting the synthesis of triglycerides, preventing lipid storage. Since triglyceride synthesis 
does not directly affect either oxidative or non-oxidative ATP synthesis, complete inhibition of the 
process was simulated.  
4.1.3 Criteria for judging effectiveness of a treatment 
The following criteria were used to determine the effectiveness of a potential target. A process must 
firstly reduce hepatic triglyceride concentrations (roughly equal to the total lipid content) to a healthy 
level (below the 5% criteria used to define NAFLD). Lipids must be cleared in all regions of the sinusoid. 
As discussed above, potential targets which reduce the hepatic triglyceride concentration by forcing 
142 
 
lipids into the blood stream are not considered in this report since they would be associated with the 
build-up of fats in other tissues around the body. 
Secondly, FFAs, along with closely related molecules including ceramides and DAGs, are known to be 
particularly potent in promoting mitochondrial stress and IR [8, 146, 247, 248, 253-259]. Although the 
mechanisms by which hepatic FFAs cause hepatic damage are not included in the model, potential 
drug targets which case reduction of the hepatic FFA concentration specifically, in addition to total 
lipid content, are likely to be associated with an improvement in liver injury.  
Any pharmacological intervention must not further reduce ATP concentrations to avoid loss of 
function resulting from defective energy metabolism. Furthermore, to avoid mitochondrial stress and 
ROS production from the ETC, the treatment must not cause excess flux through the ETC. The 
combination of excess ETC flux and dysfunctional ETC enzymes seen in NAFLD is known to result in 
superoxide radical anion and hydrogen peroxide (ROS) production which should be resolved by a 
potential treatment [229, 230, 501, 512, 514-516].  The ETC flux and ATP concentration were assessed 
in each region of the sinusoid for all three stages of NAFLD and for individuals on a low fat diet, to 
ensure the intervention does not disrupt metabolism in the model. 
Finally, any intervention should not cause excessively raised plasma glucose, lactate, FFA and 
triglyceride concentrations. In particular, glycogen synthesis should not be blocked. Although glycogen 
synthesis is defective in insulin resistant individuals, an improvement in hepatic steatosis would be 
expected to be associated with an improvement in insulin sensitivity in vivo (section 1.3.4.2.2). 
4.2 Results 
4.2.1 Simulated Stages of NAFLD Development 
As discussed in chapters 3, when simulating an insulin sensitive, metabolically normal individual on a 
moderate diet, the average hepatic lipid content was 2.3% (figure 4.2c, table 4.2). This towards the 
low end of values measured in the US general population by Szczepaniak et al. [211], consistent with 
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a healthy individual on a healthy diet. The simulated concentration increased from 2.0% to 2.7% 
between periportal and pericentral ends of the sinusoid (figure 4.2c) similar to the increase measured 
by Guzman et al. in vivo [86]. The hepatic and plasma concentrations of various molecules when 
simulating the three stages of NAFLD, along with metabolically normal individuals on moderate and 
low fat diets are shown in table 4.2. 
To represent steatosis arising from very high fat intake alone (early-stage), the rate of lipid intake was 
increased so that the simulated plasma FFA and triglyceride concentrations matched the highest 
values measured in obese individuals by Sindelka et al. [141] (FFA: 0.9mM, TG: 4.1mM, table 4.2). This 
is equal to the very high fat intake diet (27.75g/meal) simulated in chapter 3. When simulating these 
conditions, the average hepatic triglyceride content more than tripled to 7.2%, with a gradient in 
concentration from 5.8% to 9.0% across the sinusoid (figure 4.2c). 
To represent a mid-stage in NAFLD development, developing IR (5% detection) was simulated in 
individuals with a sustained high fat intake diet (24.6g/meal). At this stage the system begins to 
become hyperglycaemic with an average plasma glucose concentration of 6.5mM, but 
hyperinsulinaemia compensates for the most severe effects of IR. The average hepatic triglyceride 
content was 9.1% with the largest rise in pericentral cells (12.3%) (figure 4.2c). The simulated plasma 
triglyceride (6.0mM) and FFA (1.1mM) concentrations were severely raised (table 4.2).  
Finally, to represent a later stage, severe IR (2.5% detection) was simulated in individuals with a raised 
lipid intake diet (23.2g/meal). Additionally, as discussed in chapter 3, when studied in vivo, NAFLD 
patients show a counter intuitive increase in SREBP-1c expression, a protein which stimulates 
lipogenesis and triglyceride synthesis [36-39]. In chapter 3, it was shown that this increase in SREBP-
1c expression must be simulated in addition to IR to fully replicate the metabolic changes seen in 
NAFLD patients in vivo. Therefore, to represent later-stage NAFLD, the effects of increased SREBP-1c 
expression were included through continuous stimulation of hepatic lipogenesis and triglyceride 
synthesis (equivalent to 1nM). When simulating these conditions, hyperglycaemia occurred post-
144 
 
prandially, with a peak concentration of 12.7mM as insulin could no longer stimulate the storage of 
glucose as glycogen (table 4.2). The average hepatic triglyceride content was 8.9% (figure 4.2c). Due 
to the up-regulation of lipogenesis, which occurs primarily in pericentral cells, an increased periportal-
pericentral gradient in triglyceride concentration was seen relative to the other stages of steatosis 
development (PP->PC: 6.0%->12.7%). Severe increases occurred in the simulated plasma triglyceride 
and FFA concentrations (table 4.2).  
In addition to the total lipid content, the hepatic FFA concentrations were increased when simulating 
all three stages of NAFLD (figure 4.2b). The average concentration was markedly increased when 
simulating the early stage of NAFLD to 39.0µM from 21.5µM when simulating a metabolically normal 
individual on a moderate intake diet. When simulating the mid- and later disease stages, lower FFA 
inputs were used resulting in less severely raised FFA concentrations (mid stage 30.0µM, later stage 
26.2µM).  
The ATP concentration was progressively reduced when simulating early to later stages of NAFLD, as 
is seen in vivo [44, 227, 228, 505, 506] (figure 4.2a). For the later stage of NAFLD, the simulated average 
concentration fell by 18% to 2.3mM compared with 2.8mM in a metabolically normal individual. A 
switch to deriving ATP almost exclusively from FA oxidation reduced the additional ATP synthesized in 
glycolysis. Secondly increased SREBP-1c expression caused increased ATP consumption in lipogenesis 
[44, 227, 228, 505-509]. The decrease in ATP concentration was particularly severe in hypoxic 
pericentral cells which rely heavily on non-oxidative metabolism. In these cells, the simulated 
concentration fell from 2.5mM to 1.9mM in later-stage NAFLD. In vivo, in the later stages of NASH, 
further reductions in ATP concentration occur due to a loss of function in the oxidative 
phosphorylation enzymes [501]. 
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Figure 4.2: Simulated stages of NAFLD development. The (a) the hepatic lipid content, (b) the hepatic FFA concentration and (c) the hepatic ATP concentration across the sinusoid when simulating 
the early, mid and later stages of NAFLD development. The average concentration is depicted when simulating a 4-hour intake/output cycle of the form discussed in the model building section. 
 
a) b) 
c) 
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Table 4.2: The concentrations of key hepatic and plasma molecules when simulating different stages of NAFLD development.  
 Average 
Hepatic FFA 
Concentration 
Average 
Hepatic ATP 
Concentration 
Average Plasma 
Triglyceride 
Concentration 
Average 
Plasma FFA 
Concentration 
Average Plasma 
Glucose 
Concentration 
Average Plasma 
Lactate 
Concentration 
Average Hepatic 
Triglyceride 
Content 
Average Ox-Phos 
Rate (% of MN 
rate) 
Moderate Intake, 
Metabolically Normal  
21.5 µM 2.8 mM 1.2 mM 0.2 mM 5.0 mM 1.2 mM 2.3% 118 μM ATP/s 
Early Stage: Very High 
FFA Intake, 
Metabolically Normal 
39.0 µM 2.7 mM 4.1 mM 0.9 mM 5.0 mM 1.2 mM 7.2% 122 μM ATP/s 
Mid-Stage: Developing 
IR, High FFA Intake;  
30.0 µM 2.4 mM 6.0 mM 1.1 mM 6.5 mM 1.2 mM 9.1% 127 μM ATP/s 
Later Stage: Severe IR, 
Raised FFA Intake 
26.2 µM 2.3 mM 5.4 mM 3.9 mM 6.7 mM 1.4 mM 8.9% 128 μM ATP/s 
Low Fat Diet, 
Metabolically Normal 
17.0 µM 2.9 mM 0.9 mM 0.15 mM 5.0 mM 1.3 mM 1.7% 115 μM ATP/s 
The hepatic triglyceride, FFA and ATP concentrations, hepatic rate of oxidative phosphorylation and plasma triglyceride, FFA, glucose and lactate concentrations when simulating the early to later 
NAFLD stages and a metabolically normal individual on a moderate and a low-fat intake diet. 
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Despite this drop in ATP concentration, the rate of ATP production through the citrate cycle was 
increased when simulating the mid- and later- stages of NAFLD by 8.4% and 9.2% respectively (table 
4.2). Mitochondrial stress and ROS production occur in NAFLD in vivo, and this excess ETC flux, in 
addition to reduced mitochondrial function, is likely to contribute [501, 512, 514-516]. Excess ETC flux 
results in production of the superoxide anion radical, particularly when the ETC enzymes are not fully 
functional, which can in turn be converted to hydrogen peroxide. These disruptions to energy 
metabolism have been suggested as possible mechanisms for the progression of NAFLD to NASH [229, 
230]. 
4.2.2 Targeting hepatic processes in the model 
4.2.2.1 Glycolysis 
Partial inhibition of the conversion of glucose to G6P prevented the uptake of glucose for storage or 
glycolysis, resulting in increased glucose and insulin concentrations when simulating all stages of 
NAFLD (table 4.3). For later stage NAFLD, the post-prandial peak plasma glucose concentration rose 
to 15.4mM, well above the acceptable range. Furthermore, the raised plasma glucose and insulin 
concentrations resulted in continuous lipogenesis in adipose tissue, in turn causing the hepatic lipid 
content to increase through uptake of excess plasma FFAs (figure 4.3a,b; table 4.3). Therefore, rather 
than improving steatosis, the treatment caused an increase in hepatic triglyceride concentration (later 
stage: 8.9%->12.5% when partially inhibited; figure 4.3a). In a NAFLD patient in vivo, a larger 
percentage of these excess lipids are likely to be stored in adipose tissue rather than released into the 
plasma. However, the simulated data show that partial inhibition of GK increases plasma glucose levels 
even in insulin sensitive individuals. 
Targeting either of the two processes further along the glycolysis caused disruptions to pericentral 
energy metabolism when simulating all stages of NAFLD (figure 4.3c, table 4.3). This effect was small 
for the early stage of NAFLD (when either process was inhibited the ATP concentration fell to 2.6mM 
compared with 2.7mM when uninhibited). However, for the later stage of NAFLD, the pericentral ATP
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Table 4.3: The effect of targeting the various hepatic processes on key hepatic and plasma molecules. 
 Average 
Hepatic FFA 
Concentration 
Average 
Hepatic ATP 
Concentration 
Average Plasma 
Triglyceride 
Concentration 
Average 
Plasma FFA 
Concentration 
Average Plasma 
Glucose 
Concentration 
Average Plasma 
Lactate 
Concentration 
Average Hepatic 
Triglyceride 
Content 
Average Ox-Phos 
Rate (% of MN 
rate) 
Early Stage NAFLD/IR Development: Very high fat diet in insulin sensitive individuals 
Standard Parameter 
Values (Untreated) 
39.0 µM 2.7 mM 4.1 mM 0.9 mM 5.0 mM 1.2 mM 7.2% 122 μM ATP/s 
Partial Inhibition of 
Glucokinase 
45.7 µM 2.8 mM 6.8 mM 1.0 mM 5.2 mM 1.3 mM 12.1% 119 μM ATP/s 
Partial Inhibition of 
G6P->GADP 
41.9 µM 2.6 mM 3.0 mM 0.5 mM 5.0 mM 0.7 mM 5.1% 120 μM ATP/s 
Partial Inhibition of 
GADP->Pyr 
26.3 µM 2.6 mM 2.9 mM 0.5 mM 5.0 mM 0.6 mM 5.1% 122 μM ATP/s 
Partial Inhibition of 
Pyruvate Oxidation 
25.0 µM 2.7 mM 2.4 mM 0.4 mM 5.0 mM 3.2 mM 4.1% 121 μM ATP/s 
Inhibited Lipogenesis 29.6 µM 2.9 mM 2.9 mM 0.5 mM 5.0 mM 0.9 mM 5.1% 117 μM ATP/s 
Stimulated β-oxidation 17.3 µM 2.5 mM 2.0 mM 0.3 mM 5.0 mM 1.3 mM 3.4% 125 μM ATP/s 
Stimulation of β-
oxidation with 
inhibition of DNL 
14.3 µM 2.8 mM 1.8 mM 0.3 mM 5.0 mM 0.9 mM 2.9% 118 μM ATP/s 
Inhibition of 
Triglyceride Synthesis 
230.4 µM 2.7mM 2.3mM 0.4mM 5.0mM 1.1mM 2.5% 121 μM(ATP)/s 
Mid-Stage NAFLD/IR Development: High fat diet in individuals developing insulin resistance 
Standard Parameter 
Values (Untreated) 
30.0 µM 2.4 mM 6.0 mM 1.1 mM 6.5 mM 1.2 mM 9.1% 127 μM(ATP)/s 
Partial Inhibition of 
Glucokinase 
35.1 µM 2.5 mM 8.5 mM 1.6 mM 6.6 mM 1.1 mM 12.5% 126 μM(ATP)/s 
Partial Inhibition of 
G6P->GADP 
31.6 µM 2.4 mM 4.5 mM 0.7 mM 6.7 mM 0.7 mM 6.3% 125.7 μM(ATP)/s 
Partial Inhibition of 
GADP->Pyr 
19.2 µM 2.3 mM 4.3 mM 0.7 mM 6.7 mM 0.6 mM 6.2% 127 μM(ATP)/s 
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Partial Inhibition of 
Pyruvate Oxidation 
15.8 µM 2.4 mM 3.1 mM 0.5 mM 6.6 mM 3.3 mM 4.0% 126 μM(ATP)/s 
Inhibited Lipogenesis  20.8 µM 2.6 mM 4.0 mM 0.6 mM 6.8 mM 0.9 mM 5.6% 123 μM(ATP)/s 
Stimulated β-oxidation 10.8 µM 2.2 mM 2.6 mM 0.4 mM 6.7mM 1.2 mM 3.6% 128 μM(ATP)/s 
Stimulation of β-
oxidation with 
inhibition of DNL 
7.9 µM 2.5 mM 2.4 mM 0.4 mM 6.9 mM 0.8 mM 3.2% 123 μM(ATP)/s 
Inhibition of 
Triglyceride Synthesis 
122µM 2.4 mM 3.1 mM 0.6mM 6.7 mM 1.1 mM 3.2% 127 μM(ATP)/s 
Later Stage NAFLD/IR Development: Severe insulin resistance + Increased SREBP-1c expression 
Standard Parameter 
Values (Untreated) 
26.2 µM 2.3 mM 5.4 mM 3.9 mM 6.7 mM 1.4 mM 8.9% 128 μM(ATP)/s 
Partial Inhibition of 
Glucokinase 
25.6 µM 2.3 mM 7.4 mM 6.5 mM 9.6 mM 1.3 mM 12.5% 128 μM(ATP)/s 
Partial Inhibition of 
G6P->GADP 
25.8 µM 2.2 mM 5.9 mM 3.3 mM 7.3 mM 0.9 mM 9.3% 129 μM(ATP)/s 
Partial Inhibition of 
GADP->Pyr 
15.8 µM 2.1 mM 5.8 mM 3.4 mM 7.3 mM 0.7 mM 9.4% 130 μM(ATP)/s 
Partial Inhibition of 
Pyruvate Oxidation 
14.7 µM 2.2 mM 4.4 mM 0.6 mM 8.1 mM 6.0 mM 6.1% 128 μM(ATP)/s 
Inhibited Lipogenesis 12.3 µM 2.6 mM 5.1 mM 0.6 mM 8.5 mM 1.0 mM 7.0% 123 μM(ATP)/s 
Stimulated β-oxidation 8.9 µM 1.9 mM 3.5 mM 0.5 mM 8.2 mM 1.5 mM 4.8% 131 μM(ATP)/s 
Stimulation of β-
oxidation and 
inhibition of DNL 
5.8 µM 2.5 mM 3.0 mM 0.4 mM 8.8 mM 0.9 mM 3.8% 124 μM(ATP)/s 
Inhibition of 
Triglyceride Synthesis 
135.1 µM 
 
2.2 mM 3.9 mM 0.6 mM 8.3 mM 1.3mM 3.9% 130 μM(ATP)/s 
Low fat diet in metabolically normal individuals 
Standard Parameter 
Values (Untreated) 
17.0 µM 2.9 mM 0.9 mM 0.15 mM 5.0 mM 1.3 mM 1.7% 115 μM(ATP)/s 
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Partial Inhibition of 
Glucokinase 
23.2 µM 3.0 mM 1.0 mM 0.2 mM 5.2 mM 1.3 mM 2.2% 113 μM(ATP)/s 
Partial Inhibition of 
G6P->GADP 
18.3 µM 2.9 mM 0.8 mM 0.1 mM 4.9 mM 0.7 mM 1.4% 112 μM(ATP)/s 
Partial Inhibition of 
GADP->Pyr 
12.5 µM 2.8 mM 0.8 mM  0.1 mM 4.9 mM 0.6 mM 1.4% 114 μM(ATP)/s 
Partial Inhibition of 
Pyruvate Oxidation 
12.1 µM 2.8mM ** 
notably reduced 
in periportal cells 
0.7 mM 0.13 mM 5.0 mM 4.5 mM 1.4% 113 μM(ATP)/s 
Inhibited Lipogenesis  12.3-13.6 µM 3.0 mM 0.8mM 0.13 mM 5.0 mM 1.0 mM 1.4% 110 μM(ATP)/s 
Stimulated β-oxidation 
 
8.9 µM 2.8 mM 0.7 mM 0.12 mM 5.0 mM 1.3 mM 1.3% 117 μM(ATP)/s 
Stimulation of β-
oxidation and 
inhibition of DNL 
7.0 µM 3.0 mM 0.7 mM 0.11 mM 5.0 mM 0.9 mM 1.1% 111 μM(ATP)/s 
Inhibition of 
Triglyceride Synthesis 
89.3 µM 2.9mM 0.7 mM 0.13 mM 5.0mM 1.2mM 1.0% 114 μM(ATP)/s 
Reference Values: Metabolically normal individuals on moderate diet 
Standard Parameter 
Values 
21.5 µM 2.8 mM 1.2 mM 0.2 mM 5.0 mM 1.3 mM 2.4% 118 μM(ATP)/s 
The effect of targeting the various hepatic processes on hepatic triglyceride, FFA and ATP concentrations, the hepatic rate of oxidative phosphorylation, and plasma triglyceride, FFA, glucose and 
lactate concentrations. The interventions simulated in each case are described in section 4.1.2.
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Figure 4.3: Simulating inhibition of glycolysis. The simulated effects of reducing the rate constant for 
glycolysis by one third on (a) hepatic lipid content, (b) hepatic FFA concentration and (c) hepatic ATP 
concentrations when simulating the range of NAFLD stages. 
a) 
b) 
c) 
Partial Inhibition of Glycolysis (3 stages) 
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concentration fell to 1.7mM when simulating partial inhibition of the conversion of G6P to GADP and 
to 1.5mM for partial inhibition of the conversion of GADP to pyruvate glycolysis. These reductions in 
pericentral ATP concentration, compared with 2.5mM when simulating a metabolically normal 
individual, occurred because pericentral cells, which inhabit a hypoxic environment, rely on glycolysis 
to produce additional ATP. Furthermore, although the hepatic triglyceride concentration decreased 
slightly when simulating partial inhibition of these two glycolysis processes in early stage, insulin 
sensitive NAFLD (7.2% -> 5.1% when either process was inhibited; figure 4.3a), no notable change in 
triglyceride content occurred in any region of the sinusoid for the mid- and later NAFLD stages (figure 
4.3a; table 4.3). A decrease in hepatic FFA concentration was seen when targeting the conversion of 
GADP to pyruvate (later stage 25.6-39.0µM -> 15.8-26.3µM), but not when inhibiting the conversion 
of G6P to GADP. 
Due to the changes in ATP concentration and ineffective clearance of steatosis, none of the processes 
along the glycolysis chain are predicted to be suitable as a target for reducing steatosis. 
4.2.2.2 Pyruvate Oxidation 
Halving the rate constant of pyruvate oxidation reduced the hepatic lipid content to less than 5% when 
simulating the early and mid-stages of NAFLD development. However, when simulating the later stage, 
the average hepatic lipid content was only reduced to 6.1% and remained notably raised in pericentral 
cells. (4.8->8.2% from periportal to pericentral ends of the sinusoid) (figure 4.4a). Hepatic FFA 
concentrations were reduced for all three NAFLD stages (26.2-39.0µM -> 14.7-25.0µM when inhibited; 
figure 4.4b). Plasma FFA and triglyceride concentrations were additionally markedly reduced, 
particularly when simulating the early and mid-stages of NAFLD development (table 4.3). 
However, some adverse metabolic changes were predicted when simulating the partial inhibition of 
pyruvate oxidation. Plasma lactate concentrations increased, particularly when simulating the later 
stage of the disease where the average concentration rose to greater than 6mM (figure 4.4c and table 
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Figure 4.4: Simulating inhibition of pyruvate oxidation. The simulated effects of reducing the rate constant for 
pyruvate oxidation by a half on (a) hepatic lipid content, (b) hepatic FFA concentration and (c) plasma lactate 
concentration when simulated the NAFLD stages and (d) the hepatic ATP concentration when simulating a low-
fat diet. 
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4.3). Lactic acidosis is diagnosed when plasma concentrations exceed 5mM [530]. Additionally, 
inhibiting pyruvate oxidation caused more severe post-prandial hyperglycaemia. When simulating the 
later stage of NAFLD development, the post-prandial peak in glucose concentration increased from an 
already hyperglycaemic value of 12.7mM to 14.9mM, well outside of a healthy range. Furthermore, 
when simulating a low-fat intake diet, ATP concentrations fell in periportal cells (compartment 1: 
3.2mM -> 2.7mM when inhibited; figure 4.4d), even though only partial inhibition of pyruvate 
oxidation was simulated. In this oxygen rich part of the sinusoid, the cells do not supplement their ATP 
production through glucose-lactate cycling. With a normal or raised plasma FFA concentration, 
periportal cells are able to compensate for reduced glucose oxidation by increasing β-oxidation. 
However, when simulating conditions in which plasma FFAs were no longer available, insufficient 
acetyl-CoA was available for the citrate cycle. 
4.2.2.3 Lipogenesis 
When simulating the inhibition of lipogenesis, ATP concentrations were partially restored (later stage: 
2.3mM->2.6mM) (figure 4.5c) and the excess ETC flux was reduced when simulating all three stages 
of NAFLD (table 4.3). However, only a small improvement in simulated hepatic lipid content occurred. 
The lipid content remained above the 5% criteria at which NAFLD is diagnosed for all stages of NAFLD 
(early stage: 7.6%->5.1%, mid stage: 8.7%->5.6%, later stage: 9.6%->7.0%) (figure 4.5a). FFAs were 
readily available from uptake to compensate for reduced hepatic synthesis and inhibition of 
lipogenesis caused an increase in G3P concentration, allowing more rapid triglyceride synthesis. 
Despite not effectively clearing triglycerides, a decrease in hepatic FFA concentration occurred in all 
three stages of NAFLD when simulating inhibition of lipogenesis (26.2-39.0µM->12.3-29.6µM; figure 
4.5b). Additionally, plasma FFA concentrations were notably reduced at all stages of NAFLD 
development (table 4.3), which may reduce lipid build-up in muscle, pancreas, heart and other organs. 
The model simulations suggest that pharmacological inhibition of lipogenesis in NAFLD may reduce 
the mitochondrial stress, ROS production and IR resulting from excess FFAs and excess ETC fluxes, but 
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Figure 4.5: Simulating inhibition of lipogenesis. The simulated effects of complete inhibition of lipogenesis on 
(a) hepatic lipid content, (b) hepatic FFA concentration and (c) hepatic ATP concentrations when simulating the 
range of NAFLD stages. 
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would fail to reduce overall steatosis, particularly in insulin resistant patients. A treatment targeting 
lipogenesis, therefore, would not be expected to remove the underlying cause of damage in NAFLD, 
which would return after the cessation of treatment. 
4.2.2.4 β-oxidation 
Stimulation of β-oxidation provided a notable improvement to steatosis. The average hepatic lipid 
content was reduced to below the 5% criteria when simulating all three stages of NAFLD development 
(figure 4.6a). However, since β-oxidation enzymes have higher expression in periportal cells, the 
pericentral triglyceride concentration remained greater than 5% when simulated later stage NAFLD. 
The hepatic FFA concentration was also reduced in all three NAFLD stages (26.9-39.0µM->8.9-17.2µM; 
figure 4.6b) and plasma FFA and plasma triglyceride levels were notably reduced (table 4.3).  
However, when simulating stimulation of β-oxidation, ATP production was disrupted in intermediate 
and pericentral cells. For later stage NAFLD, the simulated pericentral ATP concentration fell to 1.2mM 
(figure 4.6c). Stimulation of β-oxidation resulted in cycling between β-oxidation and lipogenesis, both 
of which consume ATP. Additionally, non-oxidative ATP production was reduced due to the allosteric 
inhibition of glycolysis by acetyl-CoA derived from increased β-oxidation. Since pericentral cells rely 
more heavily on glycolysis from energy production, and contain a greater capacity for lipogenesis, the 
largest fall in ATP concentration was seen in these cells. Furthermore, the rate of oxidative 
phosphorylation increased further when simulating stimulation of β-oxidation to 10% higher than 
when simulating metabolically normal individuals (table 4.3).  
Based on these simulations, stimulation of β-oxidation alone is not considered to be a suitable 
treatment for NAFLD. However, to avoid the consumption of ATP in cycling between acetyl-CoA and 
FAs when stimulating β-oxidation, it may be effective to additionally inhibit lipogenesis. In vivo, this 
could be achieved by reducing the cytoplasmic and mitochondrial malonyl-CoA concentration by 
targeting the two isoforms of acetyl-CoA carboxylase (ACC1 and ACC2) (chapter 5). 
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When simulating pharmacological stimulation of β-oxidation (doubling the rate constant) in 
combination with complete inhibition of lipogenesis, ATP concentrations increased for all NAFLD 
stages (figure 4.6c). For the later stage of NAFLD, the simulated average concentration increased from 
2.2mM to 2.5mM. Furthermore, the rate of oxidative phosphorylation was reduced to near 
metabolically normal levels, reducing the possibility of ROS production due to excess ETC flux (table 
4.3).  
Hepatic steatosis was effectively cleared when simulating targeting of both processes (figure 4.6a). 
The simulated hepatic lipid content was reduced to less than the 5% cut off at which NAFLD is 
diagnosed for all simulated stages of the disease. Since lipogenesis enzymes show pericentral 
expression, the additional reduction in lipid content was largest in pericentral cells, whilst stimulation 
of β-oxidation had a larger effect on the lipid content of periportal cells. As a result, when simulating 
stimulation of β-oxidation combined with inhibition of lipogenesis, the hepatic lipid content was less 
than 5% across the sinusoid. The hepatic FFA concentration was also notably reduced (26.2-39.0µM -
> 5.8-17.3µM; figure 4.5b). 
The plasma glucose concentration increased when simulating the treatment in the mid- and later 
stages of NAFLD. In these later stages, IR prevents the additional glucose from being stored as glycogen 
(table 4.3). The average glucose concentration for the later stage NAFLD increased from 6.7mM to 
8.8mM. It is therefore important that any treatment based on inhibition of lipogenesis rapidly restores 
insulin sensitivity through clearing hepatic lipids to avoid hyperglycaemia in insulin resistant patients, 
or is given in combination with other treatments to reduce the plasma glucose concentration. 
4.2.2.5 Triglyceride Synthesis 
Blocking triglyceride synthesis had a dramatic effect on simulated hepatic triglyceride levels (figure 
4.7a). For all three NAFLD stages, the average concentration was reduced to well below the 5% criteria 
at which NAFLD is diagnosed in all regions of the sinusoid. Furthermore, plasma triglyceride and FFA 
concentrations were notably reduced. 
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Figure 4.7: Simulating inhibition of triglyceride synthesis. The simulated effects of complete inhibition of 
triglyceride synthesis on (a) hepatic lipid content, (b) hepatic FFA concentration and (c) hepatic ATP 
concentrations when simulating the range of NAFLD stages. 
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However, blocking triglyceride synthesis also caused a vast increase in the simulated hepatic FFA 
concentration (figure 4.7b), which is likely to be far more harmful to the cells than the original 
triglyceride build-up. When simulating the later stage NAFLD, inhibition of triglyceride synthesis 
increased the simulated FFA concentration five-fold from 26.2µM to 135.1µM. As discussed, FFAs, 
along with ceramides and DAGs are thought to promote mitochondrial stress and IR more rapidly than 
fats stored as triglycerides [8, 146, 247, 248, 253-259]. A large increase in plasma glucose 
concentration was also predicted as glucose oxidation was replaced with β-oxidation. 
No notable change in ATP concentration occurred when simulating inhibition of triglyceride synthesis 
(figure 4.7c), although the rate of oxidative phosphorylation was marginally increased (table 4.3). 
4.2.3 Inter-Individual Variability in Model Simulations 
The model simulations suggest that inhibition of lipogenesis in combination with stimulation of β-
oxidation would provide an effective mechanism for clearing hepatic steatosis and reducing plasma 
FFA and triglyceride concentrations without adversely affecting energy metabolism. However, as 
discussed in the previous section, notable inter-individual variation in metabolism exists between 
patients and it is important that a treatment is effective across a range of patients. To assess the 
impact of the treatment across a broader range of patients, inhibition of lipogenesis and stimulation 
of β-oxidation (doubling the rate constant) was simulated for the 15 patients discussed in section 
3.4.3. These example patients have rate constants randomly generated within 10% of the standard 
parameter value and zonation constants randomly generated within ±0.2 of the standard value (tables 
3.2 and 3.3). The effects of the treatment in mid-stage NAFLD were simulated to provide conditions 
of both IR and high dietary lipid intake. For statistical significance testing in this section, a paired, 2 
tailed T-test was performed between the simulated treated and untreated patients with the same 
parameter values. A p value of 0.05 was considered to represent statistical significance. 
Despite a wide variability in the pre-treatment hepatic lipid content across the 15 simulated patients 
(3.8%-24%), the lipid content in the treated patients was reduced to less than 5% in every case (2.5%-
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4.5%; p<0.001) (figure 4.8a). This is consistent with the decrease in lipid content from 9.1% to 2.9% 
when using the standard parameter values. For most of the simulated patients the hepatic triglyceride 
content was reduced to less than 5% in all regions of the sinusoid. Three patients showed a hepatic 
triglyceride content of greater than 5% in the two compartments nearest the central vein 
(compartments 7 and 8). These were the three simulated patients with the highest zonation constant 
for ATP synthesis via the citrate cycle (most periportally zonated). Additionally, the Pearson product-
moment correlation coefficient between the post-treatment pericentral triglyceride content and ATP 
synthesis zonation constant was high at 0.823 (p<0.001). Therefore, pericentral oxidative capacity is 
the most important determinant of the ability for the treatment to fully clear steatosis in all regions 
the sinusoid. 
The simulated plasma and hepatic FFA concentrations were also reduced by the treatment in all 
patients (figure 4.8b,d), consistent with the predictions when using standard parameter values. 
Additionally, an increase in ATP concentration occurred for all of the simulated patients after 
treatment. The average concentration increased by 0.16±0.04mM from 2.29±0.26mM to 
2.45±0.25mM (p<0.001) (closer to the simulated metabolically normal range of 2.72±0.20mM) (figure 
4.8c). 
Therefore, across the range of simulated patients, the treatment reduced hepatic steatosis, reduced 
FFA levels and increased the hepatic ATP concentration. However, as seen when using standard 
parameter values, an increase in glucose concentration of 0.39±0.07mM from 6.6±0.1mM to 
6.9±0.1mM occurred when simulating the treatment due to defective glycogen storage (p<0.001, 
figure 4.8e). Therefore, the treatment would have to either rapidly restore insulin sensitivity of 
glycogenesis, or be accompanied by alternative treatments to prevent hyperglycaemia. The largest 
increase in glucose concentration was seen for the patients with lower rate constants for oxidative 
phosphorylation, such that less of the extra acetyl-CoA generated from increased β-oxidation could 
be metabolised (Pearson’s correlation=-0.65; p=0.008).  
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Figure 4.8: Inclusion of inter-individual variability. The effect of stimulation of β-oxidation in combination 
with inhibition of lipogenesis in mid-stage NAFLD when simulating using the parameter values for the 15 
randomly generated patients discussed in section 3.4.3. 
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4.3  Discussion 
4.3.1 Adverse effects are predicted when targeting most hepatic processes 
The model simulations suggest that most the hepatic processes tested do not provide suitable drug 
targets for effectively reducing hepatic steatosis without causing adverse effects. Targeting β-
oxidation and glycolysis disturbed pericentral energy metabolism in the simulations, whilst targeting 
pyruvate oxidation caused a reduction in periportal ATP concentration. In reality, cells are likely to 
adapt and upregulate alternative ATP producing pathways, or downregulate ATP consumption to 
partially reduce this effect. However, given that ATP concentrations are already significantly depleted 
in the livers of insulin resistant NAFLD patients, additional large reductions in ATP concentration are 
likely to be associated with some loss of function. It has been hypothesized that disturbed energy 
metabolism may be responsible for the progression of NAFLD to NASH [229, 230]. This would be 
consistent with the observation that fibrosis tends to develop from the pericentral side of the organ 
where ATP is most depleted [15, 16], highlighting the importance of studying the sinusoid as a whole. 
Targeting several processes in the model caused more severe hyperglycaemia in insulin resistant 
individuals including inhibition of glucose uptake, any stage of glycolysis, pyruvate oxidation and 
lipogenesis and stimulation of β-oxidation. However, if sufficient fats are removed, it is possible that 
insulin sensitivity would be improved to a degree where glycogen synthesis is restored (e.g. [531]). 
Inhibition of pyruvate oxidation also caused severe hyperlactataemia when simulating late stage 
NAFLD.  
When inhibition of the triglyceride synthesis step was simulated, FA concentrations increased 
markedly. Rather than protecting the cells, this would be expected to expedite cellular damage. As 
discussed, FFAs, along with closely related molecules including ceramides and DAGs, are known to be 
particularly potent in promoting mitochondrial stress and IR [8, 146, 247, 248, 253-259]. 
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Numerous potential targets were ineffective at clearing steatosis in the model, particularly when 
simulating insulin resistant individuals. This includes all of the processes involved in the de novo 
synthesis of FAs from glucose. However, despite not reducing the simulated total hepatic fat content, 
inhibition of the lipogenesis step (predominantly mediated by ACC and FAS) reduced the hepatic FFA 
concentration and increased hepatic ATP concentrations. Therefore, despite not removing the 
underlying cause of the disease, inhibition of lipogenesis may reduce cellular damage and improve IR. 
Some of these processes have been targeted in in vivo systems previously and the results have largely 
been consistent with those the simulated data. The increase hepatic FFA concentration seen when 
simulating inhibition of triglyceride synthesis have been noted in mice along with resulting adverse 
effects. Yamaguchi et al. investigated the effects of inhibiting diglyceride acyltransferase-2 (DGAT-2), 
one of the enzymes responsible for the addition of a third acyl-CoA to a DAG to form triglycerides, in 
mice [254]. In this study, hepatic steatosis was reduced. However, the hepatic FFA concentration rose 
from around 300nMoles/g in NAFLD mice (fed a diet deficient in methionine and choline) to around 
1.5µMoles/g in NAFLD mice with inhibited DGAT-2, consistent with the roughly 5-fold increase seen 
in the simulated data [254]. Furthermore, despite the improved triglyceride levels, Yamaguchi et al. 
showed more severe development of fibrosis in these mice demonstrating that the damage caused by 
the increased levels of FFAs (or closely related molecules) outweighed any benefits from clearing 
triglycerides themselves. In model simulations, the most severe adverse effects of the treatment were 
seen in pericentral cells. Unfortunately, the effects of the treatment on individual regions of the 
sinusoid were not investigated in the experimental study. Whilst there is conflicting evidence to 
suggest that IR may or may not be improved if triglyceride synthesis is blocked before the formation 
of DAG rather than blocking the addition of the final acyl-CoA ([532] vs [533]), it remains likely that 
sustained severely increased FFA concentrations will cause mitochondrial stress independent of the 
enzyme targeted. Therefore, triglyceride synthesis is not considered to be a suitable target for drugs 
aiming to reduce hepatic steatosis. Interestingly, in both the experimental study and the model 
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simulations, despite a severe rise in hepatic FFA concentration, plasma FFA concentrations fell [254]. 
In the model this occurred because of a reduction in adipose lipolysis. 
Inhibition of pyruvate dehydrogenase has not been widely studied as a treatment for NAFLD in vivo. 
However, consistent with the simulations, genetically inherited system-wide (not liver specific) 
deficiency of PDH is associated with severe lactate build-up along with neurological problems resulting 
from reduced cellular energy production [534]. Neurons rely heavily on glucose metabolism substrates 
rather than lipids as an energy source. Furthermore, heart and muscle specific PDH-knockout mice 
survive less than 7 days unless kept on a high fat diet [535]. However, more promising results have 
been published for liver-specific PDH knockout mice. These mice show significant reductions in liver 
FA synthesis, in body mass and in fat mass [531]. An increase in hepatic glycogen content, rather than 
plasma glucose concentration was measured due to an improvement in insulin sensitivity. 
Unfortunately, the plasma lactate concentration was not measured in this study. It therefore remains 
unknown whether this treatment would cause the hyperlactataemia predicted for insulin resistant 
NAFLD patients, or if insulin sensitivity would be restored rapidly enough for the additional lactate to 
be stored as glycogen. Furthermore, no specific test from the minor disruption to periportal ATP 
concentrations predicted by the model was performed. 
The inhibition of de novo lipogenesis has been studied experimentally through inhibition of FAS with 
mixed results. FAS is the main enzyme responsible for adding additional malonyl-CoA molecules to the 
chain of FAs. System-wide knockout of FAS is lethal in embryo development [536]. Liver-specific 
deletion of the FAS gene was shown to expedite rather than protect against the development fatty 
liver in a mouse model of NAFLD. On a normal diet, little difference was seen between the control and 
FAS knockout mice. However, on a high fat diet, the FAS knockout mice developed more severe 
steatosis due to a reduction in β-oxidation [537]. This may result from increased allosteric inhibition 
of β-oxidation by malonyl-CoA, given that the physically separation of lipogenesis and β-oxidation 
enzymes has been shown to break down under abnormal conditions [538]. On the other hand, 
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platensimycin, an inhibitor of FAS specific to liver, has been demonstrated to reduce lipid build-up in 
hepatocytes because of a reduction in lipogenesis [539]. However, these mice were fed a high fructose 
diet rather than the high fat. In the model simulations, inhibition of lipogenesis was only effective at 
clearing steatosis when FAs were not readily available in the plasma. Mice lacking FAS in adipose tissue 
meanwhile, showed a reduction in diet-induced obesity, suggesting that adipose rather than hepatic 
lipogenesis may provide a pertinent target for reducing hepatic steatosis [540]. The analysis in this 
study focussed on potential hepatic targets. 
4.3.2 Acetyl-CoA carboxylase may provide a pertinent target for NAFLD 
Targeting β-oxidation alone caused a fall in the simulated hepatic ATP concentration, particularly in 
pericentral cells. However, when stimulation of β-oxidation was combined with inhibition of 
lipogenesis, ATP concentrations were improved relative to untreated NAFLD and steatosis was 
effectively cleared. The simulated triglyceride content was reduced to a metabolically normal range 
for all three NAFLD stages. Furthermore, the rate of oxidative phosphorylation was returned to normal 
values, reducing the chance of damage due to ROS production resulting from excess ETC flux. The 
simulated hepatic and plasma FFA concentrations also improved which is likely to be associated with 
an improvement mitochondrial stress and IR [8, 146, 247, 248]. One adverse effect was an increase in 
plasma glucose concentration when simulating an insulin resistant individual. Therefore, it is 
important that any treatment targeting β-oxidation and lipogenesis restores insulin sensitivity rapidly 
such that glycogen synthesis can prevent hyperglycaemia from occurring. 
The two forms of acetyl-CoA carboxylase (ACC1 and ACC2) provide a potential target for both 
inhibiting lipogenesis and stimulating β-oxidation. ACC1 is in the cytosol and produces malonyl-CoA 
which can be accessed by FAS for lipogenesis. ACC2, meanwhile, is in the mitochondria and produces 
malonyl-CoA to negatively regulate β-oxidation [462, 541]. Malonyl-CoA synthesized by ACC2 is 
physically separated from FAS under normal physiological conditions [462]. Therefore, inhibition of 
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ACC1 provides a target for inhibiting lipogenesis, whilst inhibiting ACC2 will lead to stimulation of β-
oxidation.  
Some in vivo studies have investigated the inhibition of ACC1 and ACC2 either together or separately. 
Globally knocking out ACC1 in mice is lethal in embryonic development [542]. However, liver specific 
ACC1 knockout mice have been developed. Mao et al. demonstrated a significant reduction in liver 
triglycerides, hepatic FA synthesis and serum FFAs despite compensatory up-regulation of ACC2, but 
no improvement in glucose concentration or resensitization to insulin [543]. In another liver-specific 
ACC1 knockout, Harada et al. found that up-regulation of ACC2 entirely compensated for the reduction 
in ACC1 expression suggesting that, under these non-physiological conditions, FAS is able to access 
malonyl-CoA produced by ACC2 [538]. De novo lipogenesis was only reduced with the addition of 5-
(tetradecyloxyl)-2-furancarboxylic acid (TOFA), an inhibitor of both ACC1 and ACC2.  
In another study, Savage et al. used antisense oligonucleotide inhibiters to knock down ACC1 and ACC2 
both separately and together in a rat model of NAFLD. Suppression of ACC1 alone caused a reduction 
in mitochondrial as well as cytoplasmic malonyl-CoA, suggesting some stimulation of β-oxidation in 
addition to inhibition of lipogenesis [526].  This suppression of lipogenesis combined with partial 
stimulation of β-oxidation caused reductions in the rate of oleic acid and glycerol incorporation into 
triglycerides. Knockdown of ACC2 alone caused a larger increase in the rate of β-oxidation than ACC1 
knockdown but a smaller reduction in triglyceride synthesis. This suggests that stimulation of β-
oxidation alone, without inhibiting lipogenesis, is only moderately effective at treating steatosis. 
Consistent with model simulations, the largest improvements were seen when both ACC1 and ACC2 
were knocked down, leading to a 45% reduction in hepatic triglyceride levels. No adverse changes to 
energy metabolism were noted after ACC1 and ACC2 inhibition and the plasma ALT concentration, a 
marker of hepatic injury, was not increased. 
When ACC1 and ACC2 were inhibited in a hamster model through feeding with a chow diet containing 
0.15% TOFA, their plasma triglyceride concentration reduced by around 50% after 6 days [544]. In the 
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same study, the intracellular triglyceride concentrations of cultured hamster hepatocytes treated with 
20µM TOFA were reduced compared to untreated cells by around 80% when grown in FA-free medium 
and 40% when cultured in medium containing 1mM oleic acid.  
Global suppression of ACC2 has been demonstrated to reduce the risk of development of T2DM, 
metabolic syndrome and obesity in mice due to upregulation of β-oxidation [523]. ACC2 knockout 
mice also showed 50% less fat storage in adipose tissue [524, 525]. Neither of these studies reported 
pericentral centred damage or loss of function. In another study, down-regulation of ChREBP, a key 
regulator of lipogenic gene transcription (including FAS and ACC), led to improved FFA and triglyceride 
levels in ob/ob KO mice and offered protection against IR as a result of reduced hepatic lipogenesis 
[200]. 
Collectively these data suggest that steatosis is improved when ACC1 and ACC2 are suppressed due to 
a reduction of lipogenesis and stimulation of β-oxidation, consistent with the model simulations. 
Furthermore, none of the experimental studies have noted adverse effects in energy metabolism 
when inhibiting ACC1 and ACC2. 
4.4 Conclusions of Chapter 
The computational model of hepatic metabolism across the sinusoid was used to assess potential 
processes which could be targeted to reduce steatosis in NAFLD patients. The model simulates cell 
across the porto-central axis of the sinusoid allowing the effects of targeting specific processes on 
both steatosis and energy metabolism in individual regions of the sinusoid to be simulated. 
Furthermore, by simulating varying dietary intake and degrees of metabolic dysregulation, the effects 
of each treatment could be studied for a range of NAFLD patients. 
Substantial adverse effects were predicted, either in the hepatocytes themselves or through changes 
in plasma concentrations of lipids, glucose or lactate when targeting most metabolic processes. Many 
of these adverse effects occurred in specific regions of the sinusoid highlighting the importance of 
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studying the sinusoid as a whole. Where possible the predicted effects of each treatment were 
compared with previously published experimental data and were shown to be consistent. However, 
since experiments in specific regions of the sinusoid are largely missing from the literature, the 
predictions highlight potential adverse effects which may be missed when performing measurements 
on bulk liver tissue. 
No single hepatic process was predicted to provide a pertinent drug target for clearing steatosis. 
However, stimulation of β-oxidation combined with inhibition of lipogenesis showed promising results 
in reducing both hepatic and plasma FFA and triglyceride concentrations. Energy metabolism was not 
disturbed and ATP levels were slightly improved. This is supported by experimental data from the 
literature for mice lacking both ACC1 and ACC2 which show improvements in steatosis due to an 
increased rate of β-oxidation and suppressed lipogenesis. 
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5 Chapter 5: Experimental Validation of Model Predictions 
5.1 Introduction to Chapter 
In the previous chapter, the model was used to simulate the effects of pharmacologically targeting 
various processes in order to clear hepatic steatosis in NAFLD without disrupting energy metabolism. 
In this chapter, five of these pharmacological interventions are tested experimentally on HepG2 cells, 
a cell culture line derived from a differentiated hepatocellular carcinoma. These results allow 
comparison with the model simulations to test the predictive capacity of the model.  
Before testing the effects of the pharmacological interventions, it is first necessary to ensure the key 
changes occurring in NAFLD in vivo can be replicated in the cultured cells. This was performed by 
adding a cocktail of FFAs to the medium of the cells, corresponding to the raised plasma FFA levels in 
NAFLD in vivo. In vivo, hepatocytes show increasing steatosis [15], cell damage [545, 546], oxidative 
stress [501, 512, 514-516, 547, 548], IR [146, 549, 550], reduced ATP levels and reduced mitochondrial 
function [44, 227, 228, 506, 510-513, 547, 548] as NAFLD develops. It is important that a cell culture 
model used to validate model predictions also replicates this disease progression. After establishing 
and describing the cell culture model of NAFLD, the cells were treated with a range of small molecule 
inhibitors known to target specific metabolic processes (section 5.4). The impact of inhibiting key 
processes on cell viability and function was studied for FA treated cells and compared with the model 
simulations. 
It should be noted that the cell culture model does not allow testing of zonated effects as seen in the 
model simulations. However, as discussed below, the HepG2 cells are most similar in metabolism to 
pericentral cells and most adverse effects occurred in these cells in simulations.  
5.1.1 HepG2 cells 
HepG2 cells are a perpetual cell line of well-differentiated hepatocellular carcinoma cells derived from 
a 15 year old Caucasian [551]. Although derived from a liver carcinoma, rather than healthy liver cells, 
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due to their high level of differentiation, HepG2 cells retain epithelial morphology and continue to 
perform a wide range of liver cell functions [551]. They also continue to express insulin receptor and 
insulin-like growth factor II receptor despite showing little glycogen content [552, 553]. 
Despite retaining many liver cell functions, HepG2 cells show notable differences from healthy primary 
liver cells. Firstly they contain a higher numbers of chromosomes with some variation (50-56) around 
a modal number of 55 [551]. Additionally, they contain a high quantity of fat, even when cultured in 
FA free, normoglycaemic (5mM glucose) medium (see section 5.3.2). The cellular rate of lipogenesis 
is similar to primary cultures of rat hepatocytes and freshly prepared rat hepatocytes [554]. Instead, 
the build-up of fat in HepG2 cells is due to reduced secretion of FAs in lipoproteins [554]. They also 
show increased anaerobic metabolism through glycolysis [555] due to their background as cancer cells 
[556]. This production of energy through glycolysis followed by lactic acid fermentation rather than 
oxidative metabolism is known as the Warburg effect. Due to both their high fat content, and 
dependence on glycolysis for ATP synthesis, HepG2 cells are most similar to pericentral cells which 
exist in a hypoxic environment and show a higher lipid content. 
When treated with saturated FAs, HepG2 cells have previously been shown to reproduce a number of 
the metabolic changes occurring in in vivo hepatocytes in NAFLD [557]. However, due to the 
differences between HepG2 cells and healthy in vivo hepatocytes, the first section of this chapter is 
dedicated to assessing the suitability of HepG2 cells as a model for steatotic hepatocytes in NAFLD. 
5.1.2 Treatments 
5.1.2.1 Fatty acids 
Five FFAs treatments were tested, either individually or in combination. These were butyric acid (4:0), 
lauric acid (12:0), palmitic acid (16:0), oleic acid (16:1) and linoleic acid (16:2).  
Butyric acid is a short chain, saturated FA found in milk and dairy products predominantly in its 
triglyceride form. It is additionally produced in the gut. It has been demonstrated to improve insulin 
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sensitivity and reduce adiposity due to increased energy expenditure in mouse models of diabetes 
[558, 559]. 
Lauric acid is a medium chain FA found in human breast milk and cow’s milk along with coconut milk, 
coconut oil (44-52%), laurel oil, and palm kernel oil (40-52%) [560]. It is additionally synthesized in 
human tissues, although at a lower rate than palmitic and oleic acids. The effects of lauric acid on the 
liver are debatable since, although it’s consumption has been shown to improve the high density 
lipoprotein (HDL) to low density lipoprotein (LDL) ratio relative to other saturated fats, it is also 
thought to increase the probability of cardiovascular disease due to an increase in plasma cholesterol 
[561, 562]. Additionally, any potential benefits of lauric acid may result from an antibacterial effect on 
the microbiome rather than a direct effect on liver cells. These microbiome effects would not be seen 
in the cell culture experiments presented here [563, 564]. 
Palmitic acid is the most common FA in mammals, plants and microorganism. It is a saturated FA 
present in numerous food types in addition to being synthesized in the body. It accounts for 20-30% 
of fat stored in adipose tissues [41, 42, 565]. It is linked with an increased probability of developing 
cardiovascular disease and IR and is thought to increase the LDL content in the blood [566, 567]. It is 
therefore considered to be one of the more detrimental common FAs found in the diet. 
Oleic acid is the second most abundant FA in human tissues, and the most abundant in adipose FA 
stores (of humans and other mammals) comprising around 45% in these tissues [41, 42, 565]. It is an 
omega-9 monounsaturated FA. Due to its presence in animal fat, it is abundant (in triglyceride form) 
in lard. Additionally, it is abundant in olive (65-80%) after which it is named, peanut oil (52-60%), 
sesame oil (40-50%), sunflower oil (14-35%) and other oils [560, 568]. Oleic acid consumption is linked 
with reduced cholesterol levels in comparison with lauric and palmitic acids and increases the ratio of 
HDL to LDL [569]. It also may be responsible for the reduction in blood pressure that results from olive 
oil consumption [570]. 
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Linoleic acid is an omega-6 polyunsaturated FA. In humans, it is derived exclusively from diet. It is 
abundant in sunflower seed oil (44-75%),  maize oil (34-62%), hemp seed oil (54-56%), poppy seed oil 
(72%) and other vegetable and nut oils [560]. Compared with saturated acids, linoleic acid 
consumption is associated with reduced probability of developing coronary heart disease [571]. The 
effects of linoleic acid supplementation on IR remain unclear, with health benefits of linoleic acid 
consumption widely reported, but adverse effects also shown in several studies [572-574]. 
5.1.2.2 Small Molecule Inhibitors 
 
Figure 5.1: The processes (as represented in the model) targeted by the small molecule inhibitors TOFA, 
C75, T863, 2DG and 3BP in HepG2 cells. Additionally, the known increase in glycolysis [555] and decrease 
in glycogen synthesis [553] and triglyceride release [554] in HepG2 relative to hepatocytes are labelled. 
Five inhibitory molecules were studied. These were lipogenesis inhibitor and β-oxidation stimulator 5-
(tetradecyloxy)-2-furoic Acid (TOFA), lipogenesis inhibitor 4-Methylene-2-octyl-5-oxotetrahydrofuran 
-3-carboxylic acid (C75), triglyceride synthesis inhibitor 2-((1,4-trans)-4-(4-(4-Amino-7,7-dimethyl-7H-
pyrimido[4,5-b][1,4]oxazin-6-yl)-phenyl)cyclohexyl)acetic acid (T863) and glycolysis inhibitors 3-
bromopyruvate (3BP) and 2-deoxy-D-glucose (2DG). The processes targeted by each of these 
inhibitory molecules are shown in figure 5.1. 
Firstly, to test the model predictions for simultaneous inhibition of lipogenesis and stimulation of β-
oxidation, TOFA, a potent inhibitor of both forms of acetyl-CoA carboxylase (ACC1 and ACC2), was 
used [575-578] (figure 5.1). ACC1 produces cytosolic malonyl-CoA accessible to FAS for use in 
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lipogenesis (figure 5.2) [462, 541]. ACC2 meanwhile is restricted to the mitochondria and produces 
malonyl-CoA which negatively regulates β-oxidation [462, 541]. Therefore, treatment with TOFA both 
directly reduces lipogenesis by reducing the malonyl-CoA available to FAS, and reduces the inhibition 
of β-oxidation by mitochondrial malonyl-CoA. 
 
Figure 5.2: The effect of ACC1 and ACC2 inhibition with 5-(tetradecyloxy)-2-furoic Acid (TOFA) on 
metabolism. 
TOFA is converted intracellularly into a CoA analogue which blocks ACC activity [575]. It has been 
shown to reduce FA synthesis and TG secretion in cell culture models [544, 575, 579] and animal 
models [544, 580, 581] including rhesus monkeys. It has been suggested that TOFA may additionally 
have an effect on enzymes involved in the metabolism of long-chain FAs due to its similarity to long 
chain FAs [581, 582]. However, its predominant site of action is its potent inhibition of ACC. Since only 
the stimulation of β-oxidation and inhibition of lipogenesis are simulated in the model, the specific 
enzymes targeted to achieve these effects are of lesser importance. Inhibition of lipogenesis combined 
with stimulation of β-oxidation was simulated in section 4.2.2.4. 
Secondly C75, a potent synthetic inhibitor of FAS was used to directly inhibit lipogenesis [577, 578, 
583, 584] (figure 5.1). Since FAS inhibition does not alter mitochondrial malonyl-CoA production, C75 
has little effect on the rate of β-oxidation [577, 578, 583, 584]. It should be noted, however, that whilst 
under normal conditions cytoplasmic and mitochondrial malonyl-CoA are physically separated [462], 
it is possible that under non-physiological conditions this separation may breakdown [538]. Therefore, 
some stimulation of β-oxidation may occur with C75 treatment, but this would be notably lower than 
for TOFA treatment. Inhibition of lipogenesis was simulated in section 4.2.2.3. 
Untreated + TOFA 
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T863 was used to inhibit triglyceride synthesis by DGAT1 (figure 5.1). DGAT1 is one of the enzymes 
which mediates the final binding of a FA (in the form of acyl-CoA) to diacylglycerol molecule to form a 
triglyceride [585]. Therefore, inhibiting this enzyme leads to the build-up of precursors to triglyceride 
synthesis including FAs and DAGs. DAGs in particular have been suggested as a major molecule type 
responsible for the development of hepatic damage and IR in NAFLD [8, 146]. Inhibition of triglyceride 
synthesis was simulated in section 4.2.2.5. 
Finally, two glycolysis inhibitors, 3BP and 2DG were used to assess the impact of inhibiting glycolysis 
at different stages (figure 5.1). 3BP inhibits the glycolysis enzyme glyceraldehyde-3-phosphate 
dehydrogenase which takes glyceraldehyde-3-phosphate (GADP) as a substrate and produces 1,3-
biphosphoglycerate [586, 587]. 2DG competitively inhibits at the stage of GK and, therefore, prevents 
the storage of glucose as glycogen in addition to reducing glycolysis [588, 589]. Inhibition of glycolysis 
at various stages was simulated in section 4.2.2.1. 
5.1.3 Properties measured and relationship to model simulations  
The first results section of this chapter describes the effects of FA treatment of HepG2 cells on several 
properties to investigate whether the HepG2 model represents the key features of NAFLD seen both 
in vivo and in the model simulations. The second section, then describes the effects of treating the 
cells with the five small molecules inhibitors, which correspond to some of the pharmacological 
interventions simulated in the previous chapter. Treatment with each inhibitor is investigated for 
whether the adverse effects resulting from FFA treatment are exacerbated or resolved and to 
investigate whether the results are consistent with the model simulations. In this section, the 
relationships between the predicted data in the previous chapter and the experimental 
measurements presented in this chapter are discussed. 
5.1.3.1 Steatosis 
Hepatic steatosis is the defining feature of NAFLD in vivo. When simulating NAFLD resulting from high 
fat intake, IR and increased SREBP-1c expression in the model (chapter 3), an increase in cellular lipid 
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content occurred, particularly in pericentral cells, because of both increased uptake and increased de 
novo lipogenesis. In this chapter, to assess the effects of FAs and the various treatments on cellular 
steatosis in the HepG2 cell culture model, staining for neutral lipids using oil red O (ORO) was 
performed. By comparing the ratio of stained and unstained regions, the effects of each treatment on 
lipid content was determined.  
5.1.3.2 Glycogen, and Hyperglycaemia and Insulin Resistance 
In the previous chapters, defective glycogen storage (particularly in pericentral cells) and 
hyperglycaemia were seen when simulating insulin resistant NAFLD patients in the model. In the cell 
culture model, staining for glycogen was performed to assess the content within cells when treating 
with FAs and the small molecule inhibitors. The glucose concentration in the medium of cells was also 
measured to assess changes in glucose uptake and release. In the model, insulin sensitivity is set as a 
parameter, and the pathways mediating exacerbation or resolution of IR are not included. Only the 
changes in total lipid content and FFA concentration thought affect insulin sensitivity are simulated. 
However, in the cell culture model, the effects of FAs and of the small molecule inhibitors on IR was 
assessed by comparing glycogen content and glucose consumption in insulin treated and insulin-free 
cells. 
5.1.3.3 FFAs and β-Oxidation 
When simulating NAFLD in the model, the overall increase in lipid content was accompanied by an 
increase in cellular FFA concentration in pericentral cells. Furthermore, when simulating high intake 
and IR, notable increases in the rates of β-oxidation and mitochondrial oxidative metabolism occurred. 
Experimentally, the intracellular FFA concentration is difficult to measure since FFAs are rapidly bound 
to a CoA molecule and used in glycerolipid synthesis or β-oxidation after entering a cell. Similarly, any 
potential overactivation of oxidative phosphorylation pathways would be challenging to study 
directly. However, many of the adverse effects known to occur in NAFLD result from the presence of 
excess FFAs and excessive β-oxidation [8, 146, 247, 248, 501, 512, 514-516], and these were 
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investigated in the HepG2 model. These include oxidative stress, cell death, lipotoxicity, reduced 
mitochondrial function and IR. These measures do not allow direct comparison with the model 
simulations, but treatments which reduce the hepatic FFA concentration and return the rates of β-
oxidation and oxidative phosphorylation to metabolically normal levels would be expected to also 
improve these measures. 
5.1.3.4 Mitochondrial Function 
In NAFLD in vivo, mitochondrial function is known to be reduced and this is thought to arise due to 
mitochondrial stress resulting from increased rates of β-oxidation [547, 548, 590, 591]. Mitochondrial 
function was assessed in the HepG2 cell culture model by measuring the activity of key ETC enzymes. 
The ETC comprises of a series of enzymes which mediate transfers of electrons between donor and 
acceptor molecules coupled to the movement of protons from the mitochondrial matrix into the 
intermembrane space. The resulting proton gradient is used to power ATP synthesis by the enzyme 
ATP synthase. Complex I (NADH:ubiquinone oxidoreductase) and complex II (succinate 
dehydrogenase) mediate the transfer of electrons from NADH and succinate (via FAD) respectively to 
ubiquinone producing ubiquinol. NADH reduction through complex I additionally causes proton 
transport into the intermembrane space. Complex III (CoQH2-cytochrome c reductase) mediates the 
transfer of electrons from the resulting ubiquinol to cytochrome c, coupled with the movement of 
protons into the intermembrane space. Complex IV (cytochrome c oxidase), the final enzyme in the 
chain, mediates the transfer of electrons from the reduced cytochrome c to molecular oxygen 
(producing water), and is also coupled with transfer of protons into the intermembrane space. This 
pathway is fundamental to cellular energy metabolism. Reduced mitochondrial function after FFA 
treatment would be indicative of stress on mitochondria resulting from lipotoxicity. 
5.1.3.5 Intracellular ATP Concentration 
In the model simulations, a reduction in intracellular ATP concentration occurred due to increased ATP 
consumption in lipogenesis, β-oxidation and triglyceride synthesis and reduced non-oxidative ATP 
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synthesis. In vivo larger drops in ATP concentration [548, 591, 592] are seen as a result of reduced 
mitochondrial function [547, 548, 590, 591]. The ATP concentration was measured directly in the cell 
culture model after addition of FFAs and the various small molecule inhibitors. 
5.1.3.6 ROS Production 
Excess FFA concentrations and excess β-oxidation are thought to contribute to oxidative stress and 
ROS production seen in NAFLD in vivo [225, 382, 547, 591, 593]. Increased mitochondrial FA oxidation 
is seen in NAFLD as an adaptive mechanism to clear excess fats [548]. However, reduced ETC enzyme 
function and excessive flow of electrons through the ETC can result in ROS production predominantly 
in the form of superoxide. Most electrons passing through the ETC are eventually combined with 
molecular oxygen to form water. Even under normal metabolic conditions, a small fraction leak to 
form the superoxide anion radical before being converted to hydrogen peroxide by manganese 
superoxide dismutase [548]. The majority of this is then converted to water, removing all but a small 
residual amount of ROS used for signalling. However, a combination of reduced ETC enzyme activity 
and increased flow of electrons along the chain results in overproduction of superoxide [548, 591, 
594]. Excessive production of ROS can cause oxidative stress in mitochondria by causing oxidative 
damage to lipids, proteins and nucleic acids as is observed in both NASH and NAFLD [547, 591, 593]. 
Oxidative stress was assessed experimentally using two techniques. Lipid peroxidation in cell 
homogenates was measured as a marker of intracellular ROS production. Lipid peroxidation was 
assayed using a TBARS test to determine the presence of the breakdown products of lipid 
peroxidation, particularly MDA, in the sample. It should be noted that the assay shows only a 
moderate specificity for MDA or the products of lipid peroxidation breakdown. To minimise the 
reaction with other unwanted chemicals in the sample, EDTA was added to chelate heavy metals 
which catalyse oxidation, and anhydrous sodium sulphate in addition to sodium dodecyl sulphate was 
included to prevent oxidization of further lipids during heating. However, only large increases in the 
TBARS reading were considered to correspond to increased lipid peroxidation. 
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 Secondly, the redox potential and antioxidant capacity of the supernatant media were measured as 
a marker of extracellular ROS release. The redox potential, usually measured in patient blood samples, 
has been shown to correlate with the degree of oxidative injury in a number of conditions [595-598]. 
The antioxidant capacity is a measure of the amount of oxidative reserves in the sample which relates 
to the ability of the patient (or cells) to respond to the injury. An increase in redox potential has been 
demonstrated in patients with T2DM and the metabolic syndrome [595], although no changes in redox 
potential or antioxidant capacity were seen in obese individuals [597]. An increase in redox potential 
is measured in the perfusate after human liver perfusion, an instance in which liver cells are known to 
produce ROS [599].  
5.1.3.7 Cell Viability and Markers of Hepatic Function 
The effects of a treatment on the number of viable cells, number of dead cells and proliferation rate 
per cell were measured to assess the overall beneficial or damaging effects of each treatment to the 
cells.  
5.2 Materials and Methods 
5.2.1 Statistics 
Throughout this section, where two groups were compared, significance was calculated by an 
unpaired, unequal variance, 2 tailed T-test. Where multiple treatments were compared against 
control, an ANOVA was performed to assess statistical significant of variation between the groups 
before the Holm-Sidak method was used to calculate a t-test adjusted to account the multiple 
comparisons performed [600]. The tests performed are stated in the legend of each figure and table. 
The calculations were performed using GraphPad Prism. A p value of less than 0.05 was considered to 
represent a significant difference. 
5.2.2 Maintenance of Cell Cultures 
Cells were cultured in Eagles minimum essential medium (EMEM) with Earl’s salts, L-glutamine and 
sodium bicarbonate (Sigma M4655) supplemented with 10% FBS and 1X MEM non-essential amino 
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acids (Sigma M7145) in T75 culture flasks. For passaging, Dulbecco’s Phosphate Buffered Saline (PBS; 
Sigma D8662) and trypsin-EDTA solution (Sigma T4049) were used. Cells were incubated at 37ºC in a 
sterile environment containing 5% carbon dioxide. The following volumes of medium were used for 
each container when culturing cells and running experiments: T75 flask – 15ml, T25 flask – 4ml, 6 well 
plate – 3ml, 24 well plate – 1 ml, 48 well plate – 500µL and 96 well plate – 300µL. 
5.2.3 Preparation of Treatments 
5.2.3.1 Fatty Acids 
To solubilize lauric acid and palmitic acid, they were first dissolved in ethanol at 50µM and 100µM 
concentrations respectively. These stocks were replaced every 2-4 weeks. The stocks were diluted in 
medium and sterilized before use. Once diluted in medium, the fatty acid solutions were discarded 
within 3 days. Oleic, linoleic and butyric acids were diluted directly in medium from pure stocks, then 
sterilized a using 20µm filter. Fatty acid free medium containing ethanol was prepared to validate that 
any effects of lauric and palmitic acid additions arose due to the fatty acids themselves and not the 
ethanol. Additionally, a fatty acid cocktail containing equal molar mass of palmitic, lauric, oleic, linoleic 
and butyric acids was prepared and sterilized using a 20µm filter. Oleic, linoleic and butyric acids were 
added directly from pure stocks using multiple dilutions in medium, whilst lauric and palmitic acids 
were added from the stocks in ethanol. In the final solution, each 100µM of total fatty acid contained 
0.06% ethanol. The fatty acid cocktail was replaced every 2-4 days.  
5.2.3.2 TOFA 
Pure TOFA powders were dissolved in dimethyl sulfoxide (DMSO) to give a 5mg/ml stock solution. This 
was then diluted in medium to give the desired concentration of 1-40µg/ml before being sterilized 
using a 20µm filter. 
5.2.3.3 C75 
Pure C75 powders were dissolved in DMSO to give a 10mg/ml stock solution. This was diluted in 
medium to give treatment solutions of 0.5-40µg/ml before sterilizing using a 20µm filter. 
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5.2.3.4 T863 
Pure T863 powders were dissolved in DMSO to form a 5mg/ml stock solution. This was diluted in 
medium to give solutions of 5-400ng/ml before sterilizing using a 20µm filter. 
5.2.3.5 3-Bromopyruvate 
Pure 3BP powders were dissolved in water to give a 10mg/ml stock solution. This was then diluted in 
medium to give treatment solutions of 40ng/ml-10µg/ml before sterilizing using a 20µm filter. 
5.2.3.6 2-deoxyglucose 
Pure 2DG powders were dissolved in DMSO to give a 3mg/ml stock solution. This was then diluted in 
medium to give treatment solutions of 30ng/ml-3µg/ml before sterilizing using a 20µm filter. 
5.2.4 Cellular Viability and Proliferation. 
5.2.4.1 MTS assay 
To assess viability for a large number of treatments when performing initial dose-response 
experiments (section S2), an MTS assay was used. The MTS viability assay is based on the reduction of 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to 
generate a formazan product which absorbs light at 490nm. This conversion is largely carried out by 
mitochondrial NADPH (reduced nicotinamide adenine dinucleotide phosphate) dependent enzymes, 
and the assay therefore assesses total mitochondrial metabolic activity rather than cell numbers 
specifically. As well as not specifically measuring cell numbers, the assay tends to be associated with 
large dispersion in results. However, the assay is rapid and allows many conditions to be assessed, 
before validation through a trypan blue exclusion assay. 
Cells were seeded in 96-well plates at a density of 26000 cells/cm3 and grown initially in 200μL 
unaltered MEM (fatty acid-free) medium. After 24 hours, the medium was removed and replaced with 
medium containing the stated treatment. The treated medium was replaced every 24 hours until the 
end of the experiment. To take readings, the medium was removed and replaced with 100μL fresh 
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medium in each well. 20μL of MTS solution (CellTiter Aqueous One Solution) was additionally added 
to each well. After 1 hour, the absorbance at 490nm was measured using the FLUOstar Omega multi-
mode microplate reader.  
5.2.4.2 Trypan Blue Exclusion Assay 
HepG2 cells were seeded in 6 well plates at a density of 26000 cells/cm3 and initially grown in 3ml of 
unaltered MEM (fatty acid free) medium. After 24 hours, the medium was removed and replaced with 
3 ml of medium containing the stated treatment. The treated medium was replaced every 24 hours 
until the end of the experiment. The cells were dissociated by 5-minute incubation at 37ºC with 250µL 
trypsin-EDTA solution (trypsinization), before adding 750µL medium and syringing to break up clumps. 
A 10µL sample was used to count in a glass cytometer. 0.4% Trypan Blue (Sigma T8154) was added to 
distinguish viable and non-viable cells. 
5.2.4.3 Culture doubling time 
The time constants (doubling times), τ, were calculated for each treatment using the difference 
between the viable cell counts after 0 hours and 48 hours and assuming exponential growth of the 
form N=N02t/τ. When cells grown in untreated medium were counted at several time points, this 
pattern of growth was followed until near confluence was reached. For the studies in this report, the 
cells seeded at 26000 per cm2 were far from confluence at the 48-hour time point such that contact 
inhibition would not be expected to notably influence results.  
5.2.4.4 BrDU Incorporation 
To measure the division/proliferation rate of the cells, an assay based on the incorporation of marker 
bromodeoxyuridine (BrDU) into DNA was used. The Roche ‘Cell Proliferation ELISA, BrDU 
(colorimetric)’ assay kit was used. BrDU is incorporated into newly synthesized DNA as an analogue of 
thymidine during the S-phase. Cells were seeded at a density of 26000 per cm2 in 96 well plates and 
allowed to attach for 24 hours in 200µL untreated medium. After this time, 200µL of medium 
containing both the treatments and the BrDU marker was added to the cells. Measurements of 
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incorporated BrDU were taken after 24 hours using an ELISA (enzyme-linked immunosorbent assay) 
according to the kit’s protocol. 
5.2.5 Intracellular Lipid Staining using ORO 
5.2.5.1 Experimental Protocol 
HepG2 cells were seeded on to sterilized glass cover slips placed in 24 well plates at a density of 26000 
cells/cm3 and initially grown in 1ml unaltered MEM medium. For each set of conditions (and each 
repeat) two wells were seeded. In one of these both the lipids and the nuclei were stained. In the 
other only the lipids were stained. After 24 hours, once the cells had adhered to the glass cover slip, 
the medium was removed from each well and replaced with 1ml of medium containing the stated 
treatment. This medium was replaced every 24 hours until measurements were taken.  
The medium was aspirated and the cells were washed for 5 minutes twice with PBS. To fix the cells, 
10% formalin was added to each well for a minimum of 60 minutes. The formalin was removed and 
the cells were washed twice with diH2O before incubating for 5 minutes in 60% isopropanol. The cells 
were then incubated for 20 minutes in Oil Red O (ORO) working solution (0.18% ORO in 60% 
isopropanol, 40% diH2O) (Sigma O1391). 2-5 diH2O washes were performed until the stain was no 
longer apparent in the water. For each fatty acid preparation, one well was left with the cells in diH2O 
and imaged. From the second well the diH20 was aspirated and one drop of haematoxylin was added 
to stain the nuclei. This was rapidly washed away (within 10 seconds) with 2-5 diH2O washes before 
imaging.  
184 
 
5.2.5.2 Image Analysis 
 
 
Previous ORO staining protocols suggested measuring the total lipid content in the sample by breaking 
up the cells with 100% isopropanol and measuring the change in light absorbance due to the release 
of ORO. However, since a large number cells were detached from the well plate and during the imaging 
process (particularly when adding isopropanol), it was impossible to know the number of cells in the 
plate and, therefore, the quantity of lipid per cell could not be measured in this way. Instead, the 
percentage of cellular area stained for lipid and the average lipid droplet size were calculated from 
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the images. Image J was used to perform the image analysis. Since the image analysis performed was 
only partially automatic, the images were numbered randomly and analysed without knowledge of 
the treatment to avoid bias. The images were cropped to exclude the areas without cells or where 
cells had grown on top of one another (often near the edges of the well), leaving only the one-cell-
thick regions. To calculate the percentage of area that was stained by ORO, the cropped image regions 
were separated by into RBG channels. Although the stain is red, numerous areas other than those 
containing lipid stain also showed up bright in the red channel. Instead, the lipid stained regions were 
more clearly identified by using the dark regions in the blue channel. Unfortunately, due to post-image 
capture changes automatically applied by the microscope software, the images varied significantly in 
brightness and saturation such that no fixed threshold could be set between images to define stained 
and unstained regions. Instead, the threshold was set manually for each image, with a peak in the low 
intensity of blue corresponding to stained regions (see image above). Lipid droplet size was 
determined by manually circling single separate lipid droplets using images at fixed magnification and 
saving the measured areas. This was again performed using randomly numbered images to avoid bias. 
5.2.6 Staining and Quantifying Glycogen Using a Periodic Acid Schiff Stain 
Glycogen was stained by treating fixed cells with a periodic acid solution followed by a Schiff solution 
(PS stain). Since this stains both glycogen and glycoproteins, a second well was treated with diastase 
followed by periodic acid and Schiff solutions (PSD stain). Diastase breaks down glycogen to maltose 
such that it is no longer stained. By comparing the two, the amount of glycogen can be calculated.  
Cells were seeded at a density of 26’000 per cm2 on glass slips in 24 well plates in 1ml untreated 
medium. After 24 hours, 1ml medium containing the stated treatment was added.  The cells were 
grown in the treated medium for 48 hours. Two wells were seeded for each set to allow for both PS 
and PSD stains to be performed. The cells were washed twice with PBS, then fixed with 10% formalin 
for a minimum of 1 hour. The PS wells were left in formalin whilst the PSD wells were washed twice 
with ddH2O incubated in 0.5% diastase solution for 20 minutes. After this, all wells were washed twice 
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with ddH2O and incubated with 1% periodic acid solution for 5 minutes. After two ddH2O washes, the 
cells were incubated in Schiff’s solution for 15 minutes. 2-5 tap water washes were performed until 
the water was clear before imaging. 
Finally, to quantify total hepatic glycogen, the cells were broken up by the addition of tween-20 in 
100% isopropanol with shaking. The absorbance at 550nm minus 650nm was measured using the 
FLUOstar Omega multi-mode microplate reader. The PSD reading was subtracted from the PS reading 
to give the absorbance corresponding to glycogen. These readings were compared with visual 
observation for validation. 
5.2.7 Mitochondrial Enzyme Activity Assays 
Cells were seeded at a density of 26000 per cm2 in T25 culture flasks and allowed to attach for 24 
hours in 4ml of untreated medium. 4ml of medium containing the stated treatments was added and 
replaced after 24 hours. After 48 hours, the cells were harvested and stored at -20C in PBS for less 
than a week. The cell-PBS suspensions were thawed on ice and re-frozen twice to break up the cell 
membranes. Finally, they were thawed a third time before performing the enzyme activity assays. For 
all three ETC enzyme measurements, the rates were normalised to citrate synthase activity in the 
sample to give the activity per total mitochondria as discussed below. 
5.2.7.1 Preparation of Cells for Mitochondrial Assays 
Cells were grown and treated as described above. To prepare cell homogenates, firstly the medium 
was removed and, if required, a sample was transferred to an Eppendorf. The cells were then 
dissociated with 500µL trypsin before resuspending in medium to a total volume of 1.5ml. The 
suspension was transferred to an Eppendorf and the number of cells was counted using a 10µL sample. 
Each Eppendorf was centrifuged for 2 minutes at 200RCF (relative centrifugal force). The supernatant 
was removed before the pellet was resuspended in 1ml of iced PBS. The suspension was centrifuged 
for 2 minutes at 200RCF and the PBS removed. Finally, the pellet was resuspended to a volume of 
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0.5mM in iced PBS and rapidly moved to -20ºC. The cell suspensions were put through at least three 
freeze-thaw cycles, defrosting slowly in ice, before use. 
A biuret test was used to quantify the presence of peptide bonds and hence the protein content of 
each sample. To make the biuret working solution 1.5g copper sulphate pentahydrate, 6g sodium 
potassium tartrate and 30g sodium hydroxide were dissolved in 1 litre of water. To provide reference 
protein solution, bovine serum albumin was dissolved in PBS at 100mg/ml, 50mg/ml, 25mg/ml, 
12.5mg/ml, 6.25mg/ml, 3.125mg/ml, 1.5625mg/ml and 0.78125mg/ml. 150µL of working solution and 
20µL of cell solution or reference protein solution were added to each well of a 96 well plate, with at 
least 2 repeats in each case. After 30-60 minutes, the 550nm absorbance was measured using the 
FLUOstar Omega multi-mode microplate reader. The FLUOstar Omega data analysis software was 
used to calculate the concentration of protein in the sample. 
5.2.7.2 Citrate Synthase 
Firstly, the activity of citrate synthase was measured. As a mitochondrial matrix protein known to be 
largely unaffected by loss of mitochondrial function, citrate synthase is commonly used as a marker 
for the amount of mitochondria in a sample (e.g. [601]). The enzyme catalyses the reaction between 
acetyl-CoA, oxaloacetic acid and water to form citrate along with a CoA molecule with a thiol group 
(CoA-SH). In the assay, 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) is additionally provided which reacts 
with the thiol group to form 5-thio-2-nitrobenzoic acid (TNB) which absorbs at 412nm. It is this 
absorbance which is measured. The method used was a slightly modified version of that used 
previously in HepG2 cells by Garcia-Ruiz [557]. 
A stock buffer of 200mM k+ HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) in ddH2O was 
prepared and adjusted to PH8 using a potassium hydroxide (KOH) solution. Stock solution of 5mM 
oxaloacetate, 2mM DTNB and 10mM acetyl-CoA in ddH2O were prepared on ice and stored at -20ºC. 
To perform the assay, the cell suspensions and stock solutions were defrosted slowly on ice. 10µL of 
cell suspension (containing a total protein concentration of around 4µg/ml) was used in a total volume 
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of 200µL of solution in a 96 well plate. A solution containing the cell suspension and final 
concentrations of 100mM k+ HEPES, 250µL oxaloacetate and 100µL DTNB was prepared in each well. 
The mixture was briefly incubated at 37ºC. Finally, the acetyl-CoA was added to start the reaction at a 
final concentration of 500µM and the absorbance was read at 412nm minus 640nm for a period of ~4 
minutes. The gradient over time was used to measure of citrate synthase activity. 
5.2.7.3 Complex 1 
Complex 1 catalyses electron transfer from NADH to decylubiquinone (Q10). The reduction in UV 
absorption of NADH (340nm) was measured in this assay. High concentrations of NADH and Q10 were 
provided to ensure maximum activity is measured. Complex 4 inhibitor potassium cyanide was added 
to minimise activity elsewhere in metabolism. To account for any NADH consumption or production 
by enzymes other than complex 1, measurements were taken with and without the addition of 
rotenone, a potent complex 1 inhibitor. The protocol used was a slightly modified version of that used 
previously in HepG2 cells by Garcia-Ruiz [557]. 
A stock buffer of 50mM potassium phosphate (KPi) in ddH2O was prepared and adjusted to PH 7.2 
using a KOH solution. Stock solutions of 200mM magnesium chloride, 2mM potassium cyanide (in a 
strongly alkaline solution), 50mg/ml bovine serum albumin (BSA), 2mM NADH, 500µM 
decylubiquinone and 40mM rotenone were prepared on ice and stored at -20ºC.  
To perform the assay, the cell suspensions and stock solutions were defrosted slowly on ice. 20µL of 
cell suspension was used in a total volume of 200µL of solution in a 96 well plate. Two wells were run 
for each sample allowing measurement of the rate with and without the addition of rotenone. A 
solution containing the cell suspension and final concentrations of 25mM KPi buffer, 10mM 
magnesium chloride, 200µM potassium cyanide, 2.5mg/ml BSA, 100µM NADH and 0mM or 2mM 
rotenone was prepared in each well. The mixture was heated to 30ºC. To initiate the reaction, the Q10 
was added at a final concentration of 25µM and the absorbance was read at 340nm minus 380nm for 
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a period of ~60 minutes. The maximum rate over a 20minute period was taken subtracting the value 
with the addition of rotenone from the value without. 
5.2.7.4 Complex 2/3 
It is difficult to separate the activities of complexes 2 and 3 experimentally and a combined assay was 
performed. The rate of production of reduced cytochrome C by complex 3 from complex 2 substrate 
succinate is measured. The reduction of cytochrome C was measured through a change in its 
absorbance spectrum. Complex 3 requires ubiquinol (reduced Q10) to reduce cytochrome C, and a 
high concentration of succinate was provided to stimulate ubiquinol synthesis by complex 2. Sodium 
azide was provided to prevent the re-oxidation of reduced cytochrome c by complex 4. To compensate 
for any reduction or oxidation of cytochrome c by other enzymes, the assay was run with and without 
the addition of antimycin A, a potent complex 3 inhibitor. The protocol used was a slightly modified 
version of that used previously in HepG2 cells by Garcia-Ruiz [557]. 
A 322mM KPi buffer was prepared and adjusted to PH7.4 using a KOH solution. Stock solutions of 
6mM dipotassium ethylenediaminetetraacetic acid (diK-EDTA), 1mM cytochrome C oxidase, 50mg/ml 
BSA, 20mM sodium azide, 200mM sodium succinate and 40mM antimycin A were prepared on ice and 
stored at -20ºC.  
To perform the assay, the cell suspensions and stock solutions were defrosted slowly on ice. 20µL of 
cell suspension was used in a total volume of 200µL of solution in a 96 well plate. Two wells were run 
for each cell suspension allowing measurement of the rate with and without the addition of antimycin 
A. A solution containing the cell suspension and final concentrations of 166mM KPi buffer, 300µM diK 
EDTA, 50µM cytochrome c, 2.5mg/ml BSA, 1mM sodium azide, and 0mM or 2mM antimycin A was 
prepared in each well. The mixture was heated to 30ºC. To initiate the reaction, the sodium succinate 
was added at a final concentration of 10mM and the absorbance was read at 550nm minus 630nm for 
a period of ~60 minutes. The maximum rate over a 20minute period was taken subtracting the value 
with the addition of rotenone from the value without. 
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5.2.7.5 Complex 4 
Cytochrome c oxidase (complex 4) is the final enzyme in the electron transport chain. Electrons are 
taken from reduced cytochrome c oxidase, converting it to its reduced form and moving protons into 
the intermembrane space in the process. The change in absorption resulting in the oxidation of 
reduced cytochrome c was measured in this assay. To account for cytochrome c oxidation elsewhere 
in metabolism, the change in absorbance was measured with and without the addition of potassium 
cyanide, a potent complex 4 inhibitor. Lauryl maltoside, a detergent, was added to further break up 
the inner membranes of the cells. The protocol used was a slightly modified version of that used 
previously in HepG2 cells by Garcia-Ruiz [557]. 
A 100mM KPi buffer was prepared and adjusted to PH7 using a KOH solution. Stock solutions of 0.3% 
lauryl maltoside, 600µM reduced cytochrome c and 2mM potassium cyanide were prepared on ice 
and stored at -20ºC. Reduced cytochrome c was produced by adding one or two crystals of sodium 
dithionite to oxidised cytochrome c and passing through a PD10 column to remove the sodium 
dithionite. The solution was washed through by a 322mM ph7.4 KPi buffer (see complex 2/3). 
To perform the assay, the cell suspensions and stock solutions were defrosted slowly on ice. 20µL of 
cell suspension was used in a total volume of 200µL of solution in a 96 well plate. Two wells were run 
for each cell suspension allowing measurement of the rate with and without the addition of potassium 
cyanide. A solution containing the cell suspension and final concentrations of 50mM KPi buffer, 
0.015% lauryl maltoside, and 0µM or 200µM potassium cyanide was prepared in each well. The 
mixture was heated to 30ºC. To initiate the reaction, the reduced cytochrome c was added at a final 
concentration of 30µM and the absorbance was read at 550nm minus 630nm for a period of 60 
minutes. The maximum rate over a 20minute period was taken, subtracting the value with the addition 
of rotenone from the value without. 
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5.2.8 Intracellular ATP Concentrations 
A luminescence ATP detection kit (abcam Luminescent ATP Detection Assay Kit (ab113849) was used 
to quantify the ATP concentration in cultured cells. Cells were seeded at a density of approximately 
26000 cells/cm2 in 96 well plates. After 24 hours, the medium was replaced with fresh medium 
containing the stated treatment. This was replaced after 24 hours before readings were taken at 48 
hours. To take readings, the treated medium was removed and replaced with 100µL of fresh medium. 
100µL of medium containing 1µM, 2µM, 5µM, 10µM and 20µM reference concentration of ATP was 
added to additional wells in triplicate. Following the suggested protocol, 50µL of detergent solution 
was added to each well before shaking at 800rpm for 5 minutes. Avoiding direct light, 50µL of 
substrate buffer was added before shaking at 800rpm for 5 minutes in darkness. 100µL of the solution 
from each well was transferred to a 96 well assay plate avoiding direct light. Luminescence was 
measured using the FLUOstar Omega multi-mode microplate reader with a gain of 3000 over a period 
of 10 minutes to ensure no change in emission occurred as a result of any exposure to light. Since no 
changes were seen in any of the tests run, the average luminescence over the 10 minutes was taken. 
A linear fit was performed to the reference data and used to quantify the ATP concentration in the 
50µL of medium. Finally, the measured concentration was divided by the calculated number of cells 
to give the μMoles ATP per million cells. The number of cells was calculated based on an initial 
concentration of 26000 cells and using the measured time constants for exponential growth for each 
treatment. 
5.2.9 Oxidative Stress 
Two assays were used to assess oxidative stress in treated cells. The redox potential (measured as the 
static oxidation reduction potential (ORP)) and antioxidant capacity (measured as the capacity ORP) 
were measured as markers of extracellular ROS and extracellular antioxidant reserves respectively 
(using the REDOXSYS system). A Thiobarbituric acid reactive substances (TBARS) assay was performed 
on cell homogenates to assess for intracellular lipid peroxidation. 
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Cells were seeded in T25 flasks at a density 26000 per cm2 in unaltered medium and allowed to attach 
for 24 hours. After this time, medium containing the stated treatment was added and replaced after 
24 hours. After 48 hours, a 1ml sample of medium was taken from each flask, put into an Eppendorf 
and centrifuged for 2 minutes at 200RCF at 4ºC to remove any floating cells. After centrifugation, the 
supernatant was transferred into a new Eppendorf and stored at -20ºC for less than 1 week. The cells 
were harvested as described in section 5.2.7.1 and stored in PBS at -20C for less than a week.   
To assess extracellular ROS in the supernatant medium, 20µL of each sample was added to the 
REDOXSYS and the static ORP and capacity ORP were measured by the REDOXSYS machine. To assess 
lipid peroxidation, a standard assay was performed to assess the presence thiobarbituric acid reactive 
substances (TBARS), most notably malondialdehyde, which are produced as degradation products of 
fats after peroxidation. This assay shows only moderate specificity for lipid peroxidation byproducts, 
and should be studied with caution, but large increases in readings are thought to signify increased 
lipid peroxidation. 
A reaction mixture was produced with a base containing 1 part each of 0.25 N hydrochloric acid, 15% 
trichloroacetic acid (TCA) and .375% thiobarbituric acid with 2.5mM butylated hydroxytoluene. To this 
was added 0.3 parts of sodium dodecyl sulfate. Finally, to the reaction mixture, 0.03 parts of 2.5mM 
EDTA and 0.03 parts of 1.5mM sodium sulfate were added.  
150ml of each cell homogenate sample, along with 150ml PBS for blanks, was added to 300ml of 
reaction mixture in an Eppendorf and heated for 1 hour at 70 degrees. The Eppendorfs were allowed 
to cool before 500ml of 1-butanol was added. After vortexing each tube repeatedly to mix, they were 
next centrifuged at 8000rpm for 1 minute. A 100ml sample was taken from the butanol layer and put 
in a glass 96 well plate. Absorbance was measured at 532-570nm and black corrected. 
5.2.10 Glucose Consumption, Lactate Output and Insulin Sensitivity 
The rates of glucose consumption and lactate output were measured through changes in the 
concentration in the medium. Insulin sensitivity was measured through the change in glucose 
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consumption resulting from the addition of insulin. Cells were seeded at a density of 26000 per cm2 in 
48 well plates containing 500µL untreated or T25 flasks containing 4ml untreated as stated and 
allowed to attach for 24 hours. Additional wells containing no cells were used to control for the effects 
of evaporation on medium concentrations. After this time, medium containing the stated treatments, 
insulin concentrations and glucagon concentrations was added and replaced after 24 hours. The 
medium was collected after 48 hours, such that consumption is assessed over the second 24-hour 
period.  250 µL of medium was harvested from each well and stored at -20C for less than one week.  
A COBAS machine was used to measure the change in glucose and lactate concentrations. A 200µL 
sample of medium from each well was added into COBAS tubes (including the cell-free wells) before 
running automated assays for glucose and lactate using the GLUC3 and LACT2 cartridges. The 
concentrations measured for each treatment were subtracted from the concentration measured from 
the cell-free wells to get the rate of consumption/output. 
5.3 Results 1: Effects of Fatty acids on Metabolism in HepG2 Cells – 
Characterisation of the experimental model of NAFLD 
5.3.1 Effect of FFAs on cell numbers, cell death and proliferation 
Firstly, the effects of FA treatment on cell viability and proliferation rates were assessed to identify 
the concentrations at which lipotoxicity lead to reduced viability in the cell culture model. This was 
performed both for the FA cocktail (containing equal molar concentrations of butyric, lauric, palmitic, 
oleic and linoleic acids) and for each of the FAs individually. 
5.3.1.1 Fatty Acid Cocktail 
Figure 5.3 shows the effects of increasing concentrations of the FA cocktail up to 800µM on cellular 
viability after 24 and 48 hours of treatment and on the proliferation rate per cell. Table 5.1 shows the 
effects of the FA cocktail treatments on the culture doubling time based on the 48 hour counts.  
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FA treatments were compared with both an unaltered, FA free medium naive control and a vehicle 
control containing 0.48% EtOH, equal to the amount used to solubilize the 800µM FA treatment. The 
0.48% EtOH vehicle control had no significant effect on the percentage of viable cells or total number 
of viable cells after either 24 hours of 48 hours or on the proliferation rate when compared with the 
naive control and so only the vehicle control data is presented here.  
The percentage of cellular viability was significantly decreased after 48 hours of treatment with 
400µM or greater of FA cocktail and after 24 hours with 800µM FA cocktail relative to control. 48 
hours of treatment with 800µM caused a notable decreased the percentage of cell viability to 
79.3±1.4% relative to the control value of 98.2±0.7% (n=3; p<0.001). Significant increases in the 
culture doubling times were seen for 400µM FA cocktail or greater (table 5.1). For 400µM, the 
doubling time of the cultures increased from 2.0−0.1
+0.1  to 2.7−0.3
+0.5  days, whilst almost no increase in 
viable cell numbers occurred over the 48 hours of treatment with 800µM FA cocktail (n(t=48 
hours)/n(t=0)=1.08±0.07, p<<0.001 for both controls). Conversely, no significant difference in the rate 
of proliferation occurred between the FA free and FA cocktail treated cells (rate for 400µM FA cocktail 
= 1.01±0.18 times control; p=0.86). Therefore, the measured reduction in viable cell numbers (table 
5.1) resulted from reduced viability rather than reduced proliferation. 
Table 5.1: the effects of varying FA cocktail concentrations on the doubling time of HepG2 cultures. 
Treatment Doubling time, τ (days) 
Control 2.0−0.1
+0.1  (n=6) 
0.48% EtOH 1.9−0.1
+0.1  (n=3) 
200µM FA cocktail 2.0−0.2
+0.2 (n=6) 
400µM FA cocktail 2.7−0.3
+0.5 (n=6) * 
600µM FA cocktail 4.7−0.8
+1.3 (n=3) * 
800µM FA cocktail 17.3−7.6
+82.0 (n=6) * 
Calculated based on cell counts using a trypan blue exclusion assay at t=0 and t=48 hour counts 
assuming grown of the form N=N02t/τ. After conversion from measurement of the numbers of viable cells 
to the time constants, the data is no longer centrally distributed (due to taking the logarithm). To show 
the equivalent of standard deviation, the upper and lower bounds displayed correspond to the 15.9 th 
and 83.1st percentile. * p<0.05 vs control as assessed by a one-way ANOVA using the 48-hour viable cell 
count data. The FA cocktail comprised of an equal molar mix of butyric, palmitic, lauric, oleic and linoleic 
acids. 
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Figure 5.3: The effects of FA treatment on the cellular viability the rate of proliferation per cell. The 
effect of treatment with 0-800µM FA cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and 
linoleic acids) on (a) percentage viability (the number of viable cells divided by the total number of cells) 
as assessed by a trypan blue exclusion assay and (b) the proliferation rate per cell as assessed by the 
rate of incorporation of BrDU into cellular DNA. (a) Cells were seeded at 26’000 cells per cm2 in 6 well 
plates and allowed to attach for 24 hours before the treatments were added. After the stated treatment 
time, the cells were dissociated and the number of viable cells and non-viable cells were counted using 
a trypan blue exclusion assay (section 5.2.4.2). Each data point is the average of 3 independent repeat 
measurements. A statistically significant effect of both the FA cocktail concentration and the treatment 
time was first determined using a two-way ANOVA (p<0.0001 in both cases) before statistical 
significance between treated and vehicle control groups was performed using Holm-Sidak adjusted t-
tests. * - p<0.05 vs both vehicle controls and untreated control. (b) Cells were seeded at 26’000 cells per 
cm2 in 96 well plates and allowed to attach for 24 hours before the treatments and BrDU marker were 
added. Measurements were made after 24 hours of treatment as described in section 5.2.4.4. 3 repeat 
readings were performed with 2-4 replicates in each case. The bars show the mean the mean and the 
error bars show the standard deviation (mean ±SD). The vehicle control is the addition 0.48% ethanol 
equal to the concentration required to solubilize 800µM ethanol. A one-way ANOVA showed no 
statistical difference between the proliferation rate of FA treated and untreated cells. 
5.3.1.2 Effects of Individual Short, Medium and Long Chain Fatty Acids on Viability  
To understand which FAs within the cocktail were causing the reduction in cell viability, HepG2 
cultures were next treated with butyric, lauric, oleic, linoleic and palmitic acids individually. Figure 5.4 
shows the effects of treatment with individual FAs on cell viability as assessed by a trypan blue 
exclusion assay.  
Treatment with oleic and linoleic acids for 48 hours had no significant effect on cellular viability up to 
a concentration of 400µM. This suggests that these mono- and poly- unsaturated FAs are not primarily 
responsible for the decrease in cell numbers resulting from treatment with the FA cocktail. Conversely, 
the saturated long chain FA palmitic acid caused a notable reduction in cell viability at 200µM or 
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greater. The percentage viability fell from 98.2±1.1% in control cells to 90.8±2.3 when treated with 
200µM palmitic acid (n=3, p=0.022) and 84.1±3.4% when treated with 400µM (n=3; p=0.015). 
Similarly, treatment with 400µM of the saturated medium chain FA lauric acid caused a significant 
reduction in cell viability to 86.7±2.1% (n=3; p=0.005) respectively.  
Finally, treatment with 400µM of the short chain FA butyric acid caused a significant reduction in cell 
numbers. This effect was less severe than in the case of palmitic and lauric acids and the percentage 
viability only reduced to the doubling time of the culture only increased 94.8±0.9% (n=3; p=0.003).  
Therefore, the reduction in viable cell numbers resulting from the FA cocktail primarily occurs due to 
the saturated medium and long chain palmitic and lauric acids, although the saturated short chain 
butyric acid may also contribute. 
  
Figure 5.4: The effects of treatment with individual fatty acids on viability. The effect of 48 hour 
treatment with individual fatty acids on the percentage viable cells as assessed by a trypan blue 
exclusion assay. Cells were seeded at 26’000 cells per cm2 in 6 well plates and allowed to attach for 24 
hours before treatments were added. The treated medium was replaced after 24 hours. After 48 hours 
of treatment the cells were dissociated and counted using a cytometer using trypan blue to identify dead 
cells. In all cases 3 repeats of 4 replicate counts were performed. The graph shows the mean ±SD. A two-
way ANOVA was used to determine significant variation between the groups sets before Holm-Sidak 
adjusted t-tests were used to calculate significance of each treatment from control at each FA 
concentration. * - p<0.05 vs control. 
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5.3.2 Steatosis 
Having established that reduced viability occurs for FA cocktail concentrations of greater than 400µM, 
the effect of the FA treatments on cellular lipid content was next assessed. Steatosis is the defining 
feature of NAFLD and severely increased lipid content was seen when simulating high fat intake and 
IR in the model. It is therefore important that it is seen in the cell culture model. 
The effects of treatment for 48 hours with varying concentrations of the FA cocktail and with each FA 
individually on cellular lipid content are shown in figure 5.5. In the control cells, 20±5% of cellular area 
was stained by ORO. Although this is a percentage of area in the images rather than a percentage of 
mass, it is still high relative to the lipid content seen in healthy liver cells in vivo and HepG2 cells are 
known to contain a high lipid content due to reduced secretion of triglycerides [554]. Treatment with 
a 0.48% ethanol vehicle control, equal to the highest ethanol content used for 800µM FA cocktail, 
increased the percentage of area stained compared with control to 24±5% (p<0.01). 
As would be expected, addition of increasing concentrations of FA cocktail to the culture medium 
caused a significant increase in hepatic lipid concentrations (figure 5.5a). After treatment with 200µM, 
400µM, 600µM and 800µM FA cocktail over 48 hours, the percentage of cell area stained for lipid 
increased to 32±4%, 43±5%, 50±3% and 66±9% respectively (p<0.05 compared with both unaltered 
medium and vehicle controls). In the case of 800µM, the cells were almost entirely full of lipids with 
only the nuclei remaining unstained (figure 5.5c).  
Increasing the concentration of FA cocktail in the medium not only increased the total lipid content of 
the cells, but also increased the sizes of lipid droplets (figure 5.5b). When treated with 800µM the 
median lipid droplet area nearly doubled from 83 pixels to 161 pixels whilst the 95th percentile droplet 
area increased from 133 pixels to 321 pixels. 
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Figure 5.5: The effect of fatty acid treatment on cellular steatosis. (a) The effect of the fatty acid 
cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic acids) on percentage of cellular 
area stained for lipid. (b) The effect of the fatty acid cocktail on the distribution of lipid droplet sizes. 
Horizontal lines represent the average median, boxes represent the average 25th and 75th percentiles 
and whiskers represent the average 5th and 95th percentiles. (c) Representative images of control and 
800µM FA cocktail treated HepG2 cells taken at 40x magnification. (d) The effect of treatment the 
individual FAs on the percentage of the cellular area stained for lipid. The mean ±SD is presented from 
a minimum of 3 independent repeats.  
Cells were seeded at 26’000 cells per cm2 in 24 well plates containing glass coverslips in untreated 
medium and allowed to attach. After 24 hours, the untreated medium was aspirated and replaced with 
medium containing the stated treatment. The treated medium was replaced after 24 hours. The cells 
were stained with ORO after 48 hours of treatment before imaging. Quantification was performed using 
Image J as discussed in section 5.2.5. A minimum 3 independent repeats of at least 7 technical replicates 
were analysed for the fatty acid cocktail treatments and a minimum of 3 independent repeats of 3 
technical replicates were analysed for the individual fatty acid treatments. A minimum of 250 droplets 
were analysed from each independent repeat to calculate the distributions in (b). An ANOVA was used 
to determine significance between the treatment groups sets before Holm-Sidak adjusted t-tests were 
used to calculate the significance of the difference between each treatment and both untreated and 
(EtOH) vehicle controls. *- p<0.05 vs control and vehicle control. 
 
To investigate which FAs within the cocktail resulted in steatosis, HepG2 cells were treated with 
200µM of each individual FA and stained with ORO after 48 hours (figure 5.5d). The percentage area 
stained for lipid was not significantly increased by treatment with 200µM of butyric acid (18±6%; n=8; 
p=0.57), oleic acid (22±4%; n=6; p=0.06) or linoleic acid (22±4%; n=11; p=0.07) compared with control 
(20±5%; n=39). However, a significant increase occurred when the cells were treated with 200µM of 
either palmitic (43±6%; n=8; p<0.001) or lauric acids (67±12%; n=8; p<0.001).  
It should be noted that equal molar concentrations rather than equal masses or volumes of each FA 
were used as treatments. The four medium and long-chain FAs have similar molar masses in the range 
200-300 grams per mole and densities in the range 0.85-0.9g/cm3 (dependent on the temperature as 
well as the type of fat). However, the short-chain butyric acid has a much lower molecular mass of 
88.1 grams per mole (33.4% of the molar mass of palmitic acid). Therefore, although the same number 
of molecules were added, the total mass (and volume) of FA in the case of butyric acid was around a 
third of that for the other FAs. However, since 200µM butyric acid failed to cause even a non-
significant increase in hepatic lipid levels, this is unlikely to account for the difference in lipid content 
between butyric acid and palmitic acid treated cells. 
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5.3.3 Mitochondrial Function and Oxidative Stress 
As discussed above, reduced mitochondrial function and oxidative stress are both known to occur in 
NAFLD in vivo and are thought to arise because of increased hepatic FFA concentrations and increased 
oxidation of fats. In the model simulations, increases in hepatic FFA concentration and overactivation 
of oxidative phosphorylation occurred, although the pathways mediating the resulting effects on 
mitochondria are not currently included in the model. Conversely, experimentally it is possible to 
measure oxidative stress and mitochondrial function but difficult to measure intracellular FFA 
concentrations due to their rapid binding to CoA and use in glycerolipid synthesis or β-oxidation. In 
the next section, the effects of FFA treatment on markers of oxidative stress and mitochondrial 
function (ETC enzyme activity) are assessed in the cell culture model. 
5.3.3.1 Electron Transport Chain Activities and ATP levels 
Figure 5.6 shows the effects of 48-hour treatment with different concentrations of the FA cocktail on 
the activity of citrate synthase per million cells as a marker of the mitochondria per cell, on the 
activities of ETC enzymes complex I-IV per mitochondria and on intracellular ATP concentrations. 
Treatment with 200µM of the FA cocktail had no effect on citrate synthase activity (1.4±0.4x10-3 
absorbance units per second per million cells (au s-1 mc-1) (n=4) compared with control: 1.4±0.2x10-3 
au s-1 mc-1 (n=4)) (figure 5.6a). However, 400µM and 800µM FA cocktail significantly increased citrate 
synthase activity to 1.9±0.3 au s-1 mc-1 (n=4; p=0.007) and 3.0±0.6x10-3 au s-1 mc-1 (n=4; p<0.001) 
respectively. Therefore, the total mitochondrial level was increased in the FA treated cells. The 
increase in activity failed to reach significance for cells treated with 600µM FA cocktail (1.6±0.3 au s-1 
mc-1; n=4; p=0.21).  
Treatment with 400µM or greater of the FA cocktail significantly decreased both the activity of 
complex I (figure 5.6b) and the combined activities of complexes II and III (figure 5.6c). Treatment with 
600µM or greater also significantly reduced complex IV activity (figure 5.6d). This demonstrates 
reduced mitochondrial function after 48-hour FA treatment. 
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Figure 5.6: The effect of FA treatment on mitochondrial function. The effect of 48-hour treatment with 
varying concentrations of FA cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic 
acids) on (a) the activity of citrate synthase as a marker for total mitochondrial level, (b) the activity of 
complex I, (c) the combined activities of complexes II and III, (d) the activity of complex IV and (e) the 
intracellular ATP concentration. Cells were seeded at 26’000 cells per cm2 in (a-d) T25 culture flasks and 
(e) 96 well plates in untreated medium and allowed to attach. After 24 hours, the untreated medium 
was aspirated and medium containing the stated treatment was added. The treated medium was 
replaced after 24 hours. The cells were harvested and measurements performed after 48 hours of 
treatment. Numbers of independent repeats performed are stated in the axes. For (a-d) each 
independent repeat is based on two replicate reaction rate measurements. For (e) each independent 
repeat is based on 3-7 replicate measurements. (a,e) Normalised to the number of cells. (b-d) 
Normalised against citrate synthase to give activity per total mitochondria. The mean ±SD is shown. A 
one-way ANOVA was used to determine significant variation between the treatment groups before t-
tests were used to calculate the significance of the differences between each FA treatment and the 
control. * p<0.05 vs control.  
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The measured increase in citrate synthase activity, and hence total mitochondria, may partially 
compensate for the reduced mitochondrial function. For example, the complex I, II/III and IV activities 
in cells treated with 800µM FA cocktail were reduced to 26±18%, 19±2% and 29±17% of their activities 
in control cells respectively when normalised per mitochondria. However, when the increase in the 
amount of mitochondria (activity of citrate synthase) per cell is accounted for, the calculated total 
complex I, II/III and IV activities per cell were 57±40%, 41±8% and 63±40% of their activities in control 
cells respectively. 
Figure 5.6e shows the intracellular ATP concentration in cells treated with varying FA cocktail 
concentrations for 48 hours. Treatment with 800µM of the FA cocktail significantly reduced the ATP 
concentration to roughly 60% of that measured in control cells (p=0.046). No significant change in ATP 
concentration occurred in cells treated with 200µM, 400µM or 600µM FA cocktail. Therefore, reduced 
ATP levels result from FA treatment of HepG2 cells, but a higher FA concentration is required than for 
the development of mitochondrial dysfunction. 
5.3.3.2 Oxidative Stress 
Oxidative stress is known to result from excess FA oxidation and increased FFA levels, particularly in 
the context of reduced mitochondrial function. Figure 5.7 shows the effects of treatment for 48 hours 
with the FA cocktail on the redox potential and antioxidant reserves in the supernatant medium and 
on lipid peroxidation as assessed by a TBARS assay in the cell homogenates.  
Figures 5.7 a and b shows the effects of varying concentrations of FA cocktail on the redox potential 
and antioxidant capacity in the medium of cells which had been treated with varying concentrations 
of the FA cocktail. The redox potential (measured as the static ORP (section 5.2.9)) increased 
significantly when cells were treated with 400µM (228±3mV; n=3; p=0.001), 600µM (230±8mV; n=3; 
p=0.03) and 800µM (224±4mV; n=3; p=0.005) of the FA cocktail compared to control (206±2mV; n=3). 
Although the differences in redox potential  are small relative to the absolute values, they lie within a 
similar range to the values measured in the blood of type 2 diabetic and control patients [595]. The 
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antioxidant capacity (measured as the capacity ORP (section 5.2.9)), meanwhile, decreased 
significantly for FA cocktail concentrations of 600µM (0.18±0.02µC vs control 0.24±0.01µC; n=3; 
p=0.016) and 800µM (0.19±0.01µC; n=3; p=0.003). This data shows that, in the medium of cells treated 
with high FA cocktail concentrations, oxidative stress was increased whilst antioxidant reserves were 
depleted.  
 
Figure 5.7: The effect of FA treatment on oxidative stress. The effect of varying concentrations of a FA 
cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic acids) on (a) the redox potential 
in the supernatant medium, (b) the antioxidant capacity in the supernatant medium and (c) lipid 
peroxidation as assessed by a TBARS assay in the cell homogenates. 
Cells seeded at 26’000 cells per cm2 in T25 flasks plates in untreated medium and allowed to attach. 
After 24 hours, the untreated medium was aspirated and medium containing the stated treatment was 
added. The treated medium was replaced after 24 hours. The supernatant medium and cells were 
harvested after 48 hours of treatment. The tested supernatant medium had been in contact with the 
cells from the 24th to the 48th hour of treatment.  The medium was measured for redox capacity and 
antioxidant reserves whilst the cells were homogenised and assessed for lipid peroxidation (section 
5.2.9). The graphs show the mean ±SD based on the numbers of independent repeats shown on the axes 
of the graphs. A one-way ANOVA was used to determine significant variation between the treatment 
groups before t-tests were used to calculate the significance of the difference between each FA 
treatment and the control. * - p<0.05 relative to control.  
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Figures 5.7c shows the presence of lipid peroxidation as assessed by a TBARS assay in cell 
homogenates after 48 hours of treatment with varying concentrations of the FA cocktail. No significant 
change in TBARS occurred when the cells were treated with 400µM FA cocktail (1.2±0.5 cell-1 (n=5) vs 
1.0±0.2 cell-1 (n=6); p=0.51). However, when treated with 800µM, TBARS increased significantly to 
almost three times the value in control cells (2.7±1.1 cell-1 (n=5); p<0.01). An increase in TBARS 
measurement this large is strongly indicative of the presence of lipid peroxidation. 
5.3.4 Glucose Consumption and Insulin Sensitivity 
In vivo, NAFLD is often associated with IR, defective glycogen storage and hyperglycaemia. This is 
caused by increased intracellular concentrations of FFAs and closely related ceramides and DAGs [8, 
146, 247, 248]. In the following sections, the effects of FFAs on glucose consumption and insulin 
sensitivity are assessed.  
Figure 5.8 compares the rates of glucose consumption by cells grown in medium containing varying 
FA cocktail and insulin concentrations. Cells were treated for a total of 48 hours, with the medium 
replaced after 24 hours. The medium provided to the cells contained 5mM glucose equivalent to 
normoglycaemia. In each repeat, the rate of glucose consumption was calculated by subtracting the 
measured glucose concentration in the supernatant medium of each well after the 48 hours from the 
concentration measured in a blank (cell-free). This gives the blank corrected change in medium 
glucose concentration over the second 24-hour period. Since some medium evaporates occurs over 
24 hours, the measured average glucose concentration in the blank wells was slightly higher at 
5.45mM. 
In the absence of insulin, the glucose consumption over 24 hours was notably larger for cells treated 
with 200µM FA cocktail compared with FA free control cells (3.28±0.18 vs 2.27±0.23mM; p=0.012) 
(figure 5.8a). When treated with 400µM fatty acid, glucose consumption returned to a rate close to 
that seen in cells grown in control medium (2.36±0.75mM; p=0.85) (figure 5.8a). 
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Figure 5.8: The effects of 48-hour treatment with insulin and FA cocktail on the rate of glucose 
consumption. (a) The change in supernatant medium glucose concentration (as a measurement of the 
rate of glucose consumption) when treated with varying FA cocktail concentrations (an equal molar mix 
of butyric, palmitic, lauric, oleic and linoleic acids) along with the addition of either no insulin, a 
moderate insulin concentration (250pM) or a high insulin concentration (1nM) in normoglycaemic 
medium (5mM). (b) The change in glucose consumption as a result of the addition of 1nM insulin in cells 
treated with varying FA cocktail concentrations.  
Cells were seeded at 26’000 per cm2 in 48 well plates in untreated medium containing 5mM glucose 
and allowed to attach. After 24 hours, the untreated medium was aspirated and medium containing the 
stated treatment was added. The treated medium was replaced after 24 hours. The supernatant 
medium was collected and analysed after 48 hours of treatment as described in section 5.2.10. In each 
case, the data is based on 3 repeats of 2-7 replicate measurements. A two-way ANOVA was used to 
determine significant variation between the FFA and insulin treatment groups sets before Holm-Sidak 
adjusted t-tests were used to calculate significance of the difference between each FA cocktail treatment 
and the FFA free value for the same insulin concentration in addition to the significance of the difference 
between each insulin treatment and the insulin free measurement for the same FA cocktail 
concentration.  * p<0.05 when treated with insulin vs corresponding FA cocktail concentration without 
insulin. † p<0.05 when treated with FA vs corresponding insulin concentration without FA. Bars show 
mean ±SD. 
Cells grown in FA free medium showed a statistically significant increase in glucose consumption when 
treated with 1nM insulin (3.22±0.29mM; p=0.034) and a non-significant increase when treated with 
250pM insulin (2.95±0.30mM; p=0.011) and compared with those grown in the absence of insulin 
(2.27±0.23mM) (figure 5.8b). However, cells treated with 200µM or 400µM FA cocktail, showed no 
increase in glucose consumption with the addition of 1nM insulin (figures 5.8b). This shows that low 
concentrations of the FA cocktail cause a complete loss of insulin sensitivity in glucose consumption 
in HepG2 cells.  
When a Schiff stain was performed to assess the glycogen content in cells treated with a high insulin 
concentration, no glycogen was observed irrespective of the FA concentration. This was assessed both 
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through simple observation in the images and through the absorbance spectra at 550nm. The 
measured absorption after adding diastase (which breaks down glycogen to simple sugars) was 
subtracted from the absorption measured in the absence of diastase to give the glycogen-specific 
absorption. For control cells the glycogen specific absorption was -2.1±1.8 mOD per million cells (n=3) 
whilst for cells treated with 400µM FA cocktail it was 0.3±0.6 mOD per million cells (n=3). Therefore, 
although the control cells showed insulin sensitivity in glucose consumption, the glucose is not used 
in glycogen synthesis. 
5.4 Results 2: Treatment with inhibitory molecules 
The data in the previous section show that several metabolic changes result from FA treatment in 
HepG2 cells. These include reduced cell viability due to increased cell death, the development of 
steatosis, reduced mitochondrial function, reduced ATP concentrations oxidative stress and IR. As 
discussed below, these data are corroborated by numerous previous observations of changes in 
cellular metabolism in NAFLD and, although in some cases not directly comparable, are consistent 
with the model simulations. In the following section, 5 small molecule inhibitors (TOFA, C75, T863, 
2DG and 3BP) were used to test the effects of inhibiting specific processes in HepG2 cells when grown 
in medium containing varying concentrations of FAs.  
A range of concentrations of each inhibitor were first tested for their effect on cell viability to 
determine treatment concentrations which were not toxic to the cells when grown in FA free medium. 
This data is presented in supplementary material S2. It should be noted that HepG2 cells are derived 
from hepatocellular carcinoma, and cancer cells are known to rely on upregulated glycolysis and 
lipogenesis to permit rapid proliferation under conditions of reduced blood supply [555, 556]. HepG2 
cells are therefore susceptible to damage as a result of inhibitions preventing glycolysis and 
lipogenesis than primary cells. Inhibiting lipogenesis by targeting FAS or ACC1 as well as targeting 
glycolysis using 2DG or 3BP have been suggested as potential cancer treatments in the literature [602-
605]. Therefore, rather than adding the inhibitors at high concentration to fully inhibit each process, 
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we instead investigated whether low concentrations of the inhibitors (at which they do not cause 
reduced viable cells numbers when grown in control medium), ameliorate or exacerbate the 
mitochondrial damage and cell death resulting from FA treatment. Both in the model simulations 
described in the previous chapters, and when studied in vivo [15-17, 377], the majority of adverse 
effects in NAFLD occur in pericentral cells. Since pericentral cells also rely heavily on glycolysis for 
energy production and are the most lipogenic group of hepatocytes, the HepG2 model can be thought 
to most closely resemble these cells. Based on the data, treatment concentrations of 2µg/ml TOFA, 
2µg/ml C75, 200ng/ml T863, 500ng/ml 2DG and 2µg/ml 3BP were chosen. 
5.4.1 Viability and Steatosis 
Figure 5.9 shows the effect of the various inhibitors on cell viability and steatosis for cells grown in 
medium containing a range of FA cocktail concentrations. Additionally, figure 5.9c shows the effect of 
TOFA on the distribution of droplet sizes in the cells.  
Treatment with 2µg/ml TOFA significantly increased cell viability in for cells grown in medium 
containing 800µM FA cocktail 79.1±1.3% to 86.1±3.0% (figure 5.9a) (p=0.007). The gradient of 
reducing viability with increasing FA cocktail concentration was significantly reduced by TOFA 
treatment (TOFA: 15±2%/µM vs control: 25±2%/µM; p<0.01).  Viability was unchanged by TOFA 
treatment in control cells (98.1±0.4% vs 97.5±0.4%; p=0.56). 
TOFA treatment significantly reduced the lipid content of cells grown in medium containing FA 
concentrations of 400-800µM by 40-50% (figure 5.9b) (p<<0.05) and significantly reduced the gradient  
between cellular lipid content and FA cocktail treatment concentration (TOFA: 31±2%/mg vs control: 
55±2%/mg; p<0.01). For control, 0.48% EtOH and 200µM FA cocktail treated cells, the reduction in 
steatosis as a result of TOFA treatment was near significance (0.05<p<0.08). For cells grown in medium 
containing a FA cocktail concentration of 400µM or greater, the addition of 2µg/ml TOFA also caused 
a significant decrease in the median droplet size (p<0.05), giving a lipid droplet distribution more 
similar to that of control cells (figure 5.9c).  
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Figure 5.9: Effect of 48-hour treatment with the various inhibitors on viability and steatosis. The 
effects of 2µg/ml TOFA, 2µg/ml C75, 200ng/ml T863, 0.5µg/ml 2DG and 2µg/ml 2BP on (a) cell viability 
(the number of living cells divided by the total number of cells) as assessed by a trypan blue exclusion 
assay and (b) the percentage of cell area stained for lipid by ORO in cells grown at a range of FA cocktail 
concentration (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic acids). (c) The effect of 
2µg/ml TOFA on the distribution of lipid droplet sizes in cells grown at a range of FA cocktail 
concentration. (a) Cells were seeded at a density of 26’000 per cm2 in 6 well plates and allowed to attach 
in untreated medium for 24 hours. The treated medium was added and replaced after 24 hours before 
counting after 48 hours, using trypan blue to identify dead cells. The graph shows the means ± SD based 
on 3 independent repeats of 4 replicate counts except for the untreated curve which is based on 6 
independent repeats. (b, c) Cells were seeded at a density 26000 per cm2 on glass cover slips in 24 well 
plates and allowed to attach for 24 hours in untreated medium. After the cells had attached, medium 
containing the stated treatment was added. This was replaced after 24 hours before the cells were 
stained and imaged after 48 hours of treatment. Image J was used to quantify the lipid content and 
droplet sizes. The graphs are based on analysis of at least 3 replicates form 3-4 independent repeat. The 
box and whisker plots show the average means, average 25th and 75th percentiles and average 5th and 
95th percentiles from 3 repeat experiments in which a minimum of 250 droplets were analysed. 
A statistically significant effect of both the FA cocktail concentration and the treatments was first 
determined using a two-way ANOVA before statistical significance of the differences between each 
treated group and the control group were calculated using Holm-Sidak adjusted t-tests. * p<0.05 vs 
untreated for same FA concentration. 
Treatment with FAS inhibitor C75 had no effect on cell viability (figure 5.9a) when tested across the 
range of FA cocktail concentrations (0-800µM). Therefore, the C75 treatment neither improved nor 
exacerbated FA induced cell death. C75 treatment also had little effect on cellular steatosis (figure 
5.9b). Treating with 2µg/ml C75 only caused a significant reduction in cellular lipid levels for cells 
grown in FA free medium (2µg/ml C75: 8±4% vs control: 20±5%; p=0.023). In FA free medium all lipids 
must arise through de novo lipogenesis so it is expected that inhibition of the process would reduce 
the hepatic lipid concentration. However, when cells were grown in medium containing 200-800µM 
FA cocktail, inhibition of lipogenesis with C75 had no effect on hepatic lipid levels. Since raised plasma 
lipid concentrations are seen in NAFLD patients, these results suggest the treatment would not be 
effective at clearing steatosis in NAFLD patients. 
Partial inhibition of triglyceride synthesis using T863 in HepG2 cells caused a reduction in cellular lipid 
levels for all FA cocktail concentrations (0-400µM) (figure 5.9a). For cells grown in medium containing 
400µM cocktail, the area stained for steatosis was reduced by nearly 40% (26±5% vs 42±5%; p=0.015) 
and for cells grown in FA free medium, the percentage decrease was even larger (6±2% vs 20±3%; 
p=0.003). However, despite the reduction in steatosis, treatment with 200ng/ml T863 of cells grown 
in medium containing 200µM or 400µM FA cocktail caused a reduction in cell viability (figure 5.9a) 
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(p<0.05). T863 treatment did not alter cell viability when the cells were grown in FA free medium.  
Therefore, despite clearing steatosis, T863 treatment exacerbated rather than improved FA-induced 
cell death. 
Treatment with 500ng/ml 2DG notably decreased the number of viable cells when grown in medium 
containing 200µM and 400µM FA cocktail (figure 5.9a). Similarly, treatment with 2µg/ml 3BP caused 
a significant reduction in the number of viable cells for 400µM FA cocktail and a non-significant 
reduction for 200µM. Glycolysis inhibition by both 2DG and 3BP has previously been shown to cause 
apoptosis in cancer cells. However, the low 2DG and 3BP treatment concentrations used in this study 
did not cause significant decreases in the number of viable cells when added to the medium of cells 
cultured in FA free conditions, as discussed in supplementary material S2. Instead, the results in figure 
5.9a show that the low concentrations of 2DG and 3BP acted to exacerbate the cell death resulting 
from FA treatment. 
Neither of the glycolysis inhibitors tested had any effect on the lipid content (figure 5.9b). This 
suggests that inhibition of glycolysis at either stage (GK or glyceraldehyde-3-phosphate 
dehydrogenase) has toxic effects on metabolism at concentrations below those at which it reduces 
lipid levels.  
To assess the extent to which glycolysis was inhibited by 3BP and 2DG, the rates of glucose uptake and 
lactate output were measured for cells grown in either FA free medium or medium containing 400µM 
FA cocktail with the addition of either no treatment, the 1µg/ml BP, 2µg/ml 3BP, 250ng/ml DG or 
500ng/ml 2DG treatments (figure 5.10). For both FA free and FA cocktail treated cells, 1µg/ml and 
2µg/ml BP reduced the rates of glucose uptake and lactate output, and hence the rate of glycolysis, 
by approximately 5-15% and 10-25% respectively. 250ng/ml and 500ng/ml 2DG meanwhile reduced 
the rates by 25-35% and 40-50% respectively. Therefore, in the case of the high 2DG concentration, 
even with 40-50% inhibition of glycolysis no change in cellular lipid content occurred. Conversely, in 
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the case of the low 3BP concentration, resulting in only 5-15% inhibition of glycolysis, increased FA 
induced cell death occurred. 
 
Figure 5.10: The effect of 2DG and 3BP on glucose uptake and lactate output. The effects of 1µg/ml 
3BP, 2µg/ml 3BP, 250ng/ml 2DG and 500ng/ml 2DG on (a) glucose uptake per cell and (b) lactate output 
per cell for HepG2 cells grown in FA free medium or medium containing 400µM FA cocktail (an equal 
molar mix of butyric, palmitic, lauric, oleic and linoleic acids). Cells were seeded at 26’000 per cm2 in T25 
culture flasks in untreated medium and allowed to attach for 24 hours. After the cells had attached, the 
untreated medium was aspirated and medium containing the stated treatment was added. The treated 
medium was replaced after 24 hours. After 48 hours of treatment, the supernatant medium was 
collected and analysed (section 5.2.10). n=4 for all measurements. A statistically significant effect of the 
treatments was first determined using an ANOVA before the statistical significance of the differences 
between each treated group and the control group were calculated using Holm-Sidak adjusted t-tests. 
* p<0.05 vs untreated for same FA concentration. 
FA Free 400µM FA Cocktail 
400µM FA Cocktail FA Free 
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5.4.2 Oxidative Stress 
Next the effect of the various inhibitors on the redox balance and antioxidant reserves in the medium 
were measured as markers of oxidative stress (figure 5.11). The effects of TOFA on lipid peroxidation 
were also assessed (figure 5.11c).  
2µg/ml TOFA treatment caused a significant decrease in redox potential for cells grown in medium 
containing 400µM FA cocktail (TOFA: 216±7mV (n=6) vs control 228±3mV (n=3); p=0.025), returning 
the marker of oxidative stress to nearer control levels (206±2mV (n=3)) (figure 5.11a). For all other FA 
cocktail concentrations, a non-significant decrease in redox potential was measured. Furthermore, 
other than in FA free medium, addition of 2µg/ml TOFA caused a non-significant increase in the 
antioxidant capacity compared with control suggesting that TOFA may also improving the cells’ 
capacity to recover from oxidative injury (figure 5.11b). Treatment with TOFA also caused a significant 
decrease in lipid peroxidation for cells grown in FA free medium (0.21±0.07mOD.10-3cells vs 
0.41±0.07mOD.10-3 cells; n=6; p<0.01) and medium containing 800µM FA cocktail (0.3±0.2mOD.10-3 
cells (n=3) vs 1.1±0.5mOD.10-3 cells (n=5); p=0.036) (figure 5.11c). Despite the lack of specificity in the 
TBARS assay, the large reduction in reading for cells grown in 800µM FA cocktail after treatment with 
2µg/ml TOFA is strongly indicative of a reduction in intracellular lipid peroxidation. Together, these 
data show that TOFA treatment reduces FA induced oxidative stress in HepG2 cells. 
Despite not improving cell viability or steatosis, treatment with 2µg/ml C75 caused a significant 
reduction in redox potential for cells grown in medium containing 400µM FA cocktail (215±2mV vs 
228±3mV; n=3; p=0.016) (figure 5.11a) and non-significant reductions at all other FA cocktail 
concentrations. Therefore, the treatment reduced the mitochondrial stress resulting from FA 
treatment. No significant change in antioxidant capacity resulted from C75 treatment for any of the 
FA cocktail concentrations (figure 5.11b). 
Treatment with 200ng/ml T863 caused a significant increase in redox potential for cells grown in FA 
free medium (220±5mV vs 206±2mV; n=3; p=0.006) (figure 5.11a). A non-significant increase in redox 
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Figure 5.11: The effect of the various inhibitors on fatty acid induced oxidative stress. The effect of 48 
hour treatment with 2µg/ml TOFA, 2µg/ml C75, 200ng/ml T863, 0.5µg/ml 2DG and 2µg/ml 3BP on (a) 
the redox potential and (b) antioxidant reserves in the supernatant medium of cells treated with 0-
800µM FA cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic acids). (c) The effect 
of 48 hour treatment with 2µg/ml TOFA on lipid peroxidation as assessed by a TBARS assay on HepG2 
cells grown in medium containing 0-800µM FA cocktail.Cells were seeded at 26’000 cells per cm2 in T25 
culture flasks in untreated medium and allowed to attach. After 24 hours, the untreated medium was 
aspirated and medium containing the stated treatment was added. The treated medium was replaced 
after 24 hours. The supernatant medium and cells were harvested after 48 hours of treatment. The 
tested supernatant medium had been in contact with the cells from the 24th to the 48th hour of 
treatment.  The medium was measured for redox capacity and antioxidant reserves whilst the cells were 
homogenised and assessed for lipid peroxidation (section 5.2.9). 3 independent repeats were performed 
in each case other than the ORP measurements for control + TOFA and 400µM FA + TOFA where 6 
repeats were performed. A statistically significant effect of the treatments was first determined using a 
two-way ANOVA before the statistical significance of the differences between each treated group and 
the control group were calculated using Holm-Sidak adjusted t-tests. * p<0.05 vs untreated for same FA 
concentration. Bars show mean ±SD. 
 
potential was measured after T863 treatment for 200µM FA cocktail (226±3mV vs 215±6mV; n=3; 
p=0.087) and no notable change after treatment with 400µM FA cocktail (230±14mV vs 228±3mV; 
n=3; p=0.65). Similarly, a significant decrease in antioxidant capacity was measured after T863 
treatment for cells grown in FA free medium (0.22±0.01µC vs 0.24±0.01µC; n=3; p=0.047), but no 
significant change was measured in medium supplemented with 200µM and 400µM FA cocktail (figure 
5.11b). Therefore, although no decrease in viability resulted from treatment with 200ng/ml T863 for 
cells grown FA free medium, it was associated with an increase in oxidative stress and a decrease in 
antioxidant reserves.  
No significant change in redox potential or antioxidant capacity was measured for either 2DG or 3BP 
across the range of FA cocktail concentrations (figure 5.11). Therefore, although glycolysis inhibition 
resulted in reduced viability (figure 5.9), it was not shown to result in the release of additional ROS. 
5.4.3 Mitochondrial Function 
Figure 5.12 shows the effects of 2µg/ml TOFA on the activity of complexes I-IV, the activity of citrate 
synthase and the ATP concentration for cells grown in medium containing a range of FA cocktail 
concentrations. Additionally, the effect of 2µg/ml C75, 200ng/ml T863, 0.5µg/ml 2DG and 2µg/ml 3BP 
on ATP concentrations are shown (figure 5.12e). 2µg/ml TOFA treatment caused near-significant 
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Figure 5.12: The effect of TOFA treatment on mitochondrial function. The effects of treatment for 48 
hours with 2µg/ml TOFA on (a) the activity of citrate synthase, (b) the activity of complex I, (c) the 
combined activities of complexes II and III and (d) the activity of complex IV and (e) the effects of 
treatment for 48 hours with 2µg/ml TOFA, 2µg/ml C75, 200ng/ml T863, 0.5µg/ml 2DG and 2µg/ml 3BP 
on the intracellular ATP concentration in HepG2 cultures treated with varying concentrations of FA 
cocktail (an equal molar mix of butyric, palmitic, lauric, oleic and linoleic acids). Cells were seeded at 
26’000 cells per cm2 in (a-d) T25 culture flasks and (e) 96 well plates in untreated medium and allowed 
to attach. After 24 hours, the untreated medium was aspirated and medium containing the stated 
treatment was added. The treated medium was replaced after 24 hours. The cells were harvested and 
measurements performed after 48 hours of treatment. The data in (a) and (e) was normalised to the 
number of cells whilst the data in (b-d) was normalised against citrate synthase to give activity per total 
mitochondria. For graphs (a-d) the data is based on the numbers of independent repeats stated in the 
axes and for (e) it is based on 3 repeats of 2-7 replicates. Cells were seeded at 26’000 cells per cm2 in 
T25 culture flasks in untreated medium and allowed to attach. After 24 hours, the untreated medium 
was aspirated and medium containing the stated treatment was added. The treated medium was 
replaced after 24 hours. The supernatant medium and cells were harvested after 48 hours of treatment. 
The tested supernatant medium had been in contact with the cells from the 24th to the 48th hour of 
treatment.  The medium was measured for redox capacity and antioxidant reserves whilst the cells were 
homogenised and assessed for lipid peroxidation (section 5.2.9). 3 independent repeats were performed 
in each case other than the ORP measurements for control + TOFA and 400µM FA + TOFA where 6 
repeats were performed. A statistically significant effect of the treatments was first determined using a 
two-way ANOVA before the statistical significance of the differences between each treated group and 
the control group were calculated using Holm-Sidak adjusted T-Tests. * p<0.05 vs untreated for same 
FA concentration. The mean ±SD is presented. 
decreases in citrate synthase activity (a marker for total mitochondria) in cells grown in medium 
containing 400µM and 800µM FA cocktail (figure 5.12a). Furthermore, a significant reduction in the 
gradient between citrate synthase activity and FA cocktail treatment concentration was measured 
with TOFA treatment, demonstrating that the treatment lessened the FA induced increase in citrate 
synthase activity (p<0.01). 
Treatment with 2µg/ml TOFA significantly restored complex II/III activity for cells grown in medium 
containing 400-800µM of FA cocktail (figure 5.12c) and significantly restored complex I activity for 
cells grown in medium containing 400µM FA cocktail (figure 5.12b). Non-significant increases in 
complex I activity were measured after TOFA treatment at all other FA cocktail concentrations. No 
significant changes in complex IV activity were seen with TOFA treatment across the range of FA 
cocktail concentrations (figure 5.12d). These data suggest that treatment with 2µg/ml TOFA has the 
potential to partially restore mitochondrial dysfunction in steatotic hepatocytes through both 
complex I and complexes II/III. Furthermore, no adverse changes to mitochondrial function occurred 
in non-steatotic cells grown in control medium after TOFA treatment.  
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Treatment with either 2µg/ml TOFA or 2µg/ml C75 did not significantly change intracellular ATP 
concentrations in either FA free or 400µM FA cocktail treated cells (figure 5.12e). Since ATP 
concentrations were not significantly reduced after treatment with 400µM FA cocktail (despite the 
reduction in ETC enzyme activities), no increase in concentration would be expected. However, these 
data show that ATP concentrations were not detrimentally affected by the treatments.  
Treatment with T863, however, caused a significant decrease in intracellular ATP concentration for FA 
treated cells (400µM FA cocktail: treated - 142±106 (n=10) vs untreated - 242±80 (n=14); p=0.004) but 
no change for cells grown in FA free medium (figure 5.12e). This shows that, when excess FAs are 
present, inhibition of triglyceride synthesis disrupts energy metabolism in the cells. 
Treatment with 2µg/ml 3BP also caused a significant reduction in intracellular ATP concentration for 
cells grown in medium containing 400µM FA cocktail (treated: 177±100 (n=10) vs untreated: 242±80 
(n=14); p=0.024), but no significant change in concentration for cells grown in FA free medium (figure 
5.12e). This suggests that the duel effects of the 10-25% decrease in glycolysis resulting from 3BP 
treatment (figure 5.10) combined with the decreased mitochondrial function resulting from 400µM 
FA cocktail treatment resulted in decreased cellular ATP concentrations. 
Treatment with 500ng/ml 2DG resulted in a severely reduced ATP concentration in both control and 
400µM FA cocktail treated cells (figure 5.12e). For 400µM FA cocktail, almost no ATP was present, 
showing that the majority of cells were no longer viable. Therefore, reducing glycolysis by 40-50% 
through treatment with 500ng/ml 2DG caused a decrease in cellular ATP concentration in HepG2 cells 
and, when combined with reduced mitochondrial function resulting from FA treatment, complete 
disruption of energy metabolism. 
5.4.4 Glucose Consumption 
Figure 5.13 shows the effect of TOFA and C75 on glucose consumption and insulin stimulation of 
glucose consumption for cells grown in a range of FA cocktail concentrations. Based on the simulated 
data in chapter 4, a decrease in glucose would be expected to result from both treatments due to 
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reduced use of glucose in lipogenesis and increased β-oxidation. However, if the treatments reduce 
steatosis or the toxic effects resulting from excess fat build-up, an improvement in insulin stimulation 
of fatty acid uptake might be expected in fatty acid treated cells.  
 
Figure 5.13: The effects of with TOFA and C75 on the rate of glucose consumption. (a) The change in 
supernatant medium glucose concentration (as a measurement of the rate of glucose consumption) 
when treated with varying FA cocktail concentrations along with the addition of either C75 or TOFA in 
hyperglycaemic medium (15mM). (b) The change in glucose consumption as a result of the addition of 
1nM insulin in cells treated with varying FA cocktail concentrations along with the addition of either C75 
or TOFA in hyperglycaemic medium (15mM). Cells were seeded at 26’000 per cm2 in 48 well plates in 
untreated medium containing 15mM glucose and allowed to attach. After 24 hours, the untreated 
medium was aspirated and medium containing the stated treatment was added. The treated medium 
was replaced after 24 hours. The supernatant medium was collected and analysed after 48 hours of 
treatment as described in section 5.2.10. In each case, the data is based on 3 repeats of 2-7 replicate 
measurements. A two-way ANOVA was used to determine significant variation between the FFA and 
treatment groups sets before Holm-Sidak adjusted t-tests were used to calculate significance of the 
difference between each treated and control group. * p<0.05 vs untreated for same FA concentration. 
The mean ±SD is presented. 
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Consistent with the model predictions both TOFA and C75 caused significant decreases in glucose 
consumption in cells cultured in both FA free medium and medium containing 400µM FA cocktail 
(figure 5.13a). However, insulin sensitivity in the consumption of glucose was significantly improved 
when cells grown in medium containing 400µM FA cocktail were treated with 2µg/ml C75 
(27.3±19.3µMoles Vs -2.1±14.9µMoles; n≥4; p=0.032) (figure 5.13b). TOFA treatment of cells grown 
in medium supplemented with 400µM FA also appeared to cause an increase in the additional glucose 
caused by the addition of 1nM insulin but this failed to reach significance (TOFA: 30±34µMoles (n=5) 
vs control: -2±15 µMoles (n=5); p=0.090).  
5.5 Discussion 
5.5.1 Fatty acid treated HepG2 cells show steatosis, reduced mitochondrial function, 
oxidative stress and insulin resistance consistent with in vivo NAFLD 
In the first section of this chapter HepG2 cells, a cell culture line derived from a well-differentiated 
hepatoma, were treated with varying concentrations of a FA cocktail (an equal molar mix of palmitic, 
lauric, oleic, linoleic and butyric acids) in order to provide a cell culture model of steatotic hepatocytes 
in NAFLD. The effects of the FAs on viability, steatosis, mitochondrial function, oxidative stress and 
metabolism in these cells were analysed to assess their utility as a model of in vivo NAFLD. 
Firstly, a cell culture model of hepatocytes in NAFLD should develop steatosis and cell damage 
dependent on the medium FA concentrations. Even when grown in control medium (FA free, 5mM 
glucose), HepG2 cells show a high lipid content. This has previously been shown to result from reduced 
output of fats in lipoproteins rather than excess de novo lipogenesis [554]. In addition to a higher 
baseline lipid content, the cells showed higher susceptibility to FA treatment than would be expected 
for in vivo hepatocytes. When treated with 400µM of the FA cocktail, which represents a normal pre-
prandial plasma FFA concentration, a notable increase in steatosis occurred accompanied by increased 
cell death. When treated with 800µM of the FA cocktail, towards the high end of plasma FFA 
concentrations seen in NAFLD patients [139, 435, 466], severe steatosis and cell death occurred. 
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Therefore, HepG2 cells are damaged by increased medium FA concentrations and have an intracellular 
lipid content dependent on the medium concentration, consistent with in vivo cells. However, they 
show a lower tolerance to raised FFA concentrations and a higher baseline lipid content compared 
with in vivo hepatocytes. 
When the cells were treated with each FA individually, the saturated long chain FA palmitic acid and 
saturated medium chain FA lauric acid had the largest effect on cell viability and cellular steatosis. 
200µM of long chain, monounsaturated FA oleic acid and long chain, polyunsaturated FA linoleic acid 
caused no change in viability or lipid content of cells, whilst 200µM saturated, short chain FA butyric 
acid only caused a small decrease in viability. These results are consistent with the data published by 
Garcia-Ruiz et al. which showed a number of adverse effects including mitochondrial dysfunction and 
increased ROS when HepG2 cells were treated with 200µM of saturated palmitic and stearic FAs, but 
not when treated with 200µM of unsaturated oleic acid [557]. 
When assayed using a diastase corrected PAS-Schiff stain, the cells showed almost no glycogen 
content, even in FA free medium containing insulin. This observation has been made previously in the 
literature [553]. Therefore, it is not possible to study the effects of FAs or other treatments on 
glycogen storage using these cells. However, insulin stimulation of both glucose consumption was 
seen in cells grown in FA free medium but not in medium treated with 400µM FA cocktail. Palmitate 
has previously been shown to cause IR in HepG2 cells [606-608]. 
Hepatocytes in NAFLD in vivo are known to show reduced mitochondrial function and reduced ATP 
production [547, 548, 591, 592] and it has been suggested that this disruption to energy metabolism 
may account for the progression from NAFLD to NASH [229, 230]. When treated with the FA cocktail, 
the HepG2 cells showed reduced activity of complex I, complexes II and III combined and complex IV. 
As with the development of steatosis in HepG2 cells, this occurred at lower medium FA concentrations 
(400-800µM) than would be expected in vivo. For 400µM and 600µM concentrations of the FA cocktail, 
the reductions in ETC enzyme activities were not accompanied by a reduction in ATP concentration, 
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suggesting that the cells either contain excess ETC capacity or were able to compensate for reduced 
oxidative phosphorylation. Increased total mitochondria was measured in FA treated cells and is seen 
under conditions of excess fat availability in vivo [590], which may partially compensate for reduced 
mitochondrial function. However, when the cells were treated 800µM FA cocktail, a reduction in ATP 
concentration was measured, consistent with the severe increase in cell death measured for this 
concentration. 
The results are consistent with the data published by Garcia-Ruiz et al. showing reduced activities of 
complexes I-IV and of ATP synthase along with reduced ATP concentrations in HepG2 cells treated 
with 200µM palmitic acid or stearic acid [557]. In the study by Garcia-Ruiz et al., no change in ETC 
activity was seen after treatment with 200µM oleic acid, suggesting that the saturated FAs in the 
cocktail, particularly palmitic acid, are likely to drive the decrease in ETC activity. 
In addition to a loss of mitochondrial function, NAFLD patients show increased hepatic oxidative stress. 
In the cell culture model, oxidative stress was assessed through two indirect methods. Firstly, the 
redox potential of the culture medium was measured to detect extracellular ROS. Secondly, a TBARS 
test for lipid peroxidation was performed on cell homogenates. In FA treated cells, increases in both 
the redox potential and in lipid peroxidation products were measured. Consistent with this, Garcia-
Ruiz et al. showed that treatment with 200µM of the saturated FAs palmitic acid and stearic acid, but 
not with 200µM of the unsaturated FA oleic acid, resulted in an increase in lipid peroxidation [557]. 
This is consistent with the reduced cell viability seen when treating with palmitic acid (and the other 
saturated FAs lauric and butyric acids) but not when treating with equivalent concentrations of the 
unsaturated oleic and linoleic acids. Additionally, Soardo et al. showed increases in several mediators 
of oxidative stress including glutathione, malondialdehyde and nitric oxide when treating HepG2 cells 
with a cocktail of FAs [609].  In NAFLD patients, oxidative stress and lipid peroxidation have been also 
shown to occur [225, 382, 547, 591, 593], particularly in pericentral cells. Combined, these data show 
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that increased oxidative stress accompanies the reduction in mitochondrial function measured in FA 
treated HepG2 cells. 
The cells can therefore be used to test the ability of potential treatments to resolve FA induced cell 
death, steatosis, oxidative stress, loss of mitochondrial function, ATP depletion and loss of insulin 
sensitivity in glycolysis. These results can be compared to the model simulations. 
However, HepG2 cells show several differences to in vivo hepatocytes, as would be expected for an 
immortalized line derived from a liver cancer. Firstly, they are constantly proliferating with a doubling 
time of 2 days. Additionally, cancer cells are heavily reliant on glycolysis for ATP synthesis. Given that 
two of the treatments studied were direct glycolysis inhibitors and two inhibit lipogenesis causing 
allosteric inhibition of glycolysis, the background of HepG2 cells as cancer cells must be remembered 
whilst interpreting the results. However, the majority of adverse effects in NAFLD occur in pericentral 
cells (both in the model simulations and experimentally [15-17, 377]), which are reliant on glycolysis 
due to their low oxygen environment. The HepG2 model can therefore be considered to most closely 
resemble these cells. 
5.5.2 Validation of the model predictions for targeting specific processes in pericentral 
cells. 
In the chapter 4, the computational model was used to simulate the effects of targeting several 
different processes on cells across the sinusoid for individuals with NAFLD resulting from high intake 
and IR. In this chapter, HepG2 cells grown in medium containing FAs were treated with small molecule 
inhibitors to provide validation of the model’s predictions. In particular, due to the reliance of HepG2 
cells on glycolysis for energy production, the measurements from the cell culture model are most 
comparable to the predictions for hypoxic pericentral cells [553]. Five inhibitors were used, which are 
known to act on specific enzymes. The corresponding targeted processes within the model for each 
treatment are shown in figure 5.1. The simulated treatments are shown in figure 4.2. 
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Glycolysis  
When partial inhibition of glycolysis was simulated in the model, severely reduced pericentral ATP 
concentrations were predicted without any notable decrease in steatosis for insulin resistant 
individuals. This was seen when glycolysis was inhibited at either the conversion of glucose to G6P, 
the conversion of G6P to GADP or the conversion of GADP to pyruvate. Additionally, when inhibition 
of glycolysis was simulated at the stage of GK, glycogen synthesis was reduced in the cells leading to 
plasma hyperglycaemia. Based on these simulations, reduced cellular viability resulting from defective 
energy metabolism would be expected when inhibiting any of the enzymes in the glycolysis pathway 
in cell culture. 
When studied in HepG2 cells, partial inhibition of glycolysis through either inhibiting GK using 2DG or 
inhibiting the conversion of GADP to pyruvate using 3BP caused reduced ATP concentrations and FA 
induced cell death without any notable change in steatosis consistent with the model predictions. Due 
to the lack of glycogen synthesis in untreated HepG2 cells, the effects of the treatment on glycogen 
synthesis could not be studied. However, both the model predictions and cell culture experiments 
show that partial inhibition of glycolysis disrupts energy metabolism without notably improving 
steatosis. It remains unknown whether glycolysis inhibition causes increased apoptosis in cancer cells 
specifically due to the blocking of ATP production through glycolysis alone, or whether additional 
factors contribute [610]. Given that mitochondrial dysfunction was shown to result from FA 
treatment, it is possible that a duel hit of reduced mitochondrial function and reduced ATP production 
from glycolysis caused the increase in cell death.   
Triglyceride Synthesis 
When inhibition of triglyceride synthesis was simulated in the model in chapter 4, steatosis was 
cleared effectively by the treatment. However, vast increases in hepatic FFA concentration were 
predicted to occur. FFAs and closely related molecules including DAGs and ceramides are particularly 
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potent in promoting mitochondrial stress and IR [8, 146, 247, 248]. Based on these simulations, 
increased mitochondrial stress and FFA induced cell damage would be expected despite the clearance 
of steatosis when inhibiting triglyceride synthesis in cell culture. 
Experimentally, partial inhibition of triglyceride synthesis with the DGAT1 inhibitor T863 significantly 
reduced the cellular lipid content of the HepG2 cells consistent with model predictions. However, 
despite reducing steatosis, the treatment exacerbated FA-induced cell death. In control cells viability 
was unchanged, but after the addition of FAs, treatment with T863 caused reduced viability. 
Additionally, T863 treatment caused a reduction in ATP concentrations in FA treated but not control 
cells. This suggests that, when grown in in FA free medium, insufficient FAs are produced for the 
inhibition of triglyceride synthesis to damage the cells. However, when excess FFAs are present, 
inhibition of triglyceride synthesis forces lipids to remain in forms which are more potent than 
triglycerides in causing mitochondrial dysfunction. Previously published in vivo studies have linked 
inhibition of DGAT2, which performs the same function as DGAT1, with increased liver damage in mice 
despite a reduction in steatosis [254].  
The cell culture data are therefore consistent with the model predictions, although only a vast increase 
in triglyceride synthesis precursors is predicted by the model and the mechanisms responsible for the 
effects of FA on mitochondrial function are not included.  
Lipogenesis 
In model simulations, inhibition of lipogenesis reduced the hepatic lipid content in insulin sensitive 
individuals, but had little effect when simulating insulin resistant NAFLD where most FFAs are derived 
from plasma. However, the simulated hepatic FFA concentration and rate of FA oxidation were 
decreased when lipogenesis was inhibited, and simulated ATP concentrations increased to nearer 
metabolically normal levels. Therefore, based on the model simulations, improvements in 
mitochondrial function, oxidative stress and insulin sensitivity would be expected to occur in the cell 
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culture model despite little improvement in steatosis. Increased plasma glucose concentrations arose 
in simulations as a result of the inhibition of lipogenesis when simulating insulin resistant individuals. 
However, this excess was stored as glycogen when simulating insulin sensitive individuals.  
Total inhibition of lipogenesis could not be tested experimentally due to the known toxic effect of 
lipogenesis inhibition of cancer derived cells. Instead, lipogenesis inhibitor C75 was added at a lower 
concentration such that lipogenesis was only partially inhibited and cell viability was unaffected in FA-
free medium.   
Partial inhibition of lipogenesis had no effect on the cellular lipid content of cells grown in medium 
containing FA cocktail. This consistent with the model predictions when simulating insulin resistant 
NAFLD in which most FFAs are derived from plasma. Additionally, C75 treatment had no effect on FA-
induced cell death. However, a fall in the redox potential was measured in the supernatant medium 
of cells treated with C75 suggesting a reduction in mitochondrial stress. Additionally, a significant 
increase in insulin stimulation of glucose consumption was measured when cells grown in medium 
containing the FA cocktail were treated with C75, showing re-sensitisation to insulin. These results are 
consistent with the predicted reduction in hepatic FFA concentration when inhibition of lipogenesis 
was simulated in the model. 
Lipogenesis and β-oxidation 
When inhibition of lipogenesis in addition to stimulation of β-oxidation was simulated in the model, 
steatosis was resolved and ATP concentrations increased to nearer metabolically normal levels. 
Furthermore, decreases in intracellular FFA concentrations and the rate of FA oxidation were 
predicted, both of which are thought to be causes of disrupted mitochondrial function and 
mitochondrial stress. As an adverse effect, when simulating inhibition of lipogenesis in addition to 
stimulation of β-oxidation in insulin resistant individuals an increased plasma glucose concentration 
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occurred. However, when simulating insulin sensitive individuals, increased glycogen synthesis 
occurred instead. 
Stimulation of β-oxidation in combination with inhibition of lipogenesis was tested experimentally 
through the inhibition of ACC1 and ACC2 using TOFA. As with C75, only partial inhibition by TOFA could 
be tested due to the known toxic effect of lipogenesis inhibition on HepG2 cells. Treatment with TOFA 
caused a notable decrease in cellular lipid levels across the range of treatments consistent with the 
model predictions. Furthermore, this was accompanied by an improvement in viability and 
mitochondrial function and a reduction in oxidative stress.  
In the model predictions, a reduction in glycolysis was predicted resulting in either increased 
glycogenesis in insulin sensitive individuals or hyperglycaemia in insulin resistant individuals. It is 
therefore important that any treatment rapidly restores insulin sensitivity whilst clearing steatosis in 
insulin resistant NAFLD individuals. Since HepG2 cells do not synthesize glycogen even when grown in 
FA free medium containing insulin, the effects of TOFA treatment on glycogen storage could not be 
tested experimentally. However, a reduction in glucose consumption was measured consistent with 
model predictions. Furthermore, an increase in the insulin stimulation of glycolysis approached but 
failed to reach significant in FA-treated cells when treated with TOFA, suggesting that improved insulin 
sensitivity may occur. 
It should be noted that, in the literature, TOFA has been extensively shown to cause cell death in 
cancer cell derived lines such as HepG2 [579, 611-613]. This is consistent with the results in 
supplementary material S2 showing that, for higher TOFA concentrations (10-20µg/ml or greater), 
reduced cell viability was measured. In human lung and prostate cancer cells, TOFA has been shown 
to cause a reduction in the number of viable cells even at 1µg/ml [614]. However, the results 
presented in this report show that, at a concentration below its toxicity threshold, TOFA reduces the 
cell death and oxidative stress caused by FA treatment. Interestingly, a previous study has shown that 
addition of palmitate reduces the cell death caused by higher TOFA concentrations in HepG2 cells 
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[614]. In another study, treatment with TOFA, in contrast to C75 and [6]-gingerol (an additional 
lipogenesis inhibitor), was shown to inhibit lipogenesis without promoting apoptosis in HepG2 cells 
[615]. TOFA treatment was additionally shown to reduce the apoptosis after treatment with [6]-
gingerol [615]. In non-cancer cells, which are less reliant on glycolysis and lipogenesis, ACC inhibition 
would be expected to be less damaging to hepatocytes than in cancer cells. 
5.6 Conclusions of Chapter 
The in vitro data in this chapter demonstrates reduced steatosis, improved mitochondrial function and 
reduced oxidative stress when both stimulating β-oxidation and inhibiting lipogenesis with TOFA. The 
data also suggest that inhibition of lipogenesis alone may reduce the oxidative stress and IR caused by 
steatosis without clearing the underlying steatosis. Finally, the experimental data provides validation 
of the adverse effects predicted when inhibiting triglyceride synthesis or glycolysis as potential 
treatments for steatosis. These findings are consistent with the model simulations when inhibiting 
these processes in chapter 4. 
6 Conclusions and Future Work 
6.1 A Computational Model of Hepatic Metabolism across the Liver 
Sinusoid 
The first objective of this study was to build a computational model of hepatic glucose and lipid 
metabolisms capable of representing differences in metabolism across the sinusoid. A model 
containing the major pathways in glucose regulation, lipid storage and ATP synthesis was developed 
with hepatocytes split into compartments across the sinusoid and with zonation of key enzymes 
included based on previously published periportal to pericentral ratios.  
The model gives realistic values for average plasma and hepatic concentrations and for changes in 
concentrations of key molecules under known feeding concentrations when compared with 
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experimental data. It also produces realistic average hepatic rates of processes and relative rates in 
different regions of the sinusoid. The simulated data was consistent with in vivo measurements for 
both healthy and insulin resistant individuals.  
A model of glucose and lipid metabolisms which includes zonation across the sinusoid was previously 
lacking from the literature and the model presented here may be applicable to study the development 
and treatment of a range of metabolic liver diseases in addition to NAFLD. Furthermore, since zonated 
damage is seen in almost all liver diseases and mitochondrial metabolism is involved in the progression 
of a wide range of these, the model may be useful for studying zonated effects in other conditions. 
For example, the mechanisms by which alcohol poisoning damages the liver are closely related to 
those occurring in NAFLD and with some modification, the model could be adapted to study zonation 
in the damage resulting from metabolism of ethanol. This would require inclusion of the pathways 
converting ethanol to acetyl-CoA (three enzymes) along with a full representation of NAD/NADH 
(where they are only represented through their effects on ATP levels in the current model) due to the 
known importance of the NAD/NADH ratio in causing steatosis after excess ethanol consumption. 
6.2 The Development of Zonated Steatosis 
The second objective of the project was to study in detail the build-up of fats in different regions of 
the sinusoid when simulating conditions leading to NAFLD in the model. The tendency for pericentral 
cells to show more severe steatosis and damage is widely referred to in the literature, but not fully 
understood due to the experimental difficulty of taking measurements in each region of the sinusoid 
and the large number of potential variables. Combining existing knowledge of metabolism and 
zonation into a model, and simulating conditions leading steatosis allowed detailed study of the 
changes occurring across the sinusoid in the model. 
By studying the resulting simulated metabolic flux and metabolite concentration changes, it was 
demonstrated that, whilst pericentral steatosis arose because of high fat intake and the direct effects 
or IR alone, increased SREBP-1c expression seen in vivo was additionally required to fully replicate the 
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metabolic changes seen in NAFLD patients. When high fat intake, IR and increased SREBP-1c 
expression were simulated, pericentral centred triglyceride synthesis arose due to an increased 
pericentral concentrations of both substrates for triglycerides synthesis, G3P and FFAs. Disrupted 
glycogen synthesis caused a build-up of glucose intermediates including G3P. Due to the periportal 
zonation of glycogen synthase and phosphorylation, the loss of glycogenesis was most severe in 
pericentral cells. Additionally, pericentral cells undergo glucose oxidation at a slower rate, causing 
reduced clearance of excess glucose metabolism intermediates in these cells. 
Changes in FA uptake, β-oxidation and lipogenesis all contribute to an increase in pericentral FFA 
availability for triglyceride synthesis. Most additional FFAs arose from uptake. Although fatty acid 
scavenging enzymes are known to show periportal zonation, the switch from insulin stimulated active 
fatty acid uptake when simulating insulin sensitive individual with low plasma fatty acid 
concentrations (metabolically normal) to passive facilitated diffusion in an insulin resistant individual 
with a high plasma fatty acid concentration (NAFLD) partially reduced the effects of the zonated 
expression. The switch from glucose oxidation to additional fatty acid oxidation, which occurs both in 
the model and experimentally, cleared a large percentage of the additional fatty acids in periportal 
cells, which have a high oxidative capacity, but not in pericentral cells which inhabit a hypoxic 
environment. Finally, increased SREBP-1c expression caused increased lipogenesis which occurs 
predominantly in pericentral cells due to the pericentral zonation of lipogenesis enzymes. 
These changes in metabolic rates in the model will allow targeted future in vivo validation, reducing 
the number of experimentally challenging measurements in individual regions of the sinusoid required 
to understand zonated damage in NAFLD. As discussed in chapter 3, experimental validation of these 
simulated data could be performed through the addition of radiolabelled substrates to measure the 
rates of conversion within individual regions of the sinusoid or through assessing the change in overall 
metabolism after ablation of particular cell types [518]. 
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6.3 Predicting Inter-Individual Susceptibility to Steatosis 
The third objective was to assess the hepatic metabolic variations which had the largest effects on 
susceptibility to developing steatosis and on the pattern of steatosis development. Experimentally, 
this would require comparison of enzyme activity and distribution with liver fat content and 
distribution for many different enzymes involved in various processes for a large number of 
individuals, whilst accounting for potential confounding factors. In the model, by simulating small 
variations in the rate constants of each process in the model, we can establish the effects of realistic 
variations in activity on metabolism. 
Two methods of analysis were used. Firstly, sensitivity analysis was used to assess the impact of 
altering the rate and zonation constants for each process in isolation. Secondly, patients with rate 
constants randomly generated within realistic bounds were simulated to investigate the effects of 
variations in each rate constant within the context of overall inter-individual variability. 
In both data sets, the hepatic lipid content was most sensitive to inter-individual variations in the 
capacity for FFA oxidation, either through differences in the overall capacity oxidation of acetyl-CoA 
or through differences in the FFA oxidation to glucose oxidation ratio. Due to the increasing prevalence 
of NAFLD and the related conditions, research improving our ability predict an individual’s risk of 
developing the disease at an early stage is vital. As discussed in chapter 3, some evidence exists in the 
literature to support the prediction that mitochondrial capacity is an important determinant of liver 
fat in vivo. The predominant location of steatosis across the sinusoid, meanwhile, was most sensitive 
to changes in the zonation of proteins mediating FFA uptake or VLDL synthesis and release in the 
model, although it also showed moderate sensitivity to the zonation of enzymes mediating FA 
oxidation. This simulated data will allow for targeted future experimental validation, in which a smaller 
number of measurements would be required by focussing on the processes predicted to be most 
important. 
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6.4 ACC Inhibition as a Potential Drug Target and Future Work 
The final objectives of the project were to use the model to assess the impact of targeting various 
hepatic processes on lipid content and energy metabolism across the sinusoid before, where possible, 
validating these predictions in a cell culture model. Simulations were run for steatosis arising from 
high fat intake alone, developing IR in addition to high fat intake and severe IR in addition to increased 
SREBP-1c expression to assess the impact of potential drug targets across a range of patients. 
Experimental validation was performed in HepG2 cells, ensuring to consider their cancer cell 
background when interpreting results.  
The model simulations suggest that stimulation in β-oxidation in combination with inhibition of 
lipogenesis provides an effective method of clearing steatosis without causing disruptions to energy 
metabolism. In the model, hepatic steatosis was reduced, hepatic FFA concentrations (which, along 
with closely related DAGs and ceramides, are particularly potent in promoting oxidative stress and IR 
[8, 146, 247, 248]) were reduced and ATP concentrations were increased. Furthermore, the cells 
become less reliant on overactive oxidative phosphorylation. Numerous zone-specific effects were 
noted when simulating various treatments highlighting the importance of studying the sinusoid, rather 
than treating the liver as a homogenous mass of cells. 
The effects of inhibition of lipogenesis in combination with stimulation of β-oxidation were validated 
in HepG2 cells experimentally by inhibiting ACC1 and ACC2 using TOFA. A cell culture system does not 
allow validation of predicted zone specific effects, which is left for future rodent experiments. 
However, HepG2 metabolism most closely resemble that of pericentral hepatocytes, in which most 
adverse effects were centred. When treated with TOFA, both steatosis and FFA-induced cell death 
were reduced consistent with the model simulations. Mitochondrial function was improved by the 
treatment as evidenced by restoration of ETC enzyme activity. Oxidative stress, indirectly measured 
by both the medium oxidation-reduction potential and a TBARS assay for lipid peroxidation, was 
reduced. An increase in medium (corresponding to plasma) glucose concentration was measured, 
232 
 
consistent with the model simulations for the treatment in insulin resistant individuals. However, if 
insulin signalling were sufficiently restored in in vivo hepatocytes which, unlike HepG2 cells, are 
capable of glycogenesis, increased glycogen concentrations would be expected rather than 
hyperglycaemia. 
Future work should further validate these results in an in vivo model. Firstly, an appropriate in vivo 
model (e.g. rodent) which develops steatosis and the resulting IR, mitochondrial stress and fibrosis 
across the sinusoid in a reasonable time frame should be identified and characterised. This should 
then be used to study the effects of either genetically or pharmacologically inhibiting ACC when 
considering all sets of hepatocytes across the sinusoid. It is vital to account for differences between 
rapidly developing NAFLD in a rodent model and the development of the disease over decades in 
humans when interpreting results from these in vivo experiments.  
There is additionally scope for expanding the model in future work to increase its scope. At present, 
the model has been shown to provide realistic predictions for the effects of suppressing or stimulating 
overall hepatic processes across the sinusoid without considering the drug used to achieve this effect. 
Whilst this is an important step in attempting to predict drug behaviour, a more detailed model may 
further aid drug development. Firstly, by including each individual enzyme within the pathways 
currently represented by the overall processes, the model may be able to highlight the most pertinent 
individual enzymes to target. The model could also be expanded to include the action, metabolism 
and degradation of drugs known to target each enzyme to provide predictions for optimal dosing. 
Furthermore, the representation outside of metabolism could be expanded to investigate the effects 
of targeting processes outside of liver and to further study the interactions between targeting of 
hepatic processes and peripheral organs.  
The model could be additionally expanded to include the pathways leading to oxidative stress as a 
result of increased FFA concentrations and β-oxidation. At present increased FFA concentrations, 
increased β-oxidation and reduced ATP concentrations are used as markers to predict oxidative stress. 
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Including the subsequent pathways would further elucidate the mechanisms leading to oxidative 
stress and improve comparison between simulated and experimentally measured data. Furthermore, 
there is evidence that different fatty acids are more or less potent in causing oxidative stress than 
others and some of the major genetic variations known to be associated with susceptibility to NAFLD 
such as PNPLA3 are thought to affect the fatty acid profile within cells [194]. Therefore, the model 
could be expanded to allow prediction of the concentrations of individual FAs and triglycerides within 
the cells. The limiting factor within this would be the availability of data for the various enzyme kinetics 
when using each fatty acid as a substrate and for any possible interactions between the different fatty 
acids with the enzymes along with a vast increase in the number of fitted parameters. However, as 
the system becomes better characterised experimentally, the expansion of the model to include the 
individual FAs would allow for prediction of the heterogeneous effects resulting from fats of different 
chain lengths and saturations.  
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S1 Supplementary Material 1: Comparisons of Model Simulations 
with Experimental Data 
In the following sections, data produced by the model are compared with several sources of 
experimental data. This validation focusses on model predictions for hepatic and plasma 
concentrations and hepatic metabolic rates when simulating metabolically normal and insulin 
resistant individuals. Additional comparison the simulated data with experimental data related to the 
development of NAFLD is performed in chapter 3 when establishing a representation of the disease in 
the model. 
In section S1.1, the model simulations are compared with experimental data for metabolically normal 
individuals. Firstly, the average concentrations of the various hepatic molecules over a moderate 
dietary intake cycle are compared with experimental data from a range of sources (section S1.1.1). 
Next, the change in hepatic glycogen concentration, along with plasma glucose and FFA 
concentrations after a mixed meal is compared with data published by Taylor et al. [428] (section 
S1.1.2). In section S1.1.3, the rate at which various metabolic processes occur under conditions leading 
to hepatic glucose production and to hepatic glucose clearance are compared with experimental data 
from Ainscow and Brand [444], Edgerton et al. [443] and Mandarino et al. [431]. In section S1.1.4, the 
effects of a daily intake/use cycle on plasma concentrations of glucose, lactate, FFAs, triglycerides and 
insulin are compared with experimental data from Daly et al. In section S1.1.5, the heterogeneity in 
the rates of various processes across the sinusoid in the model are compared with experimental data 
from a range of sources. Very little data regarding the concentrations of molecules in different regions 
of the sinusoid have been published. Instead the variation in rates of different glucose and lipid 
metabolism processes are compared with experimental data.  
In section S1.2, the effects of IR on plasma variables are validated against experimental data from a 
range of sources. Firstly, the average concentrations of various plasma molecules are compared with 
experimental data for insulin resistant and metabolically normal individuals (section S1.2.1). Secondly, 
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the changes in glucose and lactate concentrations after intake of a glucose load in insulin resistant and 
metabolically normal individuals are compared with experimental data (section S1.2.2). The relative 
contributions of various sources of fatty acids to hepatic steatosis are compared with experimental 
data for NAFLD patients in section S1.2.3. 
Finally, in section S1.3, the simulated post-prandial changes in the relative rates of glucose oxidation 
and β-oxidation are compared with experimental data from Daly et al. [452] and Seal et al. [453] when 
simulating metabolically normal and insulin resistant individuals. 
S1.1 Validation of Liver Metabolism in Healthy Patients 
S1.1.1 Concentrations of intermediates and of the energy molecule 
In table S1.1, the average concentrations of the various hepatic metabolism intermediates and the 
mono-, di-, and tri-phosphate molecules (when simulating the 4-hour moderate intake cycle 
discussed in section 2.2.4.2) are compared with experimentally measured values. It is important 
that, when simulating normal physiological conditions, the simulated concentrations remain in a 
realistic range. The values are the average over the 4-hour cycle. For hepatic molecules, the average 
concentration across the hepatic compartments is shown. For plasma molecules, the concentration 
in the body compartment is shown.  
The simulated average values for hepatic glucose and triglycerides along with glucose metabolism 
intermediates G6P, G3P and acetyl-CoA are within the experimentally measured ranges. Similarly, the 
simulated average concentrations for inorganic phosphate, ATP, ADP, AMP, GTP and GDP are all within 
the experimentally measured confidence intervals. This shows that, when an input approximating a 
daily meal cycle is provided, the model gives realistic values for the average values of key 
intermediates of glucose and lipid metabolism in hepatocytes, along with the adenosine and guanine 
phosphate molecules. 
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Table S1.1: The concentration of various hepatic metabolism intermediates and of the mono-, di-, 
and tri-phosphate molecules included in the model when simulating a mixed meal. 
Protein Average Value (Low-high over intake cycle) 
– Model (mM) 
Average Value (Confidence Interval)  
– Experimental (mM) 
Inorganic 
Phosphate 
3.96 (3.871-4.011) 4.07 (3.55-4.07)  [429] 
ATP 2.82 (2.64-2.96) 2.78 (2.71-2.85)  [429] 
ADP 0.832 (0.765-0.926) 0.885 (0.794-0.976)  [486] 
AMP 0.269 (0.223-0.337) 0.237 (0.200-0.272)  [429] 
UTP 0.324 (0.205-0.365) 0.285 (.255-.315)  [486] 
UDP 0.069 (0.031-0.188) 0.108 (0.096-0.120)  [486] 
GTP 0.274 (0.271-0.275) 0.277 (0.266-0.288)  [486] 
GDP 0.101 (.100-.104) 0.098  (0.091-0.105)  [427, 486] 
Hepatic Glucose 8.24 (7.28-10.0) 9.86-10.20 [426, 427],[616] 
G6P 0.085 (0.031-0.126) 0.071 ± 0.004mM – starved rats, 
0.133 ± 0.010mM – well fed rats [429] 
GADP 0.236 (0.195-0.312) 0.2-1.0  [426] 
Acetyl-CoA 0.046 (0.035-0.058) 0.039  [426] 
Glycogen ~200mM of glucose 
(0 – 500mM of glucose depending on 
previous feeding conditions) 
Since glycogen is used for glucose storage, 
the liver glycogen concentration is 
strongly dependent on previous feeding 
conditions. See section S1.1.2 for 
comparison with Taylor et al. [428]. 
Hepatic 
Triglyceride 
Average: 38.1mM (37.6-38.4mM) 
  2.31% (2.28-2.33%) 
Periportal: 33.6mM (33.1-34.0mM) 
 2.05% (2.01-2.07%) 
Pericentral: 45.5mM (45.0-45.7mM) 
 2.75% (2.72-2.76%) 
Model values are slightly lower than the 
average but within the 90th percentile of 
liver triglyceride concentrations measured 
in the population by Szczepaniak et al. 
consistent with simulating a healthy diet 
[211]. The change across the sinusoid is 
consistent with the values of 
59.2±5.8nmol/mg of protein and 
65.7±4.0nmol/mg in isolated periportal 
and pericentral cells respectively 
measured by Guzman et al. [487]. 
 
Average values when simulating a moderate intake diet of 70% carbohydrate: 30% FFA, averaged over 
each 4-hour input cycle.  
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Only the simulated UTP and UDP concentrations are outside of the experimentally measured 
confidence intervals. The simulated average UTP concentration is 13% higher (+39µM) than the 
value measured experimentally, whilst the UDP concentration is 39µM lower, suggesting that the 
activity of NDKU in converting UDP to UTP is overestimated in the model. Therefore, a potential 
solution to return these concentrations to the experimentally measured range would be to reduce 
the rate constant for NDKU in the model. However, due to the strong dependence of the UTP 
concentration on feeding state in the model, if the rate constant for NDKU is reduced by more 
than around 20% from its value in the model, the simulated UTP concentration in periportal cells 
falls to near zero during periods of high glycogenesis. This disrupts the storage of glucose as 
glycogen in these cells after feeding. On the other hand, since the Michaelis-Menten constant for 
UTP in glycogen synthase is low (48µM) relative to the average UTP concentration (285µM 
experimental/324µM simulated), the small increase in simulated average UTP concentration has 
little effect on overall metabolism. It is possible that NDK shows zonated expression in vivo with 
higher activity in the periportal zone to match the increased glycogenesis in this region of the 
sinusoid.  
The relative concentrations of hepatic molecules are also consistent with concentrations 
measured in other experimental studies Faupel et al. [430] and Saggerson et al. [467]. However, 
since the Faupel et al. data was normalised against DNA weight rather than total protein or cell 
volume and the Saggerson et al. data was measured in adipose tissue, absolute comparison was 
not possible in either case and these relative comparisons are not presented. 
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S1.1.2 Glycogen Synthesis after a mixed meal 
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Figure S1.1: Comparison of simulated and experimental data for glycogen synthesis after a mixed 
meal. (a) The glucose and FFA input used to represent the mixed meal and the simulated 
concentrations of (b) glucose, (c) FFA and (d) glycogen concentrations after input of a mixed meal in 
which 62% of the energy comes from carbohydrate and 38% from lipid compared with experimental 
data from Taylor et al. [428]. Experimental data approximated from the graphs provided using Image J 
to determine the position of each point relative to the x and y axes. The error bars on the experimental 
data are the SD based on the SEM provided. 
In addition to providing realistic values for average concentrations, the model outputs must also 
match experimental data for the change in plasma and hepatic concentrations under conditions of 
known intake. The liver is the major tissue responsible for the storage of glucose as glycogen. 
Therefore, the model must give reasonable values for the change in glycogen storage, along with 
plasma glucose and FFA concentrations under conditions in which known quantities of glucose and fat 
are consumed. The simulated data were compared with experimental data published by Taylor et al. 
[428] for glucose, FFA and glycogen concentrations after intake of a mixed meal in which 62% of the 
energy comes from carbohydrate and 38% from lipid (neglecting the protein content of the meal 
provided experimentally) [428] (figure S1.1). Since the exact rates at which glucose and FFAs enter the 
blood stream are unknown, as an approximation, inputs with an initial spike followed by a slow linear 
decrease were used (figure S1.1a). 
The average differences between the simulated and measured glucose and FFA curves over the first 5 
hours (excluding t=0) are 0.3 standard deviations (420µM) and 0.51 standard deviations (34µM) 
respectively. After 6 hours, the simulated glucose concentration falls to a slightly lower baseline value 
than the experimental data, whilst the simulated increase in FFA concentration is delayed relative to 
the experimental data. However, in both cases the simulated data remain within one standard 
deviation of the experimental data, and the shape of the simulated curves remains consistent with 
the experimental data.  
The simulated average glycogen concentration is on average less than 0.1 standard deviations from 
the experimentally measured mean concentrations for the first 6 hours after the mixed meal. This 
shows that the model is able to accurately represent the storage of glucose as glycogen after intake 
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of a mixed meal. After 6 hours, the fall in glycogen concentration was larger in the experimental data 
than in the simulated data, but the difference between the two curves remains well within one 
standard deviation. Over a period of longer than 6 hours, numerous factors may explain the more 
rapid fall in the experimental curve compared with the simulated data. For example, the model does 
not account for any variation in the activity of the patient and energy is consumed at a roughly 
constant rate (dependent on plasma concentrations of hormones, FFA and glucose). 
The simulated compartment 1 (proximal periportal) and compartment 8 (distal pericentral) 
concentrations are also plotted to show the difference in glycogen storage across the sinusoid. Both 
in vivo [45] and in the simulated data, a higher rate of glycogen synthesis is seen in periportal cells 
post-prandially. 
S1.1.3 Metabolic Rates 
The data in the previous sections provide validation of the simulated concentrations of molecules in 
hepatocytes. However, the model must also produce realistic data for the rates of various processes 
occurring within hepatocytes. In the following sections, the relative rates of various hepatic processes 
are compared with experimental data during glycogen breakdown and glycogen synthesis. Further 
validation of the rates of oxidation in both insulin resistant and metabolically normal individuals is 
provided in section S1.3. 
S1.1.3.1 During glycogen breakdown 
The simulated rates of various metabolic processes were next compared with experimental data 
presented by Ainscow and Brand under conditions of hepatic glucose production [444]. Rather than 
simulating Glucose and FFA inputs as in the previous sections, to allow comparison with the 
experimental data, the plasma fatty acid, glucose, lactate, glycerol, insulin and glucagon 
concentrations were set to fixed values of 0.4mM, 5mM, 0.45mM, 0.04mM, 0pM and 31.5pM in the 
simulations. Rates were taken after 2000s, once they had reached equilibrium.  
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Table S1.2: Simulated Hepatic metabolic rates compared with experimental data under conditions of 
glycogen breakdown. 
Process Simulated % of Glycogen 
Breakdown (mM/s) 
Experimental % of Glycogen 
Breakdown (nmol.mg-1.min-1) 
[444] 
Glycogen Breakdown 100% (5.63 [Glucose]) 100% (8.67 [Glucose]) 
Glucose Production 54.7% (3.08 [Glucose]) 54.4% (4.72 [Glucose]) 
Glycolysis 45.3% (2.55 [Glucose]) 45.7% (3.96 [Glucose]) 
Lactate Release 31.3% (1.76 [Glucose]*) 35.6% (3.09 [Glucose]*) 
Pyruvate Oxidation 24.3% (1.37 [Glucose]*) ~20.1% (8.72 [Ox]) 
Lipogenesis 3.3% (0.19 [Glucose]*) ~0 
Mitochondrial Oxidation 115 [ATP] 18.01 [ATP] 
ATP Consumption 199 [ATP] 31.63 [ATP] 
Simulated hepatic metabolic rates compared with experimental data from Ainscow and Brand under 
conditions of glycogen breakdown [444]. To simulate conditions of constant glycogen breakdown, the 
plasma fatty acid, glucose, lactate, insulin and glucagon concentrations were set to fixed values of 
0.4mM, 5mM, 0.45mM, 0mM and 31.5pM. Rates were taken after 2000s, once they had reached 
equilibrium. * equivalents of glucose. 
Although comparison of the absolute values is not possible due to the different units in the two data 
sets, the relative rates of all of the processes provide a reasonable approximation to the experimental 
data (table S1.2). In both the simulated and experimental data, approximately 55% of G6P derived 
from glycogen breakdown was converted to glucose, whilst 45% underwent glycolysis. 31.3% of the 
G6P was released as lactate in the model compared with 35.6% experimentally. 24.3% underwent 
oxidation to acetyl-CoA compared with 20.1% experimentally. Therefore, a slightly higher relative rate 
of pyruvate oxidation occurred in the model than is seen experimentally, but the values remain well 
within a range which could be accounted for by small differences in plasma and hepatic metabolite 
concentrations. Only a very low rate of lipogenesis occurred when simulating the presence of glucagon 
but not insulin, consistent with the experimental study. The ratio of ATP consumption to mitochondrial 
oxidation (1.73:1) is within 2% of the experimentally measured ratio (1.75:1). However absolute 
comparison is not possible since the experimental data is provided in units of moles per milligram of 
tissue rather than moles per litre. These results demonstrate that the model provides realistic relative 
metabolic rates under conditions of glycogen breakdown. 
242 
 
S1.1.3.2 During glycogen synthesis. 
A similar study under conditions of glycogen synthesis was not available. However, the relative effects 
of basal and high insulin concentrations on glucose removal and gluconeogenesis are consistent with 
experimentally measured values for canine livers from Edgerton et al. [443]. For comparison, 
simulations were run using 3 fixed plasma insulin concentrations, a fixed plasma glucagon 
concentrations of 93.75pM and fixed plasma glucose, lactate and FFA concentrations at the values 
measured experimentally. Absolute comparison was not possible since the experimental data were 
measured in mg/kg/min. However, the relative rates after addition of insulin (leading to a plasma 
concentration of 700pM and 173pM) in comparison with no addition (basal) were compared between 
the data sets (tables S1.3 and S1.4). 700pM insulin caused the simulated rate of glucose storage as 
glycogen to fall to -1.01 times the rate of clearance at basal insulin, showing a switch from glucose 
clearance to production (table S1.3). The experimental data is presented for the rate of glucose uptake 
and the rate of glycogenesis separately. In this case, 700pM caused the experimentally measured rates 
of glucose uptake and for glycogen synthesis to fall to -0.69 and -1.67 of the basal rates, consistent 
with the simulated data. In both cases gluconeogenesis was heavily stimulated by 700pM insulin (table 
S1.4). 
The relative effects of moderate to high insulin perfusion on the system are similar in the simulated 
and experimental data. The change in rate due to 173pM insulin was roughly 80% of that due to 
700pM Insulin in both the simulated data and the experimental data sets for both glucose removal 
and glycogen synthesis. At the moderate insulin concentration, the suppression of gluconeogenesis 
was approximately 20% of the change for the high insulin concentration in both the simulated and 
experimental data. 
Additional validation of the model simulations for the rates of glucose and fatty acid oxidation under 
conditions of glucose storage is presented in section S1.3. 
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Tables S1.3: Comparison of the simulated effects of insulin stimulation on hepatic glucose clearance 
with experimentally measured values. 
Hepatic Glucose Clearance Basal Moderate Insulin 
(173pM) 
High Insulin 
(700pM) 
Simulated Glucose Storage as 
Glycogen:  
μmol/L/s  
(fold change from basal) 
11.3  
(1.00 basal) 
-7.1  
(-0.62 basal) 
-11.4  
(-1.01 basal) 
Experimental Glucose Uptake:  
mg/kg/min  
(fold change from basal) 
1.3±0.4  
(1.00 basal) 
-0.2±0.2  
(-0.15 basal) 
-0.9±.7  
(-0.69 basal) 
Experimental Glycogen Synthesis: 
mg/kg/min  
(fold change from basal) 
0.9±0.4  
(1.00 basal) 
-1±0.4  
(-1.11 basal) 
-1.5±0.5  
(-1.67 basal) 
Table S1.4: Comparison of the simulated effects of insulin stimulation on gluconeogenesis with 
experimentally measured values. 
Gluconeogenesis Basal Insulin Moderate Insulin 
(173pM) 
High Insulin 
(700pM) 
Simulated: Change in 
Gluconeogenesis 0 μmol/L/s -1.2 μmol/L/s -4.7 μmol/L/s 
Simulated: Change in 
Net Gluconeogenesis 0 μmol/L/s -0.56 μmol/L/s -3.4 μmol/L/s 
Experimental: Change in 
Flux to G6P 
 
0±0.4 mg/kg/min -0.1±0.7 mg/kg/min -0.5±0.7 mg/kg/min 
Tables S1.3 and S1.4: Comparison of the simulated effects of insulin stimulation on hepatic glucose 
production and storage with experimentally measured values for canine livers [443]. Simulated using 
a fixed plasma glucagon concentrations of 93.75pM and fixed plasma glucose, lactate, insulin and FFA 
concentrations at the values measured experimentally. 
S1.1.4 Plasma Concentrations throughout the day 
The data in the previous sections focussed on hepatic concentrations and rates. However, the model 
additionally aims to produce realistic data for plasma concentrations under conditions of known 
dietary intake. Figure S1.2 compares the simulated plasma glucose, FFA, insulin and triglyceride 
concentrations (red) plotted with experimental data measured by Daly et al. (blue) throughout a daily 
meal cycle [17]. The model was provided with an equal spiked input every four hours and twenty 
minutes roughly corresponding to the food intake provided experimentally (as discussed in section 
2.2.4.2). The glucose and FFA inputs were matched to the average values provided per meal 
experimentally. However, in the experimental study, the meals were not equally spaced and differed 
in size through the day.  
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Since the spiked periodic input provided is only a crude approximation to the rate of intake of glucose 
and fatty acids, it was considered inappropriate to base the comparison of the simulated and 
experimental curves on a simple calculation of the squared difference between the curves. When this 
analysis was performed, the differences in food intake times meant that, whilst the differences 
between the simulated (χ) and experimental (𝑥) curves remained low for most time points, high errors 
were seen around meal times (e.g. 13:00-14:00). This was particularly true for glucose and lactate, for 
which the summed error (difference from experimental data) over variance (in the experimental data) 
for glucose and lactate were 1.30 and 1.08 respectively (calculated as 
∑
|𝑥(𝑖)−χ(i)|
𝜎(𝑖)
𝑖=𝑛
𝑖=1
𝑛
, where 𝑖 = 1: 𝑛 are 
times at which experimental data points were available). The summed error over variance for 
triglyceride was also large at 1.59. 
Instead, to give a more representative quantitative comparison of simulated and experimental data, 
table S1.5 compares the peak, trough and average concentrations for each variable along with the 
offset in the peak time from the glucose peak. Values for lactate and glycerol are additionally included 
in this table. These measures are less dependent on the differences in meal time and size between 
the two data sets. Since data points were taken at 30 minute intervals in the data, there is a 30-minute 
uncertainty in the time at which peaks occurred in the experimental study. 
The simulated glucose, insulin and FFAs concentrations replicate the key features of experimental 
data. In both the simulated and experimentally measured data, the glucose and insulin concentrations 
show sharp post-prandial peaks followed by broad troughs between meals. The FFA concentration 
gradually rises between meals before falling rapidly postprandially in both data sets.  
The simulated peak concentrations are equal in magnitude because equal meal sizes were simulated, 
whilst the experimental peaks increase throughout the day due to increases in the size of the meal. 
As a result, the final peak matched the experimental data well, but the simulated first and second 
post-prandial glucose peaks were 1.09 and 0.74 standard deviations higher than measured 
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respectively. The simulated peak concentrations were 0.79 standard deviations higher than the 
average peak in the experimental data. However, since readings were taken at 30 minute intervals in 
the experimental study, and the peaks in glucose concentration are very sharp, the true peak 
concentration is likely to be higher than the experimentally measured peak. 
The simulated average peak insulin concentration closely matches the experimentally measured value 
(0.27 standard deviations). However, the simulated plasma concentration falls to effectively zero 
between meals whilst the experimentally measured value only falls to at 29±24pM. This is because no 
insulin release occurs between meals in the model, where some release would be expected in vivo. A 
concentration this small is unlikely to have a large effect on metabolism and will be dwarfed by the 
effects of the raised glucagon concentration. 
The simulated FFA concentration curve matches the experimental data well. Sharp pre-prandial peaks 
in concentration occurred in the simulated data. This would not be seen experimentally because the 
experimental data provides an average over several patients with readings taken at half hour intervals. 
Therefore, comparison of this aspect of the simulated data with the experimental data is not possible.  
In both the simulated and experimental data, the lactate concentration follows a similar pattern to 
the glucose concentration but with a slightly delayed peak. The simulated peak concentrations match 
the experimental data well in both magnitude and time relative to the peak in glucose concentration. 
However, the simulated concentration only fell to 0.82mM between meals in the model, compared 
with 0.52±0.15mM experimentally. 
The triglyceride and glycerol concentrations show stronger periodic behaviour in the model 
simulations than in the experimental data. This difference occurs because adipose tissue storage of 
triglycerides is not included in the model. Since the focus of the study is on hepatic metabolism a 
separate adipose compartment allowing adipose triglyceride storage was not included. However, 
hepatic uptake of triglycerides from plasma is slow, such that the hepatic triglyceride concentration is 
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more strongly dependent on the longer-term average plasma concentration than on short-term 
fluctuations. Once equilibrium is reached, less than a 5% variation is seen in hepatic triglyceride 
concentration throughout a meal cycle, and most of this results from variation in hepatic synthesis. 
Additionally, very little lipolysis occurs in hepatocytes such that variations in hepatic triglyceride 
concentration only very weakly feed back into the rest of hepatic metabolism. Therefore, in 
developing a model to study hepatic metabolism, it is more important that the longer-term average 
triglyceride concentration remains in the experimentally measured range. From figure S1.2 and table 
S1.5, it can be seen that the simulated triglyceride concentration remains in the same range as the 
experimental data. It is also important that the experimentally measured changes in average 
triglyceride concentration under conditions of insulin resistance are reproduced in the simulated data 
as discussed in section S1.1.5.3.  
  
Figure S1.2: Comparison of the model predictions for plasma concentrations over a daily meal cycle 
with experimental data. Comparison of the model simulations (red) for plasma glucose, FFA, lactate, 
insulin, triglycerides and glycerol throughout a daily feeding cycle with experimental data from Daly et 
al. [17] (blue). Experimental data approximated from the graphs provided using Image J. 
a) b) 
d) c) 
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Table S1.5: Comparison of the simulated peak, trough and average concentrations and peak times 
with experimental data for plasma concentrations throughout a daily feeding cycle. 
 Peak Concentrations Trough 
Concentrations 
Average 
Concentration 
Difference in 
peak time from 
peak glucose 
Glucose 
Simulated 7.43mM 4.08mM 4.92mM - 
Experimental Av.) 6.81±0.78mM 
(Δ = 0.79 σ) 
1) 7.27±0.67mM  
(0.24 σ) 
2) 6.86±0.77mM 
(0.74 σ) 
3) 6.29±0.90mM 
(1.09 σ) 
Av.) 3.84±0.56mM 
(Δ = 0.43 σ) 
1) 3.75±0.50mM  
(0.66 σ) 
2) 3.93±0.62mM 
(0.24 σ) 
 
4.59±0.65mM 
(Δ = 0.51 σ) 
- 
FFAs 
Simulated 557µM 100µM 229μM -45.6 mins 
Experimental Av.) 445±186µM 
(Δ = 0.60 σ) 
1) 460 ± 208 
(0.47 σ) 
2) 429 ± 161 
(.80 σ) 
Av.) 86±32µM 
(Δ =0.44 σ) 
1)104±35 
(0.11 σ) 
2) 67±29 
(1.14 σ) 
234±93μM 
(Δ =0.05 σ) 
-30 mins 
(-60<t<0 mins) 
 
Triglycerides 
Simulated 1.79mM 0.56mM 1.19mM 47.64 Minutes 
Experimental -No peaks or troughs following intake, 
but an increase from 0.77mM increase to 
1.66mM throughout the day. 
1.08±0.30mM 
(Δ =0.37 σ) 
- 
Lactate 
Simulated 2.70 mM 0.82 mM 1.23mM 19.7minutes 
Experimental Av.) 2.29 ± 0.92 mM 
(Δ =0.45σ) 
2.11 ± 0.63mM  
2.39 ± 1.20mM  
2.38 ± 0.93mM  
Av.) 0.52 ± 0.15mM 
(Δ =2σ) 
0.52±0.17 mM 
0.52±0.13 mM 
1.21 ± 0.55mM 
(Δ =0.04 σ) 
30 mins 
(0<t<60 mins) 
Insulin 
Simulated 391pM 1pM 89pM 2.3 mins 
Experimental Av.) 363 ± 123 pM 
(Δ =0.23σ) 
366 ± 146 pM 
315 ± 91 pM 
409 ± 133 pM 
Av.) 29±24pM 
(Δ =1.17σ) 
19±24pM 
38±24pM 
118 ± 90pM 
(Δ = 0.32 σ) 
0 mins 
(-30<t<30 mins) 
Glycerol 
Simulated 39µM 21µM 30 μM 2.0 hours 
Experimental 39±19µM **Not 
periodic with meal 
cycle 
22±10µM ** Not 
periodic with 
meal cycle 
32±15 μM 
(Δ =.13 σ) 
3.5±0.5, 4.5±0.5 
hours  
Comparison of the simulated peak, trough and average concentrations and peak times relative to the 
glucose peak for plasma glucose, FFA, lactate, insulin, triglycerides and glycerol throughout a daily 
feeding cycle with experimental data from Daly et al. [17]. Experimental data approximated from the 
graphs provided using Image J. 
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S1.1.5 Validation of Zonation 
A major aim of this study was to develop a model which is able to represent the zonation of processes 
across the sinusoid. To achieve this, the zonation in the rate constants of processes across the sinusoid 
was based on experimental data for differences in the activities of key enzymes (section 2.2.6). In the 
following section, simulated data within different zones of the sinusoid are compared with 
experimental data. 
S1.1.5.1 ATP across sinusoid 
Data measuring the concentrations of molecules in specific regions of the sinusoid are relatively few. 
As a result, hepatic heterogeneity in the model was largely validated against measurements of the 
relative rates of various processes occurring in different regions of the sinusoid. However, Nauck et 
al. approximated the change in ATP concentration across the sinusoid in an in vitro experiment by 
comparing cells grown in culture conditions similar those seen by periportal and pericentral cells in 
vivo [69]. Cells cultured in periportal oxygen and hormone concentrations had an ATP concentration 
of 2.9±0.2mM whilst those grown in pericentral conditions had a concentration of 2.5±0.2mM [69]. 
When simulating a moderate diet in a metabolically normal individual (section 2.2.4.2), the ATP 
concentration falls from 3.0mM in the periportal half of the sinusoid to 2.6mM in the pericentral side. 
Therefore, as well as the average values matching those measured in vivo [429], the change in ATP 
concentration across the sinusoid matches that measured between isolated periportal and pericentral 
cells [69]. It is important that the energetics are represented properly since the inability of pericentral 
cells to produce sufficient ATP through oxidative phosphorylation is the primary motivation for 
zonation. Unfortunately, data was not available for the relative contribution of oxidative 
phosphorylation and glycolysis across the sinusoid. However the relative rates of gluconeogenesis and 
glycolysis across the sinusoid are compared with experimental data in section S1.1.5.2, whilst the 
energetic benefit resulting from zonated enzyme expression is demonstrated in section S1.1.5.3. 
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S1.1.5.2 Processes  
Although the zonation of enzymes in the model was based upon experimental data, the relative rates 
of processes across the sinusoid are also determined by other factors such as substrate concentrations 
and allosteric regulation. In this section, the relative rates of some of the key processes in the model 
are compared with experimental data to validate the representation of zonation in the model. In each 
case, model values are the average when the model was provided with an input cycle representing a 
moderate diet as discussed in section 2.2.4.2. 
S1.1.5.2.1 β-oxidation 
In two studies, Guzman et al. measured the rate of β-oxidation to be 1.2±0.3, and 1.4±0.3 times higher 
in periportal than in pericentral cells in fed animals [83, 86, 87]. Consistent with these studies, the 
simulated rate of β-oxidation is 1.25 times higher in the periportal half of the sinusoid than the 
periportal half. The simulated rate is 1.47 times higher in the proximal periportal compartment 
(compartment 1) compared to the distal pericentral compartment (compartment 8). 
S1.1.5.2.2 Triglyceride synthesis, storage and release as very low density lipoproteins (VLDL) 
In two different in vivo studies by Guzman et al., pericentral cells were measured to synthesize 
triglycerides at 1.6±0.4 and 1.3±0.3 times the rate of periportal cells, and release triglycerides as VLDL 
at 1.5±0.5 and 1.3±0.3 times the periportal rate [83] [86]. In the model, triglycerides are synthesized 
in pericentral cells at 1.64 times the rate in periportal cells.  
Guzman et al. also measured an 11% increase in triglyceride concentration between periportal and 
pericentral hepatocytes, although this was not statistically significant [86]. In the model, the average 
triglyceride concentration in the pericentral half of the sinusoid is 22% larger than in the periportal 
half, slightly overestimating this difference. However, this is strongly dependent on the glucose and 
FFA inputs. A higher glucose to FFA ratio gives more evenly distributed triglyceride levels. 
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S1.1.5.2.3 Fatty acid uptake 
Using fluorescently tagged fatty acids, Fitz et al. measured higher fatty acid uptake in periportal cells 
[92]. However, no quantitative comparison was made. In the model, the rate of fatty acid uptake in 
the periportal half of the sinusoid was 1.21 times higher than in pericentral cells. 
S1.1.5.2.4 Lipogenesis 
When measured in vivo by Guzman et al. in two studies, the pericentral rate of lipogenesis was 
measured to be 1.6±0.4 and 1.7±0.5 times that in periportal cells [83, 86]. When simulated in the 
model, the pericentral rate of lipogenesis was 1.9 times higher than the periportal rate. This is within 
one standard deviation of the experimental data but slightly higher than the average. However, the 
relative rates of lipogenesis across the sinusoid are dependent on the ratio of glucose to FFA input. 
S1.1.5.2.5 Gluconeogenesis and glycolysis 
Wolfe et al. performed an in vitro study in which they measured the relative rates of gluconeogenesis 
and glycolysis in cells cultured in periportal or pericentral oxygen and hormone concentrations [77]. 
Their results show that glycolysis is 1.5-2.5 times more rapid in pericentral-like cells whilst 
gluconeogenesis is 1.5-2.5 times more rapid in periportal-like cells [77]. When simulating a moderate 
diet in the model, glycolysis occurs 1.7 times more rapidly in pericentral cells whilst gluconeogenesis 
occurs 2.3 times as quickly in periportal cells consistent with the in vitro data.  
Both the simulated data and the results of this in vitro study are consistent with the idea of glucose-
lactate cycling known to occur in vivo [50]. In glucose-lactate cycling, hypoxic pericentral cells undergo 
glycolysis to supplement ATP production from oxidative phosphorylation. This produces lactate which 
cycles around the body and is converted back to glucose by the oxygen rich periportal cells. Due to 
their higher oxygen environment, periportal hepatocytes can produce sufficient ATP through oxidative 
phosphorylation to survive and to fuel the additional gluconeogenesis, largely using fatty acids. 
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S1.1.5.3 Validating the role of zonation in hepatic energy metabolism 
The low oxygen concentration of pericentral cells is major motivation for the presence of zonation in 
energy metabolism (see chapter 1). In the absence of sufficient oxygen, pericentral cells are unable to 
produce sufficient ATP through oxidative phosphorylation and are forced to upregulate glycolysis, 
whilst suppressing ATP consumption in gluconeogenesis. To ensure that zonation in energy 
metabolism is properly represented in the model, simulations were next used run with both zonated 
enzyme expression and with homogenous enzyme expression. The simulated data in these two cases 
were compared to ensure that zonated enzyme expression leads to increased ATP concentrations 
across the sinusoid.  
In figure S1.3, the average rates of glycolysis, gluconeogenesis and average ATP concentrations when 
simulating a moderate intake diet of the form discussed in section 2.2.4.2 are compared when running 
simulations with zonated and homogenous enzyme expression.  
Removing the zonation in glucose and lipid metabolism enzymes caused severely reduced pericentral 
ATP concentrations (figure S1.3a) because of higher gluconeogenesis (figure S1.3b) and lower 
glycolysis (figure S1.3c) in these cells. The ATP concentration in the most pericentral compartment fell 
to below 1.2mM when simulating homogenous enzyme expression. ATP is required for most cellular 
processes and concentrations this low would cause loss of function or cell death. A slight increase in 
ATP concentration was seen in periportal cells when simulating homogenous enzyme expression 
relative to zonated expression due to reduced gluconeogenesis in these cells. However, zonated 
enzyme expression increased the average ATP concentration across the sinusoid (zonated enzyme 
expression: 2.81mM, heterogeneous enzyme expression 2.57mM) and resulted in a much more even 
distribution across the sinusoid. Therefore, a clear increase in fitness is results from zonation in the 
model.  
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Figure S1.3: The effects of simulating zonated and homogenous enzyme expression on energy 
metabolism. The effects of zonated enzyme expression on a) the ATP concentration b) the rate of 
gluconeogenesis and c) the rate of glycolysis. The average concentration is shown when simulating a 
moderate intake 70% carbohydrate 30% lipid diet with (grey) homogenous enzyme expression or (black) 
zonated enzyme expression.  
S1.2 Validation of Simulated Data for Insulin Resistant Patients 
Having shown that the model is able to produce realistic data for the average concentrations of 
hepatic molecules, for plasma concentrations of key variables during a daily feeding cycle and after a 
mixed meal, for glycogen storage after a mixed meal, for the rates of key metabolic processes during 
periods of glycogen synthesis and breakdown and for the zonation of key metabolic processes in 
metabolically normal individuals, the model outputs were next compared with experimental data 
when simulating insulin resistance. Insulin resistance is simulated in the model by multiplying the 
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detected insulin by a constant 0≤KIR<1 where KIR=0 would correspond to total insulin resistance and 
KIR=1 would correspond to normal insulin sensitivity. 
S1.2.1 Average plasma values in metabolically normal and insulin resistant individuals 
Firstly, the average plasma values of triglycerides, glucose and FFAs are compared with experimental 
data when simulating metabolically normal and insulin resistant individuals. The simulated average 
plasma concentrations are dependent on the inputs provided and on the severity of IR. To provide the 
data for table S1.6, simulations were run with the moderate diet intake cycle discussed in section 
2.2.4.2 with two severities of IR. Developing and severe IR were simulated by reducing the detected 
insulin concentration to 5% and 1.5% respectively. 
Table S1.6: The simulated and experimentally measured average triglyceride, glucose and FFA 
concentrations in metabolically normal and insulin resistant patients.   
 Simulated Experimental 
Average Triglyceride (mM) 
Metabolically Normal 1.2±0.4 0.9±0.4a 
Insulin Resistant Developing: 2.1±0.8 
Severe: 3.7±0.9 
2.6±0.5a 
Average Glucose (mM) 
Metabolically Normal 4.9±1.1 4.7±0.7a, 5.3±1.5 (4.5 - 6.8) d 
Insulin Resistant Developing: 6.3±2.4 
Severe: 8.1±3.9 
9.0±2.2a 
Low TG group (less severe): 6.3±0.5 c 
High TG group (more severe): 6.8±0.5 c 
 Mild NIDDM: 8.0±2.7 (6.7 - 10.9) d 
Severe NIDDM: 19.6±5.3 (16.9 - 23.7) d 
Average FFA (mM) 
Metabolically Normal 0.23±0.12 0.3±0.1b, 0.3±0.1 (0.16 - 0.52) d 
Insulin Resistant Developing: 0.48±0.16 
Severe: 0.84±0.70 
0.6±0.1b 
Low TG group (less severe): 0.54±0.07 c 
High TG group (more severe): 0.81±0.07 c 
Mild T2DM: 0.4±0.1  (0.19 - 0.59) d 
Severe T2DM: 0.6±0.1  (0.37 - 0.75) d 
Experimental data from: a – Sindelka et al. [141], b – Berndt et al. [435], c – Monti et al. [466], d – Reavan 
et al. [139] (a,b standard deviations calculated based on the SEM provided, d – averages, ranges and 
error bars taken from the graphs provided using Image J). Simulated data are averages ± the average 
deviation from the mean value over each feeding cycle. 
For metabolically normal individuals, the simulated data are within one standard deviation of the 
experimental data for glucose, FFAs and triglycerides further validating the ability of the model to give 
realistic data for non-insulin resistant patients (table S1.6). 
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The FFA and triglycerides concentrations measured by Sindelka et al. [141] and Berndt et al. [435] in 
insulin resistant individuals lie between the simulated values for developing IR and for severe IR (table 
S1.6). This is consistent with the experimental groups containing individuals with a range of severities 
of IR. Monti et al. measured FFA levels in T2DM individuals grouped according to their plasma 
triglyceride levels [466]. The measured concentrations in the low and high triglyceride concentration 
groups match the simulated data for developing and severe IR respectively. Reavan et al. meanwhile 
measured slightly lower average FFA concentrations in mild and severe T2DM than the simulated data 
[139]. 
Large heterogeneity was seen in the experimental measurements of glucose concentrations in insulin 
resistant individuals. The mean concentration measured by Sindelka et al. in insulin resistant 
individuals is slightly higher than the simulated value when simulating severe IR (0.4 standard 
deviations) [141]. Conversely the concentrations measured in both groups by Monti et al. are several 
standard deviations lower than the simulated concentration for severe IR. Meanwhile, the glucose 
concentration measured in mild T2DM by Reavan et al. matches that when simulating severe insulin 
resistance (0.03 standard deviations), whilst the concentration measured in severe T2DM is more than 
double this [139]. 
This variation is likely to result from differences in the severity of IR within the group and differences 
in feeding. When simulating severely insulin resistant patients on a moderate diet, hyperglycaemia is 
seen post-prandially due to reduced glycogenesis. However, between meals the blood glucose 
concentration becomes hypoglycaemic because there are no glycogen stores to break down. It is 
because of this that the average glucose concentration to show only a modest increase. When 
simulating a high intake diet, sustained hyperglycaemia occurs in IR patients more consistent with the 
measurements of Reavan et al. [139]. 
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S1.2.2 Change in glucose and lactate concentrations after a glucose load 
Having shown that the model provides reasonable values for average plasma concentrations in both 
metabolically normal and insulin resistant individuals, it was next compared with data for the change 
in plasma glucose and lactate concentrations after an oral glucose load. Table S1.7 shows the 
simulated and experimental data for the change in plasma lactate and glucose concentrations after 
intake of an 100g glucose load [434]. Since the rate at which the oral glucose load glucose entered the 
blood stream in the experimental study is unknown, as an approximation a spiked input of the form 
sin6(t), starting from zero input at t=0 and reaching peak input at 30 minutes was used. However, to 
account for the possibility that the sugars may enter the blood stream more or less rapidly than this, 
two additional input functions were used of the same form and with the same total input, but with 
peak inputs at 20 minutes (rapid intake) and 45 minutes (slow intake). The simulated data in these 
two cases are shown by the upper and lower error bars respectively. In all three cases, the total 
glucose input was equal to that in the experimental study (assuming 5L of blood in the body). Severe 
IR was simulated using an IR constant, KIR, of 0.015. 
For both metabolically normal and insulin resistant individuals, the experimentally measured and 
simulated changes in glucose and lactate concentrations are well within one standard deviation of the 
experimental data. This shows that the model can accurately represent the changes in hepatic 
glycogenesis and glycolysis resulting from IR after a glucose load. 
Table S1.7: The simulated change in glucose and lactate concentrations after a 100g glucose load in 
metabolically normal and insulin resistant individuals compared with experimental data. 
Change in Glucose Metabolically Normal Insulin Resistant 
Simulated 2.1−1.0
+1.0 8.5−3.6
+2.1 
Experimental 2.8 ± 2.0 9.7 ± 4.6 
Change in Lactate Metabolically Normal Insulin Resistant 
Simulated 0.46−0.29
+1.50 0.40−0.12
+0.09  
Experimental 0.46 ± 0.12 0.31 ± 0.13 
The simulated change in glucose and lactate concentrations after a 100g glucose load in metabolically 
normal and insulin resistant individuals compared with experimental data from Prando et al. [434]. 
Experimental data approximated from the graph presented using Image J. 
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S1.2.3 Contribution of lipogenesis, FFA uptake and diet to hepatic triglycerides across 
the sinusoid 
Table S1.8: The simulated contribution of hepatic de novo lipogenesis, FFA uptake and dietary 
triglycerides to hepatic steatosis compared with experimental data. 
Metabolically Normal, Moderate Intake 
 Simulated Experimental 
Plasma FFA 54.0% - 
Hepatic DNL 12.0% - 
Dietary Triglycerides 34.0% - 
Severe IR + Raised SREBP-1c expression (NAFLD) 
 Simulated (Liver & VLDL) Experimental - NAFLD 
Plasma FFAs 60.0%  Liver: 59.0±9.9% 
VLDL: 62.4±11.7% 
Hepatic DNL 20.2% Liver: 26.1±6.7% 
VLDL: 22.9±6.2% 
Dietary Triglycerides 19.8% Liver: 14.9±7.0% 
VLDL: 14.7±8.5% 
The simulated contribution of hepatic de novo lipogenesis, FFA uptake and dietary triglycerides to 
hepatic steatosis compared with experimental data from Donnelly et al. [26]. 
Table S1.8 compares the contribution of plasma FFAs, hepatic de novo lipogenesis and uptake of 
dietary triglycerides to overall hepatic triglyceride levels (averaged across the sinusoid) when 
simulating severe IR combined with increased SREBP-1c expression (as seen in NAFLD; see chapter 3) 
with the contributions measured experimentally by Donnelly et al. in NAFLD patients [26]. Donnelly 
et al. measured the contribution of these three sources to both liver triglycerides and VLDL. However, 
in the model, the composition of VLDL is solely determined by the composition of liver triglycerides 
such that the two are equal. Additionally, the contributions when simulating a metabolically normal 
individual are shown. 
The contributions of each source of FAs to both liver triglycerides and VLDL are all within one standard 
deviation of the values measured by Donnelly et al. when simulating NAFLD [26]. The contribution of 
dietary triglycerides is towards the high end of the measured values suggesting this may be slightly 
overestimated. However, this component is the most susceptible to changes in dietary input, and the 
simulated values remain in the correct range.  
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Experimental data comparing the contributions of different sources to FA levels in individuals without 
excessive liver fat was not available. However, the simulated contribution of plasma FFAs was slightly 
higher when simulating NAFLD than for metabolically normal individuals (60.0% vs 54.0%). The 
simulated contribution of dietary triglycerides was lower when simulating NAFLD compared with 
metabolically normal individuals on the same diet (19.8% vs 34.0%). If higher dietary intake was 
additionally simulated, as is often seen in NAFLD patients in vivo, this difference would be expected 
to fall. The percentage of hepatic triglycerides arising from de novo lipogenesis was higher when 
simulating NAFLD (20.2% vs 12.0%). 
S1.3 Validation of the relative contributions of lipids and carbohydrates to 
oxidative phosphorylation 
Finally, to properly integrate hepatic glucose and lipid metabolisms, it is important that the model can 
produce realistic values for the rates at which fatty acids and glucose are oxidised before and after 
dietary intake. Relatively little time series data exists investigating the rates of oxidation in liver. 
However, in the following sections the model simulations for the rates in liver are compared with 
experimental data for the rates in the whole body. Experimental and simulated rates are compared 
after a mixed meal in metabolically normal individuals (section S1.3.1) and after the intake of starch 
with either slow or fast hydrolysis rates in metabolically normal and T2DM individuals (section S1.3.2). 
S1.3.1 Energy production after a mixed meal 
Daly et al. measured the rates of carbohydrate and fatty acid oxidation after a high sucrose/low starch 
meal with 65% of energy as carbohydrate and 26% as fat (2.5:1) [452]. Using the number of ATP 
molecules produced per glucose and per palmitate in the model, this corresponds to 6.9 moles of 
glucose per mole of palmitate (or 4.85 grams of glucose per gram of palmitate). The model was 
provided with glucose and FFA inputs with the total magnitude to match the inputted carbohydrate 
(high sugar/low starch) and fat in the meal. The meal was inputted in the form of a single sin6(t) spike 
rising from 0 at t=0 to a peak input at 30 minutes. The simulated FFA and glucose concentrations are 
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Figure S1.4: Comparison of the simulated plasma glucose and fatty acid concentration after intake of a mixed 
meal with data measured experimentally. Experimental data from Daly et al. [452]. The model was provided 
with glucose and FFA inputs with the total magnitude to match the inputted carbohydrate (high sugar/low 
starch) and fat in the meal. The meal was inputted in the form of a single sin6(t) spike rising from 0 at t=0 to a 
peak input at 30 minutes. 
well within one standard deviation of the experimental data at all time points when this input was 
simulated in the model (figure S1.4a,b), although the simulated glucose concentration has a less sharp 
peak and shows a slower decrease initially after the peak concentration. This suggests that the 
simulated input provides a reasonable approximation to the meal provided experimentally. 
a) 
b) 
259 
 
In the experimental study, the rates of carbohydrate and lipid oxidation were measured in grams per 
minute in the body as a whole (figure S1.5a,c). These results cannot be compared quantitatively with 
the simulated data for the rate of pyruvate oxidation and β-oxidation in liver alone calculated in moles 
per minute (figure S1.5b,d). However, qualitative comparison of the changes occurring postprandially 
can be made.  
 
Figure S1.5: Comparison of simulated fatty acid and glucose oxidation rates with experimental data. 
The rates of oxidation of (a,b) glucose and (c,d)  fatty acids and when (a,c) measured experimentally in 
the body as a whole by Daly et al. [452] and (b,d) simulated in liver alone after intake of a mixed meal 
as discussed in the text. 
The simulated curves for the rates of fatty acid and carbohydrate oxidation follow a similar shape over 
the 6 hours to those measured experimentally. The rate of carbohydrate oxidation doubles 
postprandially before falling back to its initial value in both the simulated and experimental data. 
Similarly, in both cases the rate of fatty acid oxidation falls by half before rising to slightly above its 
a) b) dc
260 
 
initial value. The peak in carbohydrate oxidation and the trough in lipid oxidation appear sharper and 
occur more rapidly after intake in the simulated data than experimentally. This may be because only 
the liver is simulated, rather than the body as a whole. Due to the role of liver in the storage of glucose, 
and the large quantities of blood that pass through the organ, hepatocytes would be expected to react 
particularly quickly to changes in plasma insulin and glucagon levels. When considering the body as a 
whole, less responsive organs would slow this effect. 
S1.3.2 Comparison of energy production in metabolically normal and diabetic 
individuals 
Seal et al. compared the rates of carbohydrate and lipid oxidation in metabolically normal and T2DM 
patients fed 50g of rapidly or slowly hydrolysed starch [453]. In this study, the rates at which the two 
starches were broken down to sugars were also measured, allowing a more accurate approximation 
of the rate at which glucose entered the blood stream. To validate the models simulations for energy 
metabolism in insulin resistant individuals, the model was provided with glucose inputs set to match 
the rates at which carbohydrates were broken down in vivo. For the fast release starch, an input was 
provided with a sharp peak at 30 minutes before falling rapidly to zero (figure S1.6). For slow release 
starch an input with a smaller peak centred after an hour was used before falling more slowly, such 
that the rate of input remained at 17% of its peak rate after 6 hours (as measured experimentally) 
(figure S1.6). Experimentally, only 70% of the slowly hydrolysed starch was broken down over the 6 
hours compared to 96% for the rapidly hydrolysed starch. As a result, the total glucose inputted to the 
model was larger when simulating the rapidly hydrolysed starch to match these values. In both cases, 
the model was run for 1.5 hours with no input before the starch intake to allow variables to 
equilibrate. 
IR was simulated by multiplying the detected insulin concentration by a constant (K IR) smaller than 
one. Three severities of IR were simulated to account for variability in the degree of insulin sensitivity 
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between T2DM individuals. Mild, moderate and severe IR correspond to 90%, 95% and 98.5% de-
sensitivity respectively in the graphs.  
For the metabolically normal individuals, the simulated glucose concentrations match the 
experimental data closely with the average difference between the simulated and experimental 
curves well within one standard deviation. This provides further validation of the simulated data for 
the plasma glucose concentration under conditions where the rate of input is known (figure S1.7).  
The simulated data for the glucose concentration in insulin resistant individuals match the 
experimental data through the initial postprandial rise and initial subsequent fall (figure S1.7). The 
experimentally measured concentration remains within one standard deviation of the simulated data 
for moderate IR and between the simulated data for mild and severe IR over the first 4-5 hours. 
However, around 4 hours after the intake of fast release starch and 5 hours after the intake of slow 
release starch, a drop of glucose concentration to well below the pre-prandial value was measured 
experimentally but not seen in the simulated data. This was, accompanied by a widening of the error 
bars in the experimental data. When simulating IR, the only change that was made was to multiply the 
detected insulin concentration by an IR constant less than 1 to allow direct comparison. However, in 
vivo, diabetics additionally show severely depleted glycogen stores reducing their capacity to provide 
glucose to the blood when plasma concentrations fall. Therefore, the difference between the 
simulated and experimental data is likely to arise because in the simulations the initial glycogen stores 
were set to 200mM for both insulin resistant and metabolically normal individuals. Due to this 
difference in plasma concentrations after 4-5 hours, the rates of oxidation are only compared for the 
first 300 minutes. 
As with section S1.3.1, the model simulates the rates of pyruvate oxidation and fatty acids in liver and 
so cannot be compared quantitatively with the experimentally measured rates of carbohydrate and 
lipid oxidation in the body as a whole (figures S1.8 and S1.9). However, the change in the rates of these 
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processes occurring postprandially in the liver should be qualitatively similar to those for the body as 
a whole. 
Over the 360 minutes, the changes in the rates of oxidation relative to baseline match the 
experimental data closely with an upregulation of carbohydrate oxidation and reduction in lipid 
oxidation occurring. In the case of fast release starch, a slightly larger increase in carbohydrate 
oxidation and reduction in lipid oxidation is seen in T2DM than metabolically normal individuals after 
the intake of fast release starch in both the simulated and experimental data (figures S1.8). In the case 
of slow release starch the change in the rate of fatty acid oxidation was roughly the same for T2DM 
and insulin sensitive individuals in both the simulated and experimental data (figure S1.9). A slightly 
lower increase in carbohydrate oxidation was seen for T2DM individuals experimentally, perhaps due 
to depleted glycogen stores. 
 
Figure S1.6: The rates of glucose input used when simualting the intake of 50g of rapidly and slowly 
hydrolysing starch. When simulating quick release starch 100% of the 50g was inputted to the blood 
stream over the 6 hours whilst for slow release starch, 83% entered the blood stream for consistency 
with the experimental data. 
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Figure S1.7: Comparison of simulated and experimentally measured glucose concentrations after slow and fast release starch intake. The glucose concentration 
after intake of a (top) 50g of quick release starch and (bottom) 50g of slow release starch when measured experimentally by Seal et al. [453] and simulated by the 
model in (left) metabolically normal and (right) T2DM individuals.  
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Figure S1.8: Simulated and experimentally measured rates of carbohydrate and fatty acid oxidation after intake of quick release carbohydrate. The rates of 
oxidation of fatty acids and glucose in metabolically normal and T2DM individuals when (left) measured experimentally in the body as a whole by Seal et al. [453] 
and (right) when simulated in liver alone after intake of 50g of quick release starch as discussed in the text. 
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Figure S1.9: Simulated and experimentally measured rates of carbohydrate and fatty acid oxidation after intake of slow release carbohydrate. The rates of 
oxidation of fatty acids and glucose in metabolically normal and T2DM individuals when (left) measured experimentally in the body as a whole by Seal et al. [453] 
and (right) when simulated in liver alone after intake of 50g of slow release starch as discussed in the text. Error bars in experimental data are SEM rather than SD 
with n=8 for metabolically normal and n=13 for T2DM.
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S2 Determining Treatment Concentrations 
S2.1 Assessing treatment concentration ranges using an MTS assay 
To determine an approximate range of appropriate treatment concentrations, an MTS assay was used 
to assess the effects of a range of concentrations on cell viability after 48 hours. The MTS assay allows 
rapid measurement of viability for a range of different treatments, but is associated with fairly large 
variation in the readings. Note also that only one independent repeat of this experiment was 
performed and the numbers stated in the graphs are for technical replicates (in this section only). As 
a result, the statistical significances presented in this section are only applicable to the particular cells 
used under the exact conditions tested. Therefore, once appropriate treatment concentrations were 
determined through the MTS assay, the effect of these treatments on viability were validated with a 
trypan blue exclusion assay (see section S2.2). The tested ranges were based on ranges of effect and 
toxicity published in the literature (TOFA [579, 611-613], C75 [617-619], T863 [585, 620], 2DG [603, 
621], 3BP [622, 623]). 
20µg/ml and 40µg/ml TOFA significantly reduced cell viability whilst 10µg/ml caused non-significant 
decrease (figure S2.1a). No significant changes in cell numbers were seen for concentrations of 5µg/ml 
or lower. This suggest that TOFA is less toxic to HepG2 cells than other cancer derived lines such as 
lung and colon cancer cells in which 1µg/ml of TOFA caused cell death [614]. Similarly, treatment with 
20µg/ml or higher caused a significant decrease in cell viability whilst 10µg/ml C75 caused a non-
significant decrease (figure S2.1b). No significant change in viability was noted for lower 
concentrations.  
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Figure S2.1: The effct of varying concentrations of TOFA, C75, T863, 2DG and 3BP on cell viability of 
48 hours of treatment as assessed by the MTS assay. The effect of varying concentrations of (a) TOFA, 
(b) C75, (c) T863, (d) 2-DG and (e) 3-BP on cell numbers of 48 hours of treatment as assessed by the MTS 
assay (section 5.2.4.1). Note that the number of repeats shown on the axes of the graphs are technical 
replicates and not independent repeats. Only one independent repeat was performed. Furthermore, the 
statistics calculations were based on these technical replicates. As a result, the data in these graphs 
were only used to determine approximate treatment ranges before validating these in a second trypan 
exclusion assay. The statistical significances of the differences calculated can only be considered to show 
a statistically significant change for the specific cells used under the exact conditions tested. * - p<0.05 
compared with control. ±SD 
No significant change in MTS reading occurred for the range of T863 concentrations assessed (5ng/ml-
400ng/ml) (figure S2.1c). Therefore, in the range measured, partial inhibition of DGAT1 by T863 did 
not cause a reduction in cell viability. On observation of the cells by eye, a clear reduction in lipid 
droplets was noted for treatments in the range 100-400ng/ml demonstrating that partial triglyceride 
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synthesis inhibition was occurring in this range (the effects of T863, along with the other treatments, 
on hepatic lipid levels is assessed in section 5.3.2). 
3BP concentrations up to 6mg/ml caused no significant change in MTS reading (figure S2.1e). 
However, a significant decrease was measured when treating with 8µg/ml or higher. Treatment with 
2µg/ml or higher 2DG significantly reduced the MTS reading, whilst lower concentrations did not 
significantly change the readings (figure S2.1d). Therefore, consistent with expectation for a cell 
culture line derived from hepatocellular carcinoma, inhibition of glycolysis above a certain threshold 
at either stage causes a reduction in the number of viable cells. However, below this, cells remained 
viable.  
Treatment concentrations were selected below the concentrations at which reduced viability was 
measured in the MTS assay. For TOFA treatments concentrations of 2µg/ml and 4µg/ml were used. 
For C75, treatment concentrations of 1µg/ml and 2µg/ml were used. In both cases these test 
concentrations are well below the 20µg/ml concentration at which significant reductions in viability 
were measured by the MTS assay. For T863, treatment concentrations of 100ng/ml and 200ng/ml 
were tested. No change in viability occurred with T863 treatment in FA free medium (0-400ng/ml) but 
a reduction in the presence of lipid droplets was observed at 100ng/ml and 200ng/ml (quantitative 
assessment of the effects of T863 on steatosis is performed in section 5.3.2). For 2DG, treatment 
concentrations of 250ng/ml and 500ng/ml were used, corresponding to 1/8 and 1/4 of the 2µg/ml 
concentration at which a reduction in viability was measured. Similarly, for 3BP treatment 
concentrations of 1µg/ml and 2µg/ml were tested corresponding to 1/8 and 1/4 of the 8µg/ml 
concentration at which a reduction in viability was measured. 
S2.2 Validation of treatment concentrations using a trypan blue exclusion 
assay 
Due the lack of independent repeats of the MTS data, the impact of each treatment concentration 
on cell viability was next validated in a second trypan blue exclusion assay (figure S2.2). Consistent 
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with the MTS data, none of the proposed treatment concentrations caused a significant reduction in 
cell numbers at 48 hours. However, when the cells were treated with 2DG, nonsignificant decreases 
were seen in the number of viable cells for both 250ng/ml (1.81±0.15 (n=3) vs control: 2.02±0.07 
(n=9); p=0.13) and 500ng/ml (1.85±0.19 (n=3); p=0.15) suggesting that at these concentrations, 2DG 
may cause a reduction in viable cells. However, this is small relative to the FFA induced cell death 
discussed in section 5.3. 
 
Figure S2.2: The effects of treatment concentrations for each inhibitor on viable HepG2 cell numbers. 
The effects of the two treatment concentrations for each inhibitor (TOFA, T863, C75, 2DG and 3BP) on 
viable. HepG2 cell numbers after 48 hours of treatment as assessed by a trypan blue exclusion assay 
(section 5.2.4.4). The n numbers shown in the axes correspond to numbers of independent replicates. 
The mean ±SD is shown. 
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